Nothing Special   »   [go: up one dir, main page]

CN1346271A - Quinazoline derivatives as angiogenesis inhibitors - Google Patents

Quinazoline derivatives as angiogenesis inhibitors Download PDF

Info

Publication number
CN1346271A
CN1346271A CN00806085A CN00806085A CN1346271A CN 1346271 A CN1346271 A CN 1346271A CN 00806085 A CN00806085 A CN 00806085A CN 00806085 A CN00806085 A CN 00806085A CN 1346271 A CN1346271 A CN 1346271A
Authority
CN
China
Prior art keywords
alkyl
group
amino
quinazoline
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00806085A
Other languages
Chinese (zh)
Other versions
CN1167422C (en
Inventor
L·F·A·亨尼奎
P·普勒
E·S·E·斯托克斯
D·麦克雷切
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1346271A publication Critical patent/CN1346271A/en
Application granted granted Critical
Publication of CN1167422C publication Critical patent/CN1167422C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R<2> represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR<3>R<4> (wherein R<3> and R<4>, which may be the same or different, each represents hydrogen or C1-3alkyl), or R<5>X<1>- (wherein X<1> and R<5> are as defined herein; R<1> represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, <u>N</u>-C1-4alkylcarbamoyl, <u>N</u>,<u>N</u>-di(C1-4alkyl)carbamoyl, aminosulphonyl, <u>N</u>-C1-4alkylaminosulphonyl, <u>N</u>,<u>N</u>-di(C1-4alkyl)aminosulphonyl, <u>N</u>-(C1-4alkylsulphonyl)amino, <u>N</u>-(C1-4alkylsulphonyl)-<u>N</u>-(C1-4alkyl)amino, <u>N</u>,<u>N</u>-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R<56>X<10> (wherein X<10> and R<56> are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Description

Quinazoline derivant as angiogenesis inhibitor
The present invention relates to quinazoline derivant, its preparation method, contain they as pharmaceutical composition, treatment and the angiogenesis of active component and/or vascular permeability increase method that related disorders is arranged, they are used for producing purposes aspect the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in preparation as the application of medicine and they.
Normal angiogenesis is comprising fetal development, plays an important role in the various procedures of some ingredients of wound healing and female reproduction function.Bad or pathologic angiogenesis with comprise diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, sebaceous cyst, Kaposi sarcoma and hemangioma are at interior various disease conditions relevant (Fan etc., 1995, TrendsPharmacol.Sci.16:57-66; Folkman, 1995, Nature Medicine 1:27-31).It is believed that the change of vascular permeability is at normal all work in pathologic physiological process (Cullinan-Bove etc., 1993, the Endocrinology 133:829-837 of reaching; Senger etc., 1993, Cancer and Metastasis Reviews, 12:303-324).Identify several and had vitro endothelial cell growth and promote active polypeptide, comprised acid and basic fibroblast growth factor (aFGF﹠amp; BFGF) and vascular endothelial cell growth factor (VEGF).Consider the restricted expression of its receptor, compare that the growth factor activity of VEGF has relative specificity to endotheliocyte with FGFs.Nearest studies show that, VEGF is not only important stimulus thing (Jakeman etc., 1993, Endocrinology, 133:848-859 normal and that pathologic vessels generates; People such as Kolch, 1995, Breast CancerResearch and Treatment, 36:139-155), but also be vascular permeability the important stimulus thing (Connolly etc., 1989, J.Biol.Chem.264:20017-20024).By in conjunction with VEGF and antibody antagonism VEGF effect, the result can suppress tumor growth (Kim etc., 1993, Nature 362:841-844).Basic FGF (bFGF) be a kind of effective angiogenesis stimulus object (for example, Hayek etc., 1987, Biochem.Biophys.Res.Commun.147:876-880), and cancer patient's serum (Fujimoto etc., 1991, Biochem.Biophys.Res.Commun.180:386-392) and urine (Nguyen etc., 1993, J.Natl.Cancer.Inst.85:241-242) the middle concentration of FGFs of finding increases.
Receptor tyrosine kinase (RTKs) is important in the biochemical signals transmission of crossing over cytoplasma membrane.The feature of these transmembrane molecules is by the outer part of the born of the same parents that are connected with tyrosine kinase domain in the born of the same parents by the fragment in the plasma membrane-form in conjunction with the territory.The tyrosine kinase activity that part is relevant with the costimulatory receptor as a result of receptors bind, and then cause tyrosine residue phosphorylation on receptor and the interior molecule of other born of the same parents.In the tyrosine phosphorylation these change the priming signal cascade and amplify, and the result produces various cell responses.Up to now, at least 19 kinds of different RTK subfamilies have been identified by the amino acid sequence homology definition.One of these subfamilies are at present by fms sample tyrosine receptor, and Flt or FLt1 contain the receptor that kinases inserts the territory, KDR (being also referred to as Flk-1), and another fms sample tyrosine kinase receptor Flt4 forms.Proved already that two among these relevant RTKs was that Flt and KDR can combine (De Vries etc., Science255:989-991 in high-affinity ground with VEGF; Terman etc., 1992, Biochem.Biophys.Res.Comm.1992,187:1579-1586).The combination of these receptors of expressing in VEGF and the allos cell is relevant with the variation of the tyrosine phosphorylation degree of cell protein and calcium current amount.
The present invention is based on this discovery, find that promptly VEGF is had unexpected inhibiting chemical compound, this rejection characteristic is for very important with the treatment of angiogenesis and/or vascular permeability rising diseases related, described disorders such as cancers, diabetes, psoriasis, rheumatoid arthritis, the Kaposi sarcoma, hemangioma, acute and chronic nephropathy, sebaceous cyst, arterial restenosis, autoimmune disease, acute inflammation, cicatrization and adhesion are excessive, endometriosis, anovulatory dysfunctional uterine hemorrhage and the oculopathy relevant with the retinal vessel hypertrophy.The effectiveness of the anti-vegf receptor tyrosine kinase of The compounds of this invention is usually above the effectiveness of anti-epidermal growth factor (EGF) receptor tyrosine kinase.Tested the proof The compounds of this invention and had the activity of anti-vegf receptor tyrosine kinase, thereby made them can not have the amount use of remarkable activity simultaneously to the EGF receptor tyrosine kinase so that vegf receptor tyrosine kinase is produced enough inhibitory action.The effectiveness of the anti-vegf receptor tyrosine kinase of The compounds of this invention is usually above the effectiveness of anti-FGF R1 receptor tyrosine kinase.Tested the proof The compounds of this invention and had the activity of anti-vegf receptor tyrosine kinase, thereby made them can not have the amount use of remarkable activity simultaneously to FGF R1 receptor tyrosine kinase vegf receptor tyrosine kinase there are enough inhibitory action.
One aspect of the present invention provides formula I compound or its salt or its prodrug (for example ester or amide) to be used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in preparation: Wherein:
Ring C is 8,9,10,12 or 13 yuan of bicyclo-or three loop sections, and it can be saturated or undersaturated, fragrance or nonaromatic, and can choose wantonly and comprise 1-3 hetero atom that independently is selected from O, N and S;
Z is-O--NH-,-S-,-CH 2-or direct key;
N is integer 0-5;
M is 0-3;
R 2Represent hydrogen, hydroxyl, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3R 4(R wherein 3And R 4Can be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5X 1-(X wherein 1Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2-,-NR 6C (O)-,-C (O) NR 7-,-SO 2NR 8-,-NR 9SO 2-or-NR 10-(R wherein 6, R 7, R 8, R 9And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 5Be selected from one of following 22 groups of groups:
1) hydrogen, Oxyranyle C 1-4Alkyl or C 1-5Alkyl, this C 1-5Alkyl can be unsubstituted or can be replaced by one or more hydroxyl, fluorine, chlorine, bromine and amino groups of being selected from;
2) C 1-5Alkyl X 2COR 11(X wherein 2Representative-O-or-NR 12-(R wherein 12Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, represent hydrogen separately, C 1-5Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-5Alkyl X 3R 16(X wherein 3Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 17C (O)-,-C (O) NR 18-,-SO 2NR 19-,-NR 20SO 2-or-NR 21-(R wherein 17, R 18, R 19, R 20And R 21The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 16Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, described cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
4) C 1-5Alkyl X 4C 1-5Alkyl X 5R 22(X wherein 4And X 5Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 23C (O)-,-C (O) NR 24-,-SO 2NR 25-,-NR 26SO 2-or-NR 27-(R wherein 23, R 24, R 25, R 26And R 27The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 22Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
5) R 28(R wherein 28For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
6) C 1-5Alkyl R 28(R wherein 28As above definition);
7) C 2-5Alkenyl R 28(R wherein 28As above definition);
8) C 2-5Alkynyl R 28(R wherein 28As above definition);
9) R 29(R wherein 29Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 30R 31,-NR 32C (O) R 33(R wherein 30, R 31, R 32And R 33Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl) and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
10) C 1-5Alkyl R 29(R wherein 29As above definition);
11) C 2-5Alkenyl R 29(R wherein 29As above definition);
12) C 2-5Alkynyl R 29(R wherein 29As above definition);
13) C 1-5Alkyl X 6R 29(X wherein 6Representative-O-,-S-,-SO-,-SO 2,-NR 34C (O)-,-C (O) NR 35,-SO 2NR 36-,-NR 37SO 2-or-NR 38-(R wherein 34, R 35, R 36, R 37And R 38The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
14) C 2-5Alkenyl X 7R 29(X wherein 7Representative-O-,-S-,-SO-,-SO 2,-NR 39C (O)-,-C (O) NR 40-,-SO 2NR 41-,-NR 42SO 2-or-NR 43-(R wherein 39, R 40, R 41, R 42And R 43The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
15) C 2-5Alkynyl X 8R 29(X wherein 8Representative-O-,-S-,-SO-,-SO 2,-NR 44C (O)-,-C (O) NR 45-,-SO 2NR 46-,-NR 47SO 2-or-NR 48-(R wherein 44, R 45, R 46, R 47And R 48The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
16) C 1-4Alkyl X 9C 1-4Alkyl R 29(X wherein 9Representative-O-,-S-,-SO-,-SO 2,-NR 49C (O)-,-C (O) NR 50-,-SO 2NR 51-,-NR 52SO 2-or-NR 53-(R wherein 49, R 50, R 51, R 52And R 53The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
17) C 1-4Alkyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition);
21) C 1-5Alkynyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition); With
22) C 1-4Alkyl R 54(C 1-4Alkyl) q(X 9) rR 55(X wherein 9As above definition, q is 0 or 1, r is 0 or 1, and R 54And R 55Be selected from hydrogen independently of one another, C 1-3Alkyl, cyclopenta, cyclohexyl and contain 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and cyclic group wherein can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this heterocyclic radical can have one or more and be selected from C 1-4The substituent group of alkyl), condition is R 54Can not be hydrogen);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from).
R 1Represent hydrogen, oxo, halogen, hydroxyl, C 1-4Alkoxyl, C 1-4Alkyl, C 1-4Alkoxy methyl, C 1-4Alkanoyl, C 1-4Haloalkyl, cyano group, amino, C 2-5Alkenyl, C 2-5Alkynyl, C 1-3Alkanoyloxy, nitro, C 1-4Alkanoylamino, C 1-4Alkoxy carbonyl, C 1-4Alkylthio group, C 1-4Alkyl sulphinyl, C 1-4Alkyl sulphonyl, carbamoyl, N-C 1-4Alkyl-carbamoyl, N, N-two (C 1-4Alkyl) carbamoyl, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl, N, N-two (C 1-4Alkyl) amino-sulfonyl, N-(C 1-4Alkyl sulphonyl) amino, N-(C 1-4Alkyl sulphonyl)-N-(C 1-4Alkyl) amino, N, N-two (C 1-4Alkyl sulphonyl) amino, the C that is connected with two ring carbon atoms 3-C 7Alkylidene chain, C 1-4Alkanoylamino C 1-4Alkyl, carboxyl or radicals R 56X 10(X wherein 10Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2,-NR 57C (O)-,-C (O) NR 58-,-SO 2NR 59-,-NR 50SO 2-or-NR 61-(R wherein 57, R 58, R 59, R 60And R 61The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 56Be selected from one of following 22 groups of groups:
1) hydrogen, Oxyranyle C 1-4Alkyl or C 1-5Alkyl, this C 1-5Alkyl can be unsubstituted or can be replaced by one or more hydroxyl, fluorine, chlorine, bromine and amino groups of being selected from;
2) C 1-5Alkyl X 11COR 62(X wherein 11Representative-O-or-NR 63-(R wherein 63Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 62Represent C 1-3Alkyl ,-NR 64R 65Or-OR 66(R wherein 64, R 65And R 66Can be identical or different, represent hydrogen separately, C 1-5Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-5Alkyl X 12R 67(X wherein 12Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 68C (O)-,-C (O) NR 69-,-SO 2NR 70-,-NR 71SO 2-or-NR 72-(R wherein 68, R 69, R 70, R 71And R 72The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 67Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, described cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
4) C 1-5Alkyl X 13C 1-5Alkyl X 14R 73(X wherein 13And X 14Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 74C (O)-,-C (O) NR 75-,-SO 2NR 76-,-NR 77SO 2-or-NR 78-(R wherein 74, R 75, R 76, R 77And R 78The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 73Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
5) R 79(R wherein 79For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
6) C 1-5Alkyl R 79(R wherein 79As above definition);
7) C 2-5Alkenyl R 79(R wherein 79As above definition);
8) C 2-5Alkynyl R 79(R wherein 79As above definition);
9) R 80(R wherein 80Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 81R 82,-NR 83C (O) R 84(R wherein 81, R 82, R 83And R 84Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl) and group-(O-) f(C 1-4Alkyl) g(wherein f is O or 1 to ring D, and g is O or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
10) C 1-5Alkyl R 80(R wherein 80As above definition);
11) C 2-5Alkenyl R 80(R wherein 80As above definition);
12) C 2-5Alkynyl R 80(R wherein 80As above definition);
13) C 1-5Alkyl X 15R 80(X wherein 15Representative-O-,-S-,-SO-,-SO 2,-NR 85C (O)-,-C (O) NR 86,-SO 2NR 87-,-NR 88SO 2-or-NR 89-(R wherein 85, R 85, R 87, R 88And R 89The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
14) C 2-5Alkenyl X 16R 80(X wherein 16Representative-O-,-S-,-SO-,-SO 2,-NR 90C (O)-,-C (O) NRR 91-,-SO 2NRR 92-,-NR 93SO 2-or-NR 94-(R wherein 90, R 91, R 92, R 93And R 94The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
15) C 2-5Alkynyl X 17R 80(X wherein 17Representative-O-,-S-,-SO-,-SO 2,-NR 95C (O)-,-C (O) NR 96,-SO 2NR 97-,-NR 98SO 2-or-NR 99(R wherein 95, R 96, R 97, R 98And R 99The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
16) C 1-4Alkyl X 18C 1-4Alkyl R 80(X wherein 18Representative-O-,-S-,-SO-,-SO 2,-NR 100C (O)-,-C (O) NR 101-,-SO 2NR 102,-NR 103SO 2-or-NR 104-(R wherein 100, R 101, R 102, R 102And R 104The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
17) C 1-4Alkyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition);
21) C 2-5Alkynyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition); With
22) C 1-4Alkyl R 105(C 1-4Alkyl) x(X 18) yR 106(X wherein 18As above definition, x is 0 or 1, y is 0 or 1, and R 105And R 106Be selected from hydrogen independently of one another, C 1-3Alkyl, cyclopenta, cyclohexyl and contain 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and cyclic group wherein can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl), condition is R 105Can not be hydrogen); In addition, R wherein 56X 10-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from).
Another aspect of the present invention provides formula I chemical compound and salt thereof and its prodrug (for example ester, amide and thioether) to be used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in production: Wherein:
Ring C is 9-10 unit two loop sections, and it can be saturated or undersaturated, fragrance or nonaromatic, and can choose wantonly and comprise 1-3 hetero atom that independently is selected from O, N and S;
Z is-O--NH-,-S-,-CH 2-or direct key;
R 1Represent hydrogen, oxo, halogen, hydroxyl, C 1-4Alkoxyl, C 1-4Alkyl, C 1-4Alkoxy methyl, C 1-4Alkanoyl, C 1-4Haloalkyl, cyano group, amino, C 2-5Alkenyl, C 2-5Alkynyl, C 1-3Alkanoyloxy, nitro, C 1-4Alkanoylamino, C 1-4Alkoxy carbonyl, C 1-4Alkylthio group, C 1-4Alkyl sulphinyl, C 1-4Alkyl sulphonyl, carbamoyl, N-C 1-4Alkyl-carbamoyl, N, N-two (C 1-4Alkyl) carbamoyl, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl, N, N-two (C 1-4Alkyl) amino-sulfonyl, N-(C 1-4Alkyl sulphonyl) amino, N-(C 1-4Alkyl sulphonyl)-N-(C 1-4Alkyl) amino, N, N-two (C 1-4Alkyl sulphonyl) the amino or C that is connected with two ring carbon atoms 3-C 7Alkylidene chain;
N is integer 0-5;
M is integer 0-3;
R 2Represent hydrogen, hydroxyl, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3R 4(R wherein 3And R 4Can be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5X 1-(X wherein 1Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2-,-NR 6C (O)-,-C (O) NR 7-,-SO 2NR 8-,-NR 9SO 2-or-NR 10-(R wherein 5, R 7, R 8, R 9And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 5Be selected from one of following 21 groups of groups:
1) hydrogen or C 1-5Alkyl, this can be unsubstituted or can be replaced by one or more hydroxyl, fluorine and amino groups of being selected from;
2) C 1-5Alkyl X 2COR 1(X wherein 2Representative-O-or-NR 12-(R wherein 12Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, represent hydrogen separately, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-6Alkyl X 3R 16(X wherein 3Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 17C (O)-,-C (O) NR 18-,-SO 2NR 19-,-NR 20SO 2-or-NR 21-(R wherein 17, R 18, R 19, R 20And R 21The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 16Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and described cyclic group can have 1 or 2 and is selected from oxo, hydroxyl, halogen, C 1-4Alkyl, C 1-4Hydroxy alkyl and C 1-4The substituent group of alkoxyl);
4) C 1-5Alkyl X 4C 1-5Alkyl X 5R 23(X wherein 4And X 5Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 23C (O)-,-C (O) NR 24-,-SO 2NR 25-,-NR 26SO 2-or-NR 27(R wherein 23, R 24, R 25, R 26And R 27The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl and C 1-4Alkyl sulphonyl C 1-4Alkyl);
6) C 1-5Alkyl R 28(R wherein 28As above definition);
7) C 2-5Alkenyl R 28(R wherein 28As above definition);
8) C 2-5Alkynyl R 28(R wherein 28As above definition);
9) R 29(R wherein 29Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group on carbon atom: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 30R 31With-NR 32C (O) R 33(R wherein 30, R 31, R 32And R 33Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl));
10) C 1-5Alkyl R 29(R wherein 29As above definition);
11) C 2-5Alkenyl R 29(R wherein 29As above definition);
12) C 2-5Alkynyl R 29(R wherein 29As above definition);
13) C 1-5Alkyl X 6R 29(X wherein 6Representative-O-,-S-,-SO-,-SO 2,-NR 34C (O)-,-C (O) NR 35-,-SO 2NR 36,-NR 37SO 2-or-NR 38-(R wherein 34, R 35, R 36, R 37And R 38The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
14) C 2-5Alkenyl X 7R 29(X wherein 7Representative-O-,-S-,-SO-,-SO 2,-NR 39C (O)-,-C (O) NR 40-,-SO 2NR 41-,-NR 42SO 2-or-NR 43(R wherein 39, R 40, R 41, R 42And R 43The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
15) C 2-5Alkynyl X 8R 29(X wherein 8Representative-O-,-S-,-SO-,-SO 2,-NR 44C (O)-,-C (O) NR 45-,-SO 2NR 46-,-NR 47SO 2-or-NR 48-(R wherein 44, R 45, R 46, R 47And R 48The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
16) C 1-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9Representative-O-,-S-,-SO-,-SO 2,-NR 49C (O)-,-C (O) NR 50-,-SO 2NR 51-,-NR 52SO 2-or-NR 53-(R wherein 49, R 50, R 51, R 52And R 53The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
17) C 1-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition); With
21) C 2-5Alkynyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition).
Preferred ring C contains 1-3 first aromatics two cyclic groups of heteroatomic 9-1O-that independently are selected from O, N and S for choosing wantonly.
More preferably encircling C is to contain 1-3 first heteroaromatic two cyclic groups of heteroatomic 9-10-that independently are selected from O, N and S.
Particularly encircling C is 9-10-unit heteroaromatic two cyclic groups that contain 1 or 2 nitrogen-atoms.
According to an aspect of the present invention, ring C is 9-unit heteroaromatic two cyclic groups that contain 1 or 2 nitrogen-atoms, for example indyl.
According to a further aspect in the invention, containing C is 10-unit heteroaromatic two cyclic groups that contain 1 or 2 nitrogen-atoms, for example quinolyl.
Ring C is indyl or quinolyl particularly.
Preferred Z be-O-,-NH-,-S-or-direct key.
More preferably Z is-O-,-NH-or-S-.
Particularly Z be-O-or-S-, particularly-O-.
X advantageously 10Represent direct key ,-O-,-S-,-NR 57C (O)-,-NR 60SO 2-or-NR 61-(R wherein 57, R 60And R 61The independent separately hydrogen, C represented 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 10Represent direct key ,-O-,-S-,-NR 57C (O)-,-NR 60SO 2-(R wherein 57And R 60Independent separately hydrogen or the C of representing 1-2Alkyl) or NH.
More preferably X 10Representative-O-,-S-,-NR 57C (O)-(R wherein 57Represent hydrogen or C 1-2Alkyl) or NH.
X particularly 10Representative-O-or-NR 57C (O)-(R wherein 57Represent hydrogen or C 1-2Alkyl), be more particularly-O-or-NHC (O)-, especially-O-.
According to a further aspect in the invention, X 10Representative-O-or direct key.
X advantageously 12Representative-O-,-S-,-SO-,-SO 2-,-NR 68C (O)-,-NR 71SO 2-or-NR 72-(R wherein 68, R 71And R 72The independent separately hydrogen, C represented 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 12Representative-O-,-S-,-SO-,-SO 2-or-NR 72-(R wherein 72Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
More preferably X 12Representative-O-or-NR 72-(R wherein 72Represent hydrogen or C 1-2Alkyl).
According to a further aspect in the invention, X 12Representative-O-,-SO 2-,-NR 71SO 2-or-NR 72-(R wherein 71And R 72Represent hydrogen independently of one another, C 1-2Alkyl or C 1-2Alkoxyethyl).
X advantageously 18Representative-O-,-S-or-NR 104-(R wherein 104Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 18Representative-O-or-NR 104-(R wherein 104Represent hydrogen or C 1-2Alkyl).
According to a further aspect in the invention, X 18Representative-O-,-CONR 101Or-NR 104-(R wherein 101And R 104Independent separately hydrogen or the C of representing 1-2Alkyl).
R 67Should represent to have 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, this cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this heterocyclic radical can have one or more and be selected from C 1-3The substituent group of alkyl).
Preferred R 67Be pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl (azetidinyl), in morpholino or thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl).
More preferably R 67Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 67Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
Preferred R 79Be pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, in morpholino or thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl).
More preferably R 79Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 79Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R advantageously 105And R 106Independent separately representative has 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, and this cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl).
Preferred R 105And R 106Independently be selected from pyrrolidinyl separately, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, in morpholino and thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl).
More preferably R 105And R 106Independently be selected from pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino and thiomorpholine generation separately, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 105And R 106Independently be selected from pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino and thiomorpholine generation separately, these groups can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R advantageously 1Represent oxo, halogen, hydroxyl, C 1-4Alkoxyl, C 1-4Alkyl, C 1-4Alkoxy methyl, C 1-4Alkanoyl, C 1-4Haloalkyl, cyano group, amino, C 2-5Alkenyl, C 2-5Alkynyl, C 1-3Alkanoyloxy, nitro, C 1-4Alkanoylamino, C 1-4Alkoxy carbonyl, C 1-4Alkylthio group, C 1-4Alkyl sulphinyl, C 1-4Alkyl sulphonyl, carbamoyl, N-C 1-4Alkyl-carbamoyl, N, N-two (C 1-4Alkyl) carbamoyl, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl, N, N-two (C 1-4Alkyl) amino-sulfonyl, N-(C 1-4Alkyl sulphonyl) amino, N-(C 1-4Alkyl sulphonyl)-N-(C 1-4Alkyl) amino, N, N-two (C 1-4Alkyl sulphonyl) amino, the C that is connected with two ring carbon atoms 3-C 7Alkylidene chain, C 1-4Alkanoylamino C 1-4Alkyl, carboxyl or radicals R 56X 10(X wherein 10As above definition, and R 56Be selected from one of following 9 groups of groups:
1) C 1-5Alkyl X 12R 67(X wherein 12And R 67As above definition);
2) R 79(R wherein 79As above definition);
3) C 1-5Alkyl R 79(R wherein 79As above definition);
4) C 2-5Alkenyl R 79(R wherein 79As above definition);
5) C 2-5Alkynyl R 79(R wherein 79As above definition);
6) C 1-3Alkyl X 18C 1-3Alkyl R 79(X wherein 18And R 79As above definition);
7) C 2-5Alkenyl X 18C 1-4Alkyl R 79(X wherein 18And R 78As above definition);
8) C 2-5Alkynyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition); With
9) C 1-3Alkyl R 105(C 1-3Alkyl) x(X 18) yR 106(X wherein 18, x, y, R 105And R 106As above definition);
In addition, R wherein 56X 10-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from,
Condition is to work as X 10During for direct key, R 56Can not be R 79).
Preferred R 1Represent oxo, halogen, hydroxyl, C 1-2Alkoxyl, C 1-2Alkyl, C 1-2Alkoxy methyl, C 2-3Alkanoyl, C 1-2Haloalkyl, cyano group, amino, C 2-4Alkenyl, C 2-4Alkynyl, C 2-3Alkanoyloxy, nitro, C 2-3Alkanoylamino, C 1-2Alkoxy carbonyl, C 1-2Alkylthio group, C 1-2Alkyl sulphinyl, C 1-2Alkyl sulphonyl, carbamoyl, N-C 1-2Alkyl-carbamoyl, N, N-two (C 1-2Alkyl) carbamoyl, amino-sulfonyl, N-C 1-2Alkyl amino sulfonyl, N, N-two (C 1-2Alkyl) amino-sulfonyl, N-(C 1-2Alkyl sulphonyl) amino, N-(C 1-2Alkyl sulphonyl)-N-(C 1-2Alkyl) the amino or C that is connected with two ring carbon atoms 3-C 7Alkylidene chain.
More preferably R 1Represent oxo, hydroxyl, C 1-2Alkoxy methyl, amino, halogen, C 1-2Alkyl, C 1-2Alkoxyl, trifluoromethyl, cyano group, nitro, C 2-3Alkanoyl.
R particularly 1Represent methylidene, ethyl, trifluoromethyl or halogen.
R 1Especially represent methylidene, fluorine, chlorine or bromine more in particular is methyl or fluorine.
Preferred n is integer 0-3.
More preferably n is 0,1 or 2.
Preferred m is integer 0-2, more preferably 1 or 2, most preferably 2.
X advantageously 1Represent direct key ,-O-,-S-,-NR 6C (O)-,-NR 9SO 2-or-NR 10-(R wherein 6, R 9And R 10The independent separately hydrogen, C represented 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 1Represent direct key ,-O-,-S-,-NR 6C (O)-,-NR 9SO 2-(R wherein 6And R 9Independent separately hydrogen or the C of representing 1-2Alkyl) or NH.
More preferably X 1Representative-O-,-S-,-NR 6C (O)-(R wherein 6Represent hydrogen or C 1-2Alkyl) or NH.
X particularly 1Representative-O-or-NR 6C (O)-(R wherein 6Represent hydrogen or C 1-2Alkyl), be more particularly-O-or-NHC (O)-, especially-O-.
According to a further aspect in the invention, X 1Representative-O-or direct key.
X advantageously 2Representative-O-or NR 12(R wherein 12Represent hydrogen, C 1-3Alkyl or C 1-2Alkoxyethyl).
X advantageously 3Representative-O-,-S-,-SO-,-SO 2-,-NR 17C (O)-,-NR 20SO 2-or-NR 21-(R wherein 17, R 20And R 21The independent separately hydrogen, C represented 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 3Representative-O-,-S-,-SO-,-SO 2-or-NR 21-(R wherein 21Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
More preferably X 3Representative-O-or-NR 21-(R wherein 21Represent hydrogen or C 1-2Alkyl).
According to a further aspect in the invention, X 3Representative-O-,-SO 2-,-NR 20SO 2-or-NR 21-(R wherein 20And R 21The independent separately hydrogen, C represented 1-2Alkyl or C 1-2Alkoxyethyl).
X advantageously 4And X 5Can be identical or different, and representative-O-separately ,-S-,-SO-,-SO 2-or-NR 27-(R wherein 27Represent hydrogen, C 1-3Alkyl or C 1-2Alkoxyethyl).
Preferred X that can be identical or different 4With X 5Representative-O-separately ,-S-or-NR 27-(R wherein 27Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
More preferably X that can be identical or different 4With X 5Separately representative-O-or-NH-.
X advantageously 6Representative-O-,-S-or-NR 38-(R wherein 38Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 6Representative-O-or-NR 38-(R wherein 38Represent hydrogen or C 1-2Alkyl).
X advantageously 7Representative-O-,-S-or-NR 43-(R wherein 43Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 7Representative-O-or-NR 43-(R wherein 43Represent hydrogen or C 1-2Alkyl).
X advantageously 8Representative-O-,-S-or-NR 48-(R wherein 48Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 8Representative-O-or-NR 48-(R wherein 48Represent hydrogen or C 1-2Alkyl).
X advantageously 9Representative-O-,-S-or-NR 53-(R wherein 53Represent hydrogen, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 9Representative-O-or-NR 53-(R wherein 53Represent hydrogen or C 1-2Alkyl).
According to a further aspect in the invention, X wherein 9Representative-O-,-CONR 50-or-NR 53-(R wherein 50And R 53Represent hydrogen or C independently of one another 1-2Alkyl).
R 28Be preferably pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, in morpholino or thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl).
R advantageously 28Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
In one embodiment of the invention, R 28Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 28Be pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl.
According to a further aspect in the invention, preferred R 28Be pyrrolidinyl, piperazinyl, piperidyl, morpholino or thiomorpholine generation, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl.
Work as R 29During for 5-6-unit aromatic heterocyclic radical, it preferably contains 1 or 2 hetero atom (more preferably one of them is N) that is selected from O, N and S, and can be substituted as mentioned above.
R 29Be in particular pyridone, phenyl, pyridine radicals, imidazole radicals, thiazolyl, thienyl, triazolyl or pyridazinyl, these groups can be substituted as mentioned above; Be more particularly pyridone, pyridine radicals, imidazole radicals, thiazolyl or triazolyl, especially pyridone, pyridine radicals, imidazole radicals or triazolyl, these groups can be substituted as mentioned above.
In one embodiment of the invention, R 29Represent pyriconyl, phenyl or contain 1-3 and be selected from O, N and the heteroatomic 5-6-of S unit aromatic heterocyclic radical, described group preferably have two of as many as and are selected from substituent group in the above-mentioned definition substituent group, more preferably have this substituent group at the most.
At R 29Definition in, suitable substituent group is selected from halogen, C 1-4Alkyl, C 1-4Alkoxyl, cyano group and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl).
At R 29Definition in, substituent group preferably is selected from chlorine, fluorine, methyl, ethyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
According to another embodiment of the present invention, at R 29Definition in, suitable substituent group is selected from halogen, C 1-4Alkyl, C 1-4Alkoxyl and cyano group, substituent group preferably is selected from chlorine, fluorine, methyl and ethyl.
R advantageously 54And R 55Independently be selected from O, S and the heteroatomic 5-6-of N unit saturated heterocyclyl for containing 1-2 independently of one another, this cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl).
Preferred R 54And R 55Be selected from pyrrolidinyl separately, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, in morpholino or thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Fluorine-based alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl).
More preferably R 54And R 55Be selected from pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation separately, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-3Alkoxy C 1-3Alkyl, C 1-3Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 54And R 55Be selected from pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation separately, these groups can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R more especially 54And R 55Be selected from unsubstituted pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino or thiomorpholine generation separately.
That suitable is R 2Representation hydroxy, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, amino or R 5X 1-[X wherein 1As preceding definition, R 5Be selected from one of following 22 groups of group groups:
1) Oxyranyle C 1-4Alkyl or C 1-5Alkyl, this C 1-5Alkyl can be unsubstituted or can be replaced by one or more groups that are selected from fluorine, chlorine and bromine; Or C 2-5Alkyl, it can be unsubstituted or is selected from hydroxyls and amino groups replace by one or more;
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As preceding definition, and R 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, and the C that respectively does for oneself 1-4Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As above definition, and R 16Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-3The substituent group of alkoxyl, described cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28As above definition);
6) C 1-5Alkyl R 107(R wherein 107For containing 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical is by carbon atom and C 1-5Alkyl connects, and can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4Or C the substituent group of alkyl)) 2-5Alkyl R 108(R wherein 108For containing 1-2 hetero atom, one of them is N, and remaining can independently be selected from the 5-6-unit saturated heterocyclyl of O, S and N, and this heterocyclic radical is by nitrogen-atoms and C 2-5Alkyl connects, and can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
7) C 3-4Alkenyl R 109(R wherein 109Represent R as defined above 107Or R 108);
8) C 3-4Alkynyl R 109(R wherein 109Represent R as defined above 107Or R 108);
9) R 29(R wherein 29As above definition);
10) C 1-5Alkyl R 29(R wherein 29As above definition);
11) C 3-5Alkenyl R 29(R wherein 29As above definition);
12) C 3-5Alkynyl R 29(R wherein 29As above definition);
13) C 1-5Alkyl X 6R 29(X wherein 6And R 29As above definition);
14) C 4-5Alkenyl X 7R 29(X wherein 7And R 29As above definition);
15) C 4-5Alkynyl X 8R 29(X wherein 8And R 29As above definition);
16) C 2-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9And R 29As above definition);
17) C 2-5Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
21) C 2-5Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
22) C 1-3Alkyl R 54(C 1-3Alkyl) q(X 9) rR 55(X wherein 9, q, r, R 54And R 55As above definition);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from).
R advantageously 2Representation hydroxy, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, amino or R 5X 1-[X wherein 1As above definition, and R 5Be selected from one of following 22 groups of groups:
1) unsubstituted or be selected from the C that fluorine, chlorine and bromine replace by one or more 1-4Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino groups replace by one or more 2-5Alkyl;
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As preceding definition, and R 11Representative-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, C respectively does for oneself 1-4Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As above definition, R 16For being selected from C 1-3The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl and THP trtrahydropyranyl, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-2The substituent group of alkoxyl, and described cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl or THP trtrahydropyranyl can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl));
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28As preceding definition);
6) C 1-4Alkyl R 110(R wherein 110For being selected from following carbon atom and the C of passing through 1-4The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, imidazolidine-1-base, azelidinyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, and described group can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3Or C the substituent group of alkyl)) 2-4Alkyl R 111(R wherein 111For being selected from morpholino, thiomorpholine generation, azetidin-1-base, pyrrolidine-1-base, the group of piperazine-1-base and piperidino, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl));
7) C 3-4Alkenyl R 112(R wherein 112Represent R as defined above 110Or R 111);
8) C 3-4Alkynyl R 112(R wherein 112Represent R as defined above 110Or R 111);
9) R 29(R wherein 29As above definition);
10) C 1-4Alkyl R 29(R wherein 29As above definition);
11) 1-R 29Third-1-alkene-3-base or 1-R 29But-2-ene-4-base (R wherein 29As above definition, condition is to work as R 5Be 1-R 29When third-1-alkene-3-is basic, R 29Be connected with alkenyl through carbon atom);
12) 1-R 29Third-1-alkynes-3-base or 1-R 29Fourth-2-alkynes-4-base (R wherein 29As above definition, condition is to work as R 5Be 1-R 29When third-1-alkynes-3-is basic, R 29Be connected with alkynyl through carbon atom);
13) C 1-5Alkyl X 6R 29(X wherein 6And R 29As above definition);
14) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As above definition);
15) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As above definition);
16) C 2-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9And R 29As above definition);
17) C 2-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be selected from hydroxyl, fluorine, amino, C by one or more fluorine atoms or by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be selected from hydroxyl, fluorine, amino, C by one or more fluorine atoms or by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-4Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
21) C 2-4Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
22) C 1-3Alkyl R 54(C 1-3Alkyl) q(X 9) rR 55(X wherein 9, q, r, R 54And R 55As above definition);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from].
Preferred R 2Representation hydroxy, halogen, nitro, trifluoromethyl, C 1-3Alkyl, cyano group, amino or R 5X 1-[X wherein 1As above definition, R 5Be selected from one of following 20 groups of groups:
1) C unsubstituted or that replaced by one or more groups that are selected from fluorine, chlorine and bromine 1-3Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino groups replace by one or more 2-3Alkyl;
2) 2-(3,3-dimethyl urea groups) ethyl, 3-(3,3-dimethyl urea groups) propyl group, 2-(3-methyl urea groups) ethyl, 3-(3-methyl urea groups) propyl group, 2-urea groups ethyl, 3-urea groups propyl group, 2-(N, N-dimethylamino formyloxy) ethyl, 3-(N, N-dimethylamino formyloxy) propyl group, 2-(N-methylamino formyloxy) ethyl, 3-(N-methylamino formyloxy) propyl group, 2-(carbamoyloxy) ethyl, 3-(carbamoyloxy) propyl group or 2-(N-methyl-N-(butoxy carbonyl) amino) ethyl;
3) C 2-3Alkyl X 3R 16(X wherein 3As above definition, R 16For being selected from C 1-3The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperidyl, piperazinyl, azelidinyl, imidazolidinyl and THP trtrahydropyranyl, these groups are by carbon atom and X 3Connect, and described C 1-3Alkyl can have 1 or 2 and be selected from hydroxyl, halogen and C 1-2The substituent group of alkoxyl, described cyclopenta, cyclohexyl, pyrrolidinyl, piperidyl, piperazinyl, azelidinyl, imidazolidinyl or THP trtrahydropyranyl can have one and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-2Cyano group alkyl, C 1-2Alkyl, C 1-2Hydroxy alkyl, C 1-2Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-2Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation);
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-2Alkyl);
5) R 28(R wherein 26As above definition);
6) C 1-3Alkyl R 110(R wherein 110For being selected from following carbon atom and the C of passing through 1-3The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, imidazolidinyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-2Cyano group alkyl, C 1-2Alkyl, C 1-2Hydroxy alkyl, C 1-2Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-2Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation)) or C 2-3Alkyl R 111(R wherein 111For being selected from morpholino, thiomorpholine generation, azetidin-1-base, pyrrolidine-1-base, the group of piperazine-1-base and piperidino, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-2Chloro alkyl, C 1-2Alkyl, C 1-2Hydroxy alkyl, C 1-2Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-2Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation));
7) R 29(R wherein 29As above definition);
8) C 1-4Alkyl R 29(R wherein 29As above definition);
9) 1-R 29But-2-ene-4-base (R wherein 29As above definition);
10) 1-R 29Fourth-2-alkynes-4-base (R wherein 29As above definition);
11) C 1-3Alkyl X 6R 29(X wherein 6And R 29As above definition);
12) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As above definition);
13) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As above definition);
14) C 2-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9And R 29As above definition);
15) C 2-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
16) C 2-5Alkenyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
17) C 2-5Alkynyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N.N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
18) C 2-3Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition);
19) C 2-3Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
20) C 1-3Alkyl R 94(C 1-3Alkyl) q(X 9) rR 55(X wherein 9, q, r, R 54And R 55As above definition);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from].
More preferably R 2Representation hydroxy, C 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent methylidene, ethyl, benzyl; trifluoromethyl, 2,2; the 2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl; the 2-methoxy ethyl, 3-methoxy-propyl, 2-(methanesulfinyl) ethyl; 2-(mesyl) ethyl, 2-(ethyl sulfinyl) ethyl, 2-(ethylsulfonyl) ethyl; 2-(N, N-dimethylamino sulfonyl) ethyl, 2-(N-methylamino sulfonyl) ethyl; 2-amino-sulfonyl ethyl, 2-(methylamino) ethyl, 3-(methylamino) propyl group; 2-(ethylamino) ethyl, 3-(ethylamino) propyl group, 2-(N; the N-dimethylamino) ethyl; 3-(N, N-dimethylamino) propyl group, 2-(N; the N-diethylamino) ethyl; 3-(N, N-diethylamino) propyl group, 2-(N-methyl-N-sulfonyloxy methyl amino) ethyl; 3-(N-methyl-N-sulfonyloxy methyl amino) propyl group; 2-morpholino ethyl, 3-morpholino propyl group, 2-piperidino ethyl; 3-piperidino propyl group; 2-(methyl piperidine subbase) ethyl, 3-(methyl piperidine subbase) propyl group, 2-(ethyl piperidine subbase) ethyl; 3-(ethyl piperidine subbase) propyl group; 2-((2-methoxy ethyl) piperidino) ethyl, 3-((2-methoxy ethyl) piperidino) propyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyl; 3-((2-mesyl) ethyl piperidine subbase) propyl group; piperidines-3-ylmethyl, piperidin-4-yl methyl, 2-(piperidines-3-yl) ethyl; 2-(piperidin-4-yl) ethyl; 3-(piperidines-3-yl) propyl group, 3-(piperidin-4-yl) propyl group, 2-(piperidines-2-yl) ethyl; 3-(piperidines-2-yl) propyl group; (1-methyl piperidine-3-yl) methyl, (1-methyl piperidine-4-yl) methyl, (1-cyano methyl piperidines-3-yl) methyl; (1-cyano methyl piperidin-4-yl) methyl; 2-(methyl piperidine-3-yl) ethyl, 2-(methyl piperidine-4-yl) ethyl, 2-(1-cyano methyl piperidines-3-yl) ethyl; 2-(1-cyano methyl piperidin-4-yl) ethyl; 3-(methyl piperidine-3-yl) propyl group, 3-(methyl piperidine-4-yl) propyl group, 3-(1-cyano methyl piperidines-3-yl) propyl group; 3-(1-cyano methyl piperidin-4-yl) propyl group; 2-(ethyl piperidine-3-yl) ethyl, 2-(ethyl piperidine-4-yl) ethyl, 3-(ethyl piperidine-3-yl) propyl group; 3-(ethyl piperidine-4-yl) propyl group; ((2-methoxy ethyl) piperidines-3-yl) methyl, ((2-methoxy ethyl) piperidin-4-yl) methyl, 2-((2-methoxy ethyl) piperidines-3-yl) ethyl; 2-((2-methoxy ethyl) piperidin-4-yl) ethyl; 3-((2-methoxy ethyl) piperidines-3-yl) propyl group, 3-((2-methoxy ethyl) piperidin-4-yl) propyl group, (1-(2-mesyl ethyl) piperidines-3-yl) methyl; (1-(2-mesyl ethyl) piperidin-4-yl) methyl; 2-((2-mesyl ethyl) piperidines-3-yl) ethyl, 2-((2-mesyl ethyl) piperidin-4-yl) ethyl, 3-((2-mesyl ethyl) piperidines-3-yl) propyl group; 3-((2-mesyl ethyl) piperidin-4-yl) propyl group; 1-isopropyl piperidines-2-ylmethyl, 1-isopropyl piperidines-3-ylmethyl, 1-isopropyl piperidin-4-yl methyl; 2-(1-isopropyl piperidines-2-yl) ethyl; 2-(1-isopropyl piperidines-3-yl) ethyl, 2-(1-isopropyl piperidin-4-yl) ethyl, 3-(1-isopropyl piperidines-2-yl) propyl group; 3-(1-isopropyl piperidines-3-yl) propyl group; 3-(1-isopropyl piperidin-4-yl) propyl group, 2-(piperidin-4-yl oxygen base) ethyl, 3-(piperidin-4-yl oxygen base) propyl group; 2-(1-(cyano methyl) piperidin-4-yl oxygen base) ethyl; 3-(1-(cyano methyl) piperidin-4-yl oxygen base) propyl group, 2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyl, 3-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) propyl group; 2-(piperazine-1-yl) ethyl; 3-(piperazine-1-yl) propyl group, (pyrrolidine-2-yl) methyl, 2-(pyrrolidine-1-yl) ethyl; 3-(pyrrolidine-1-yl) propyl group; (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, 5 (R)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, 5 (S)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl; (1; 3-dioxolanes-2-yl) methyl, 2-(1,3-dioxolanes-2-yl) ethyl; 2-(2-methoxy ethyl amino) ethyl; 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl, 2-(2-hydroxyethyl amino) ethyl, 3-(2-methoxy ethyl amino) propyl group; 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group; 3-(2-hydroxyethyl amino) propyl group, 2-methylthiazol-4-ylmethyl, 2-acetylamino thiazole-4-ylmethyl; 1-Methylimidazole .-2-ylmethyl; 2-(imidazoles-1-yl) ethyl, 2-(glyoxal ethyline-1-yl) ethyl, 2-(2-ethyl imidazol(e)-1-yl) ethyl; 3-(glyoxal ethyline-1-yl) propyl group; 3-(2-ethyl imidazol(e)-1-yl) propyl group, 2-(1,2; the 3-triazol-1-yl) ethyl; 2-(1,2,3-triazoles-2-yl) ethyl; 2-(1; 2, the 4-triazol-1-yl) ethyl, 2-(1; 2; 4-triazole-4-yl) ethyl, 4-pyridylmethyl, 2-(4-pyridine radicals) ethyl; 3-(4-pyridine radicals) propyl group; 2-(4-pyridyloxy) ethyl, 2-(4-pyridinylamino) ethyl, 2-(4-oxo-1; 4-dihydro-1-pyridine radicals) ethyl; 2-(2-oxo-imidazolidine-1-yl) ethyl, 3-(2-oxo-imidazolidine-1-yl) propyl group, the 2-thiomorpholine is for ethyl; the 3-thiomorpholine is for propyl group; 2-(1,1 ,-dioxo tetrahydro-1,4-thiazine generation) ethyl; 3-(1; 1-dioxo thiomorpholine generation) propyl group, 2-(2-methoxy ethoxy) ethyl, 2-(4-methyl piperazine-1-yl) ethyl; 3-(4-methyl piperazine-1-yl) propyl group; 3-(methylsulfinyl) propyl group, 3-(mesyl) propyl group, 3-(ethyl sulfinyl) propyl group; 3-(ethylsulfonyl) propyl group; 2-(5-methyl isophthalic acid, 2,4-triazol-1-yl) ethyl; morpholino; 2-((N-(1-Methylimidazole .-4-base sulfonyl)-N-methyl) amino) ethyl, 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyl; 3-(4-morpholine oxide generation) propyl group; 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl, 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group, 2-(2-morpholino ethyoxyl) ethyl; 3-(2-morpholino ethyoxyl) propyl group; 2-(tetrahydropyran-4-base oxygen base) ethyl, 3-(tetrahydropyran-4-base oxygen base) propyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl; 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-base; 1-(2-pyrrolidinyl ethyl) piperidin-4-yl methyl, 1-(3-pyrrolidinyl propyl group) piperidin-4-yl methyl, 1-(2-piperidyl ethyl) piperidin-4-yl methyl; 1-(3-piperidyl propyl group) piperidin-4-yl methyl; 1-(2-morpholino ethyl) piperidin-4-yl methyl, 1-(3-morpholino propyl group) piperidin-4-yl methyl, 1-(the 2-thiomorpholine is for ethyl) piperidin-4-yl methyl; 1-(the 3-thiomorpholine is for propyl group) piperidin-4-yl methyl; 1-(2-azelidinyl ethyl) piperidin-4-yl methyl or 1-(3-azelidinyl propyl group) piperidin-4-yl methyl, 3-morpholino-2-hydroxypropyl, (2R)-3-morpholino-2-hydroxypropyl; (2S)-3-morpholino-2-hydroxypropyl; 3-piperidino-2-hydroxypropyl, (2R)-3-piperidino-2-hydroxypropyl, (2S)-3-piperidino-2-hydroxypropyl; 3-pyrrolidine-1-base-2-hydroxypropyl; (2R)-3-pyrrolidine-1-base-2-hydroxypropyl, (2S)-3-pyrrolidine-1-base-2-hydroxypropyl, 3-(1-methyl piperazine-4-yl)-2-hydroxypropyl; (2R)-3-(1-methyl piperazine-4-yl)-2-hydroxypropyl; (2S)-and 3-(1-methyl piperazine-4-yl)-2-hydroxypropyl, 3-(N, N-diethylamino)-2-hydroxypropyl; (2R)-3-(N; N-two-ethylamino)-the 2-hydroxypropyl, (2S)-3-(N, N-diethylamino)-2-hydroxypropyl; 3-(isopropyl amino)-2-hydroxypropyl; (2R)-3-(isopropyl amino)-2-hydroxypropyl, (2S)-3-(isopropyl amino)-2-hydroxypropyl, 3-(N; the N-diisopropylaminoethyl)-the 2-hydroxypropyl; (2R)-3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl or (2S)-3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl].
R particularly 2Represent C 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent ethyl, benzyl, trifluoromethyl; 2,2, the 2-trifluoroethyl; the 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxy ethyl; the 3-methoxy-propyl, 2-(methanesulfinyl) ethyl, 2-(mesyl) ethyl; 2-(ethyl sulfinyl) ethyl, 2-(ethylsulfonyl) ethyl, 2-(N; N-dimethylamino sulfonyl) ethyl, 2-(N-methylamino sulfonyl) ethyl, 2-amino-sulfonyl ethyl; 2-(methylamino) ethyl, 3-(methylamino) propyl group, 2-(ethylamino) ethyl; 3-(ethylamino) propyl group; 2-(N, N-dimethylamino) ethyl, 3-(N; the N-dimethylamino) propyl group; 2-(N, N-diethylamino) ethyl, 3-(N; the N-diethylamino) propyl group; 2-(N-methyl-N-sulfonyloxy methyl amino) ethyl, 3-(N-methyl-N-mesyl amino) propyl group, 2-morpholino ethyl; 3-morpholino propyl group; 2-piperidino ethyl, 3-piperidino propyl group, 2-(methyl piperidine subbase) ethyl; 3-(methyl piperidine subbase) propyl group; 2-(ethyl piperidine subbase) ethyl, 3-(ethyl piperidine subbase) propyl group, 2-((2-methoxy ethyl) piperidino) ethyl; 3-((2-methoxy ethyl) piperidino) propyl group; 2-((2-mesyl) ethyl piperidine subbase) ethyl, 3-((2-mesyl) ethyl piperidine subbase) propyl group, piperidines-3-ylmethyl; the piperidin-4-yl methyl; 2-(piperidines-3-yl) ethyl, 2-(piperidin-4-yl) ethyl, 3-(piperidines-3-yl) propyl group; 3-(piperidin-4-yl) propyl group; 2-(piperidines-2-yl) ethyl, 3-(piperidines-2-yl) propyl group, (1-methyl piperidine-3-yl) methyl; (1-methyl piperidine-4-yl) methyl; (1-cyano methyl piperidines-3-yl) methyl, (1-cyano methyl piperidin-4-yl) methyl, 2-(methyl piperidine-3-yl) ethyl; 2-(methyl piperidine-4-yl) ethyl; 2-(1-cyano methyl piperidines-3-yl) ethyl, 2-(1-cyano methyl piperidin-4-yl) ethyl, 3-(methyl piperidine-3-yl) propyl group; 3-(methyl piperidine-4-yl) propyl group; 3-(1-cyano methyl piperidines-3-yl) propyl group, 3-(1-cyano methyl piperidin-4-yl) propyl group, 2-(ethyl piperidine-3-yl) ethyl; 2-(ethyl piperidine-4-yl) ethyl; 3-(ethyl piperidine-3-yl) propyl group, 3-(ethyl piperidine-4-yl) propyl group, ((2-methoxy ethyl) piperidines-3-yl) methyl; ((2-methoxy ethyl) piperidin-4-yl) methyl; 2-((2-methoxy ethyl) piperidines-3-yl) ethyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyl, 3-((2-methoxy ethyl) piperidines-3-yl) propyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propyl group; (1-(2-mesyl ethyl) piperidines-3-yl) methyl, (1-(2-mesyl ethyl) piperidin-4-yl) methyl, 2-((2-mesyl ethyl) piperidines-3-yl) ethyl; 2-((2-mesyl ethyl) piperidin-4-yl) ethyl; 3-((2-mesyl ethyl) piperidines-3-yl) propyl group, 3-((2-mesyl ethyl) piperidin-4-yl) propyl group, 1-isopropyl piperidines-2-ylmethyl; 1-isopropyl piperidines-3-ylmethyl; 1-isopropyl piperidin-4-yl methyl, 2-(1-isopropyl piperidines-2-yl) ethyl, 2-(1-isopropyl piperidines-3-yl) ethyl; 2-(1-isopropyl piperidin-4-yl) ethyl; 3-(1-isopropyl piperidines-2-yl) propyl group, 3-(1-isopropyl piperidines-3-yl) propyl group, 3-(1-isopropyl piperidin-4-yl) propyl group; 2-(piperidin-4-yl oxygen base) ethyl; 3-(piperidin-4-yl oxygen base) propyl group, 2-(1-(cyano methyl) piperidin-4-yl oxygen base) ethyl, 3-(1-(cyano methyl) piperidin-4-yl oxygen base) propyl group; 2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyl; 3-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) propyl group, 2-(piperazine-1-yl) ethyl, 3-(piperazine-1-yl) propyl group; (pyrrolidine-2-yl) methyl; 2-(pyrrolidine-1-yl) ethyl, 3-(pyrrolidine-1-yl) propyl group, (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl; 5 (R)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl; 5 (S)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, (1,3-dioxolanes-2-yl) methyl; 2-(1; 3-dioxolanes-2-yl) ethyl, 2-(2-methoxy ethyl amino) ethyl, 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl; 2-(2-hydroxyethyl amino) ethyl; 3-(2-methoxy ethyl amino) propyl group, 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group, 3-(2-hydroxyethyl amino) propyl group; 2-methylthiazol-4-ylmethyl; 2-acetylamino thiazole-4-ylmethyl, 1-Methylimidazole .-2-ylmethyl, 2-(imidazoles-1-yl) ethyl; 2-(glyoxal ethyline-1-yl) ethyl; 2-(2-ethyl imidazol(e)-1-yl) ethyl, 3-(glyoxal ethyline-1-yl) propyl group, 3-(2-ethyl imidazol(e)-1-yl) propyl group; 2-(1; 2, the 3-triazol-1-yl) ethyl, 2-(1; 2; 3-triazole-2-yl) ethyl, 2-(1,2; the 4-triazol-1-yl) ethyl; 2-(1,2,4-triazole-4-yl) ethyl; the 4-pyridylmethyl; 2-(4-pyridine radicals) ethyl, 3-(4-pyridine radicals) propyl group, 2-(4-pyridyloxy) ethyl; 2-(4-pyridinylamino) ethyl; 2-(4-oxo-1,4-dihydro-1-pyridine radicals) ethyl, 2-(2-oxo-imidazolidine-1-yl) ethyl; 3-(2-oxo-imidazolidine-1-yl) propyl group; the 2-thiomorpholine is for ethyl, and the 3-thiomorpholine is for propyl group, and 2-(1; 1;-dioxo tetrahydro-1,4-thiazine generation) ethyl, 3-(1,1-dioxo thiomorpholine generation) propyl group; 2-(2-methoxy ethoxy) ethyl; 2-(4-methyl piperazine-1-yl) ethyl, 3-(4-methyl piperazine-1-yl) propyl group, 3-(methylsulfinyl) propyl group; 3-(mesyl) propyl group; 3-(ethyl sulfinyl) propyl group, 3-(ethylsulfonyl) propyl group, 2-(5-methyl isophthalic acid; 2; the 4-triazol-1-yl) ethyl, morpholino, 2-((N-(1-Methylimidazole .-4-base sulfonyl)-N-methyl) amino) ethyl; 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl; 2-((N-methyl-N-4-pyridine radicals) amino) ethyl, 3-(4-morpholine oxide generation) propyl group, 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl; 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group; 2-(2-morpholino ethyoxyl) ethyl, 3-(2-morpholino ethyoxyl) propyl group, 2-(tetrahydropyran-4-base oxygen base) ethyl; 3-(tetrahydropyran-4-base oxygen base) propyl group; 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl, 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-base, 1-(2-pyrrolidinyl ethyl) piperidin-4-yl methyl; 1-(3-pyrrolidinyl propyl group) piperidin-4-yl methyl; 1-(2-piperidyl ethyl) piperidin-4-yl methyl, 1-(3-piperidyl propyl group) piperidin-4-yl methyl, 1-(2-morpholino ethyl) piperidin-4-yl methyl; 1-(3-morpholino propyl group) piperidin-4-yl methyl; 1-(the 2-thiomorpholine is for ethyl) piperidin-4-yl methyl, 1-(the 3-thiomorpholine is for propyl group) piperidin-4-yl methyl, 1-(2-azelidinyl ethyl) piperidin-4-yl methyl or 1-(3-azelidinyl propyl group) piperidin-4-yl methyl; 3-morpholino-2-hydroxypropyl; (2R)-3-morpholino-2-hydroxypropyl, (2S)-3-morpholino-2-hydroxypropyl, 3-piperidino-2-hydroxypropyl; (2R)-3-piperidino-2-hydroxypropyl; (2S)-and 3-piperidino-2-hydroxypropyl, 3-pyrrolidine-1-base-2-hydroxypropyl, (2R)-3-pyrrolidine-1-base-2-hydroxypropyl; (2S)-3-pyrrolidine-1-base-2-hydroxypropyl; 3-(1-methyl piperazine-4-yl)-2-hydroxypropyl, (2R)-3-(1-methyl piperazine-4-yl)-2-hydroxypropyl, (2S)-3-(1-methyl piperazine-4-yl)-2-hydroxypropyl; 3-(N; the N-diethylamino)-the 2-hydroxypropyl, (2R)-3-(N, N-diethylamino)-2-hydroxypropyl; (2S)-3-(N; the N-diethylamino)-and the 2-hydroxypropyl, 3-(isopropyl amino)-2-hydroxypropyl, (2R)-3-(isopropyl amino)-2-hydroxypropyl; (2S)-3-(isopropyl amino)-2-hydroxypropyl; 3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl, (2R)-3-(N; the N-diisopropylaminoethyl)-2-hydroxypropyl or (2S)-3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl].
More particularly, R 2Represent C 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent ethyl, trifluoromethyl, 2; 2,2-trifluoroethyl, 2-hydroxyethyl; the 3-hydroxypropyl, 2-methoxy ethyl, 3-methoxy-propyl; 2-(methanesulfinyl) ethyl, 2-(mesyl) ethyl, 2-(ethyl sulfinyl) ethyl; 2-(ethylsulfonyl) ethyl, 2-(N, N-dimethylamino sulfonyl) ethyl; 2-(N-methylamino sulfonyl) ethyl, 2-amino-sulfonyl ethyl, 2-(methylamino) ethyl; 3-(methylamino) propyl group, 2-(ethylamino) ethyl, 3-(ethylamino) propyl group; 2-(N, N-dimethylamino) ethyl, 3-(N; the N-dimethylamino) propyl group, 2-(N, N-diethylamino) ethyl; 3-(N, N-diethylamino) propyl group, 2-(N-methyl-N-mesyl amino) ethyl; 3-(N-methyl-N-mesyl amino) propyl group, 2-morpholino ethyl, 3-morpholino propyl group; 2-piperidino ethyl, 3-piperidino propyl group, 2-(methyl piperidine subbase) ethyl; 3-(methyl piperidine subbase) propyl group, 2-(ethyl piperidine subbase) ethyl, 3-(ethyl piperidine subbase) propyl group; 2-((2-methoxy ethyl) piperidino) ethyl, 3-((2-methoxy ethyl) piperidino) propyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyl; 3-((2-mesyl) ethyl piperidine subbase) propyl group, piperidines-3-ylmethyl, piperidin-4-yl methyl; 2-(piperidines-3-yl) ethyl, 2-(piperidin-4-yl) ethyl, 3-(piperidines-3-yl) propyl group; 3-(piperidin-4-yl) propyl group, 2-(piperidines-2-yl) ethyl, 3-(piperidines-2-yl) propyl group; (1-methyl piperidine-3-yl) methyl, (1-methyl piperidine-4-yl) methyl, (1-cyano methyl piperidines-3-yl) methyl; (1-cyano methyl piperidin-4-yl) methyl, 2-(methyl piperidine-3-yl) ethyl, 2-(methyl piperidine-4-yl) ethyl; 2-(1-cyano methyl piperidines-3-yl) ethyl, 2-(1-cyano methyl piperidin-4-yl) ethyl, 3-(methyl piperidine-3-yl) propyl group; 3-(methyl piperidine-4-yl) propyl group, 3-(1-cyano methyl piperidines-3-yl) propyl group, 3-(1-cyano methyl piperidin-4-yl) propyl group; 2-(ethyl piperidine-3-yl) ethyl, 2-(ethyl piperidine-4-yl) ethyl, 3-(ethyl piperidine-3-yl) propyl group; 3-(ethyl piperidine-4-yl) propyl group, ((2-methoxy ethyl) piperidines-3-yl) methyl, ((2-methoxy ethyl) piperidin-4-yl) methyl; 2-((2-methoxy ethyl) piperidines-3-yl) ethyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyl, 3-((2-methoxy ethyl) piperidines-3-yl) propyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propyl group, (1-(2-mesyl ethyl) piperidines-3-yl) methyl, (1-(2-mesyl ethyl) piperidin-4-yl) methyl; 2-((2-mesyl ethyl) piperidines-3-yl) ethyl, 2-((2-mesyl ethyl) piperidin-4-yl) ethyl, 3-((2-mesyl ethyl) piperidines-3-yl) propyl group; 3-((2-mesyl ethyl) piperidin-4-yl) propyl group, 1-isopropyl piperidines-2-ylmethyl, 1-isopropyl piperidines-3-ylmethyl; 1-isopropyl piperidin-4-yl methyl, 2-(1-isopropyl piperidines-2-yl) ethyl, 2-(1-isopropyl piperidines-3-yl) ethyl; 2-(1-isopropyl piperidin-4-yl) ethyl, 3-(1-isopropyl piperidines-2-yl) propyl group, 3-(1-isopropyl piperidines-3-yl) propyl group; 3-(1-isopropyl piperidin-4-yl) propyl group, 2-(piperidin-4-yl oxygen base) ethyl, 3-(piperidin-4-yl oxygen base) propyl group; 2-(1-(cyano methyl) piperidin-4-yl oxygen base) ethyl, 3-(1-(cyano methyl) piperidin-4-yl oxygen base) propyl group, 2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyl; 3-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) propyl group, 2-(piperazine-1-yl) ethyl, 3-(piperazine-1-yl) propyl group; (pyrrolidine-2-yl) methyl, 2-(pyrrolidine-1-yl) ethyl, 3-(pyrrolidine-1-yl) propyl group; (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, 5 (R)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, 5 (S)-2-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl; (1,3-dioxolanes-2-yl) methyl, 2-(1; 3-dioxolanes-2-yl) ethyl, 2-(2-methoxy ethyl amino) ethyl, 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl; 2-(2-hydroxyethyl amino) ethyl, 3-(2-methoxy ethyl amino) propyl group, 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group; 3-(2-hydroxyethyl amino) propyl group, 2-(1,2; the 3-triazol-1-yl) ethyl, 2-(1,2; 3-triazole-2-yl) ethyl, 2-(1,2; the 4-triazol-1-yl) ethyl, 2-(1,2; 4-triazole-4-yl) ethyl, 4-pyridylmethyl, 2-(4-pyridine radicals) ethyl; 3-(4-pyridine radicals) propyl group, 2-(4-pyridyloxy) ethyl, 2-(4-pyridinylamino) ethyl; 2-(4-oxo-1,4-dihydro-1-pyridine radicals) ethyl, 2-(2-oxo-imidazolidine-1-yl) ethyl; 3-(2-oxo-imidazolidine-1-yl) propyl group, the 2-thiomorpholine is for ethyl, and the 3-thiomorpholine is for propyl group; 2-(1,1 ,-dioxo tetrahydro-1,4-thiazine generation) ethyl; 3-(1,1-dioxo thiomorpholine generation) propyl group, 2-(2-methoxy ethoxy) ethyl; 2-(4-methyl piperazine-1-yl) ethyl, 3-(4-methyl piperazine-1-yl) propyl group, 3-(methylsulfinyl) propyl group; 3-(mesyl) propyl group, 3-(ethyl sulfinyl) propyl group, 3-(ethylsulfonyl) propyl group; 2-(5-methyl isophthalic acid, 2,4-triazol-1-yl) ethyl; morpholino, 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyl; 3-(4-morpholine oxide generation) propyl group, 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl, 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group; 2-(2-morpholino ethyoxyl) ethyl, 3-(2-morpholino ethyoxyl) propyl group, 2-(tetrahydropyran-4-base oxygen base) ethyl; 3-(tetrahydropyran-4-base oxygen base) propyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl, 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-base; 1-(2-pyrrolidinyl ethyl) piperidin-4-yl methyl, 1-(3-pyrrolidinyl propyl group) piperidin-4-yl methyl, 1-(2-piperidyl ethyl) piperidin-4-yl methyl; 1-(3-piperidyl propyl group) piperidin-4-yl methyl, 1-(2-morpholino ethyl) piperidin-4-yl methyl, 1-(3-morpholino propyl group) piperidin-4-yl methyl; 1-(the 2-thiomorpholine is for ethyl) piperidin-4-yl methyl, 1-(the 3-thiomorpholine is for propyl group) piperidin-4-yl methyl, 1-(2-azelidinyl ethyl) piperidin-4-yl methyl or 1-(3-azelidinyl propyl group) piperidin-4-yl methyl; 3-morpholino-2-hydroxypropyl; (2R)-3-morpholino-2-hydroxypropyl, (2S)-3-morpholino-2-hydroxypropyl, 3-piperidino-2-hydroxypropyl; (2R)-3-piperidino-2-hydroxypropyl; (2S)-and 3-piperidino-2-hydroxypropyl, 3-pyrrolidine-1-base-2-hydroxypropyl, (2R)-3-pyrrolidine-1-base-2-hydroxypropyl; (2S)-3-pyrrolidine-1-base-2-hydroxypropyl; 3-(1-methyl piperazine-4-yl)-2-hydroxypropyl, (2R)-3-(1-methyl piperazine-4-yl)-2-hydroxypropyl, (2S)-3-(1-methyl piperazine-4-yl)-2-hydroxypropyl; 3-(N; the N-diethylamino)-the 2-hydroxypropyl, (2R)-3-(N, N-diethylamino)-2-hydroxypropyl; (2S)-3-(N; the N-diethylamino)-and the 2-hydroxypropyl, 3-(isopropyl amino)-2-hydroxypropyl, (2R)-3-(isopropyl amino)-2-hydroxypropyl; (2S)-3-(isopropyl amino)-2-hydroxypropyl; 3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl, (2R)-3-(N; the N-diisopropylaminoethyl)-2-hydroxypropyl or (2S)-3-(N, N-diisopropylaminoethyl)-2-hydroxypropyl].
On the other hand, R 2Represent ethyoxyl, trifluoromethoxy, 2; 2,2-trifluoro ethoxy, 2-hydroxyl-oxethyl; 3-hydroxyl propoxyl group, 2-methoxy ethoxy, 3-methoxy propoxy; 2-(methanesulfinyl) ethyoxyl, 2-(mesyl) ethyoxyl, 2-(ethyl sulfinyl) ethyoxyl; 2-(ethylsulfonyl) ethyoxyl, 2-(N, N-dimethylamino sulfonyl) ethyoxyl; 2-(N-methylamino sulfonyl) ethyoxyl, 2-aminosulfonyl base oxethyl, 2-(methylamino) ethyoxyl; 3-(methylamino) propoxyl group, 2-(ethylamino) ethyoxyl, 3-(ethylamino) propoxyl group; 2-(N, N-dimethylamino) ethyoxyl, 3-(N; the N-dimethylamino) propoxyl group, 2-(N, N-diethylamino) ethyoxyl; 3-(N, N-diethylamino) propoxyl group, 2-(N-methyl-N-mesyl amino) ethyoxyl; 3-(N-methyl-N-mesyl amino) propoxyl group, 2-morpholino ethyoxyl, 3-morpholino propoxyl group; 2-piperidino ethyoxyl, 3-piperidino propoxyl group, 2-(methyl piperidine subbase) ethyoxyl; 3-(methyl piperidine subbase) propoxyl group, 2-(ethyl piperidine subbase) ethyoxyl, 3-(ethyl piperidine subbase) propoxyl group; 2-((2-methoxy ethyl) piperidino) ethyoxyl, 3-((2-methoxy ethyl) piperidino) propoxyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyoxyl; 3-((2-mesyl) ethyl piperidine subbase) propoxyl group, piperidines-3-ylmethoxy, piperidin-4-yl methoxyl group; 2-(piperidines-3-yl) ethyoxyl, 2-(piperidin-4-yl) ethyoxyl, 3-(piperidines-3-yl) propoxyl group; 3-(piperidin-4-yl) propoxyl group, 2-(piperidines-2-yl) ethyoxyl, 3-(piperidines-2-yl) propoxyl group; (1-methyl piperidine-3-yl) methoxyl group, (1-methyl piperidine-4-yl) methoxyl group, (1-cyano methyl piperidines-3-yl) methoxyl group; (1-cyano methyl piperidin-4-yl) methoxyl group, 2-(methyl piperidine-3-yl) ethyoxyl, 2-(methyl piperidine-4-yl) ethyoxyl; 2-(1-cyano methyl piperidines-3-yl) ethyoxyl, 2-(1-cyano methyl piperidin-4-yl) ethyoxyl, 3-(methyl piperidine-3-yl) propoxyl group; 3-(methyl piperidine-4-yl) propoxyl group, 3-(1-cyano methyl piperidines-3-yl) propoxyl group, 3-(1-cyano methyl piperidin-4-yl) propoxyl group; 2-(ethyl piperidine-3-yl) ethyoxyl, 2-(ethyl piperidine-4-yl) ethyoxyl, 3-(ethyl piperidine-3-yl) propoxyl group; 3-(ethyl piperidine-4-yl) propoxyl group, ((2-methoxy ethyl) piperidines-3-yl) methoxyl group, ((2-methoxy ethyl) piperidin-4-yl) methoxyl group; 2-((2-methoxy ethyl) piperidines-3-yl) ethyoxyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyoxyl, 3-((2-methoxy ethyl) piperidines-3-yl) propoxyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propoxyl group, (1-(2-mesyl ethyl) piperidines-3-yl) methoxyl group, (1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group; 2-((2-mesyl ethyl) piperidines-3-yl) ethyoxyl, 2-((2-mesyl ethyl) piperidin-4-yl) ethyoxyl, 3-((2-mesyl ethyl) piperidines-3-yl) propoxyl group; 3-((2-mesyl ethyl) piperidin-4-yl) propoxyl group, 1-isopropyl piperidines-2-ylmethoxy, 1-isopropyl piperidines-3-ylmethoxy; 1-isopropyl piperidin-4-yl methoxyl group, 2-(1-isopropyl piperidines-2-yl) ethyoxyl, 2-(1-isopropyl piperidines-3-yl) ethyoxyl; 2-(1-isopropyl piperidin-4-yl) ethyoxyl, 3-(1-isopropyl piperidines-2-yl) propoxyl group, 3-(1-isopropyl piperidines-3-yl) propoxyl group; 3-(1-isopropyl piperidin-4-yl) propoxyl group, 2-(piperidin-4-yl oxygen base) ethyoxyl, 3-(piperidin-4-yl oxygen base) propoxyl group; 2-(1-(cyano methyl) piperidin-4-yl oxygen base) ethyoxyl, 3-(1-(cyano methyl) piperidin-4-yl oxygen base) propoxyl group, 2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyoxyl; 3-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) propoxyl group, 2-(piperazine-1-yl) ethyoxyl, 3-(piperazine-1-yl) propoxyl group; (pyrrolidine-2-yl) methoxyl group, 2-(pyrrolidine-1-yl) ethyoxyl, 3-(pyrrolidine-1-yl) propoxyl group; (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methoxyl group, 5 (R)-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methoxyl group, 5 (S)-2-(2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methoxyl group; (1,3-dioxolanes-2-yl) methoxyl group, 2-(1; 3-dioxolanes-2-yl) ethyoxyl, 2-(2-methoxy ethyl amino) ethyoxyl, 2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl; 2-(2-hydroxyethyl amino) ethyoxyl, 3-(2-methoxy ethyl amino) propoxyl group, 3-(N-(2-methoxy ethyl)-N-methylamino) propoxyl group; 3-(2-hydroxyethyl amino) propoxyl group, 2-(1,2; the 3-triazol-1-yl) ethyoxyl, 2-(1,2; 3-triazole-2-yl) ethyoxyl, 2-(1,2; the 4-triazol-1-yl) ethyoxyl, 2-(1,2; 4-triazole-4-yl) ethyoxyl, 4-pyridine radicals methoxyl group, 2-(4-pyridine radicals) ethyoxyl; 3-(4-pyridine radicals) propoxyl group, 2-(4-pyridyloxy) ethyoxyl, 2-(4-pyridinylamino) ethyoxyl; 2-(4-oxo-1,4-dihydro-1-pyridine radicals) ethyoxyl, 2-(2-oxo-imidazolidine-1-yl) ethyoxyl; 3-(2-oxo-imidazolidine-1-yl) propoxyl group, the 2-thiomorpholine is for ethyoxyl, and the 3-thiomorpholine is for propoxyl group; 2-(1,1 ,-dioxo tetrahydro-1,4-thiazine generation) ethyoxyl; 3-(1,1-dioxo thiomorpholine generation) propoxyl group, 2-(2-methoxy ethoxy) ethyoxyl; 2-(4-methyl piperazine-1-yl) ethyoxyl, 3-(4-methyl piperazine-1-yl) propoxyl group, 3-(methylsulfinyl) propoxyl group; 3-(mesyl) propoxyl group, 3-(ethyl sulfinyl) propoxyl group, 3-(ethylsulfonyl) propoxyl group; 2-(5-methyl isophthalic acid, 2,4-triazol-1-yl) ethyoxyl; 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyoxyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyoxyl, 3-(4-morpholine oxide generation) propoxyl group; 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl, 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propoxyl group, 2-(2-morpholino ethyoxyl) ethyoxyl; 3-(2-morpholino ethyoxyl) propoxyl group, 2-(tetrahydropyran-4-base oxygen base) ethyoxyl, 3-(tetrahydropyran-4-base oxygen base) propoxyl group; 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl, 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-base oxygen base, 1-(2-pyrrolidinyl ethyl) piperidin-4-yl methoxyl group; 1-(3-pyrrolidinyl propyl group) piperidin-4-yl methoxyl group, 1-(2-piperidyl ethyl) piperidin-4-yl methoxyl group, 1-(3-piperidyl propyl group) piperidin-4-yl methoxyl group; 1-(2-morpholino ethyl) piperidin-4-yl methoxyl group, 1-(3-morpholino propyl group) piperidin-4-yl methoxyl group, 1-(the 2-thiomorpholine is for ethyl) piperidin-4-yl methoxyl group; 1-(the 3-thiomorpholine is for propyl group) piperidin-4-yl methoxyl group; 1-(2-azelidinyl ethyl) piperidin-4-yl methoxyl group or 1-(3-azelidinyl propyl group) piperidin-4-yl methoxyl group, 3-morpholino-2-hydroxyl propoxyl group, (2R)-3-morpholino-2-hydroxyl propoxyl group; (2S)-3-morpholino-2-hydroxyl propoxyl group; 3-piperidino-2-hydroxyl propoxyl group, (2R)-3-piperidino-2-hydroxyl propoxyl group, (2S)-3-piperidino-2-hydroxyl propoxyl group; 3-pyrrolidine-1-base-2-hydroxyl propoxyl group; (2R)-3-pyrrolidine-1-base-2-hydroxyl propoxyl group, (2S)-3-pyrrolidine-1-base-2-hydroxyl propoxyl group, 3-(1-methyl piperazine-4-yl)-2-hydroxyl propoxyl group; (2R)-3-(1-methyl piperazine-4-yl)-2-hydroxyl propoxyl group; (2S)-and 3-(1-methyl piperazine-4-yl)-2-hydroxyl propoxyl group, 3-(N, N-diethylamino)-2-hydroxyl propoxyl group; (2R)-3-(N; the N-diethylamino)-2-hydroxyl propoxyl group, (2S)-3-(N, N-diethylamino)-2-hydroxyl propoxyl group; 3-(isopropyl amino)-2-hydroxyl propoxyl group; (2R)-3-(isopropyl amino)-2-hydroxyl propoxyl group, (2S)-3-(isopropyl amino)-2-hydroxyl propoxyl group, 3-(N; the N-diisopropylaminoethyl)-2-hydroxyl propoxyl group; (2R)-3-(N, N-diisopropylaminoethyl)-2-hydroxyl propoxyl group or (2S)-3-(N, N-diisopropylaminoethyl)-2-hydroxyl propoxyl group.
According to a further aspect in the invention, R 2Suitable representation hydroxy, halogen, nitro, trifluoromethyl, C 1-3Alkyl, cyano group, amino or R 5X 1-[X wherein 1As above definition, and R 5Be selected from one of following 21 groups of groups:
1) C unsubstituted or that replaced by one or more fluorine atoms 1-5Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino groups replace by one or more 2-6Alkyl
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As preceding definition, and R 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, C respectively does for oneself 1-2Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As above definition, R 16Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-3The substituent group of alkoxyl, and described cyclic group can have 1 or 2 and is selected from oxo, hydroxyl, halogen, C 1-4Alkyl, C 1-4Hydroxy alkyl and C 1-4The substituent group of alkoxyl);
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-3Alkyl);
5) C 1-5Alkyl R 129(R wherein 129For containing 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical is by carbon atom and C 1-5Alkyl connects, and can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl and C 1-4Alkyl sulphonyl C 1-4Alkyl) or C 2-5Alkyl R 130(R wherein 130For containing 1-2 hetero atom, one of them is N, and remaining independently is selected from the 5-6-unit saturated heterocyclyl of O, S and N, and this heterocyclic radical is by nitrogen-atoms and C 2-5Alkyl connects, and can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl and C 1-4Alkyl sulphonyl C 1-4Alkyl);
6) C 3-4Alkenyl R 131(R wherein 131Represent R as defined above 129Or R 130);
7) C 3-4Alkynyl R 131(R wherein 131Represent R as defined above 129Or R 130);
8) R 29(R wherein 29As above definition);
9) C 1-5Alkyl R 29(R wherein 29As above definition);
10) C 3-5Alkenyl R 29(R wherein 29As above definition);
11) C 3-5Alkynyl R 29(R wherein 29As above definition);
12) C 1-5Alkyl X 6R 29(X wherein 6And R 29As above definition);
13) C 4-5Alkenyl X 7R 29(X wherein 7And R 29As above definition);
14) C 4-5Alkynyl X 8R 29(X wherein 8And R 29As above definition);
15) C 2-3Alkyl X 9C 1-2Alkyl R 29(X wherein 9And R 29As above definition);
16) R 28(R wherein 28As above definition);
17) C 2-3Alkyl X 9C 1-2Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
21) C 2-5Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition)].
According to a further aspect in the invention, R advantageously 2Representation hydroxy, halogen, nitro, trifluoromethyl, C 1-3Alkyl, cyano group, amino or R 5X 1-[X wherein 1As above definition, and R 5Be selected from one of following 21 groups of groups:
1) unsubstituted or be selected from the C that fluorine atom replaces by one or more 1-4Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino group replace by one or two 2-4Alkyl;
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As preceding definition, and R 11Representative-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, C respectively does for oneself 1-2Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As above definition, R 16For being selected from C 1-3The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperidyl and THP trtrahydropyranyl, these groups are by carbon atom and X 3Connect, and wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-2The substituent group of alkoxyl, described cyclopenta, cyclohexyl, pyrrolidinyl or piperidyl can have 1 and be selected from oxo, hydroxyl, halogen, C 1-2Alkyl, C 1-2Hydroxy alkyl and C 1-2The substituent group of alkoxyl);
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-3Alkyl);
5) C 1-4Alkyl R 132(R wherein 132For being selected from following carbon atom and the C of passing through 1-4The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, and described group can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl) or C 2-4Alkyl R 133(R wherein 133For being selected from morpholino, thiomorpholine generation, pyrrolidine-1-base, the group of piperazine-1-base and piperidino, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl);
6) C 3-4Alkenyl R 134(R wherein 134Represent R as defined above 132Or R 133);
7) C 3-4Alkynyl R 134(R wherein 134Represent R as defined above 132Or R 133);
8) R 29(R wherein 29As above definition);
9) C 1-4Alkyl R 29(R wherein 29As above definition);
10) 1-R 29Third-1-alkene-3-base or 1-R 29But-2-ene-4-base (R wherein 29As above definition, condition is to work as R 5Be 1-R 29When third-1-alkene-3-is basic, R 29Be connected with alkenyl through carbon atom);
11) 1-R 29Third-1-alkynes-3-base or 1-R 29Fourth-2-alkynes-4-base (R wherein 29As above definition, condition is to work as R 5Be 1-R 29When third-1-alkynes-3-is basic, R 29Be connected with alkynyl through carbon atom);
12) C 1-5Alkyl X 6R 29(X wherein 6And R 29As above definition);
13) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As above definition);
14) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As above definition);
15) C 2-3Alkyl X 9C 1-2Alkyl R 29(X wherein 9And R 29As above definition);
16) R 28(R wherein 28As preceding definition);
17) C 2-3Alkyl X 9C 1-2Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be selected from hydroxyl, amino, C by one or more fluorine atoms or by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-4Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
21) C 2-4Alkynyl X 9C 1-2Alkyl R 28(X wherein 9And R 28As above definition)].
According to a further aspect in the invention, preferred R 2Representation hydroxy, halogen, nitro, trifluoromethyl, C 1-3Alkyl, cyano group, amino or R 5X 1-[X wherein 1As above definition, R 5Be selected from one of following 19 groups of groups:
1) unsubstituted or be selected from the C that fluorine atom replaces by one or more 1-3Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino group replace by one or two 2-3Alkyl;
2) 2-(3,3-dimethyl urea groups) ethyl, 3-(3,3-dimethyl urea groups) propyl group, 2-(3-methyl urea groups) ethyl, 3-(3-methyl urea groups) propyl group, 2-urea groups ethyl, 3-urea groups propyl group, 2-(N, N-dimethylamino formyloxy) ethyl, 3-(N, N-dimethylamino formyloxy) propyl group, 2-(N-methylamino formyloxy) ethyl, 3-(N-methylamino formyloxy) propyl group, 2-(carbamoyloxy) ethyl, 3-(carbamoyloxy) propyl group;
3) C 2-3Alkyl X 3R 16(X wherein 3As above definition, R 16For being selected from C 1-2The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperidyl and THP trtrahydropyranyl, these groups are by carbon atom and X 3Connect, and described C 1-2Alkyl can have 1 or 2 and be selected from hydroxyl, halogen and C 1-2The substituent group of alkoxyl, described cyclopenta, cyclohexyl, pyrrolidinyl or piperidyl can have one and be selected from oxo, hydroxyl, halogen, C 1-2Alkyl, C 1-2Hydroxy alkyl and C 1-2The substituent group of alkoxyl);
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As preceding definition, and R 22Represent hydrogen or C 1-2Alkyl);
5) C 1-2Alkyl R 132(R wherein 132For being selected from following carbon atom and the C of passing through 1-2The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, these groups can have 1 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl) or C 2-3Alkyl R 133(R wherein 133For being selected from the group of morpholino, thiomorpholine generation, piperidino, piperazine-1-base and pyrrolidine-1-base, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl and C 1-2Alkyl sulphonyl C 1-3Alkyl);
6) R 29(R wherein 29As above definition);
7) C 1-4Alkyl R 29(R wherein 29As above definition);
8) 1-R 29But-2-ene-4-base (R wherein 29As above definition);
9) 1-R 29Fourth-2-alkynes-4-base (R wherein 29As above definition);
10) C 1-5Alkyl X 6R 29(X wherein 6And R 29As above definition);
11) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As above definition);
12) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As above definition);
13) ethyl X 9Methyl R 29(X wherein 9And R 29As above definition);
14) R 28(R wherein 28As above definition);
15) ethyl X 9C 1-2Alkyl R 28(X wherein 9And R 28As above definition);
16) C 2-5Alkenyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
17) C 2-5Alkynyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
18) C 2-3Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition); With
19) C 2-3Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As above definition)].
According to a further aspect in the invention, more preferably R 2Representation hydroxy, C 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent methylidene, ethyl, benzyl; trifluoromethyl, 2,2; the 2-trifluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl; the 2-methoxy ethyl, 3-methoxy-propyl, 2-(methanesulfinyl) ethyl; 2-(mesyl) ethyl, 2-(N, N-dimethylamino sulfonyl) ethyl; 2-(N-methylamino sulfonyl) ethyl, 2-amino-sulfonyl ethyl, 2-(N; the N-dimethylamino) ethyl; 3-(N, N-dimethylamino) propyl group, 2-morpholino ethyl; 3-morpholino propyl group; 2-piperidino ethyl, 3-piperidino propyl group, 2-(methyl piperidine subbase) ethyl; 3-(methyl piperidine subbase) propyl group; 2-(ethyl piperidine subbase) ethyl, 3-(ethyl piperidine subbase) propyl group, 2-((2-methoxy ethyl) piperidino) ethyl; 3-((2-methoxy ethyl) piperidino) propyl group; 2-((2-mesyl) ethyl piperidine subbase) ethyl, 3-((2-mesyl) ethyl piperidine subbase) propyl group, piperidines-3-ylmethyl; the piperidin-4-yl methyl; 2-(piperidines-3-yl) ethyl, 2-(piperidin-4-yl) ethyl, 3-(piperidines-3-yl) propyl group; 3-(piperidin-4-yl) propyl group; (1-methyl piperidine-3-yl) methyl, (1-methyl piperidine-4-yl) methyl, (1-cyano methyl piperidines-3-yl) methyl; (1-cyano methyl piperidin-4-yl) methyl; 2-(methyl piperidine-3-yl) ethyl, 2-(methyl piperidine-4-yl) ethyl, 2-(1-cyano methyl piperidines-3-yl) ethyl; 2-(1-cyano methyl piperidin-4-yl) ethyl; 3-(methyl piperidine-3-yl) propyl group, 3-(methyl piperidine-4-yl) propyl group, 3-(1-cyano methyl piperidines-3-yl) propyl group; 3-(1-cyano methyl piperidin-4-yl) propyl group; 2-(ethyl piperidine-3-yl) ethyl, 2-(ethyl piperidine-4-yl) ethyl, 3-(ethyl piperidine-3-yl) propyl group; 3-(ethyl piperidine-4-yl) propyl group; ((2-methoxy ethyl) piperidines-3-yl) methyl, ((2-methoxy ethyl) piperidin-4-yl) methyl, 2-((2-methoxy ethyl) piperidines-3-yl) ethyl; 2-((2-methoxy ethyl) piperidin-4-yl) ethyl; 3-((2-methoxy ethyl) piperidines-3-yl) propyl group, 3-((2-methoxy ethyl) piperidin-4-yl) propyl group, (1-(2-mesyl ethyl) piperidines-3-yl) methyl; (1-(2-mesyl ethyl) piperidin-4-yl) methyl; 2-((2-mesyl ethyl) piperidines-3-yl) ethyl, 2-((2-mesyl ethyl) piperidin-4-yl) ethyl, 3-((2-mesyl ethyl) piperidines-3-yl) propyl group; 3-((2-mesyl ethyl) piperidin-4-yl) propyl group; 1-isopropyl piperidines-2-ylmethyl, 1-isopropyl piperidines-3-ylmethyl, 1-isopropyl piperidin-4-yl methyl; 2-(1-isopropyl piperidines-2-yl) ethyl; 2-(1-isopropyl piperidines-3-yl) ethyl, 2-(1-isopropyl piperidin-4-yl) ethyl, 3-(1-isopropyl piperidines-2-yl) propyl group; 3-(1-isopropyl piperidines-3-yl) propyl group; 3-(1-isopropyl piperidin-4-yl) propyl group, 2-(piperazine-1-yl) ethyl, 3-(piperazine-1-yl) propyl group; (pyrrolidine-2-yl) methyl; 2-(pyrrolidine-1-yl) ethyl, 3-(pyrrolidine-1-yl) propyl group, (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl; (1; 3-dioxolanes-2-yl) methyl, 2-(1,3-dioxolanes-2-yl) ethyl; 2-(2-methoxy ethyl amino) ethyl; 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl, 2-(2-hydroxyethyl amino) ethyl, 3-(2-methoxy ethyl amino) propyl group; 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group; 3-(2-hydroxyethyl amino) propyl group, 2-methylthiazol-4-ylmethyl, 2-acetylamino thiazole-4-ylmethyl; 1-Methylimidazole .-2-ylmethyl; 2-(imidazoles-1-yl) ethyl, 2-(glyoxal ethyline-1-yl) ethyl, 2-(2-ethyl imidazol(e)-1-yl) ethyl; 3-(glyoxal ethyline-1-yl) propyl group; 3-(2-ethyl imidazol(e)-1-yl) propyl group, 2-(1,2; the 3-triazol-1-yl) ethyl; 2-(1,2,3-triazoles-2-yl) ethyl; 2-(1; 2, the 4-triazol-1-yl) ethyl, 2-(1; 2; 4-triazole-4-yl) ethyl, 4-pyridylmethyl, 2-(4-pyridine radicals) ethyl; 3-(4-pyridine radicals) propyl group; 2-(4-pyridyloxy) ethyl, 2-(4-pyridinylamino) ethyl, 2-(4-oxo-1; 4-dihydro-1-pyridine radicals) ethyl; the 2-thiomorpholine is for ethyl, and the 3-thiomorpholine is for propyl group, and 2-(1; 1;-dioxo tetrahydro-1,4-thiazine generation) ethyl, 3-(1,1-dioxo thiomorpholine generation) propyl group; 2-(2-methoxy ethoxy) ethyl; 2-(4-methyl piperazine-1-yl) ethyl, 3-(4-methyl piperazine-1-yl) propyl group, 3-(methylsulfinyl) propyl group; 3-(mesyl) propyl group; 2-(5-methyl isophthalic acid, 2,4-triazol-1-yl) ethyl; morpholino; 2-((N-(1-Methylimidazole .-4-base sulfonyl)-N-methyl) amino) ethyl, 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyl; 3-(4-morpholine oxide generation) propyl group; 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl, 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group, 2-(2-morpholino ethyoxyl) ethyl; 3-(2-morpholino ethyoxyl) propyl group; 2-(tetrahydropyran-4-base oxygen base) ethyl, 3-(tetrahydropyran-4-base oxygen base) propyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl or 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-yl].
According to a further aspect in the invention, R 2C particularly 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent ethyl, benzyl, trifluoromethyl; 2,2, the 2-trifluoroethyl; the 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxy ethyl; the 3-methoxy-propyl, 2-(methanesulfinyl) ethyl, 2-(mesyl) ethyl; 2-(N, N-dimethylamino sulfonyl) ethyl, 2-(N-methylamino sulfonyl) ethyl; 2-amino-sulfonyl ethyl; 2-(N, N-dimethylamino) ethyl, 3-(N; the N-dimethylamino) propyl group; 2-morpholino ethyl, 3-morpholino propyl group, 2-piperidino ethyl; 3-piperidino propyl group; 2-(methyl piperidine subbase) ethyl, 3-(methyl piperidine subbase) propyl group, 2-(ethyl piperidine subbase) ethyl; 3-(ethyl piperidine subbase) propyl group; 2-((2-methoxy ethyl) piperidino) ethyl, 3-((2-methoxy ethyl) piperidino) propyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyl; 3-((2-mesyl) ethyl piperidine subbase) propyl group; piperidines-3-ylmethyl, piperidin-4-yl methyl, 2-(piperidines-3-yl) ethyl; 2-(piperidin-4-yl) ethyl; 3-(piperidines-3-yl) propyl group, 3-(piperidin-4-yl) propyl group, (1-methyl piperidine-3-yl) methyl; (1-methyl piperidine-4-yl) methyl; (1-cyano methyl piperidines-3-yl) methyl, (1-cyano methyl piperidin-4-yl) methyl, 2-(methyl piperidine-3-yl) ethyl; 2-(methyl piperidine-4-yl) ethyl; 2-(1-cyano methyl piperidines-3-yl) ethyl, 2-(1-cyano methyl piperidin-4-yl) ethyl, 3-(methyl piperidine-3-yl) propyl group; 3-(methyl piperidine-4-yl) propyl group; 3-(1-cyano methyl piperidines-3-yl) propyl group, 3-(1-cyano methyl piperidin-4-yl) propyl group, 2-(ethyl piperidine-3-yl) ethyl; 2-(ethyl piperidine-4-yl) ethyl; 3-(ethyl piperidine-3-yl) propyl group, 3-(ethyl piperidine-4-yl) propyl group, ((2-methoxy ethyl) piperidines-3-yl) methyl; ((2-methoxy ethyl) piperidin-4-yl) methyl; 2-((2-methoxy ethyl) piperidines-3-yl) ethyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyl, 3-((2-methoxy ethyl) piperidines-3-yl) propyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propyl group; (1-(2-mesyl ethyl) piperidines-3-yl) methyl, (1-(2-mesyl ethyl) piperidin-4-yl) methyl, 2-((2-mesyl ethyl) piperidines-3-yl) ethyl; 2-((2-mesyl ethyl) piperidin-4-yl) ethyl; 3-((2-mesyl ethyl) piperidines-3-yl) propyl group, 3-((2-mesyl ethyl) piperidin-4-yl) propyl group, 1-isopropyl piperidines-2-ylmethyl; 1-isopropyl piperidines-3-ylmethyl; 1-isopropyl piperidin-4-yl methyl, 2-(1-isopropyl piperidines-2-yl) ethyl, 2-(1-isopropyl piperidines-3-yl) ethyl; 2-(1-isopropyl piperidin-4-yl) ethyl; 3-(1-isopropyl piperidines-2-yl) propyl group, 3-(1-isopropyl piperidines-3-yl) propyl group, 3-(1-isopropyl piperidin-4-yl) propyl group; 2-(piperazine-1-yl) ethyl; 3-(piperazine-1-yl) propyl group, (pyrrolidine-2-yl) methyl, 2-(pyrrolidine-1-yl) ethyl; 3-(pyrrolidine-1-yl) propyl group; (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, (1,3-dioxolanes-2-yl) methyl; 2-(1; 3-dioxolanes-2-yl) ethyl, 2-(2-methoxy ethyl amino) ethyl, 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl; 2-(2-hydroxyethyl amino) ethyl; 3-(2-methoxy ethyl amino) propyl group, 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group, 3-(2-hydroxyethyl amino) propyl group; 2-methylthiazol-4-ylmethyl; 2-acetylamino thiazole-4-ylmethyl, 1-Methylimidazole .-2-ylmethyl, 2-(imidazoles-1-yl) ethyl; 2-(glyoxal ethyline-1-yl) ethyl; 2-(2-ethyl imidazol(e)-1-yl) ethyl, 3-(glyoxal ethyline-1-yl) propyl group, 3-(2-ethyl imidazol(e)-1-yl) propyl group; 2-(1; 2, the 3-triazol-1-yl) ethyl, 2-(1; 2; 3-triazole-2-yl) ethyl, 2-(1,2; the 4-triazol-1-yl) ethyl; 2-(1,2,4-triazole-4-yl) ethyl; the 4-pyridylmethyl; 2-(4-pyridine radicals) ethyl, 3-(4-pyridine radicals) propyl group, 2-(4-pyridyloxy) ethyl; 2-(4-pyridinylamino) ethyl; 2-(4-oxo-1,4-dihydro-1-pyridine radicals) ethyl, the 2-thiomorpholine is for ethyl; the 3-thiomorpholine is for propyl group; 2-(1,1 ,-dioxo tetrahydro-1,4-thiazine generation) ethyl; 3-(1; 1-dioxo thiomorpholine generation) propyl group, 2-(2-methoxy ethoxy) ethyl, 2-(4-methyl piperazine-1-yl) ethyl; 3-(4-methyl piperazine-1-yl) propyl group; 3-(methylsulfinyl) propyl group, 3-(mesyl) propyl group, 2-(5-methyl isophthalic acid; 2; the 4-triazol-1-yl) ethyl, morpholino, 2-((N-(1-Methylimidazole .-4-base sulfonyl)-N-methyl) amino) ethyl; 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl; 2-((N-methyl-N-4-pyridine radicals) amino) ethyl, 3-(4-morpholine oxide generation) propyl group, 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl; 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group; 2-(2-morpholino ethyoxyl) ethyl, 3-(2-morpholino ethyoxyl) propyl group, 2-(tetrahydropyran-4-base oxygen base) ethyl; 3-(tetrahydropyran-4-base oxygen base) propyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl or 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-yl].
According to a further aspect in the invention, R 2Be more particularly C 1-3Alkyl, amino or R 5X 1-[X wherein 1As mentioned above, and R 5Represent ethyl, trifluoromethyl, 2; 2,2-trifluoroethyl, 2-hydroxyethyl; the 3-hydroxypropyl, 2-methoxy ethyl, 3-methoxy-propyl; 2-(methanesulfinyl) ethyl, 2-(mesyl) ethyl, 2-(N; N-dimethylamino sulfonyl) ethyl, 2-(N-methylamino sulfonyl) ethyl, 2-amino-sulfonyl ethyl; 2-(N, N-dimethylamino) ethyl; 3-(N, N-dimethylamino) propyl group; 2-morpholino ethyl, 3-morpholino propyl group, 2-piperidino ethyl; 3-piperidino propyl group, 2-(methyl piperidine subbase) ethyl, 3-(methyl piperidine subbase) propyl group; 2-(ethyl piperidine subbase) ethyl, 3-(ethyl piperidine subbase) propyl group, 2-((2-methoxy ethyl) piperidino) ethyl; 3-((2-methoxy ethyl) piperidino) propyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyl, 3-((2-mesyl) ethyl piperidine subbase) propyl group; piperidines-3-ylmethyl, piperidin-4-yl methyl, 2-(piperidines-3-yl) ethyl; 2-(piperidin-4-yl) ethyl, 3-(piperidines-3-yl) propyl group, 3-(piperidin-4-yl) propyl group; (1-methyl piperidine-3-yl) methyl; (1-methyl piperidine-4-yl) methyl, (1-cyano methyl piperidines-3-yl) methyl, (1-cyano methyl piperidin-4-yl) methyl; 2-(methyl piperidine-3-yl) ethyl; 2-(methyl piperidine-4-yl) ethyl, 2-(1-cyano methyl piperidines-3-yl) ethyl, 2-(1-cyano methyl piperidin-4-yl) ethyl; 3-(methyl piperidine-3-yl) propyl group; 3-(methyl piperidine-4-yl) propyl group, 3-(1-cyano methyl piperidines-3-yl) propyl group, 3-(1-cyano methyl piperidin-4-yl) propyl group; 2-(ethyl piperidine-3-yl) ethyl; 2-(ethyl piperidine-4-yl) ethyl, 3-(ethyl piperidine-3-yl) propyl group, 3-(ethyl piperidine-4-yl) propyl group; ((2-methoxy ethyl) piperidines-3-yl) methyl; ((2-methoxy ethyl) piperidin-4-yl) methyl, 2-((2-methoxy ethyl) piperidines-3-yl) ethyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyl; 3-((2-methoxy ethyl) piperidines-3-yl) propyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propyl group, (1-(2-mesyl ethyl) piperidines-3-yl) methyl, (1-(2-mesyl ethyl) piperidin-4-yl) methyl; 2-((2-mesyl ethyl) piperidines-3-yl) ethyl; 2-((2-mesyl ethyl) piperidin-4-yl) ethyl, 3-((2-mesyl ethyl) piperidines-3-yl) propyl group, 3-((2-mesyl ethyl) piperidin-4-yl) propyl group; 1-isopropyl piperidines-2-ylmethyl; 1-isopropyl piperidines-3-ylmethyl, 1-isopropyl piperidin-4-yl methyl, 2-(1-isopropyl piperidines-2-yl) ethyl; 2-(1-isopropyl piperidines-3-yl) ethyl; 2-(1-isopropyl piperidin-4-yl) ethyl, 3-(1-isopropyl piperidines-2-yl) propyl group, 3-(1-isopropyl piperidines-3-yl) propyl group; 3-(1-isopropyl piperidin-4-yl) propyl group; 2-(piperazine-1-yl) ethyl, 3-(piperazine-1-yl) propyl group, (pyrrolidine-2-yl) methyl; 2-(pyrrolidine-1-yl) ethyl; 3-(pyrrolidine-1-yl) propyl group, (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methyl, (1; 3-dioxolanes-2-yl) methyl; 2-(1,3-dioxolanes-2-yl) ethyl, 2-(2-methoxy ethyl amino) ethyl; 2-(N-(2-methoxy ethyl)-N-methylamino) ethyl; 2-(2-hydroxyethyl amino) ethyl, 3-(2-methoxy ethyl amino) propyl group, 3-(N-(2-methoxy ethyl)-N-methylamino) propyl group; 3-(2-hydroxyethyl amino) propyl group; the 2-thiomorpholine is for ethyl, and the 3-thiomorpholine is for propyl group, and 2-(1; 1;-dioxo tetrahydro-1,4-thiazine generation) ethyl, 3-(1,1-dioxo thiomorpholine generation) propyl group; 2-(2-methoxy ethoxy) ethyl; 2-(4-methyl piperazine-1-yl) ethyl, 3-(4-methyl piperazine-1-yl) propyl group, 3-(methylsulfinyl) propyl group; 3-(mesyl) propyl group; morpholino-, 2-((N-(3-morpholino third sulfonyl)-N-methyl) amino) ethyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyl; 3-(4-morpholine oxide generation) propyl group; 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyl, 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propyl group, 2-(2-morpholino ethyoxyl) ethyl; 3-(2-morpholino ethyoxyl) propyl group; 2-(tetrahydropyran-4-base oxygen base) ethyl, 3-(tetrahydropyran-4-base oxygen base) propyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl or 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-yl].
On the other hand, according to an embodiment more of the present invention, R 2Representation methoxy, 2-methoxy ethoxy, 2-(2-methoxy ethoxy) ethyoxyl; the 3-methoxy propoxy, 2-mesyl ethyoxyl, 3-mesyl propoxyl group; benzyloxy; 2-(tetrahydropyran-4-base oxygen base) ethyoxyl, 3-(tetrahydropyran-4-base oxygen base) propoxyl group, 2-(4-methyl piperazine-1-yl) ethyoxyl; 3-(4-methyl piperazine-1-yl) propoxyl group; 2-morpholino ethyoxyl, 3-morpholino propoxyl group, 2-(imidazoles-1-yl) ethyoxyl; 3-(imidazoles-1-yl) propoxyl group; 2-(1,1-dioxo thiomorpholine generation) ethyoxyl, 3-(1; 1-dioxo thiomorpholine generation) propoxyl group; 2-(1,2,3-triazoles-1-yl) ethyoxyl; 3-(1; 2, the 3-triazol-1-yl) propoxyl group, 2-(1; 2; the 4-triazol-1-yl) ethyoxyl, 2-((N-methyl-N-4-pyridine radicals) amino) ethyoxyl, 2-(N; the N-dimethylamino) ethyoxyl; 3-(N, N-dimethylamino) propoxyl group, 2-(N-methoxyl group acetyl group-N-methylamino) ethyoxyl; 3-(N-methoxyl group acetyl group-N-methylamino) propoxyl group; 1-methyl piperidine-3-ylmethoxy; 1-methyl piperidine-4-ylmethoxy, (1-cyano methyl piperidines-3-yl) methoxyl group, (1-cyano methyl piperidin-4-yl) methoxyl group; 2-(1-cyano methyl piperidines-3-yl) ethyoxyl; 2-(1-cyano methyl piperidin-4-yl) ethyoxyl, 3-(1-cyano methyl piperidines-3-yl) propoxyl group, 3-(1-cyano methyl piperidin-4-yl) propoxyl group; ((2-methoxy ethyl) piperidines-3-yl) methoxyl group; ((2-methoxy ethyl) piperidin-4-yl) methoxyl group, 2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl, 4-(pyrrolidine-1-yl) but-2-ene-1-base oxygen base; 2-(2-oxo-pyrrolidine-1-yl) ethyoxyl; 3-(2-oxo-pyrrolidine-1-yl) propoxyl group, (pyrrolidine-2-yl) methoxyl group, 2-(pyrrolidine-1-yl) ethyoxyl; 3-(pyrrolidine-1-yl) propoxyl group; 2-(2-(pyrrolidine-1-yl) ethyoxyl) ethyoxyl, (2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methoxyl group, 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl; 2-piperidino ethyl; 3-piperidino propoxyl group, 2-(methyl piperidine subbase) ethyoxyl, 3-(methyl piperidine subbase) propoxyl group; 2-(ethyl piperidine subbase) ethyoxyl; 3-(ethyl piperidine subbase) propoxyl group, 2-((2-methoxy ethyl) piperidino) ethyoxyl, 3-((2-methoxy ethyl) piperidino) propoxyl group; 1-(2-mesyl ethyl) piperidines-3-ylmethoxy; 1-(2-mesyl ethyl) piperidin-4-yl methoxyl group, 2-((2-mesyl) ethyl piperidine subbase) ethyoxyl, 3-((2-mesyl) ethyl piperidine subbase) propoxyl group; piperidines-3-ylmethoxy; the piperidin-4-yl methoxyl group, 2-(piperidines-3-yl) ethyoxyl, 2-(piperidin-4-yl) ethyoxyl; 3-(piperidines-3-yl) propoxyl group; 3-(piperidin-4-yl) propoxyl group, 2-(methyl piperidine-3-yl) ethyoxyl, 2-(methyl piperidine-4-yl) ethyoxyl; 3-(methyl piperidine-3-yl) propoxyl group; 3-(methyl piperidine-4-yl) propoxyl group, 2-(ethyl piperidine-3-yl) ethyoxyl, 2-(ethyl piperidine-4-yl) ethyoxyl; 3-(ethyl piperidine-3-yl) propoxyl group; 3-(ethyl piperidine-4-yl) propoxyl group, 2-((2-methoxy ethyl) piperidines-3-yl) ethyoxyl, 2-((2-methoxy ethyl) piperidin-4-yl) ethyoxyl; 3-((2-methoxy ethyl) piperidines-3-yl) propoxyl group; 3-((2-methoxy ethyl) piperidin-4-yl) propoxyl group, 2-((2-mesyl ethyl) piperidines-3-yl) ethyoxyl, 2-((2-mesyl ethyl) piperidin-4-yl) ethyoxyl; 3-((2-mesyl ethyl) piperidines-3-yl) propoxyl group; 3-((2-mesyl ethyl) piperidin-4-yl) propoxyl group, 1-isopropyl piperidines-2-ylmethoxy, 1-isopropyl piperidines-3-ylmethoxy; 1-isopropyl piperidin-4-yl methoxyl group; 2-(1-isopropyl piperidines-2-yl) ethyoxyl, 2-(1-isopropyl piperidines-3-yl) ethyoxyl, 2-(1-isopropyl piperidin-4-yl) ethyoxyl; 3-(1-isopropyl piperidines-2-yl) propoxyl group; 3-(1-isopropyl piperidines-3-yl) propoxyl group, 3-(1-isopropyl piperidin-4-yl) propoxyl group, 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl; 3-(2-(4-methyl piperazine-1-yl) ethyoxyl) propoxyl group; 2-(2-morpholino ethyoxyl) ethyoxyl, 3-(2-morpholino ethyoxyl) propoxyl group, 2-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) vinyl or 3-((2-(pyrrolidine-1-yl) ethyl) carbamoyl) third-2-alkene-1-base.
Work as R 2One of substituent group is R 5X 1-time, substituent R 5X 1-be preferably placed at the 6-position or the 7-position of quinazoline ring, more preferably be positioned at the 7-position of quinazoline ring.
Work as R 2When one of substituent group was positioned at the 6-position of quinazoline ring, it was preferably hydrogen, halogen, C 1-3Alkyl, trifluoromethyl, C 1-3Alkoxyl, C 1-3Alkylthio group or-NR 3R 4(R wherein 3And R 4As above definition).
Work as R 2When one of substituent group was positioned on the 6-position of quinazoline ring, it is C more preferably 1-3Alkoxyl, especially methoxyl group.
Another aspect of the present invention provides formula Ia chemical compound and salt thereof and its prodrug (for example ester and amide) to be used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in preparation:
Figure A0080608500811
[wherein:
Ring C, R 1, R 2, n and Z as above define, and condition is R 2Be not hydrogen, and Z can not be CH 2Or direct key; With
R 2aRepresent hydrogen, halogen, C 1-3Alkyl, trifluoromethyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3aR 4a(R wherein 3aAnd R 4aCan be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5a(CH 2) ZaX 1a-(R wherein 5aFor containing 1-2 heteroatomic 5-or 6-unit saturated heterocyclyl that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl), za is integer 0-4, and X 1aRepresent direct key ,-O-,-CH 2-,-S-,-SO-,-SO 2-,-NR 6aC (O)-,-C (O) NR 7a-,-SO 2NR 8a-,-NR 9aSO 2-or-NR 10a(R wherein 6a, R 7a, R 8a, R 9aAnd R 10aRepresent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl)).
Formula Ia chemical compound and salt thereof and its prodrug (for example ester, amide and thioether) of providing on the one hand more of the present invention is used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in preparation: [wherein:
Ring C, R 1, R 2, n and Z as above define, and condition is R 2Be not hydrogen, and Z can not be CH 2Or direct key; With
R 2aRepresent hydrogen, halogen, C 1-3Alkyl, trifluoromethyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3aR 4a(R wherein 3aAnd R 4aCan be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5a(CH 2) ZaX 1a-(R wherein 5aFor containing 1-2 heteroatomic 5-or 6-unit saturated heterocyclyl that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from oxo, hydroxyl, halogen, C 1-4Alkyl, C 1-4Hydroxy alkyl and C 1-4The substituent group of alkoxyl, za is integer 0-4, and X 1aRepresent direct key ,-O-,-CH 2-,-S-,-SO-,-SO 2-,-NR 6aC (O)-,-C (O) NR 7a-,-SO 2NR 8a-,-NR 9aSO 2-or-NR 10a-(R wherein 6a, R 7a, R 8a, R 9aAnd R 10aRepresent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl)).
X advantageously 1aRepresentative-O-,-S-,-NR 6aC (O)-,-NR 9aSO 2-or-NR 10a-(R wherein 6a, R 9aAnd R 10aRepresent hydrogen independently of one another, C 1-2Alkyl or C 1-2Alkoxyethyl).
Preferred X 1aRepresentative-O-,-S-,-NR 6aC (O)-,-NR 9aSO 2-(R wherein 6aAnd R 9aRepresent hydrogen or C independently of one another 1-2Alkyl) or NH.
More preferably X 1aRepresentative-O-,-S-,-NR 6aCO-(R wherein 6aRepresent hydrogen or C 1-2Alkyl) or NH.
X particularly 1aRepresentative-O-or-NR 6aCO-(R wherein 6aRepresent hydrogen or C 1-2Alkyl), more particularly be-O-or-NHCO-, especially-O-.
Preferred za is integer 1-3.
Preferred R 5aFor being selected from following group: in pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation,, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and described cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl).
More preferably R 5aFor being selected from following group: in pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino and thiomorpholine generation,, described group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) gRing D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
R particularly 5aFor being selected from following group: in pyrrolidinyl, piperazinyl, piperidyl, azelidinyl, morpholino and thiomorpholine generation,, described group can have 1 or 2 and be selected from group-(O-) f(C 1-3Alkyl) gThe substituent group of ring D (wherein f is 0 or 1, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, methyl piperazine base, piperidyl, azelidinyl, morpholino and thiomorpholine generation).
According to a further aspect in the invention, preferred R 5aFor being selected from the group in pyrrolidinyl, piperazinyl, piperidyl, morpholino and thiomorpholine generation, these groups can have 1 or 2 and be selected from oxo, hydroxyl, halogen, C 1-2Alkyl, C 1-2Hydroxy alkyl and C 1-2The substituent group of alkoxyl.
R advantageously 2aRepresent C 1-3Alkyl, C 1-3Alkoxyl, amino or R 5a(CH 2) ZaX 1a-(R wherein 5a, X 1aAs above define with za).R 2Another suitable implication be hydrogen.
Preferred R 2aBe methyl, ethyl, methoxyl group, ethyoxyl or R 5a(CH 2) ZaX 1a-(R wherein 5a, X 1aAs above define with za).R 2Another preferred meaning be hydrogen.
More preferably R 2aBe methyl, ethyl, methoxyl group, ethyoxyl or R 5a(CH 2) ZaX 1a-(R wherein 5aFor being selected from the group in pyrrolidinyl, piperazinyl, piperidyl, morpholino and thiomorpholine generation, and described group can have 1 or 2 and is selected from oxo, hydroxyl, halogen, C 1-2Alkyl, C 1-2Hydroxy alkyl and C 1-2The substituent group of alkoxyl, X 1aFor-O-,-S-,-NR 5aC (O)-,-NR 9aSO 2-(R wherein 6aAnd R 9aRepresent hydrogen or C independently of one another 1-2Alkyl) or NH, and za is integer 1-3).
R particularly 2aRepresent methylidene, methoxyl group or R 5a(CH 2) ZaX 1a-(R wherein 5a, X 1aAs above define with za).
R more particularly 2aRepresentation methoxy.
Again of the present invention-aspect provide formula Ib chemical compound and salt thereof and its prodrug for example ester, amide and thioether be used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect in preparation at homoiothermic animal such as human body:
Figure A0080608500841
[wherein:
Ring C, R 1, R 2, R 2aAs above define with n, condition is R 2Be not hydrogen; And
Zb is-O-or-S-].
Preferred Zb is-O-.
Of the present invention in addition-aspect provides formula II chemical compound and salt and its prodrug thereof for example ester, amide and thioether (preferred ester and amide): [wherein:
Ring C, R 1, R 2, R 2a, Zb and n as above define, and condition is R 2Can not be hydrogen, and not comprise following compounds: 6,7-dimethoxy-4 '-(1-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(2-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(1-naphthoxy) quinazoline and 6,7-dimethoxy-4 '-(2-naphthoxy) quinazoline.
Formula IIa chemical compound and salt thereof and its prodrug for example ester, amide and the thioether (preferred ester and amide) of providing on the one hand more of the present invention: [wherein:
Ring C, R 1, R 2, R 2a, Zb and n as above define, and condition is R 2Can not have any following implication: hydrogen replaces or unsubstituted C 1-5Alkyl, halogen or phenoxy group, and do not comprise following compounds: 6,7-dimethoxy-4 '-(1-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(2-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(1-naphthoxy) quinazoline and 6,7-dimethoxy-4 '-(2-naphthoxy) quinazoline.
Another aspect of the present invention provides formula IIb chemical compound and salt and its prodrug thereof for example ester, amide and thioether (preferred ester and amide):
Figure A0080608500861
[wherein:
Ring C, R 1, R 2, R 2a, Zb and n as above define, and condition is R 2Can not have any following implication: hydrogen replaces or unsubstituted C 1-5Alkyl, halogen, C 1-5Alkoxyl, C 2-5Alkenyl, phenoxy group or phenyl C 1-5Alkoxyl].
Preferred compound of the present invention comprises: 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2-naphthoxy) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(4-methylquinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(4-methylquinoline-7-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; (R; S)-4-(3-fluorine quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline; 7-(3-N; the N-dimethylamino propoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-morpholino ethyoxyl) ethyoxyl) quinazoline; 7-(2-(N; the N-diethylamino) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidines-1-yl) ethyoxyl) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1; 2; the 4-triazol-1-yl) quinazoline ethyoxyl); 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(6-trifluoro methyl indole-5-base oxygen base) quinazoline; 7-(3-(mesyl) propoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(3-(N; the N-dimethylamino) propoxyl group)-4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-3-ylmethoxy) quinazoline; 7-(2-(N; the N-diethylamino) ethyoxyl)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-2-yl) ethyoxyl)-quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-1-yl) ethyoxyl)-quinazoline; 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 7-(3-(ethylsulfonyl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-piperidino propoxyl group)-quinazoline; 7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methylamino) ethyoxyl) quinazoline; and 7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; and their salt (especially hydrochlorate) and its prodrug, for example ester and amide.
Particularly preferred The compounds of this invention comprises: 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline; 7-((1-cyano methyl) piperidin-4-yl methoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-pyrrolidine-1-base oxethyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-methyl piperidine-3-ylmethoxy) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-piperidino ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1; 2; the 4-triazol-1-yl) quinazoline ethyoxyl); 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline; 6-methoxyl group-7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((2-(2-pyrrolidine-1-base ethyl) carbamoyl) vinyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl oxygen base) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-mesyl amino) ethyoxyl) quinazoline; 7-(2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline; (2 methyl indole-5-base oxygen base)-(3-(1 for 7-for 4-; 1-dioxo thiomorpholine generation) quinazoline propoxyl group); 4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline, 7-(3-(N, N-dimethylamino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 7-(3-(N; the N-diethylamino) propoxyl group)-and 4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group 7-(2-(4-pyridine radicals oxygen base) ethyoxyl) quinazoline; 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline, 7-(2-hydroxyl-3-morpholino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-(1-(2-methoxy ethyl) piperidin-4-yl) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-hydroxyl-3-pyrrolidine-1-base propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 7-(3-(N, N-two-ethylamino)-2-hydroxyl propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-and 6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(4-pyridine radicals oxygen base) ethyoxyl) quinazoline, 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; (2R)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline; (5R)-and 6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline, 4-(4-bromo indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-(pyrrolidine-1-yl) ethyl)-piperidin-4-yl methoxyl group) quinazoline; (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; (2R)-7-(2-hydroxyl-3-morpholino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2S)-7-(2-hydroxyl-3-((N; the N-diisopropyl) propoxyl group amino))-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; (2S)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline, (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline; (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; (2R)-and 7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-morpholino ethyl) piperidin-4-yl methoxyl group) quinazoline, 4-(3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline; 4-(3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group)-4-(1H-pyrrolo-[2,3-b] pyridine-5-base oxygen base) quinazoline, (2S)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline; and 4-(6-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, and their salt (especially hydrochlorate) and its prodrug (for example ester and amide).
More particularly preferred The compounds of this invention comprises: 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline, 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline, (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group quinazoline, and 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline, and their salt (especially hydrochlorate) and its prodrug (for example ester and amide).
Therefore, preferred The compounds of this invention comprises chemical compound and their salt (especially hydrochlorate) and its prodrug (for example ester and amide) that the following example is prepared: 23,10,5,176,7,22,13,15,177,12,35,47,44,45,157,52,62,66,75,159,87,88,89,167,83,97,101,108,113,114,121,124,178,162,165,150 and 166
Therefore, particularly preferred The compounds of this invention comprises chemical compound and their salt (especially hydrochlorate) and its prodrug (for example ester and amide) that the following example is prepared: 2,11,34,36,186,151,57,54,55,58,56,60,61,64,65,67,68,71,72,74,70,77,79,80,82,86,122,107,110,112,117,118,119,123,161,147,163,164,63,78,115,320,318,290,252,292,293,294,301,299,279,280,305,269,246,266,267,182,321 and 250.
Therefore more particularly preferred The compounds of this invention comprises chemical compound and their salt (especially hydrochlorate) and its prodrug (for example ester and amide) that the following example is prepared: 9,243,251,245,247,249,240,238,237,239,241,258 and 322.
In another embodiment; preferred compound of the present invention comprises: 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-6-base oxygen base) quinazoline; (S)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(1-naphthoxy) quinazoline; 4-(1H-indazole-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6; 7-dimethoxy-4 '-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2; 2; 4-trimethyl-1; 2-dihydroquinoline-6-base oxygen base) quinazoline; 6-methoxyl group-7-((2-piperidines-1-yl) ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2-methylquinoline-7-base oxygen base-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-4-(2-methylquinoline-7-base oxygen base)-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2-methylquinoline-7-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(2-chloro-1H-benzimidazole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(2; 4-dimethyl quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(1H-indazole-6-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 4-(1; 3-benzothiazole-6-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(3-oxo-2H-4H-1; 4-benzoxazinyl-6-base oxygen base) quinazoline; 7-hydroxyl-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2-methyl isophthalic acid; 3-benzothiazole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(tetrahydropyran-4-base oxygen base) ethyoxyl) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(1; 2-cycloheptane benzimidazole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-2-base oxygen base) quinazoline; 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(3-oxo-1; 2-dihydro-3H-indazole-1-yl) quinazoline; 4-(2; 3-dihydro-1H-indenes-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-4-(2-methyl-4-oxo-4H-.alpha.-5:6-benzopyran-7-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(4-methyl-4H-benzoxazinyl-6-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2-methyl-4-oxo-4H-.alpha.-5:6-benzopyran-7-base oxygen base)-7-((3-pyrrolidine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-4-(4-methyl-3; 4-dihydro-2H-1; 4-benzoxazinyl-6-base oxygen base)-7-((3-pyrrolidine-1-base propoxyl group) quinazoline; 7-benzyloxy-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline; 4-(2; 4-dimethyl quinoline-7-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-7-(3-mesyl propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2-methylquinoline-7-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline; 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinazoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(3-oxo-2H; 4H-1; 4-benzoxazinyl-6-base oxygen base) quinazoline; 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6; 7-dimethoxy-4 '-(2-methyl isophthalic acid H-benzimidazole-5-base oxygen base) quinazoline; and their salt (especially hydrochlorate) and its prodrug (ester for example; amide and thioether, preferred ester and amide).
In another embodiment; preferred The compounds of this invention comprises: 6-methoxyl group-4-(4-methylquinoline-7-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-6-base oxygen base)-quinazoline; 6-methoxyl group-4-(2-methyl isophthalic acid; 3-benzothiazole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; (R)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base)-quinazoline; 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(2; 2; 4-trimethyl-1; 2-dihydroquinoline-6-base oxygen base)-quinazoline; 6-methoxyl group-7-(2-morpholino ethyoxyl)-4-(quinoline-7-base oxygen base)-quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline; 4-(7-hydroxyl-2-naphthoxy)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline; 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; 7-(2-(N; the N-dimethylamino) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline; 4-(2; 3-dimethyl indole-5-base is amino)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(2; 3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; (S)-6-methoxyl group-7-((2-oxo-tetrahydrochysene-2H-pyrrolidine-5-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; and their salt (especially hydrochlorate) and its prodrug (ester for example; amide and thioether, preferred ester and amide).
In another embodiment; particularly preferred The compounds of this invention comprises: 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidines-1-yl) ethyoxyl) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-7-(3-mesyl propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(pyrrolidine-1-yl) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2-naphthoxy) quinazoline; (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(3-(1-methyl piperazine-4-yl) propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(4-methylquinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 7-((1-cyano methyl piperidin-4-yl) methoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; 4-(3-fluorine quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(3-(N; the N-dimethylamino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-(1-methyl piperazine-4-yl) ethyoxyl) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-morpholino ethyoxyl) ethyoxyl) quinazoline; 6-methoxyl group-4-(4-methylindole-7-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; (2 methyl indole-5-base oxygen base)-(2-(1 for 7-for 6-methoxyl group-4-; 2; the 4-triazol-1-yl) quinazoline ethyoxyl); 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline; and their salt (especially hydrochlorate) and its prodrug (ester for example; amide and thioether, preferred ester and amide).
On the other hand; preferred compound of the present invention comprises: 6-methoxyl group-7-((1-(2-methoxy ethyl) piperidin-4-yl) methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-(pyrrolidine-1-yl) ethylamino formoxyl) vinyl) quinazoline; 4-(3-cyano quinolines-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(4-Trifluoromethylquinocarboxylic-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2-methyl isophthalic acid H-benzimidazole-5-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(3-carbamoyl quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(1-methyl piperazine-4-yl) propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline; and their salt (especially hydrochlorate) and its prodrug (ester for example; amide and thioether, preferred ester and amide).
Particularly preferred The compounds of this invention is 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline and salt (especially hydrochlorate) and its prodrug (for example ester, amide and thioether, preferably ester and amide).
For avoiding producing doubt, should be appreciated that in this manual, when group with " as above definition " or " definition as above " when being limited, described group comprises that the broadest definition that occurs for the first time and this group every kind and all preferably define.
In this manual, term " alkyl " not only comprises straight chained alkyl, but also comprises branched alkyl, but then specially refers to straight chained alkyl for independent alkyl group as " propyl group ".Similarly agreement is applicable to other general terms.Unless otherwise indicated, term " alkyl " preferably refers to contain 1-6 carbon atom, preferably contains the chain of 1-4 carbon atom.Unless otherwise indicated, term used herein " alkoxyl " comprises " alkyl "-O-group, and " alkyl " wherein as above defines.Term used herein " aryl " unless otherwise indicated comprises C 6-10Aryl needs, and it can have one or more halogens that are selected from, alkyl, alkoxyl, nitro, the substituent group of trifluoromethyl and cyano group (wherein alkyl and alkoxyl as above define).Unless otherwise indicated, term used herein " aryloxy group " comprises " aryl "-O-group, and " aryl " wherein as above defines.Term used herein " sulfonyloxy " is meant alkylsulfonyloxy and aryl-sulfonyl oxygen, and " alkyl " wherein and " aryl " as above define.Unless otherwise indicated, term used herein " alkanoyl " comprises formoxyl and alkyl C=O group, and " alkyl " wherein as above defines, for example C 2Alkanoyl is meant acetyl group, that is CH 3C=O, C 1Alkanoyl is meant formoxyl, that is CHO.In this description, unless otherwise indicated, term " alkenyl " comprises straight chain and branched alkenyl, but then specially refers to linear form for independent alkenyl such as crotyl.Unless otherwise indicated, the term in this description " alkenyl " preferably refers to have 2-5 carbon atom, the chain of preferred 3-4 carbon atom.Unless otherwise indicated, the term in this description " alkynyl " comprises a straight chain and an alkynyl group, but then only refers to linear form for independent alkynyl such as 2-butyne base.Unless otherwise indicated, term " alkynyl " preferably is meant and contains 2-5 carbon atom, the chain of preferred 3-4 carbon atom.Unless otherwise indicated, term " haloalkyl " is meant the abovementioned alkyl that has one or more halogen groups, for example trifluoromethyl.
For avoiding producing doubt, be to be understood that working as R 2Have and replace or unsubstituted C 1-5During the implication of alkyl, it is selected from C 1-3Alkyl or be selected from radicals R 5X 1-, X wherein 1For direct key or-CH 2-, and R 5Be C 1-5Alkyl, it can be unsubstituted or can be replaced by one or more hydroxyl, fluorine, chlorine, bromine and amino groups of being selected from.
Be appreciated that within the scope of the present invention formula I compound or its salt may demonstrate tautomerism, and the structural formula in this description is only represented a kind of possible tautomeric form.Therefore it should be understood that the present invention includes and to suppress the active any tautomeric form of vegf receptor tyrosine kinase, and not only be confined to a kind of change form shown in the structural formula.Structural formula in this description is only represented a kind of possible tautomeric form, be to be understood that this description comprise shown in all possible tautomeric form of chemical compound, and just herein may forms by those of figure expression.
Should be appreciated that formula I compound or its salt may have asymmetric carbon atom.This asymmetric carbon atom is also relevant with above-mentioned tautomerism, therefore, should understand, the present invention includes and to suppress the active any chirality form of vegf receptor tyrosine kinase (comprising pure enantiomer, scalemic and racemic mixture) and any tautomeric form, and not only be confined to any tautomeric form shown in the structural formula or chirality form.Should be appreciated that the present invention includes and to suppress active any optical isomer of vegf receptor tyrosine kinase and diastereomer.Be appreciated that further that in chipal compounds name (R, S) any scalemic of expression or racemic mixture (R) and (S) are then represented enantiomer.In the chemical compound name, there is not (R, S), (R) or under the situation (S), be to be understood that its name is meant any scalemic or racemic mixture, wherein the scalemic mixture comprises the R and the S enantiomer of any relative scale amount, and racemic mixture then comprises 50: 50 quantitative R and S enantiomer.
Should know that also some formula I quinazoline and salt thereof can exist with solvate and non-solvent compound form (as hydrate forms).Therefore it should be understood that the present invention includes all these can suppress the active solvate forms of vegf receptor tyrosine kinase.
For avoiding producing doubt, should be appreciated that working as X 1For for example-NR 6C (O)-time, be to have R 6The nitrogen-atoms of group is connected with the quinazoline ring, carbonyl (C (O)) then with R 5Connect; And work as X 1Be for example formula-C (O) NR 7-group the time, then be that carbonyl is connected with the quinazoline ring, and have R 7The nitrogen-atoms of group and R 5Connect.Similarly agreement is applicable to other two atom X 1Connect base, as-NR 9SO 2-and-SO 2NR 8-.Work as X 1For-NR 10-time is to have R 10Nitrogen-atoms and quinazoline ring and R 5Connect.Similarly agreement is applicable to other group.Further be appreciated that and work as X 1Representative-NR 10-and R 10Be C 1-3Alkoxy C 2-3During alkyl, then be C 2-3Moieties and X 1Nitrogen-atoms connect, similarly agreement is applicable to other group.
For avoiding producing doubt, be to be understood that in formula I chemical compound, work as R 5Be for example formula C 1-3Alkyl X 9C 1-3Alkyl R 28Group the time, then be the end C 1-3Moieties and X 1Connect; Similarly, work as R 5Be for example formula C 2-5Alkenyl R 28Group the time, then be C 2-5Alkenyl part and X 1Connect, similarly agreement also is applicable to other group.Work as R 5Be group 1-R 29When third-1-alkene-3-is basic, first carbon atom and radicals R 29Connect the 3rd carbon atom and X 1Connect, similarly agreement also is applicable to other group.
For avoiding producing doubt, be to be understood that in formula I chemical compound, work as R 5Be for example R 28And R 28For having group-(O-) f(C 1-4Alkyl) gWhen encircling the pyrrolidine ring of D, then be-O-or C 1-4Alkyl is connected with the pyrrolidine basic ring, has only when f and g are 0, and ring D could be connected with the pyrrolidine basic ring, and similar agreement also is applicable to other group.
For avoiding producing doubt, be to be understood that working as R 29Have C 1-4During aminoalkyl substituent group, then be C 1-4Moieties and R 29Connect, and work as R 29Have C 1-4During the alkyl amino substituent group, then be amino part and R 29Connect, similarly agreement also is applicable to other group.
For avoiding producing query, be to be understood that working as R 28Have C 1-4Alkoxy C 1-4During alkyl substituent, then be C 1-4Moieties and R 28Connect, similarly agreement also is applicable to other group.
The present invention relates to aforesaid formula I chemical compound and salt thereof.The salt that is used for pharmaceutical composition should be pharmaceutically useful salt, but other salt also can be used for production formula I chemical compound and their officinal salt.For example, officinal salt of the present invention can comprise the acid-addition salts of above-mentioned formula I chemical compound, and these formulas I chemical compound has the alkalescence that is enough to form this type of salt.This class acid-addition salts for example comprises and the salt that can provide pharmaceutically acceptable anionic mineral acid or organic acid to form, as the salt that forms with halogen acids (the especially salt that forms with hydrochloric acid or hydrobromic acid (preferred especially hydrochloric acid)), or the salt that forms with sulphuric acid or phosphoric acid, or the salt that forms with trifluoroacetic acid, citric acid or maleic acid.In addition, when formula I chemical compound had enough highly acids, they can form officinal salt with pharmaceutically acceptable cationic inorganic base or organic base can be provided.The salt that this class and inorganic base or organic base form comprises for example alkali metal salt, as sodium or potassium salt, and alkali salt such as calcium or magnesium salt, ammonium salt perhaps is the salt that forms with for example methylamine, dimethylamine, triethylamine, piperidines, morpholine or three-(2-ethoxy) amine.
Formula I chemical compound, or its salt and other chemical compound of the present invention (as mentioned below) can adopt any known method preparation that is used to prepare chemical related compound.For example, these methods comprise that european patent application discloses 0520722,0566226, the method for record in 0602851 and 0635498.These methods also comprise for example solid-phase synthesis.These methods have further constituted another feature of the present invention, and are recorded in hereinafter.Essential initial substance can obtain by vitochemical standard method.The preparation of these initial substances is recorded in the appended non-limiting example.On the other hand, the essential initial substance similar approach that also can adopt the organic chemistry professional to be known obtains.
Therefore, following method (a)-(f) and (i)-(vi) constituted another feature of the present invention.Synthesizing of formula I chemical compound
(a) formula I chemical compound and salt thereof can pass through the formula III chemical compound: (R wherein 2As above define L with m 1Be displaceable group), and formula IV chemical compound prepared in reaction:
Figure A0080608501022
(its medium ring C, R 1, Z and n as above define), thus formula I chemical compound and salt thereof obtained.Suitable displaceable group L 1For example be halogen, alkoxyl (preferred C 1-4Alkoxyl), aryloxy group, alkylthio group, arylthio, alkoxyl alkylthio group or sulfonyloxy, for example chlorine, bromine, methoxyl group, phenoxy group, methyl mercapto, 2-methoxyl group ethylmercapto group, mesyloxy or toluene-4-sulfonyloxy.
Reaction should be carried out in the presence of alkali.This class alkali for example is organic amine alkali, pyridine for example, 2,6-lutidines, collidine, 4-dimethylamino naphthyridine, triethylamine, morpholine, N-methylmorpholine or diazabicylo [5.4.0] 11 carbon-7-alkene, tetramethyl guanidine; Perhaps for example be the carbonate of alkali metal or alkaline-earth metal or hydroxide (for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide).On the other hand, this class alkali also comprises for example alkali metal hydride (for example sodium hydride), or the amide of alkali metal or alkaline-earth metal (as ammonification sodium or two (trimethyl silyl) ammonification sodium, ammonification potassium or two (trimethyl silyl) ammonification potassium).Reaction is preferably carried out in the presence of atent solvent or diluent, these solvents or diluent for example ether (as oxolane or 1, the 4-diox), aromatic solvent (as toluene), or dipolar aprotic transmission solvent (as N, dinethylformamide, N, the N-dimethyl acetylamide, N-methylpyrrolidin-2-ketone or dimethyl sulfoxine).Reaction should be carried out under preferred 20-90 ℃ the temperature at for example 10-150 ℃.
When needs obtain acid salt, can adopt conventional method with acid treatment gained free alkali, for example use halogen acids (as hydrochloric acid), sulphuric acid, sulfonic acid (as methanesulfonic acid) or carboxylic acid (for example acetic acid or citric acid) are handled.
(b) at least one R wherein 2Be R 5X 1, and R wherein 5As above definition, X 1For-O-,-S-,-OC (O)-or-NR 10-(R wherein 10The independent hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) the formula I chemical compound and the preparation of salt thereof can realize by following reaction: even formula V chemical compound:
Figure A0080608501031
(its medium ring C, Z, R 1, R 2As above define X with n 1Then define, and s is integer 0-2 as this paragraph preamble) react with formula VI chemical compound:
R 5-L 1(VI) (R wherein 5And L 1As above definition), reaction should be carried out in the presence of alkali (alkali described in top method (a)).L wherein 1Be displaceable group, for example halogen or sulfonyloxy (as bromine, mesyloxy or toluene-4-sulfonyloxy), perhaps L 1Can under the Mitsunobu of standard condition, produce (" Organic Reactions ", John Wiely﹠amp on the spot by alcohol; SonsInc, 1992, vol 42, the 2 chapters, David L Hughes).This reaction is preferably carried out in the presence of alkali (described in top method (a)) and atent solvent or diluent (described in top method (a)), and favourable reaction temperature is 10-150 ℃, preferably about 50 ℃.
(c) at least one R wherein 2Be R 5X 1, and R wherein 5As above definition, X 1For-O-,-S-,-OC (O)-or-NR 10-(R wherein 10Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) but formula I chemical compound and salt through type VII chemical compound thereof: With formula VIII chemical compound prepared in reaction:
R 5-X 1-H (VIII) (L wherein 1, R 1, R 2, R 5, ring C, Z, n and s be as above definition all, X 1Then as the definition of this paragraph preamble).This reaction should be in the presence of alkali (described in top method (a)), and preferably in the presence of atent solvent or diluent (described in top method (a)), in for example 10-150 ℃, carry out under preferred about 100 ℃ temperature.
(d) by making formula IX chemical compound:
Figure A0080608501042
(L wherein 1, X 1, R 1, R 2, ring C, Z, n and s as above define) react with formula X chemical compound:
R 113-H (X) (R wherein 113As give a definition), can make formula I compound or its salt, wherein at least one R 2Be R 5X 1, and X wherein 1As above definition, R 5Be C 1-5Alkyl R 113, R wherein 113Be selected from one of following six groups of groups:
1) X 19C 1-3Alkyl (X wherein 19Representative-O-,-S-,-SO 2-,-NR 114C (O)-or-NR 115SO 2-(R wherein 114And R 115Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl));
2) NR 116R 117(R wherein 116And R 117Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
3) X 20C 1-5Alkyl X 5R 22(X wherein 20Representative-O-,-S-,-SO 2-,-NR 118C (O)-,-NR 119SO 2-or-NR 120(R wherein 118, R 119And R 120Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3And X alkyl), 5And R 22As above definition);
4) R 28(R wherein 28As above definition);
5) X 21R 29(X wherein 21Representative-O-,-S-,-SO 2-,-NR 121C (O)-,-NR 122SO 2-or-NR 123-(R wherein 121, R 122And R 123Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition); With
6) X 22C 1-3Alkyl R 29(X wherein 22Representative-O-,-S-,-SO 2-,-NR 124C (O)-,-NR 125SO 2-or-NR 126-(R wherein 124, R 125And R 126Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
In addition, R 113Can also be selected from following three groups of groups
7) R 29(R wherein 29As above definition);
8) X 22C 1-4Alkyl R 28(X wherein 22And R 28As above definition); With
9) R 54(C 1-4Alkyl) q(X 9) rR 55(q wherein, r, X 9, R 54And R 55As above definition).
This reaction can be easily in the presence of alkali (described in top method (a)), and preferably having in the presence of atent solvent or the diluent (described in top method (a)), in for example 0-150 ℃, carry out under preferred about 50 ℃ temperature.
Than method (c) and (d), more preferably method (a) and (b).
Than method (b), (c) and (d), more preferably method (a).
(e) preferably in the presence of aforesaid alkali, by making wherein substituent group (R 2) mBe the formula I chemical compound and the alkylation reactions of amino, can make these formulas I chemical compound and salt thereof, wherein substituent group (R 2) mIn one or more representative-NR 127R 128, R wherein 127And R 128One of (and another is a hydrogen) or the two be C 1-3Alkyl.This class alkylating agent is the C that has above-mentioned displaceable group 1-3The alkyl entity is as C 1-3Alkyl halide, for example C 1-3Alkyl chloride, bromide or iodide.Reaction is preferably carried out under for example 10-100 ℃ (preferably about room temperature) in the presence of atent solvent or diluent (as above described in the method (a)).Wherein one or more substituent R 2For the preparation of the formula I chemical compound of amino and salt thereof can be that the corresponding formula I chemical compound of nitro is realized by reducing one or more substituent groups on the quinazoline group relevant position wherein.Reduction can be carried out as described in following method (i) easily.According to front and back literary composition method (a-d) with the method (i-v), utilization is selected from the chemical compound (wherein the one or more substituent groups on the quinazolyl relevant position are nitro) of formula (I-XXII), and one or more substituent groups that can prepare on the quinazoline group relevant position wherein are the formula I chemical compound and the salt thereof of nitro.
(f) X wherein 1For-SO-or-SO 2-formula I chemical compound and salt thereof can be by oxidation X wherein 1For-S-or-the respective compound preparation of SO-(works as X 1For-SO 2-time then is that end product is needed).The conventional oxidizing condition and the reagent that are applicable to this type of reaction are that specialized scholar person is known.Synthesizing of intermediate
(i) for example, by halogenation formula XI chemical compound:
Figure A0080608501061
(R wherein 2As above define with m), can make wherein L 1Formula III chemical compound and salt thereof for halogen.
Suitable halogenating agent comprises inorganic carboxylic acid halides, for example thionyl chloride, Phosphorous chloride. (III), phosphorus oxychloride (V) and phosphorus pentachloride (V).Halogenation can be at atent solvent or diluent such as halogenated solvent (as dichloromethane, chloroform or carbon tetrachloride), or aromatic solvent (as benzene or toluene) exists down and carry out, and perhaps reacts and also can carry out under the situation of solvent-free existence.Reaction suits at for example 10-150 ℃, carries out under preferred 40-100 ℃ the temperature.
Formula XI chemical compound and salt thereof for example can be by making formula XII chemical compound: (R wherein 2, s and L 1Definition as above) with above-mentioned formula VIII compound.Reaction can be easily in the presence of alkali (described in top method (a)), and preferably in the presence of atent solvent or diluent (described in top method (a)), be preferable over for example 10-150 ℃, is preferably under about 100 ℃ temperature and carries out.
At least one R wherein 2Be R 5X 1, and X wherein 1For-O-,-S-,-SO-,-SO 2-,-C (O)-,-C (O) NR 7-,-SO 2NR 8-or-NR 10-(R wherein 7, R 8And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) formula XI chemical compound and salt thereof can also for example, make formula XIII chemical compound by following prepared in reaction:
Figure A0080608501072
(R wherein 2As above define with s, and X 1Then define as this paragraph preamble) react with above-mentioned formula VI chemical compound.Reaction for example can be carried out as described in top method (b).Then by with product and alkali such as ammonia, triethylamine/water, the hydroxide of alkali metal or alkaline-earth metal or alkoxide react in as alcohol (for example methanol or ethanol) at polar non-solute, cracking oxy acid methyl neopentyl group, the preferred ammonia of wherein used alkali, sodium hydrate aqueous solution or potassium hydroxide aqueous solution.The preference temperature of reaction is 20-100 ℃, preferred 20-50 ℃.
Formula XI chemical compound and salt thereof can also be by cyclisation formula XIV compound: (R wherein 2As above define with m, and A 1Be hydroxyl, alkoxyl (preferred C 1-4Alkoxyl) or amino), thereby form formula XI compound or its salt.Cyclization can be by making formula XIV chemical compound (A wherein 1Being hydroxyl or alkoxyl) equivalent can the initial ring cooperation used with Methanamide or its reacts and finishes, thus obtain formula XI compound or its salt, as [3-(dimethylamino)-2-azepine third-2-alkene subunit] alkyl dimethyl ammonium chloride.Cyclization should be in the presence of as the Methanamide of solvent or is carried out under atent solvent or diluent such as ether (for example 1,4-diox) exist.The temperature of cyclization is preferably high temperature, preferred 80-200 ℃.Formula XI chemical compound can also be by coming cyclisation formula XIV chemical compound (A wherein with formic acid or its equivalent that effective cyclization effect can take place 1Be amino) prepare, thus obtain formula XI or its salt.The formic acid equivalent that cyclisation can effectively take place comprises for example three-C 1-4Alkoxyl methane, for example triethoxy methyl and trimethoxy-methane.Cyclisation suits to carry out under catalytic amount anhydrous acid (for example right as sulfonic acid-toluenesulfonic acid) and atent solvent or diluent (as halogenated solvent dichloromethane for example, chloroform or carbon tetrachloride, ether such as ether or oxolane, or aromatic solvent such as toluene) exist.The temperature of cyclization is preferably for example 10-100 ℃, preferred 20-50 ℃.
Formula XIV chemical compound and salt thereof can be by the preparations of the nitro in the reduction-type XV chemical compound for example:
Figure A0080608501082
(R wherein 2, m and A 1Definition the same), thereby obtain above-mentioned formula XIV chemical compound.The reduction of nitro can adopt any known method that is fit to this class conversion to carry out easily.For example, reduction can be by at above-mentioned atent solvent or diluent with effectively in the presence of the metal of catalytic hydrogenation (as palladium or platinum), and the solution of stirring nitro compound carries out in the hydrogen-pressure of 1-4 atmospheric pressure.Other Reducing agent comprises that for example activated metal is as activation ferrum (for example by producing with dilute acid soln example hydrochloric acid washing iron powder).For example, reduction can in for example 50-150 ℃, be heated nitro compound and carry out by in the presence of the mixture of activated metal and solvent or diluent such as water and alcohol (for example methanol or ethanol) in the hydrogen-pressure of 2 atmospheric pressures under preferred about 70 ℃ temperature.
Formula XV chemical compound and salt thereof can be pressed described preparation: for example, make formula XVI chemical compound: (R wherein 1, s, L 1And A 1As above definition) with above-mentioned formula VIII chemical compound reaction, production XV chemical compound.The reaction of formula XVI and VIII chemical compound is suitable to be carried out under the condition described in the method (c) in the above.
At least one R wherein 2Be R 5X 1, and X wherein 1For-O-,-S-,-SO 2-,-C (O)-,-C (O) NR 7-,-SO 2NR 8-or-NR 10-(R wherein 7, R 8And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) formula XV chemical compound and salt thereof can also be pressed described preparation: for example make formula XVII chemical compound: (R wherein 2, s and A 1As above definition, and X 1Then as the definition of this paragraph front) and formula VI chemical compound reaction as defined above, formula XV chemical compound as defined above produced.The reaction of formula XVII and VI chemical compound is carried out under the described condition of method (b) in the above.
At least one R wherein 2Be R 5X 1, and X wherein 1For-CH 2-the formula III chemical compound and salt for example can be as mentioned above by formula XV (R wherein 2For-CH 3) or XIII (HX wherein 1-be-CH 3) chemical compound by following prepared in reaction: at first carry out free radical bromination or chlorination reaction, generation-CH 2Br or-CH 2The Cl group, and then be fit under the standard conditions of substitution reaction and formula R 5The reaction of-H chemical compound.
At least one R wherein 2Be R 5X 1, and X wherein 1For directly the formula III chemical compound and the salt thereof of key for example can be as mentioned above by formula XI compound, wherein R 5Group is present in already and is used for (for example being present in the formula XV chemical compound) in the intermediate of preparation formula XI chemical compound.
For example, by making wherein HX 1-be-NHR 6-or-NHR 9The formula XIII chemical compound and the formula R of-group (for example preparing (carrying out functionalized to the latter if desired) by gained amino) by the reduction nitro 5COCl or R 5SO 2The acyl chlorides of Cl or sulfonic acid chloride reaction can prepare wherein at least one R 2Be R 5X 1(X wherein 1For-NR 6C (O)-or-NR 9SO 2-) formula III chemical compound and salt thereof.
At least one R wherein 2Be R 5X 1, and X wherein 1For-O-,-S-,-SO 2-,-OC (O)-,-C (O) NR 7-,-SO 2NR 8-or-NR 10-(R wherein 7, R 8And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) formula III chemical compound and salt thereof also can be prepared as follows: for example, make formula XVIII chemical compound: (R wherein 2As above define X with s 1Define as this paragraph front, and L 2Represent replaceable protecting group) and formula VI chemical compound reaction as defined above, thereby formula III chemical compound, wherein L obtained 1By L 2Expression.
Should use wherein L 2Represent the formula XVIII chemical compound of phenoxy group, if necessary, phenoxy group wherein can have the substituent group of 5 of as many as, preferably has the substituent group of 2 of as many as, and these substituent groups are selected from halogen, nitro and cyano group.This reaction can be carried out under the described condition of method (b) easily in front.
Formula XVIII chemical compound and salt thereof for example can pass through deprotection formula XIX compound:
Figure A0080608501111
(R wherein 2, s and L 2As above definition, P 1Be protecting group, and X 1Then as described in the part of describing formula XVIII chemical compound).Protecting group P 1Selection belong to organic chemist's common practise; for example be included in standard textbook picture " protecting group in the organic synthesis " (T.W.Greene and R.G.M.Wuts; second edition; Wiley 199) in protecting group; these (for example comprise the N-sulfonyl-derivatives; ptoluene-sulfonyl), carbamate (for example tert-butyl group carbonyl), N-alkyl derivative (for example 2-chloroethyl, benzyl) and amido-acetal derivant (for example benzyloxymethyl).Removing of this class protecting group can adopt any known method (comprising the reaction condition of setting forth in for example above-mentioned standard textbook) or the correlation technique that are fit to this conversion to carry out.Deprotection can adopt the document known method to carry out, and for example, works as P 1When representing benzyl, deprotection can be handled by hydrogenolysis or with trifluoroacetic acid and realize.
If necessary, a kind of formula III chemical compound can be converted into wherein group L 1Another kind of formula III chemical compound inequality.For example, L wherein 1Can not press the described wherein L that changes into for the formula III chemical compound of halogen (for example being the optional phenoxy group that replaces) 1Formula III chemical compound for halogen: hydrolysis formula III chemical compound (L wherein 1Be not halogen), produce as the formula XI chemical compound of preceding definition, in the same formula XI chemical compound of the definition that so obtains, introduce halogenide then, produce wherein L 1Represent the formula III chemical compound of halogen.
(ii) its medium ring C is that the formula IV chemical compound of indyl and salt thereof can be with any method preparations known in the art, for example " Indoles Part I ", " Indo1es Part II ", 1972, John Wiley﹠amp; Sons Ltd and " Indoles Part III " 1979, JohnWiley﹠amp; The method of being put down in writing among the Sons Ltd (W.J.Houlihan edits).
The preparation example of the benzazolyl compounds embodiment that sees below, as embodiment 48,237,242,250 and 291.
Its medium ring C is that the formula IV chemical compound and the salt thereof of quinolyl can prepare with any method known in the art, for example see " The Chemistry of Heterocyclic Compounds:Quinolines Parts I; II and III ", 1982 (Interscience publishing house, John Wiley﹠amp; Sons Ltd, G.Jones edits) and " ComprehensiveHeterocyclic Chemistry Vol II by A.R.Katritzky " (1984Pergamon Press, A.J.Boulton and A McKillop edit) in the method put down in writing.
(iii) formula V chemical compound and salt thereof can be according to the method deprotection formula XX compound described in (i) above for example as defined above:
Figure A0080608501121
(its medium ring C, Z, R 1, R 2, P 1, the definition of n and s is the same, and X 1Then the description part suc as formula the V chemical compound defines).
Formula XX chemical compound and salt thereof can be prepared as follows: under the condition described in (a) above, make formula XIX and the reaction of IV chemical compound as defined above, production XX compound or its salt.
(iv) above-mentioned formula VII chemical compound and salt thereof can be prepared as follows: make formula XXI chemical compound:
Figure A0080608501122
(R wherein 2, s and each L 1L in the as above definition, and 4 on quinazoline ring 1With other locational another L 1Can be identical or different) and formula IV chemical compound reaction as defined above.Reaction can be carried out according to for example method described in top (a).
(v) above-mentioned formula IX chemical compound and salt thereof for example can be pressed described preparation: make the same formula V chemical compound of definition and the reaction of formula XXII chemical compound:
L 1-C 1-5Alkyl-L 1(XXII) (L wherein 1As above definition), obtain formula IX compound or its salt.The method described in (b) was carried out above reaction for example can be adopted.
(vi) X wherein 1For-SO-or-SO 2-intermediate can be by oxidation X wherein 1For-S-or-the respective compound preparation of SO-(works as X 1For-SO 2-time then is that end product is needed).The conventional oxidizing condition and the reagent that are applicable to this type of reaction are that specialized scholar person is known.
When needing the officinal salt of formula I chemical compound, available conventional method for example makes described chemical compound and for example has pharmaceutically acceptable anionic acid reaction preparation.
Many intermediate of this paper definition, for example formula V, VII, IX and XX chemical compound are noval chemical compound, and these chemical compounds have constituted another feature of the present invention.The preparation of these chemical compounds is as described herein and/or undertaken by organic chemistry filed professional known method.
Need effectively suppress the tyrosine kinase activity relevant by force to The compounds of this invention and confirm, and this also is one of theme of the present invention with the character that suppresses the rising of angiogenesis and/or vascular permeability with vegf receptor (as Flt and/or KDR).For example, these character can adopt one or more method evaluations hereinafter described: (a) extracorporeal receptor tyrosine kinase inhibition test
This test determination test-compound suppresses the ability of tyrosine kinase activity.Adopt the DNA in full gene synthetic (Edwards M, international Biotechnology Experiment chamber (InternationalBiotechnology Lab) 5 (3), 19-25,1987) or clone technology preparation coding VEGF, FGF or EGF recipient cytoplasm territory.Then they are expressed in suitable expression system, to obtain to have the polypeptide of tyrosine kinase activity.For example, can demonstrate intrinsic tyrosine kinase activity by VEGF, FGF and the EGF recipient cytoplasm domain discovery that obtains at the expressed in insect cells recombiant protein.For vegf receptor Flt (gene library registration number X51602), most of cytoplasm domain of encoding, originate in methionine 783 and comprise that the 1.7kbDNA fragment of termination codon (sees described (Oncogene such as Shibuya, 1990,5:519-524)) obtain and be cloned into by separating among the cDNA that (for example pAcYM1 is (referring to TheBaculovirus Expression System:A Laboratory Guide on the baculovirus transposition carrier, L.A.King and R.D.Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen company)).This recombination to construct thing and viral DNA (as Pharmingen BaculoGold) cotransfection are gone into insect cell (for example meadow mythimna separata 21 (Sf21)), the preparation recombinant baculovirus.(the method details of assembling recombinant DNA molecules and preparation and use recombinant baculovirus are seen standard textbook, people such as Sambrook for example, 1989, Molecular Cloning-A Laboratory Manual, second edition, people such as Cold SpringHarbour Laboratory Press and O ' Reilly, 1992, BaculovirusExpression Vectors-A Laboratory Mnual, W.H.Freeman and Co, New York).For other tyrosine kinase of using in the test, available similar approach clone and expression start from methionine 806 (KDR, gene library registration number L04947), methionine 668 (EGF receptor, gene library registration number X00588) and the kytoplasm fragment of methionine 399 (FGF R1 receptor, gene library registration number X51803).
For the expression of cFlt tyrosine kinase activity, the Sf21 cell is infected results after 48 hours with plaque pure cFlt recombinant virus with 3 infection multiplicity.The cell of results washs with ice-cold phosphate buffered saline(PBS) (PBS) (10mM sodium phosphate pH7.4,138mM sodium chloride, 2.7mM potassium chloride), be suspended in ice-cold HNTG/PMSF (20mM Hepes pH7.5 then, 150mM sodium chloride, 10%v/v glycerol, 1%v/v triton X100,1.5mM magnesium chloride, 1mM ethylene glycol-two (beta-amino ether) N, N, N ', N '-tetraacethyl (EGTA), 1mM PMSF (Phenylmethanesulfonyl fluoride); PMSF is only adding with freshly prepd 100mM methanol solution form with preceding), per 10 * 10 6Individual cell uses 1ml HNTG/PMSF.With 13,4 ℃ of centrifugal suspensions of 000rpm 10 minutes shift out supernatant (enzyme stock solution), and are distributed into several equal portions in-70 ℃ of storages.In test, each batch new system enzyme storage liquid is all used enzyme diluent (100mM Hepes pH7.4,0.2mM sodium orthovanadate, 0.1%v/v triton X100,0.2mM dithiothreitol, DTT) dilution titration.For typically a collection of, enzyme storage liquid dilutes with the enzyme diluent with 1/2000 ratio, and 50 μ l dilution enzyme is used in each mensuration hole.
With the atactic polymer that contains tyrosine [Poly (Glu for example, Ala, Tyr) 6: 3: 1 (Sigma P3899)] stock solution of preparation substrate solution, with the PBS stock solution form-20 ℃ storage of 1mg/ml, and be used for titer plate bag quilt with PBS dilution with 1/500 ratio.
Test the previous day, in the institute of assay plate (Nunc Maxisorp 96 holes immunity titer plate) is porose, distribute 100 μ l dilution substrate solution, seal also to place down and spend the night at 4 ℃.
Test the same day, discard substrate solution, will measure plate hole once with PBST (PBS that contains the 0.05%v/v polysorbas20) washing, and with 50mM Hepes pH7.4 washing once.
Test-compound is with 10% dimethyl sulfoxine (DMSO) dilution, and gets 25 μ l diluted compounds and change in the washed mensuration plate hole." always " control wells contains 10%DMSO and replaces chemical compound.Remove and comprise MnCl 2But do not have outside " blank " control wells of ATP, in all test holes, add 25 μ l 40mM contain 8 μ M adenosines-5 '-manganese chloride (II) of triphosphoric acid (ATP).Be to start reaction, in every hole, add 50 μ l new systems dilution enzyme, and with plate incubation 20 minutes at room temperature.Discard liquid then, each hole PBST washed twice.In each hole, add the anti-phosphotyrosine antibodies of 100 microliters of mouse IgG (the product 05-321 of Uptate biotech company) (diluting with the PBST that contains 0.5%w/v bovine serum albumin (BSA)) with 1/6000 ratio, and with plate incubation 1 hour at room temperature, discard liquid subsequently, wash each hole twice with PBST.Add 100 μ l horseradish peroxidases (HRP)-chain sheep anti mice Ig antibody (Amersham product NXA 931) (with containing the PBST of 0.5%w/v BSA) again with 1/500 dilution proportion, and with plate incubation 1 hour at room temperature, thereafter discard liquid, wash each hole twice with PBST.Every hole adds 100 μ l 2,2 '-(ABTS) solution of azine-two-(3-ethyl benzo thiazole phenanthroline-6-sulfonic acid), the i.e. fresh solution that in the freshly prepd 50mM phosphoric acid of 50ml-citrate buffer solution pH5.0+0.03% Dexol (being that every 100ml distilled water uses 1 phosphoric acid citrate buffer solution and Dexol (PCBS) capsule (Sigma P4922) to make), prepares with the ABTS sheet (Boehringer1204 521) of the heavy 50mg of a slice.Then at room temperature incubation 20-60 minute optical density value until " always " control wells that adopts dull and stereotyped reading spectrophotometer to record at the 405nm place of plate is about 1.0." blank " (no ATP) and " always " (no chemical compound) contrast class value are used to measure test-compound and produce the dilution range that 50% enzymatic activity suppresses.(b) external HUVEC increment test
This test determination test-compound suppresses the value-added ability of Human umbilical vein endothelial cells (HUVEC) of factors stimulated growth.
In MCDB131 (Gibco BRL)+7.5%v/v hyclone (FCS), separate the HUVEC cell, and this cell is tiled in MCDB 131+2%v/v FCS+3 μ g/ml heparin+1 μ g/ml hydrocortisone in (2-8 is for passage cell) 96 well culture plates with the concentration of 1000 cells/well.After minimum 4 hours, in them, add suitable somatomedin (being VEGF 3ng/ml, EGF 3ng/ml or b-FGF 0.3ng/ml) and chemical compound.Then with culture at 37 ℃ and 7.5%CO 2Under hatched 4 days, the 4th day, culture was with 1 μ Ci/ hole deuterate thymidine (Amersham product TRA61) pulse and hatched 4 hours.Adopt dull and stereotyped harvesting device (Tomtek) harvesting in 96-hole, measure the incorporation of deuterium then with β-plate count device.Measure chemical compound to the value-added inhibition of the cell of factors stimulated growth with value of mixing (representing) of radioactivity in the cell with cpm.(c) solid tumor disease model in the body
This test determination chemical compound suppresses the ability of solid tumor growth.
By subcutaneous injection 1 * 10 6The 100 μ l 50%Matrigel/ serum-free culture based sols of Calu-6 cell/mice are at the flank structure Calu-6 of female athymism Sweiss nu/nu Mus tumor xenogeneic graft.Behind the cell transplantation 10 days, with mice group, every group of 8-10 only, to obtain the reference group average external volume.Use vernier caliper measurement tumor size and calculate gross tumor volume according to following formula: (l * w) * √ (l * w) * (π/6), wherein l represents maximum gauge length, and w representative and the orthogonal diameter length of maximum gauge.The oral administration test-compound, once a day, minimum successive administration 21 days, control animals is given and is used the diluted chemical compound agent simultaneously.Measure tumor weekly twice.Utilize Student T check and/or Mann-WhitneyRank Sum check, by the mean tumour volume calculating growth inhibited degree of comparative control group and processed group.When p＜0.05, think that the inhibition effect of chemical compound is a significance.
Another aspect of the present invention provides pharmaceutical composition, and it comprises above-mentioned formula I compound or pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipient or carrier.
The present composition can (comprise vein for the form (for example tablet or capsule) that is fit to oral administration, the injection of non-intestinal, subcutaneous, intramuscular, in the blood vessel or infusion) form (sterile solution for example, suspension or emulsion), the form (for example ointment or cream) of local application, or the form of rectal administration (for example suppository).In general, above-mentioned composition can adopt conventional excipients to prepare according to conventional methods.
The present composition should exist with unit dosage form.Usually, chemical compound is with every square metre of animal body surface area 5-5000mg, and promptly approximately the 0.1-100mg/kg unit dose imposes on homoiothermic animal.The unit dose scope of setting is for example 1-100mg/kg, preferred 1-50mg/kg, and this has also constituted the treatment effective dose usually.Unit dosage form such as tablet or capsule contains for example active component of 1-250mg usually.
The above-mentioned formula I compound or pharmaceutically acceptable salt thereof that is used for the human or animal body Therapeutic Method that provides on the one hand more of the present invention.
We find that The compounds of this invention can suppress the vegf receptor tyrosine kinase activity, thereby have valuable blood vessel formation against function and/or cause the ability that vascular permeability reduces.
Another feature of the present invention relates to the formula I compound or pharmaceutically acceptable salt thereof as medicine, and suitable is as the formula I compound or pharmaceutically acceptable salt thereof that produces the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect in homoiothermic animal such as human body.
Therefore, another aspect of the present invention has provided formula I compound or pharmaceutically acceptable salt thereof is used for producing the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect in homoiothermic animal such as human body in production application.
One side more of the present invention has provided the method that produces angiogenesis inhibitor and/or vascular permeability reduction effect in the homoiothermic animal of this treatment of need such as human body, and this method comprises the above-mentioned formula I compound or pharmaceutically acceptable salt thereof of described animal being used effective dose.
As mentioned above, the size of therapeutic or prophylactic treatment specified disease required dosage is inevitable with the host who is treated, the order of severity of the route of administration and the disease of controlling and changing.The preferred daily dose that uses is 1-50mg/kg.Yet daily dose also must be with the host who is treated, the order of severity of concrete route of administration and the disease of controlling and changing.Therefore, optimal dose should be by attending doctor's decision of any particular patient of treatment.
Angiogenesis inhibitor mentioned above and/or vascular permeability reduce treatment and can be used for the treatment of separately, perhaps also can comprise one or more other material and/or therapeutants except that The compounds of this invention.This therapeutic alliance can or be used the single therapy component respectively and realize by while, order.In the medical science oncology, common practice is to unite to use dissimilar Therapeutic Method to treat each cancer patient.With regard to the medical science oncology, this therapeutic alliance other Therapeutic Method except that angiogenesis inhibitor mentioned above and/or vascular permeability reduction treatment can be surgery art, X-ray therapy or chemotherapy.This chemotherapy relates to three kinds of main type therapeutic agents:
(i) other anti-angiogenic agent, their mechanism of action is different from anti-angiogenic agent mentioned above (linomide for example, beta 2 integrin alpha ν β 3 depressant of functions, angiostatin, tetrahydroform, neurosedyn), and comprise (for example blood vessel injury agent described in the open WO99/02166 of combretastationphosphate and international patent application of blood-vessels target medicine, the full content of the document is incorporated into incorporated by reference at this, (for example N-acetyl group Colchinol-O-phosphate ester (N-acetylcolchinol-O-phosphate)));
(ii) cell arrestant such as estrogen antagonist agent (tamoxifen for example, toremifene, raloxifene, droloxifene, iodoxyfene), progestogen (for example megestrol), aromatase inhibitor (anastrozole for example, letrazole, vorazole, Exemastine), onapristone, antiandrogen (flutamide for example, Nilutamide, bicalutamide, cyproterone acetate), LHRH agonist and antagonist are (as the acetic acid goserelin, luprolide), testosterone 5 α-dihydro reductase inhibitor (for example Fei Nataide), resist and infect agent (for example inhibitors of metalloproteinase is as marimastat and urokinase-type plasminogen activator function of receptors inhibitor) and somatomedin depressant of functions, (this class somatomedin comprises for example platelet derived growth factor and hepatocyte growth factor, and this class inhibitor comprises growth factor antibodies, growth factor receptor antibody, tyrosine kinase inhibitor and serine/threonine kinase inhibitor); With
(iii) antiproliferative/antineoplastic agent and the compositions of using among the medical science oncology thereof is as antimetabolite (for example antifol is as methotrexate, and the fluorine miazines is as 5-fluorouracil, purine and neplanocin, cytosine arabinoside); Antitumor antibiotics (for example the anthracene nucleus class is as amycin, the erythromycin of mixing, epirubicin and the Yi Da mycin that softens, crust ametycin, dactinomycin, mithramycin); Platinum derivatives (for example along ammonia ammonia platinum, carboplatin); Alkylating agent (chlormethine for example, melphalan, chlorambucil, Busulfan, cyclophosphamide, ifosfamide, nitroso ureas, thiophene is for group); Antimitotic agent (for example vinca alkaloids as vincristine and taxanes as taxol, taxotere); Topoisomerase enzyme inhibitor (for example epipodophyllotoxin is as etoposide and teniposide, and amsacrine asks pool to replace and bears, and irinotecan); Also has enzyme (Aspartase); And thymidylate synthetase inhibitor (for example raltitrexed); And the chemotherapeutant of other type comprises:
(iv) biological response modifier (for example interferon); With
(v) antibody (for example edrecolomab).
For example, this therapeutic alliance can be by simultaneously, order or use the formula I chemical compound of the above single definition of institute respectively and WO99/02166 in blood-vessels target agent such as N-acetyl group Colchinol-O-phosphate ester (embodiment 1 of the WO99/02166) realization described.
As mentioned above, The compounds of this invention has valuable angiogenesis inhibitor and/or vascular permeability reduction effect.Thereby estimate that these chemical compounds of the present invention can be used for multiple disease, comprise cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi sarcoma, hemangioma (haemangioma), acute and chronic nephropathy, sebaceous cyst, arterial restenosis, autoimmune disease, acute inflammation, cicatrization and adhesion are excessive, endometriosis, anovulatory dysfunctional uterine hemorrhage and the oculopathy relevant with the retinal vessel hypertrophy.Estimate that particularly these chemical compounds of the present invention help slowing down for example constitutional of colon, mammary gland, prostate, lung and skin and the growth of recurrent solid tumor.More specifically say it is that these chemical compounds of the present invention are estimated to suppress the originality relevant with VEGF and the growth of recurrent solid tumor, especially those its growths and diffusion obviously depend on the solid tumor of VEGF, comprise some tumors on for example colon, mammary gland, prostate, lung, pudendum and the skin.
Except the use in medicine, formula I chemical compound and officinal salt thereof can also be used as pharmacological tool estimating the development of vegf receptor tyrosine kinase activity inhibitor to the external of laboratory animal effect and in vivo test system aspect standardization, thereby as the part of exploitation novel treatment, wherein said laboratory animal comprises as cat, Canis familiaris L., rabbit, monkey, rat and mice.
Should be appreciated that used term " ether " is meant ether in this description.
The present invention is illustrated with following non-limiting examples at this, wherein unless otherwise indicated:
(i) evaporation is to be undertaken by rotary evaporation in a vacuum, and post-processing step is to carry out after the residual solids such as desiccant in filtering;
(ii) operate in room temperature and be under 18-25 ℃ the temperature and under noble gas such as argon, carry out;
(iii) column chromatography (fast process) and medium pressure liquid chromatography (MPLC) are available from E.Merck, and Darmstadt carries out on the Merck Kieselgel silica gel (Art.9385) of Germany or MerckLichroprep RP-18 (Art.9303) reverse phase silica gel;
(iv) the yield of giving only for illustrative, and obtainable maximum yield not necessarily;
(v) fusing point is not calibrated, uses the automatic fusing point instrument of Mettler SP62, oil bath device or Koffler hot plate apparatus to measure.
(vi) the structure of formula I end product is confirmed by nuclear (being generally proton) magnetic resonance (NMR) and mass-spectrometric technique; The proton magnetic resonance chemical displacement value is represented with δ, and the multiplicity at peak is expressed as follows: s, and unimodal; D, bimodal; T, triplet; M, multiple peak; Br, broad peak; Q, quartet, quin, quintet;
(vii) intermediate does not fully characterize usually, and its purity is passed through thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and infrared (IR) or NMR analyze and determine;
(viii) HPLC carries out under following two kinds of different conditions:
1) on the super ODS 2 μ M 4.6mm * 5cm posts of TSK Gel, carry out, in 5 minutes with the 20-100% gradient liquid eluting of methanol in water (containing 1% acetic acid).Flow velocity 1.4ml/ minute.Detect: U.V., 254nm, light scattering detects;
2) on the super ODS 2 μ M 4.6mm * 5cm posts of TSK Gel, carry out, in 7 minutes with the 0-100% gradient liquid eluting of methanol in water (containing 1% acetic acid).Flow velocity 1.4ml/ minute.Detect: U.V., 254nm, light scattering detects;
(ix) petroleum ether refers to that boiling point is between 40-60 ℃ fraction.
(x) use following abbreviation-:
DMF N.N-dimethyl formamide
The DMSO dimethyl sulfoxine
The TFA trifluoroacetic acid
The NMP 1-Methyl-2-Pyrrolidone
The THF oxolane
HMDS 1,1,1,3,3, the 3-hexamethyldisiloxane
HPLC RT HPLC retention time
The DEAD diethylazodicarboxylate
The DMA dimethyl acetylamide
DMAP 4-dimethylamino naphthyridine embodiment 1
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol), potassium carbonate (106mg, 0.77mmol) and the 6-hydroxyquinoline (112mg, 0.77mmol) mixture in DFF (7.5ml) is 5 hours, is cooled to room temperature then.With 1M sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.The solid collected by filtration crude product also washes with water.The gained solid is dissolved in dichloromethane (2ml), filters by phase separation paper.Vacuum evaporation filtrate, residue is developed with ether, filters then and collects, and drying obtains 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-6-base oxygen base) quinazoline (163mg, 55%). 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H); 2.40 (m, 4H); 2.48 (t, 2H); 3.59 (m, 4H); 4.00 (s, 3H); 4.25 (t, 2H); 7.40 (s, 1H); 7.58 (m, 1H); 7.62 (s, 1H); 7.74 (dd, 1H); 7.92 (d, 1H); 8.10 (d, 1H); 8.38 (d, 1H); 8.55 (s, 1H); 8.92 (m, 1H) MS (ESI): 447 (MH) +Elementary analysis: measured value C65.9 H5.7 N12.4C 25H 26N 4O 40.5H 2O value of calculation C65.9 H6.0 N12.3%
Initial substance is prepared as follows:
Stir down, reflux 2-amino-4-benzyloxy-5-methoxy benzamide (10g, 0.04mol), (J.Med.Chem.1977, vol 20, and 146-149) (7.4g, 0.05mol) the mixture in the Zai diox (100ml) is 24 hours with Gold reagent.In reactant mixture, add sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml 0.029mol), further heated 3 hours.Steam and remove volatile matter, add entry in residue, filter and collect the gained solid, washing is also dry.With obtaining 7-benzyloxy-6-methoxyl group-3 behind the acetic acid recrystallization, 4-dihydroquinazoline-4-ketone (8.7g, 84%).
With 7-benzyloxy-6-methoxyl group-3, (35g 124mmol) is suspended among thionyl chloride (440ml) and the DMF (1.75ml) reflux 4 hours to 4-dihydroquinazoline-4-ketone.Vacuum evaporation thionyl ammonia, and with residue with toluene azeotropic three times.And then residue is dissolved in NMP (250ml), obtain 7-benzyloxy-4-chloro-6-methoxyl group quinazoline.
(29.05g 309mmol) is dissolved in NMP (210ml), adds sodium hydride (11.025g, 60% mineral oil disperses thing) under cooling in batches, stirs the gained mixture then 3 hours with phenol.Add NMP (180ml) dilution gained viscous suspension, further stir and spend the night.Add 7-benzyloxy-4-chloro-6-methoxyl group quinazoline solution then, 100 ℃ were stirred the gained suspension 2.5 hours.Cooling suspension is poured under vigorous stirring in the water (1.51) to room temperature.Filter the collecting precipitation thing, washing and vacuum drying.And then residue is dissolved in dichloromethane, and use the salt water washing, filter by phase separation paper then.Vacuum evaporation filtrate with the ether development, gets shallow white solid 7-benzyloxy-6-methoxyl group-4-phenoxy group quinazoline (87.8g, 83%) subsequently. 1H NMR spectrum: (CDCl 3) 4.09 (s, 3H); 5.34 (s, 2H); 7.42 (m, 12H); 7.68 (s, 1H) MS (ESI): 359 (MH) +
(36.95g 105.5mmol) is suspended in TFA (420ml), reflux 3 hours with 7-benzyloxy-6-methoxyl group-4-phenoxy group quinazoline.Reaction mixture, vacuum evaporation then.With residue mechanical agitation in water,, and stir and spend the night thereafter with the saturated aqueous solution of sodium bicarbonate alkalization.Decantation water is suspended in acetone with solids.After the stirring, filter and collect white solid,, thereby obtain 7-hydroxyl-6-methoxyl group-4-phenoxy group quinazoline (26.61g, 96%) with washing with acetone and dry. 1H NMR spectrum: (DMSOd 6) 3.97 (s, 3H); 7.22 (s, 1H); 7.30 (m, 3H); 7.47 (t, 2H); 7.56 (s, 1H); 8.47 (s, 1H); 10.70 (s, 1H) MS (ESI): 269 (MH) +
(52.2ml, 600mmol) (30ml 300mmol) is dissolved in dry toluene (180ml), is heated to 70 ℃ of reactions 3 hours with 1-bromo-3-chloropropane with morpholine.Filtering solids, and vacuum evaporation filtrate.Decantation goes out the grease that is produced in thus obtained solid residue, and then the vacuum distilling latter gets 1-chloro-3-morpholino propane (37.91g, 77%), is a grease. 1H NMR spectrum: (DMSOd 6) 1.85 (m, 2H); 2,30 (t, 4H); 2.38 (t, 2H); 3.53 (t, 4H); 3.65 (t, 2H) MS (ESI): 164 (MH) +
With 7-hydroxyl-6-methoxyl group-4-phenoxy group quinazoline (25.27g, 0.1mol) and 1-chloro-3-morpholino propane (18.48g 0.11mol) absorbs in the DMF (750ml), add potassium carbonate (39.1g, 0.33mmol).90 ℃ were heated this suspension 3 hours, and were cooled off then.Filtering suspension liquid, and remove volatile matter by evaporation.Residue and then with ethyl acetate development filters and collects yellow crystal solid 6-methoxyl group-7-(3-morpholino propoxyl group)-4-phenoxy group quinazoline (31.4g, 84%). 1H NMR spectrum: (DMSOd 6) 1.97 (m, 2H); 2.39 (t, 4H); 2.47 (t, 2H); 3.58 (t, 4H); 3.95 (s, 3H); 4.23 (t, 2H); 7.31 (m, 3H); 7.36 (s, 1H); 7.49 (t, 2H); 7.55 (s, 1H); 8.52 (s, 1H) MS (ESI): 396 (MH) +
(33.08g 84mmol) is dissolved in 6M aqueous hydrochloric acid solution (800ml), reflux 1.5 hours with 6-methoxyl group-7-(3-morpholino propoxyl group)-4-phenoxy group quinazoline.The decantation reactant mixture, and be concentrated into 250ml, then with saturated aqueous solution of sodium bicarbonate alkalization (pH9).(4 * 400ml) extract water layer, tell organic layer, filter by phase separation paper with dichloromethane.Solids is developed with ethyl acetate, thereby obtains white solid 6-methoxyl group-7-(3-morpholino propoxyl group)-3,4-dihydroquinazoline-4-ketone (23.9g, 89%). 1H NMR spectrum: (DMSOd 6) 1.91 (m, 2H); 2.34 (t, 4H); 2.42 (t, 2H); 3.56 (t, 4H); 3.85 (s, 3H); 4.12 (t, 2H); 7.11 (s, 1H); 7.42 (s, 1H); 7.96 (s, 1H); 12.01 (s, 1H) MS (ESI): 320 (MH) +
With 6-methoxyl group-7-(3-morpholino propoxyl group)-3, (23.9g 75mmol) is suspended among thionyl chloride (210ml) and the DMF (1.8ml) 4-dihydroquinazoline-4-ketone, and reflux is 1.5 hours then.Vacuum steam to be removed thionyl chloride, and with residue and methylbenzene azeotropic three times.And then the gained residue absorbed in the water, with saturated aqueous solution of sodium bicarbonate alkalization (pH8).(4 * 400ml) extract water layer, and water and salt water washing organic layer, dry then (MgSO with dichloromethane 4).After the filtration, the vacuum concentration organic layer obtains a yellow solid, and then the development of reuse ethyl acetate, thereby obtains Off-white solid 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (17.39g, 52%). 1H NMR spectrum: (CDCl 3) 2.10-2.16 (m, 2H); 2.48 (brs, 4H); 2.57 (t, 2H); 3.73 (t, 4H); 4.05 (s, 3H); 4.29 (t, 2H); 7.36 (s, 1H); 7.39 (s, 1H); 8.86 (s, 1H) MS-ESI:337[MH] +Embodiment 2
Stir down, 100 ℃ of heating 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol), (as preparation as described in the embodiment 1 initial substance part), potassium carbonate (106mg, 0.77mmol) and 7-hydroxyquinoline (112mg, 0.77mmol) mixture in DMF (7.5ml) 5 hours, be cooled to room temperature then.Reactant mixture is handled with 1M sodium hydrate aqueous solution (40ml), and stirred for several minute at room temperature.The solid collected by filtration crude product washes with water.The gained solid is dissolved in dichloromethane (2ml), and filters by phase separation paper.Vacuum evaporation filtrate obtains solid residue.The latter obtains 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (116mg, 39%) again after ether development, filtration, drying. 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H); 2.39 (m, 4H); 2.48 (t, 2H); 3.59 (m, 4H); 4.00 (s, 3H); 4.25 (t, 2H); 7.40 (s, 1H); 7.58 (m, 2H); 7.62 (s, 1H); 7.92 (d, 1H); 8.10 (d, 1H); 8.44 (d, 1H); 8.55 (s, 1H); 8.92 (m, 1H) MS (ES): 447 (MH) +
Elementary analysis: measured value C66.6 H5.7 N12.4C 25H 26N 4O 40.25H 2O value of calculation C66.6 H5.9 N12.4% embodiment 3
Stir down, 100 ℃ of heating 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol), (as preparation as described in the embodiment 1 initial substance part), potassium carbonate (106mg, 0.77mmol) and 1-naphthols (111mg, 0.77mmol) mixture in DMF (7.5ml) 5 hours, be cooled to room temperature then.With 1M sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.Thereafter use the ethyl acetate extraction reactant mixture, and organic extract is washed with water.Dry (magnesium sulfate) organic extract, steaming subsequently desolventizes.Residue and then by the column chromatography purification, with methylene chloride (95/5) eluting, obtain a solids, the development of latter's reuse ether, obtain 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(1-naphthoxy) quinazoline (194mg, 65%) after filtration with after the drying. 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H); 2.39 (m, 4H); 2.48 (t, 2H); 3.59 (m, 4H); 4.00 (s, 3H); 4.26 (t, 2H); 7.40 (s, 1H); 7.48 (m, 2H); 7.58 (m, 2H); 7.74 (s, 1H); 7.75 (d, 1H); 7.92 (d, 1H); 8.03 (d, 1H); 8.42 (s, 1H) MS (ES): 446 (MH) +
Elementary analysis: measured value C69.9 H6.2 N9.4C 26H 27N 3O 4Value of calculation C70.1 H6.1 N9.4% embodiment 4
Stir down, 100 ℃ of heating 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol), (as preparation as described in the embodiment 1 initial substance part), potassium carbonate (106mg, 0.77mmol) and 7-hydroxy-4-methyl quinoline (122mg, 0.77mmol), (Chem.Berich.1967,100,2077), mixture in DMF (7.5ml) 5 hours is cooled to room temperature then.With 1M sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.The solid collected by filtration crude product washes with water.Then the gained solid is dissolved in dichloromethane (2ml), and filters by phase separation paper.Vacuum evaporation filtrate obtains solid residue, latter's reuse ether development, after filtration, obtain 6-methoxyl group-4-(4-methylquinoline-7-base oxygen base)-7-(3-morpholino propoxyl group)-quinazoline (175mg, 57%) after the drying. 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H); 2.39 (m, 4H); 2.48 (t, 2H); 2.71 (s, 3H); 3.59 (m, 4H); 4.00 (s, 3H); 4.26 (t, 2H); 7.40 (s, 1H); 7.41 (m, 1H); 7.61 (dd, 1H); 7.62 (s, 1H); 7.90 (d, 1H); 8.20 (d, 1H); 8.52 (s, 1H); 8.78 (d, 1H) MS (ESI): 461 (MH) +
Elementary analysis: measured value C67.1 H5.9 N12.1C 26H 28N 4O 40.2H 2O value of calculation C67.3 H6.2 N12.1% embodiment 5
Stir down, (3-(1 for 100 ℃ of heating 4-chloro-7-, 1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group quinazoline (220mg, 0.57mmol), potassium carbonate (106mg, 0.77mmol) and 7-hydroxyquinoline (111mg, 0.76mmol) mixture in DMF (7.5ml) 5 hours, be cooled to room temperature then.Reactant mixture is handled with 1M sodium hydrate aqueous solution (40ml), and stirred for several minute at room temperature.The solid collected by filtration crude product washes with water.And then the gained solid is dissolved in dichloromethane (2ml), and filter by phase separation paper.Vacuum evaporation filtrate is with gained solid residue reuse ether development, after filtration, obtain 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline (205mg, 73%) after the drying. 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H); 2.65 (t, 2H); 2.92 (m, 4H); 3.10 (m, 4H); 4.00 (s, 3H); 4.28 (t, 2H); 7.42 (s, 1H); 7.58 (m, 2H); 7.64 (s, 1H); 7.92 (d, 1H); 8.10 (d, 1H); 8.44 (d, 1H); 8.55 (s, 1H); 8.92 (m, 1H) MS (ESI): 495 (MH) +
Elementary analysis: measured value C60.0 H5.0 N11.1C 25H 26N 4O 5S0.25H 2O value of calculation C60.2 H5.4 N11.2%
Initial substance is prepared as follows:
With 7-benzyloxy-6-methoxyl group-3, and 4-dihydroquinazoline-4-ketone (20.3g, 124mmol), (as preparation as described in the initial substance part among the embodiment 1) is dissolved in thionyl chloride (440ml) and DMF (1.75ml), and reflux is 4 hours then.The vacuum evaporation thionyl chloride, and with residue with toluene azeotropic three times, thereby obtain 7-benzyloxy-4-chloro-6-methoxyl group quinazoline.
Under 100 ℃, stir 7-benzyloxy-4-chloro-6-methoxyl group quinazoline crude product, (50mg, 362mmol) (8.8ml, 83mmol) mixture in DMF (500ml) is 5 hours, is cooled to ambient temperature overnight then with 4-chloro-2-fluorophenol for potassium carbonate.Reactant mixture is poured in the water (21), at room temperature stirred for several minute.The solid collected by filtration crude product washes with water.Subsequently the gained solid is dissolved in dichloromethane, and passes through diatomite filtration.Filtrate is handled with decolouring coal, and boiling number minute then passes through diatomite filtration.Filtrate is filtered by phase separation paper, and vaporising under vacuum obtains a solid residue then, and then with the ether development, filters and drying, thereby obtain 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline (23.2g, 76%). 1H NMR spectrum: (DMSOd 6) 3.98 (s, 3H); 5.34 (s, 2H); 7.42 (m, 9H); 7.69 (dd, 1H); 8.55 (s, 1H) MS (ESI): 411 (MH) +
(1.4g 3.4mmol) is suspended in TFA (15ml), reflux 3 hours with 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline.Reaction mixture adds toluene then, and removes volatile matter by vacuum evaporation.Residue is successively with ether and acetone development.Filter the collecting precipitation thing, drying obtains 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline (21.8g).This product need not to be further purified and is directly used in next step. 1H NMR spectrum: (DMSOd 6) 3.97 (s, 3H); 7.22 (s, 1H); 7.39 (d, 1H); 7.53 (m, 2H); 7.67 (dd, 1H); 8.46 (s, 1H) MS (ESI): 321 (MH) +
(650 μ l are 8.4mmol) with vinyl sulfone(Remzaol (1g, mixture 8.4mmol) 45 minutes for 110 ℃ of heating 3-amino-1-propanol.Cooling gained mixture, and then by the column chromatography purification, with methylene chloride (95/5) eluting, 3-(1,1-dioxo thiomorpholine generation)-1-propanol (800mg, 90%). 1H NMR spectrum: (CDCl 3) 1.7-1.8 (m, 2H); 2.73 (t, 2H); 3.06 (brs, 8H); 3.25 (s, 1H); 3.78 (t, 2H) MS-ESI:194[MR] +
(5.0g 15.6mmol) is suspended in dichloromethane (150ml), and (11.1ml 44.6mmol), then at room temperature stirred 30 minutes to add three fourth phosphines with 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline.In this mixture, add 3-(1,1-dioxo thiomorpholine generation)-1-propanol (4.2g, 21.8mmol), then add 1,1 more in batches '-(azo dicarbapentaborane) two piperidines (11.7g, 46.4mmol).Stirring at room gained mixture overnight is used ether (300ml) dilution then, and the filtering precipitate.The silica gel column chromatography residue is with dichloromethane and methanol (95/5) eluting.Merge relevant fraction, evaporation obtains solids, and then reuse ethyl acetate development, filters and dry, thereby obtains 4-(4-chloro-2-fluorophenoxy)-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group quinazoline (5.4g, 70%).This product need not to be further purified and is directly used in down the step. 1H NMR spectrum: (DMSOd 6) 1.86 (m, 2H); 2.65 (t, 2H); 2.92 (m, 4H); 3.08 (m, 4H); 3.97 (s, 3H); 4.26 (t, 2H); 7.40 (m, 1H); 7.42 (s, 1H); 7.56 (m, 2H); 7.68 (ddd, 1H); 8.54 (s, 1H) MS (ESI): 496 (MH) +
Elementary analysis: measured value C52.7 H4.4 N8.3C 22H 23N 3ClFO 5S0.25H 2O value of calculation C52.8 H4.7 N8.4%
(3.5g 7mmol) is dissolved in 2M aqueous hydrochloric acid solution (56ml), 95 ℃ of heating 2 hours with 4-(4-chloro-2-fluorophenoxy)-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group quinazoline.Handle cooled reactant mixture with solid sodium bicarbonate, obtain viscous pastes, and then thin up and filtration.Solids is transferred in the flask,, obtained drying solid with toluene azeotropic twice.By this solids of flash chromatography on silica gel, with dichloromethane and methanol (95/5) eluting.Merge relevant fraction, evaporation obtains white solid 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (2.26g, 87%).MS(ESI)：368(MH) +
With 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-3, (4.2g, 11.4mmol) among suspension thionyl chloride (45ml) and the DMF (0.1ml), reflux is 2.5 hours then for 4-dihydroquinazoline-4-ketone.Residue dilution with toluene, and vacuum evaporation thionyl chloride wherein are then with residue and methylbenzene azeotropic three times.The residue that obtains at last is absorbed in the water, with saturated aqueous solution of sodium bicarbonate alkalization (pH8).Water layer extracts with dichloromethane (x4), and with organic layer water and salt water washing, filters by phase separation paper then.The vacuum concentration organic layer obtains an orange solids.This solids is passed through flash chromatography on silica gel, with dichloromethane and methanol (95/5) eluting.Merge relevant fraction, evaporation obtains a solid, and then reuse ether development, and subsequent filtration is also dry, thereby obtains 4-chloro-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group quinazoline (2.27g, 52%).MS (ESI): 386 (MH) +. embodiment 6
With 6,7-dimethoxy-3, (290mg 1.4mmol) is suspended among thionyl chloride (5ml) and the DMF (2) reflux 2 hours to 4-dihydroquinazoline-4-ketone.Vacuum steam to be removed thionyl chloride then, and with residue with toluene azeotropic three times, obtain 4-chloro-6, the 7-dimethoxyquinazoline.Stir down, 100 ℃ of these 4-chloro-6 of heating, (970mg, 7mmol) (235mg, 1.62mmol) mixture in DMF (10ml) is 5 hours, is cooled to room temperature then with the 7-hydroxyquinoline for 7-dimethoxy-quinazoline crude product, potassium carbonate.With 1M sodium hydrate aqueous solution reaction mixture, and stirred for several minute at room temperature.
Reactant mixture is extracted with ethyl acetate (x4), and water and salt water washing organic extract.Thereafter dry (magnesium sulfate) organic extract filters and solvent removed in vacuo.Residue and then with ethyl acetate development, and use the hot ethyl acetate recrystallization, thus obtain 6,7-dimethoxy-4 '-(the basic oxygen base of quinoline-7-) quinazoline white solid (110mg, 24%). 1H NMR spectrum: (DMSOd 6) 4.00 (s, 3H); 4.00 (s, 3H); 7.40 (s, 1H); 7.59 (m, 3H); 7.92 (d, 1H); 8.08 (d, 1H); 8.42 (d, 1H); 8.55 (s, 1H); 8.92 (dd, 1H) MS (ESI): 334 (MH) +
Elementary analysis: measured value C68.2 H4.3 N12.5C 19H 15N 3O 3Value of calculation C68.5 H4.5 N12.6%
Initial substance is prepared as follows:
Stir down 190 ℃ of heating 4, the mixture of 5-dimethoxy ortho-aminobenzoic acid (19.7g) and Methanamide (10ml) 5 hours.Cooling mixture adds entry (50ml) to about 80 ℃ then.Mixture was at room temperature placed 3 hours thereafter.Filter the collecting precipitation thing, washing obtains 6,7-dimethoxy-3,4-dihydroquinazoline-4-ketone (3.65g) after the drying.Embodiment 7
100 ℃ are stirred (R, S)-4-chloro-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (183mg, 0.57mmol), potassium carbonate (106mg, 0.77mmol) and 7-hydroxyquinoline (111mg, 0.77mmol) mixture in DMF (7ml) 5 hours, be cooled to room temperature then.Reactant mixture is handled with 1M sodium hydrate aqueous solution (30ml), stirs 10 minutes.The solid collected by filtration crude product, and wash with water.The gained solid is dissolved in dichloromethane (2ml), filters by phase separation paper.Vacuum evaporation filtrate then, and with the solid residue reuse ether development that obtains, filter, obtain after the drying scalemic mixture (149mg, 61%) of 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.10 (m, 1H); 1.51 (m, 1H); 1.64 (m, 1H); 1.85 (m, 3H); 2.09 (m, 1H); 2.15 (s, 3H); 2.62 (m, 1H); 2.82 (m, 1H); 3.99 (s, 3H); 4.09 (d, 2H); 7.38 (s, 1H); 7.55 (m, 2H); 7.63 (s, 1H); 7.91 (d, 1H); 8.10 (d, 1H); 8.44 (d, 1H); 8.54 (s, 1H); 8.93 (d, 1H) MS (ESI): 431 (MH) +
Elementary analysis: measured value C68.7 H5.7 N12.8C 25FH 26N 4O 40.3H 2O value of calculation C68.9 H6.2 N12.8%
Initial substance is prepared as follows:
With (R)-nipecotic acid ethyl ester (5.7g, 365mmol), (as J.Org.Chem.1991, (56), 1168 is described, split the preparation of nipecotic acid ethyl ester by handling with L (+)-tartaric acid) be dissolved in 38.5% formalin (45ml) and formic acid (90ml), and heated this mixture 18 hours.Cooling mixture, and then dropwise be added in the saturated cold soln of sodium bicarbonate.The pH to 12 that hydro-oxidation sodium is regulated mixture uses the dichloromethane extraction mixture then.Organic extract salt water washing, dry (magnesium sulfate) and steaming desolventize, thereby obtain colorless oil (R)-1-methyl piperidine-3-carboxylic acid, ethyl ester (4.51g, 73%).MS-ESI：172[MH] +
Stir down, (36.6ml, 1M THF solution dropwise add (R)-1-methyl piperidine-3-carboxylic acid, ethyl ester (5.69g in ether 36.6mmol) (85ml) solution to lithium aluminium hydride reduction, ether 33mmol) (20ml) solution, keeping reaction temperature by cooling between charge period is 20 ℃.The stirring at room said mixture is 1.5 hours then, and order adds entry (1.4ml), 15% sodium hydrate aqueous solution (1.4ml) and water (4.3ml).The filtering insoluble matter, and remove volatile matter in the filtrate by evaporation, thus obtain colorless oil (R)-(1-methyl piperidine-3-yl) methanol (4.02g, 94%). 1H NMR spectrum: (DMSOd 6) 1.06 (q, 1H); 1.51-1.94 (m, 5H); 2.04 (s, 3H); 2.34 (br s, 1H); 2.62 (m, 1H); 2.78 (d, 1H); 3.49 (m, 1H); 3.59 (m, 1H) MS-ESI:130[MH] +
With 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methyl quinazoline (12.1g, 38mmol) (as preparation as described in the initial substance part among the embodiment 5) be suspended in dichloromethane (375ml), (29.6g 113mmol) handles, and at room temperature stirs then 30 minutes with triphenyl phasphine.Mix (1-methyl piperidine-3-yl) methanol (8.25g, 63.8mmol) with (R)-(1-methyl piperidine-3-yl) methanol (1.46g, 11.3mmol), (CAS 205194-11-2) obtains R: S (57.5: 42.5, according to chirality HPLC) (9.7g, 75mmol), and then be dissolved in dichloromethane (75ml), and be added in the above-mentioned suspension.Utilize syringe pump add in batches the diethylazodicarboxylate (17.7ml, 75mmol), warm then mixture is to room temperature, stirring is spent the night.This residue of vacuum concentration by silica gel column chromatography, is used dichloromethane and methylene chloride/ammonia (93/6/1) eluting thereafter successively.Merge relevant fraction, evaporation obtains a grease.And then develop this residue with ether, filter and dry, thereby obtain (R, S)-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (8.7g, 53%). 1H NMR spectrum: (DMSOd 6) 1.11 (m, 1H); 1.50 (m, 1H); 1.58-1.98 (m, 4H); 2.09 (m, 1H); 2.15 (s, 3H); 2.62 (d, 1H); 2.81 (d, 1H); 3.95 (s, 3H); 4.09 (d, 2H); 7.39 (m, 2H); 7.55 (m, 2H); 7.67 (d, 1H); 8.53 (s, 1H) MS (ESI): 432 (MH) +
Will (R, S)-(8.7g 20mmol) is dissolved in 2M aqueous hydrochloric acid solution (150ml) to 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline, reflux 1.5 hours.Concentrated reaction mixture is used saturated ammonia aqueous solution (0.88) alkalization (pH9) then.(4 * 400ml) extract water layer, and organic layer is filtered vacuum evaporation thereafter by phase separation paper with dichloromethane.The gained solid is developed with ether, thus obtain white solid (R, S)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-3,4-dihydroquinazoline-4-ketone (4.05g, 66%). 1H NMR spectrum: (DMSOd 6) 1.05 (m, 1H); 1.40-1.95 (m, 5H); 2.02 (m, 1H); 2.14 (s, 3H); 2.59 (d, 1H); 2.78 (d, 1H); 3.85 (s, 3H); 3.95 (d, 2H); 7.09 (s, 1H); 7.42 (s, 1H); 7.95 (s, 1H); 12.00 (s, 1H) MS (ESI): 304 (MH) +
Will (R, S)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-3, (2.72g 8.9mmol) is suspended in thionyl chloride (90ml) and DMF (0.5ml) to 4-dihydroquinazoline-4-ketone, reflux 45 minutes.Vacuum evaporation thionyl chloride then is with residue and methylbenzene azeotropic three times.Residue absorbs in the water thereafter, with saturated sodium bicarbonate aqueous solution alkalization (pH8).(4 * 400ml) extract water layer with ethyl acetate.With organic extract saturated sodium bicarbonate aqueous solution, water and salt water washing, subsequent drying (magnesium sulfate).After the filtration, the vacuum concentration organic extract spends the night in 40 ℃ of vacuum dryings then, obtain (R, S)-4-chloro-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline solid (2.62g, 91%). 1H NMR spectrum: (DMSOd 6) 1.10 (m, 1H); 1.42-1.96 (m, 5H); 2.09 (m, 1H); 2.15 (s, 3H); 2.60 (d, 1H); 2.80 (d, 1H); 3.98 (s, 3H); 4.10 (d, 2H); 7.35 (s, 1H); 7.42 (s, 1H); 8.84 (s, 1H) MS (ESI): 322 (MH) +Embodiment 8
(250mm * 4.6mm) (trade mark of Daicel Chemical IndustriesLtd) goes up chromatography (R at chirality CEL OD, S)-and 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (as preparation as described in the embodiment 7), with isohexane/ethanol/triethylamine/TFA (80/20/0.5/0.25) eluting.The relevant fraction that merges S (RT12.55) and R (RT15.88) enantiomer independently, and post processing is as follows.
The above-mentioned solution of vacuum evaporation obtains a liquid.The latter is handled with 5M sodium hydrate aqueous solution (15ml), and use ethyl acetate extraction.Organic extract is water and salt water washing successively, filters by phase separation paper thereafter.Evaporated filtrate obtains (S)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (50mg).Use identical method and obtain (R)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (71mg).Embodiment 9
100 ℃ stir 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (0.13g, 0.4mmol), 5-hydroxy-2-methyl indole (74mg, 0.5mmol) and potassium carbonate (83mg, 0.6mmol) suspension in DMF (1.5ml) is 2 hours.After being cooled to room temperature, add entry (20ml).Filter the collecting precipitation thing, washing and in 60 ℃ of vacuum dryings, thus obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (80mg, 46%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.9-2.0 (m, 2H); 2.05-2.2 (m, 2H); 2.25-2.4 (m, 2H); 2.43 (s, 3H); 3.05-3.2 (m, 2H); 3.35-3.5 (m, 2H); 3.65-3.75 (m, 2H); 4.12 (s, 3H); 4.35-4.5 (t, 2H); 7.0 (dd, 1H); 7,35 (d, 1H); 7.42 (d, 1H); 7.6 (s, 1H); 7.85 (s, 1H); 9.15 (s, 1H) MS (ESI): 433 (MH) +
Initial substance is prepared as follows:
Stir down, 100 ℃ of heating vanillic acid (8.4g, 50mmol), 3-(pyrrolidine-1-yl) propyl chloride (14.75g, 0.1mol) (J.Am.Chem.Soc.1955,77,2272), potassium carbonate (13.8g, 0.1mol) and potassium iodide (1.66g, 10mmol) mixture in DMF (150ml) is 3 hours.Cooling mixture by removing by filter insoluble matter, steams the volatile matter that removes in the filtrate then.Residue is dissolved in ethanol (75ml), adds 2M sodium hydrate aqueous solution (75ml), and heated the gained mixture 2 hours down at 90 ℃.Evaporation and concentration gained mixture is used the concentrated hydrochloric acid acidify, and then the washing of reuse ether, purification on Diaion (trade mark of Mitsubishi) HP20SS resin column, the gradient liquid eluting of water, methanol (0-25%)/dilute hydrochloric acid (pH2.2) successively then.Steam and remove methanol, the lyophilizing moist residue, thus obtain 3-methoxyl group-4-(3-(pyrrolidine-1-yl) propoxyl group) benzoate hydrochlorate (12.2g, 77%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 2.2 (m, 2H); 3.15 (t, 2H); 3.3 (t, 2H); 3.5 (d, 2H); 3.7 (t, 2H); 3.82 (s, 3H); 4.05 (d, 2H); 4.15 (t, 2H); 7.07 (d, 1H); 7.48 (s, 1H); 7.59 (d, 1H) MS-EI:279[M] +
Under 0 ℃, to 3-methoxyl group-4-(3-(pyrrolidine-1-yl) propoxyl group) benzoate hydrochlorate (12.15g, slowly add in TFA 38.17mmol) (40ml) solution fuming nitric aicd (2.4ml, 57.9mmol).Remove cooling bath, stirring at room reactant mixture 1 hour.Steam and remove TFA, in residue, add ice/water, remove by evaporation then and desolvate.Solid residue is dissolved in dilute hydrochloric acid (pH2.2), pours Diaion (trade mark of Mitsubishi) HP20SS resin column into, with methanol (gradient 0-50%)/water elution.The required fraction of evaporation and concentration filters and collects the gained precipitate, vacuum drying in the presence of phosphorus pentoxide, thus obtain 5-methoxyl group-2-nitro-4-(3-(pyrrolidine-1-yl) propoxyl group) benzoate hydrochlorate (12.1g, 90%). 1H NMR spectrum: (DMSOd 6, TFA) 1.8-1.9 (m, 2H); 2.0-2.1 (m, 2H); 2.1-2.2 (m, 2H); 3.0-3.1 (m, 2H); 3.3 (t, 2H); 3.6-3.7 (m, 2H); 3.95 (s, 3H); 4.25 (t, 2H); 7.35 (s, 1H); 7.62 (s, 1H)
Methoxyl group-(9.63g, 24mmol) solution in thionyl chloride (20ml) and DMF (50 μ l) is 1.5 hours for 2-nitro-4-(3-(pyrrolidine-1-yl) propoxyl group) benzoate hydrochlorate for 45 ℃ of heating 5-.Remove excessive thionyl chloride by evaporation with methylbenzene azeotropic (2x).The gained solids is suspended in THF (250ml) and the dichloromethane (100ml), and logical ammonia is 30 minutes in mixture, and then mixture was at room temperature stirred 1.5 hours.Steam and remove volatile matter, and residue is water-soluble, be added on Diaion (trade mark of Mitsubishi) the HP20SS resin column, with water/methanol (100/0-95/5) eluting.Remove the solvent that contains in the product fraction by evaporation, residue is dissolved in minimum methanol, dilution this solution then adds diethyl ether.Filter and collect the precipitate that produces,, obtain 5-methoxyl group-2-nitro-4-(3-(pyrrolidine-1-yl) propoxyl group) Benzoylamide (7.23g, 73%) behind the vacuum drying with the ether washing. 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.85-1.95 (m, 2H); 2-2.1 (m, 2H); 2.15-2.25 (m, 2H); 3.0-3.1 (m, 2H); 3.31 (t, 2H); 3.62 (t, 2H); 3.93 (s, 3H); 4.2 (t, 2H); 7.16 (s, 1H); 7.60 (s, 1H) MS-EI:323[M] +
(1.5g adds concentrated hydrochloric acid (5ml) in methanol 4.64mmol) (20ml) suspension, and 50 ℃ of these mixture of heating form solution to 5-methoxyl group-2-nitro-4-(3-(pyrrolidine-1-yl) propoxyl group) Benzoylamide.Add iron powder (1.3g, 23.2mmol), the heating reflux reaction mixture is 1 hour then in batches.Cooling mixture by kieselguhr filtering insoluble matter, and then steams the volatile matter that removes in the filtrate.Residue is by Diaion (trade mark of Mitsubishi) HP20SS resin column purification, water and dilute hydrochloric acid (pH2) eluting successively.Evaporation and concentration contains the product fraction, filter to collect the precipitate that is produced, so in the presence of phosphorus pentoxide vacuum drying, obtain 2-amino-5-methoxyl group-4-(3-(pyrrolidine-1-yl) propoxyl group) benzamide hydrochloride salt (1.44g, 85%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.9 (br s, 2H); 2.05 (brs, 2H); 2.2 (brs, 2H); 3.05 (brs, 2H); 3.3 (t, 2H); 3.61 (br s, 2H); 3.8 (s, 3H); 4.11 (t, 2H); 7.05 (s, 1H); 7.53 (s, 1H) MS-E1:293[M] +
(5.92g, 16.2mmol) (3.5g, 21.4mmol) the mixture in the Zai diox (50ml) is 5 hours with Gold reagent for reflux 2-amino-5-methoxyl group-4-(3-(pyrrolidine-1-yl) propoxyl group) benzamide hydrochloride salt.Add acetic acid (0.7ml) and sodium acetate (1.33g) in reactant mixture, further reflux is 5 hours.Cooling mixture is also removed volatile matter by evaporation.Residue is water-soluble, be adjusted to pH8 with the 2M sodium hydrate aqueous solution, then by Diaion (trade mark of Mitsubishi) HP20SS resin column purification, with methanol (gradient 0-50%)/water elution.Contain the product fraction by evaporation and concentration, lyophilizing obtains 4-hydroxyl-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (4.55g, 83%) then. 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.9 (m, 2H); 2.0-2.1 (m, 2H); 2.2-2.3 (m, 2H); 3.05 (m, 2H); 3.34 (t, 2H); 3.6-3.7 (brs, 2H); 3.94 (s, 3H); 4.27 (t, 2H); 7.31 (s, 1H); 7.55 (s, 1H); 9.02 (s, 1H)
(1.7g is 5mmol) with the mixture 3 hours of the thionyl chloride (25ml) that contains DMF (0.2ml) for reflux 4-hydroxyl-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline.Remove excessive thionyl chloride by evaporation with methylbenzene azeotropic (x2).Then residue is suspended in ether, in this mixture, adds 10% sodium bicarbonate aqueous solution.Separate organic layer, dry (sodium sulfate) also removes by evaporation and to desolvate, thus obtain 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (1.94g, quantitatively). 1H NMR spectrum: (CDCl 3) 1.8 (br s, 4H); 2.17 (m, 2H); 2.6 (br s, 4H); 2.7 (t, 2H); 4.05 (s, 3H); 4.3 (t, 2H); 7.35 (s, 1H); 7.38 (s, 1H); 8.86 (s, 1H) MS-ESI:322[MH] +Embodiment 10
100 ℃ of heating 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazolines (74mg, 0.23mmol), (48mg, 0.35mmol) (40.6mg, 0.28mmol) suspension in DMF (1.5ml) is 3 hours with the 7-hydroxyquinoline for potassium carbonate.After the cooling, stirring at room mixture 10 hours, 5 ℃ of stirrings are spent the night then.Add methylene chloride (5ml) dilution after, mixture is added on the silicagel column, increase liquid ethanol/methylene (10/90 with gradient, 20/80) eluting, follow dichloromethane solution (25/75) eluting of reuse ammonia/methanol (5%), after steaming, obtain 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (82mg, 88%) except that volatile matter and vacuum drying. 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.75-1.9 (m, 3H); 1.9-2.05 (m, 2H); 2.12 (s, 3H); 2.8-2.9 (d, 2H); 4.5 (s, 3H); 4.1 (d, 2H); 7.4 (s, 1H); 7.6 (dd, 1H); 7.62 (dd, 1H) MS (ES1): 431[MH] +
Initial substance is prepared as follows:
To be cooled to 5 ℃ the 4-piperidine carboxylate (30g, in ethyl acetate 0.19mol) (150ml) solution adding dropwise add Bis(tert-butoxycarbonyl)oxide (41.7g, ethyl acetate 0.19mol) (75ml) solution, during keep temperature between 0-5 ℃.After the stirring at room 48 hours, mixture is poured in the water (300ml).Tell organic layer, water (200ml), 0.1M aqueous hydrochloric acid solution (200ml), saturated sodium bicarbonate (200ml) and saline (200ml) washing successively, dry (magnesium sulfate), evaporation obtains 4-(1-tertiary butyloxycarbonyl phenylpiperidines) carboxylic acid, ethyl ester (48g, 98%). 1H NMR spectrum: (CDCl 3) 1.25 (t, 3H); 1.45 (s, 9H); 1.55-1.70 (m, 2H); 1.8-2.0 (d, 2H); 2.35-2.5 (m, 1H); 2.7-2.95 (t, 2H); 3.9-4.1 (brs, 2H); 4.15 (q, 2H)
Under 0 ℃ of cooling, to 4-(1-tertiary butyloxycarbonyl phenylpiperidines) carboxylic acid, ethyl ester (48g, dropwise add in anhydrous THF (180ml) solution 0.19mol) the 1M Lithium hydrate THF solution (133ml, 0.133mol).0 ℃ is stirred after 2 hours, adds entry (30ml) and 2M sodium hydroxide (10ml) successively.Precipitate passes through diatomite filtration, and washs with ethyl acetate.Filtrate water, salt water washing, dry (magnesium sulfate) and evaporation, thus obtain 4-methylol-1-tertiary butyloxycarbonyl phenylpiperidines (36.3g, 89%). 1H NMR spectrum: (CDCl 3) 1.05-1.2 (m, 2H); 1.35-1.55 (m, 10H); 1.6-1.8 (m, 2H); 2.6-2.8 (t, 2H); 3.4-3.6 (t, 2H); 4.0-4.2 (br s, 2H) MS (EI): 215[M.] +
To 4-methylol-1-tertiary butyloxycarbonyl phenylpiperidines (52.5g adds 1 in t-butyl methyl ether 0.244mol) (525ml) solution, 4-diazabicylo [2.2.2] octane (42.4g, 0.378mol).After the stirring at room 15 minutes, cooling mixture to 5 ℃, (keeping temperature between charge period is 0 ℃ for 62.8g, t-butyl methyl ether 0.33mmol) (525ml) solution dropwise to add toluene sulfochloride in 2 hours.After the stirring at room 1 hour, add petroleum ether (11).Remove by filter precipitate.Evaporated filtrate obtains a solids.This solids is dissolved in ether, use successively the 0.5M aqueous hydrochloric acid solution (2 * 500ml), water, saturated sodium bicarbonate and salt water washing, dry (magnesium sulfate) and evaporation, thus 4-(4-Methyl benzenesulfonyl oxygen ylmethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (76.7g, 85%) obtained. 1H NMR spectrum: (CDCl 3) 1.0-12 (m, 2H); 1.4S (s, 9H); 1.65 (d, 2H); 1.75-1.9 (m, 2H); 2.45 (s, 3H); 2.55-2.75 (m, 2H); 3.85 (d, 1H); 4.0-4.2 (br s, 2H); 7.35 (d, 2H); 7.8 (d, 2H) MS (ESI): 392[MNa] +
To 3-methoxyl group-4-nipagin A (19.6g, 0.1mol) and potassium carbonate (28g, 0.2mol) add in the suspension in dry DMF (200ml) 4-(4-Methyl benzenesulfonyl oxygen ylmethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (40g, 0.11mol).95 ℃ were stirred after 2.5 hours, and cooling mixture is to room temperature, and then were assigned between water and the ethyl acetate.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.The petroleum ether crystallization of gained grease is stored spend the night (5 ℃) with the gained suspension.The solid collected by filtration thing is used petroleum ether, obtains 3-methoxyl group-4-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) ethyl benzoate (35g, 89%) behind vacuum drying.M.p.81-83C 1H NMR spectrum: (CDCl 3) 1.2-1.35 (m, 2H); 1.4 (t, 3H); 1.48 (s, 9H); 1.8-1.9 (d, 2H); 2.0-2.15 (m, 2H); 2.75 (t, 2H); 3.9 (d, 2H); 3.95 (s, 3H); 4.05-4.25 (br s, 2H); 4.35 (q, 2H); 6.85 (d, 1H); 7.55 (s, 1H); 7.65 (d, 1H) MS (ESI): 416[MNa] +
Elementary analysis: measured value C63.4 H8.0 N3.5C 21H 31NO 60.3H 2O value of calculation C63.2 H8.0 N3.5%
To 3-methoxyl group-4-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) ethyl benzoate (35mg, add in formic acid 89mmol) (35ml) solution formaldehyde (12M, 37% aqueous solution, 35ml, 420mmol).95 ℃ are stirred after 3 hours, remove volatile matter by evaporation.And then residue is dissolved in dichloromethane, add 3M hydrogen chloride/diethyl ether solution (40ml, 120mmol).Add diethyl ether after the dilution, the development mixture is till form solid.The solid collected by filtration thing washs with ether, and spends the night in 50 ℃ of vacuum dryings, thereby obtains 3-methoxyl group-4-(1-methyl piperidine-4-ylmethoxy) ethyl benzoate (30.6g, quantitative). 1H NMR spectrum: (DMSOd 6) 1.29 (t, 3H); 1.5-1.7 (m, 2H); 1.95 (d, 2H); 2.0-2.15 (brs, 1H); 2.72 (s, 3H); 2.9-3.1 (m, 2H); 3.35-3.5 (brs, 2H); 3.85 (s, 3H); 3.9-4.05 (brs, 2H); 4.3 (q, 2H); 7.1 (d, 1H); 7.48 (s, 1H); 7.6 (d, 1H) MS (ESI): 308[MH] +
(30.6g, dichloromethane 89mmol) (75ml) solution is cooled to 0-5 ℃ to cooling 3-methoxyl group-4-(1-methyl piperidine-4-ylmethoxy) ethyl benzoate.Add TFA (37.5ml), then in 15 minutes, dropwise add 24M fuming nitric aicd (7.42ml, dichloromethane 178mmol) (15ml) solution.After finishing, warm solution stirred 2 hours to room temperature.Vacuum is removed volatile matter, and residue is dissolved in dichloromethane (50ml).Cooling gained solution adds ether to 0-5 ℃.Filter the collecting precipitation thing, in 50 ℃ of following vacuum dryings.The gained solid is dissolved in dichloromethane (500ml) again, adds 3M hydrogen chloride/diethyl ether solution (30ml), then add ether (500ml) again.The solid collected by filtration thing obtains 3-methoxyl group-4-(1-methyl piperidine-4-ylmethoxy)-6-ethyl nitrobenzoate (28.4g, 82%) behind 50 ℃ of vacuum dryings. 1H NMR spectrum: (DMSOd 6) 1.3 (t, 3H); 1.45-1.65 (m, 2H); 1.75-2.1 (m, 3H); 2.75 (s, 3H); 2.9-3.05 (m, 2H); 3.4-3.5 (d, 2H); 3.95 (s, 3H); 4.05 (d, 2H); 4.3 (q, 2H); 7.32 (s, 1H); 7.66 (s, 1H) MS (ESI): 353[MH] +
(3.89g, 10mmol) suspension in containing 10% platinum/active carbon (50% moisture) methanol (80ml) (389mg) stops until absorption of hydrogen hydrogenation 3-methoxyl group-4-under 1.8 atmospheric pressure (1-methyl piperidine-4-ylmethoxy)-6-ethyl nitrobenzoate.Filtering mixt, and evaporated filtrate.With residue water-soluble (30ml), be adjusted to pH10 with saturated solution of sodium bicarbonate.Use ethylacetate/ether diluted mixture thing then, and separate organic layer.Water layer further extracts with ethylacetate/ether, merges organic layer thereafter.Water, salt water washing organic layer, dry (magnesium sulfate), filtration and evaporation.Gained solid and then develop in ether/petroleum ether filters, and uses petroleum ether, then in 60 ℃ of vacuum dryings, thereby obtains 6-amino-3-methoxyl group-4-(1-methyl piperidine-4-ylmethoxy) ethyl benzoate (2.58g, 80%).M.p.111-112 ℃ 1H NMR spectrum: (CDCl 3) 1.35 (t, 3H); 1.4-1.5 (m, 2H); 1.85 (m, 3H); 1.95 (t, 2H); 2.29 (s, 3H); 2.9 (d, 2H); 3.8 (s, 3H); 3.85 (d, 2H); 4.3 (q, 2H); 5.55 (brs, 2H); 6.13 (s, 1H); 7.33 (s, 1H) MS (ESI): 323[MH] +
Elementary analysis: measured value C62.8 H8.5 N8.3C 17H 26N 3O 40.2H 2O value of calculation C62.6 H8.2 N8.6%
Amino-(16.1g 50mmol) is containing formamidine acetate (5.2g, the solution in 2-methyl cellosolve 50mmol) (160ml) 2 hours to 3-methoxyl group-4-(1-methyl piperidine-4-ylmethoxy) ethyl benzoate to 115 ℃ of heating 6-.In 4 hours, added every 30 minutes in batches formamidine acetate (10.4g, 100mmol).The last reinforced heating 30 minutes that continues afterwards.After the cooling, vacuum is removed volatile matter.Residual solids is dissolved in ethanol (100ml) and dichloromethane (50ml).The filtering precipitate, concentrated filtrate is to the 100ml final volume.Cool off this suspension to 5 ℃, the solid collected by filtration thing with ice-cold ethanol and ether washing, obtains 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-3,4-dihydroquinazoline-4-ketone (12.7g, 70%) successively after 60 ℃ of vacuum dryings spend the night. 1H NMR spectrum: (DMSOd 6) 1.25-1.4 (m, 2H); 1.75 (d, 2H); 1.9 (t, 1H); 1.9 (s, 3H); 2.16 (s, 2H); 2.8 (d, 2H); 3.9 (s, 3H); 4.0 (d, 2H); 7.11 (s, 1H); 7.44 (s, 1H); 7.97 (s, 1H) MS (ESI): 304[MH] +
85 ℃ of backflow 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-3, (2.8g, 9.24mmol) solution in the thionyl chloride (28ml) that contains DMF (280 μ L) is 1 hour for 4-dihydroquinazoline-4-ketone.After the cooling, steam and remove volatile matter.Precipitate is developed with ether, filters, with ether washing and dry under vacuum.The gained solid is dissolved in dichloromethane, adds saturated aqueous solution of sodium bicarbonate.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation, thus obtain 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (2.9g, 98%). 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.75-1.9 (m, 3H); 2.0 (t, 1H); 2.25 (s, 3H); 2.85 (d, 2H); 4.02 (s, 3H); 4.12 (d, 2H); 7.41 (s, 1H); 7.46 (s, 1H); 8.9 (s, 1H) MS (ESI): 322[MH] +Embodiment 11
Adopt embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (0.13g, 0.4mmol) (as preparation as described in the embodiment 10 initial substance parts) and 5-hydroxy-2-methyl indole (74mg, 0.5mol) reaction, obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (137mg, 79%). 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H); 1.7-1.95 (m, 5H); 2.15 (s, 3H); 2.4 (s, 3H); 2.8 (d, 2H); 3.98 (s, 3H); 4.05 (d, 2H); 6.14 (s, 1H); 6.88 (d, 1H); 7.29 (s, 1H); 7.32 (d, 1H); 7.35 (s, 1H); 7.6 (s, 1H); 8.45 (s, 1H) MS (ESI): 433[MH] +. embodiment 12
To 4-chloro-6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline (115mg; 0.28mmol) and 7-hydroxyquinoline (50mg; 0.33mmol) add in the solution in DMF (1.5ml) potassium carbonate (60mg, 0.42mmol).100 ℃ stirred the mixture 2 hours.After the cooling, steam and remove volatile matter, and residue is assigned between ethyl acetate and the water.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue is by the column chromatography purification, with ethyl acetate/dichloromethane/methanol (1/1/0, then 40/50/10 and 0/9/1) eluting.After removing volatile matter by evaporation, develop residue with pentane, filter also dry under vacuum, thereby obtain 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (110mg, 76%). 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H); 1.75-1.9 (m, 3H); 2.05 (t, 2H); 2.72 (t, 2H); 2.95 (d, 2H); 3.05 (s, 3H); 3.35-3.45 (m, 2H); 4.00 (s, 3H); 4.1 (d, 2H); 7.41 (s, 1H); 7.57 (dd, 1H); 7.62 (dd, 1H); 7.65 (s, 1H); 7.93 (s, 1H); 8.12 (d, 1H); 8.45 (d, 1H); 8.55 (s, 1H); 8.95 (d, 1H) MS (ESI): 523[MH] +
Elementary analysis: measured value C61.3 H6.0 N10.6C 27H 30N 4O 5S0.4H 2O value of calculation C61.2 H5.9 N10.6%
Initial substance is prepared as follows:
In 20 minutes, to 7-benzyloxy-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (8.46g, 30mmol) add sodium hydride (1.44g in DMF (70ml) solution of (as preparation as described in the initial substance part of embodiment 1) in batches, 60% mineral oil disperses thing, 36mmol), stirred this mixture 1.5 hours.Dropwise add then Chloro methyl pivalate (5.65g, 37.5mmol), stirring at room gained mixture 2 hours.Mixture is poured in ice/water (400ml) and the 2M hydrochloric acid (4ml) then with ethyl acetate (100ml) dilution.Tell organic layer, with the water layer ethyl acetate extraction, with the extract of salt water washing merging, dry (magnesium sulfate) and evaporation remove desolvates then.Residue is developed with ether and petroleum ether mixture, and the solid collected by filtration thing obtains 7-benzyloxy-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (10g, 84%) behind the vacuum drying. 1H NMR spectrum: (DMSOd 6) 1.11 (s, 9H); 3.89 (s, 3H); 5,3 (s, 2H); 5.9 (s, 2H); 7.27 (s, 1H); 7.35 (m, 1H); 7.47 (t, 2H); 7.49 (d, 2H); 7.51 (s, 1H); 8.34 (s, 1H)
With 7-benzyloxy-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (7g 17.7mm0l) stirred 40 minutes under atmospheric pressure in atmosphere of hydrogen with the mixture of 10% palladium carbon catalyst (700mg) in ethyl acetate (250ml), DMF (50ml), methanol (50ml) and acetic acid (0.7ml) 4-dihydroquinazoline-4-ketone.Filtration catalizer steams the solvent that removes in the filtrate.Residue and then with ether development filters and collects and vacuum drying, thereby obtains 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (4.36g, 80%). 1H NMR spectrum: (DMSOd 6) 1.1 (s, 9H); 3.89 (s, 3H); 5.89 (s, 2H); 7.0 (s, 1H); 7.48 (s, 1H); 8.5 (s, 1H)
Stirring at room 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, and 4-dihydroquinazoline-4-ketone (6.12g, 20mmol), (5.52g, 40mmol) suspension in DMF (60ml) is 30 minutes for potassium carbonate.(100 ℃ were stirred this mixture 2 hours for 8.86g, 24mmol) (as preparation as described in the initial substance part of embodiment 10) to add 4-(4-Methyl benzenesulfonyl oxygen ylmethyl)-1-tertiary butyloxycarbonyl phenylpiperidines.After the cooling, mixture is poured in the water/ice (400ml, 1/1) that contains 2M hydrochloric acid (10ml).Filter the collecting precipitation thing, washing and vacuum drying in the presence of phosphorus pentoxide.The gained solid is developed with ether/pentane (1/1) mixture, filter and collect and drying, thereby get 6-methoxyl group-3-((new pentane acyloxy) methyl)-7-((1-tertbutyloxycarbonyl piperidin-4-yl) methoxyl group)-3,4-dihydroquinazoline-4-ketone (7.9g, 78.5%). 1H NMR spectrum: (DMSOd 6) 1.1 (s, 9H); 1.1-1.3 (m, 2H); 1.42 (s, 9H); 1.73 (d, 2H); 1.93-2.1 (brs, 1H); 2.65-2.9 (brs, 2H); 3.9 (s, 3H); 3.9-4.1 (m, 4H); 5.9 (s, 2H); 7.2 (s, 1H); 7.5 (s, 1H); 8.35 (s, 1H) MS (ESI): 526[MNa] +
Stirring at room 6-methoxyl group-3-((new pentane acyloxy) methyl)-7-((1-tertbutyloxycarbonyl piperidin-4-yl) methoxyl group)-3, (7.9g, 16mmol) solution in the dichloromethane that contains 5.5M hydrogen chloride/isopropyl alcohol liquid (80ml) (80ml) is 1 hour for 4-dihydroquinazoline-4-ketone.Add ether, the solid collected by filtration thing with the ether washing and in 60 ℃ of vacuum dryings, gets 6-methoxyl group-7-((piperidin-4-yl) methoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-keto hydrochloride (6.9g, 100%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.15 (s, 9H); 1.5-1.7 (m, 2H); 2.0 (d, 2H); 2.2-2.3 (brs, 1H); 3.0 (t, 2H); 3.4 (d, 2H); 3.94 (s, 3H); 4.15 (d, 2H); 5.97 (s, 2H); 7.3 (s, 1H); 7.6 (s, 1H); 8.65 (s, 1H) MS (ESD:404[MH] +
To 6-methoxyl group-7-((piperidin-4-yl) methoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-keto hydrochloride (0.88g, 2mmol) and triethylamine (0.3ml, 2.1mmol) adding potassium carbonate (280mg in the solution in methanol (10ml) and the dichloromethane (10ml), 2mmol) and the methyl ethylene sulfone (0.4m1,2.1mmol).After the stirring at room 2 hours, vacuum is removed volatile matter.Residue is assigned within ethyl acetate and the water.Organic layer salt water washing, dry (magnesium sulfate) and evaporation obtain 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (0.55g, 54%). 1H NMR spectrum: (DMSOd 6) 1.09 (s, 9H); 1.25-1.4 (m, 2H); 1.7-1.9 (m, 3H); 2.0 (t, 2H); 2.7 (t, 2H); 2.95 (d, 2H); 3.02 (s, 3H); 3.25-3.45 (m, 2H); 3.9 (s, 3H); 4.0 (d, 2H); 5.9 (s, 2H); 7.15 (s, 1H); 7.49 (s, 1H); 8.35 (s, 1H) MS (ESI): 510[MH] +.
To 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-3-((new pentane acyloxy) methyl)-3; 4-dihydroquinazoline-4-ketone (90mg; 0.18mmol) methanol (3ml) suspension in add the 2M sodium hydrate aqueous solution (180 μ l, 0.35mmol).After the stirring at room 2 hours, regulate the pH to 10 of mixture with 2M hydrochloric acid.Vacuum is removed volatile matter, and residue is suspended in water, and filters; water and ether elder generation after scouring; 60 ℃ of vacuum dryings obtain 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-3,4-dihydroquinazoline-4-ketone (55mg, 79%) then. 1H NMR spectrum: (DMSOd 6) 1.2-1.4 (m, 2H); 1.7-1.85 (m, 3H); 2.0 (t, 2H); 2.7 (t, 2H); 2.9 (d, 2H); 3.02 (s, 3H); 3.3-3.5 (m, 2H); 3.9 (s, 3H); 4.0 (d, 2H); 7.11 (s, 1H); 7.45 (s, 1H); 7.97 (s, 1H) MS (ESI): 396[MH] +
Backflow 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-3, (355mg, 0.85mmol) solution in the thionyl chloride (5ml) that contains DMF (50 μ l) is 1 hour for 4-dihydroquinazoline-4-ketone.After the cooling, vacuum is removed volatile matter, and residue is developed with ether, filters thereafter.The gained solid suspension in dichloromethane, is added sodium bicarbonate.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development, filter also dry under vacuum, 4-chloro-6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline (335mg, 95%). 1H NMR spectrum: (DMSOd 6) 1.25-1.45 (m, 2H); 1.75-1.90 (m, 3H); 2.0 (t, 2H); 2.7 (t, 2H); 2.92 (d, 2H); 3.03 (s, 3H); 3.2-3.35 (m, 2H); 4.0 (s, 3H); 4.1 (d, 2H); 7.40 (s, 1H); 7.45 (s, 1H); 8.9 (s, 1H) MS (ESI): 414[MH] +Embodiment 13
Adopt embodiment 10 described similar approach, make 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (130mg, 0.4mmol) (as preparation as described in the embodiment 10 initial substance parts) and 4-methyl-7-hydroxyquinoline (80mg, 0.5mmol) (Chem.Ber.1967,100,2077) reaction obtains 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(4-methylquinoline-7-base oxygen base) quinazoline (160mg, 90%). 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.7-1.95 (m, 3H); 1.9 (t, 2H); 2.17 (s, 3H); 2.74 (s, 3H); 2.8 (d, 2H); 4.07 (s, 3H); 4.1 (d, 2H); 7.4 (m, 2H); 7.65 (dd, 1H); 7.65 (s, 1H); 7.9 (s, 1H); 8.21 (d, 1H); 8.54 (s, 1H); 8.78 (d, 1H) MS (ESI): 445[MH] +Embodiment 14
100 ℃ are stirred 4-chloro-6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline (115mg; 0.28mmol) (as preparation as described in the embodiment 12 initial substance parts), 5-hydroxy-2-methyl indole (50mg; 0.33mmol) and potassium carbonate (60mg, 0.42mmol) solution in DMF (1.5ml) is 2 hours.After the cooling, mixture is assigned within ethyl acetate and the water.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.The chromatography purification residue; use ethyl acetate/dichloromethane (1/1) and methanol/ethyl acetate/dichloromethane (1/4/5 and 1/0/9) eluting successively; obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline (60mg, 41%). 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H); 1.75-1.92 (m, 3H); 2.02 (t, 2H); 2.4 (s, 3H); 2.7 (t, 2H); 2.95 (d, 2H); 3.05 (s, 3H); 4.0 (s, 3H); 4.05 (d, 2H); 6.15 (s, 1H); 6.85 (dd, 1H); 7.25 (s, 1H); 7.3 (d, 1H); 7.38 (s, 1H); 7.6 (s, 1H); 8.45 (s, 1H) MS (ESI): 525[MH] +
Elementary analysis: measured value C60.7 H6.2 N10.5C 27H 32O 5S0.5H 2O value of calculation C60.8 H6.2 N10.5% embodiment 15
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 9) and 7-hydroxy-4-methyl quinoline (80mg, 0.5mol) (Chem.Berich.1967,100,2077) reaction generates 6-methoxyl group-4-(4-methylquinoline-7-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (155mg, 87%). 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.05 (m, 2H); 2.5 (brs, 4H); 2.6 (t, 2H); 2.75 (s, 3H); 4.02 (s, 3H); 4.3 (t, 2H); 7.41 (s, 1H); 7.45 (d, 1H); 7.65 (s, 1H); 7.65 (d, 1H); 7.95 (s, 1H); 8.25 (d, 1H); 8.55 (s, 1H); 8.8 (d, 1H) MS (ESI): 445[MH] +Embodiment 16
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 9) with 2,2,4-trimethyl-1,2-dihydroquinoline-6-alcohol (95mg, 0.5mol) (IZV.ACAD.NAVK.SSSR.Ser.Khim.1981,9,2008) reaction obtains 6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group)-4-(2,2,4-trimethyl-1,2-dihydroquinoline-6-base oxygen base) quinazoline (90mg, 47%). 1H NMR spectrum: (DMSOd 6) 1.23 (s, 6H); 1.7 (br s, 4H); 1.85 (s, 3H); 2.0 (m, 2H); 2.45 (br s, 4H); 2.57 (t, 2H); 3.95 (s, 3H); 4.25 (t, 2H); 5.35 (s, 1H); 5.9 (s, 1H); 6.5 (d, 1H); 6.8 (dd, 1H); 6.85 (s, 1H); 7.32 (s, 1H); 7.52 (s, 1H); 8.5 (s, 1H) MS (ESI): 475[MH] +Embodiment 17
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 10) with 2,2,4-trimethyl-1,2-dihydroquinoline-6-alcohol (95mg, 0.5mol) (IZV.ACAD.NAVK.SSSR.Ser.Khim.1981,9,2008) reaction obtains 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2,2,4-trimethyl-1,2-dihydroquinoline-6-base oxygen base) quinazoline (140mg, 74%). 1H NMR spectrum: (DMSOd 6) 1.15 (s, 6H); 1.3-1.45 (m, 2H); 1.7-2.0 (m, 8H); 2.16 (s, 3H); 2.65-2.85 (d, 2H); 4.0 (s, 3H); 4.05 (d, 2H); 5.35 (s, 1H); 5.9 (s, 1H); 6.5 (d, 1H); 6.80 (d, 1H); 6.82 (s, 1H); 7.33 (s, 1H); 7.5 (s, 1H); 8.52 (s, 1H) MS (ESI): 475[MH] +Embodiment 18
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 10) with 2,4-dimethyl-7-hydroxyquinoline (87mg, 0.5mol) (Chem.Berichte, 1903,36,4016) reaction obtains 4-(2,4-dimethyl quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (61mg, 33%). 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.7-1.95 (m, 5H); 2.2 (s, 3H); 2.65 (s, 3H); 2.7 (s, 3H); 2.75-2.9 (br d, 2H); 4.05 (s, 3H); 4.1 (d, 2H); 7.3 (s, 1H); 7.4 (s, 1H); 7.52 (d, 1H); 7.65 (s, 1H); 7.8 (s, 1H); 8.15 (d, 1H); 8.55 (s, 1H) MS (ESI): 459[MH] +Embodiment 19
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 10) and 6-hydroxyl-2H-4H-1,4-benzoxazinyl-3-ketone (83mg, 0.5mol) (J.Chem.Soc.C, 1971,2696) reaction, obtain 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(3-oxo-2H-4H-1,4-benzoxazinyl-6-base oxygen base) quinazoline (158mg, 88%). 1H NMR spectrum: (DMSOd 6) 1.25-1.45 (m, 2H); 1.8 (d, 2H); 1.7-1.9 (m, 1H); 1.9 (t, 2H); 2.2 (s, 3H); 2.8 (d, 2H); 3.97 (s, 3H); 4.05 (d, 2H); 4.65 (s, 2H); 6.8 (s, 1H); 6.85 (d, 1H); 7.05 (d, 1H); 7.35 (s, 1H); 7.52 (s, 1H); 8.55 (s, 1H) MS (ESI): 451[MH] +Embodiment 20
Use embodiment 9 described similar approach, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (0.13g, 0.4mol) (as preparation as described in the initial substance part of embodiment 9) and 6-hydroxyl-2H-4H-1,4-benzoxazinyl-3-ketone (83mg, 0.5mol) (J.Chem.Soc.C, 1971,2696) reaction, obtain 6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group)-4-(3-oxo-2H-4H-1,4-benzoxazinyl-6-base oxygen base) quinazoline (170mg, 94%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 1.8-2.0 (m, 2H); 2.0-2.15 (m, 2H); 2.2-2.35 (m, 2H); 3.0-3.2 (m, 2H); 3.4 (t, 2H); 3.6-3.75 (m, 2H); 4.05 (s, 3H); 4.35 (t, 2H); 4.65 (s, 2H); 6.85 (s, 1H); 6.9 (d, 1H); 7.1 (d, 1H); 7.5 (s, 1H); 7.7 (s, 1H); 8.9 (s, 1H) MS (ESI): 451[MH] +Embodiment 21
Use embodiment 10 described similar approach, make 4-ammonia-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (74mg, 0.23mmol) (as preparation as described in the initial substance part of embodiment 10) and 6-hydroxyquinoline (41mg, 0.28mol) reaction, obtain 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-6-base oxygen base) quinazoline (89mg, 94%). 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.8 (d, 2H); 1.9 (t, 2H); 1.8-1.9 (m, 1H); 2.2 (s, 3H); 2.82 (d, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 7.4 (s, 1H); 7.6 (dd, 1H); 7.65 (s, 1H); 7.75 (d, 1H); 7.95 (s, 1H); 8.15 (d, 1H); 8.4 (d, 1H); 8.55 (s, 1H); 8.95 (d, 1H) MS (ESI): 431[MH] +Embodiment 22
To 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (250mg, 0.74mmol) add 4-chloro-7-hydroxyquinoline (133mg continuously in (as preparation as described in the initial substance part of embodiment 1) suspension in DMF (4ml), 0.74mmol) and potassium carbonate (153mg, 1mmol), reacting by heating mixture to 100 ℃.(27mg 0.15mmol), continues heating 30 minutes to add 4-chloro-7-hydroxyquinoline after 1 hour again.By the cool to room temperature precipitated product.The thin up reactant mixture filters and collects product, washes with water again.Drying solid is developed with ether, filtered and obtain 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (166mg, 47%). 1H NMR spectrum: (DMSOd 6, CF 3CO 2D) 2.3 (m, 2H); 3.2 (m, 2H); 3.4 (m, 2H); 3.5 (m, 2H); 3.7 (m, 2H); 4.0 (m, 2H); 4.1 (s, 3H); 4.4 (m, 2H); 7.55 (s, 1H); 7.75 (s, 1H); 7.90 (dd, 1H); 7.95 (d, 1H); 8.15 (d, 1H); 8.45 (d, 1H); 8.80 (s, 1H); 9.05 (d, 1H) MS-ESI:481[MH] +
Elementary analysis: measured value C61.8 H5.1 N11.5C 25H 25ClN 4O 4Value of calculation C62.4 H5.2 N11.7%
Initial substance is prepared as follows:
Reflux 7-benzyloxy-4-chloroquinoline (17g, 56mmol) (Konishi etc., TFA WO96/11187) (170ml) solution 2 hours.Solvent removed in vacuo, residue is developed with ether, filters and washs with ether.With the gained solid suspension in sodium bicarbonate aqueous solution (5.5g, 65mmol are dissolved in 200ml water), stirring at room 30 minutes.The solid collected by filtration thing, washing, then vacuum drying spends the night in the presence of phosphorus pentoxide, gets 4-chloro-7-hydroxyquinoline (9.85g, 98%). 1H NMR spectrum: (DMSOd 6) 7.37 (s, 1H); 7.39 (d, 1H); 7.62 (d, 1H); 8.15 (d, 1H); 8.8 (d, 1H) MS-EI:m/z179[M.] +Embodiment 23
With 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (74mg, 0.23mmol) (as preparation as described in the embodiment 10 initial substance parts) and 2 hydroxy naphthalene (40mg, 0.28mmol) (48mg, the solution among DMF 0.35mmol) (1.5ml) stirred 3.5 hours for 100 ℃ containing potassium carbonate.After the cooling, add dichloromethane (4.5ml), then mixture is poured into (SiO2 Isolute in the silicagel column ), use dichloromethane, methylene chloride (9/1), methylene chloride/3M methanolic ammonia solution (75/20/5) eluting continuously.Vacuum evaporation contains the product fraction.The development of residue reuse ether, filtration is also dry under vacuum, obtains 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2-naphthoxy) quinazoline (80mg, 83%).MS-ESI:430[MH]+ 1H NMR spectrum: (DMSOd 6) 1.35-1.45 (m, 2H), 1.8 (d, 2H), 2.0 (t, 1H), 2.2 (s, 3H), 2.85 (d, 2H), 3.3-3.4 (m, 2H), 4.02 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.5 (dd, 1H), 7.55 (m, 2H), 7.65 (s, 1H), 7.88 (s, 1H), 7.98 (d, 1H), 8.0 (d, 1H), 8.1 (d, 1H), 8.55 (s, 1H) embodiment 24
Heating 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg, 0.23mmol) (as preparation as described in the initial substance part of embodiment 1) and 3, (63mg, 0.24mmol) solution in the isopropyl alcohol (3.5ml) that contains 5.5M hydrogen chloride isopropyl alcohol liquid (42 μ l) is 3 hours for 4-(methylene-dioxy) aniline.After being cooled to room temperature, reactant mixture is cooled to 0 ℃ again, and under this temperature, keeps spending the night.Filter the collecting precipitation thing,, behind vacuum drying, obtain 4-(1,3-benzodioxole-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (82mg, 76%) with the ethyl acetate washing.MS-ESI:439[MH] + 1H NMR spectrum: (DMSOd 6) 2.3-2.4 (m, 2H), 3.05-3.2 (m, 2H), 3.25-3.35 (m, 2H), 3.5 (d, 2H), 3.82 (t, 2H), 4.0 (d, 2H), 4.05 (s, 3H), 4.32 (t, 2H), 6.1 (s, 2H), 7.02 (d, 1H), 7.1 (dd, 1H), 7.3 (s, 1H), 7.4 (s, 1H), 8.32 (s, 1H), 8.8 (s, 1H) embodiment 25-29
Adopt embodiment 24 described similar approach, use chemical compound as described in the synthetic following table 1 of 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (as preparation as described in the embodiment 1 initial substance part), that is the chemical compound that note a)-e) is described in detail in the Table I.Table 1
The embodiment sequence number Weight (mg) Productive rate % ?MS-ESI ?[MH]+ Note ???????????????R
????25 ??104 ??90 ?435.1 ???a 1-H-indazole-6-base
????26 ??102 ??89 ?435.1 ???b 1-H-indazole-5-base
????27 ??99 ??84 ?452 ???c 1,3-benzothiazole-6-base
????28 ??108 ??91 ?466 ???d The 2-methyl isophthalic acid, 3-benzothiazole-5-base
????29 ??102 ??95 ?435.1 ???e 2,3-dihydro-1H-indenes-5-base
Note
A) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg) and 6-Aminoindazole (32mg) reaction generate 4-(1-H-indazole-6-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.3-2.4 (m, 2H), 3.05-3.2 (m, 2H), 3.2-3.3 (m, 2H), 3.52 (d, 2H), 3.85 (t, 2H), 4.0 (d, 2H), 4.05 (s, 3H), 4.32 (t, 2H), 7.42 (s, 1H), 7.45 (d, 1H), 7.85 (d, 1H), 7.98 (s, 1H), 8.1 (s, 1H), 8.42 (s, 1H), 8.85 (s, 1H)
B) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg) and 5-Aminoindazole (32mg) reaction generate 4-(1-H-indazole-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.3-2.4 (m, 2H), 3.05-3.2 (m, 2H), 3.25-3.3 (m, 2H), and 3.45-3.55 (m, 2H), 3.8-3.9 (m, 2H), 3.9-4.02 (m, 2H), 4.05 (s, 3H), 4.32 (t, 2H), 7.42 (s, 1H), 7.65 (m, 2H), 8.05 (s, 1H), 8.15 (s, 1H), 8.4 (s, 1H), 8.75 (s, 1H)
C) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg) and 6-aminothiazole (36mg) reaction generate 4-(1,3-benzothiazole-6-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.3-2.4 (m, 2H), 3.05-3.2 (m, 2H), 3.2-3.3 (m, 2H), 3.55 (d, 2H), 3.8 (t, 2H), 4.0 (d, 2H), 4.08 (s, 3H), 4.32 (t, 2H), 7.4 (s, 1H), 7.88 (dd, 1H), 8.2 (d, 1H), 8.4 (s, 1H), 8.55 (s, 1H), 8.85 (s, 1H), 9.42 (s, 1H)
D) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg) and 6-amino-2-methyl thiazole (57mg) reaction generate 6-methoxyl group-4-(2-methyl isophthalic acid, 3-benzothiazole-5-base is amino)-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.3-2.4 (m, 2H), 2.85 (s, 3H), 3.05-3.2 (m, 2H), 3.3 (t, 2H), 3.4-3.5 (m, 2H), 3.85 (t, 2H), 4.0 (d, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 7.42 (s, 1H), 7.75 (dd, 1H), 8.15 (d, 1H), 8.3 (s, 1H), 8.42 (s, 1H), 8.85 (s, 1H)
E) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (74mg) and 5-amino-2,3-dihydroindene (32mg) reaction generates 4-(2,3-dihydro-1H-indenes-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.08 (m, 2H), 2.3-2.4 (m, 2H), 2.9 (m, 4H), and 3.05-3.2 (m, 2H), 3.2-3.3 (m, 2H), 3.5 (d, 2H), 3.82 (t, 2H), 4.0 (d, 2H), 4.05 (s, 3H), 4.3 (t, 2H), 7.32 (d, 1H), 7.4 (m, 2H), 7.55 (s, 1H), 8.32 (s, 1H), 8.8 (s, 1H) embodiment 30
100 ℃ of heating 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (130mg, 0.4mmol) (as preparation as described in the embodiment 10 initial substance parts), 7-hydroxy-2-methyl chromone (88mg, 0.5mmol) (Bull.Soc.Chim.Fr.1995,132,233) and potassium carbonate (83mg, suspension 0.6mmol) 1.5 hours.After the cooling, mixture is assigned between water and the ethyl acetate.Organic layer water, salt water washing, dry (magnesium sulfate), and remove volatile matter by evaporation.Residue and then with ether development filters and collects, ether washing final vacuum drying, thus obtain 6-methoxyl group-4-(2-methyl-4-oxo-4H-.alpha.-5:6-benzopyran-7-base oxygen base)-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (170mg, 92%).MS-ESI:462[MH]+ 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.75-1.95 (m, 5H); 2.2 (s, 3H), 2.42 (s, 3H); 4.0 (s, 3H); 4.1 (d, 2H); 6.3 (s, 2H); 7.4 (s, 1H); 7.45 (dd, 1H); 7.6 (s, 1H); 7.7 (s, 1H); 8.15 (d, 1H); 8.61 (s, 1H) embodiment 31-33
Use embodiment 30 described similar approach, preparation is the described chemical compound of Table II down, i.e. the chemical compound a)-c) described in detail of Table II note.Table II Table II
The embodiment sequence number Weight (mg) Productive rate % ?MS-ESI ?[MH]+ Note ????Q ????R
???31 ??180 ??85 ??451 ??a 1-methyl piperidine-4-ylmethoxy 4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl-6-base oxygen base
???32 ??160 ??87 ??462 ??b 3-pyrrolidine-1-base propoxyl group 2-methyl-4-oxo-4H-.alpha.-5:6-benzopyran-7-base oxygen base
???33 ??100 ??56 ??451 ??c 3-pyrrolidine-1-base propoxyl group 4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl-6-base oxygen base
A) 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-base oxygen base) quinazoline (130mg) (as preparation as described in the embodiment 10 initial substance parts) is with 3,4-dihydro-4-methyl-2H-1,4-benzoxazinyl-6-alcohol (83mg) (J.Org.Chem.1971,36 (1)) reaction, generate 6-methoxyl group-4-(4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl-6-base oxygen base)-7-(1-methyl piperidine-4-ylmethoxy) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.6-1.75 (m, 2H); 1.9-2.3 (m, 5H); 2.8 (s, 3H); 2.9 (s, 3H); 3.0-3.15 (m, 2H); 3.3 (brs, 2H); 3.5-3.6 (d, 2H); 4.1 (s, 3H); 4.2 (d, 2H); 4.3 (t, 2H); 6.55 (m, 1H); 6.75 (s, 1H); 6.8 (d, 1H); 7.6 (s, 1H); 7.75 (s, 1H); 9.15 (s, 1H)
B) 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (130mg) (as preparation as described in the embodiment 9 initial substance parts) and 7-hydroxy-2-methyl chromone (88mg) (Bull Soc.Chim.Fr.1995,132,233) reaction.After the cooling, add entry (20ml), filter the collecting precipitation thing, in the presence of phosphorus pentoxide,, obtain 6-methoxyl group-4-(2-methyl-4-oxo-4H-.alpha.-5:6-benzopyran-7-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline in 60 ℃ of vacuum dryings. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.8-2.0 (m, 2H); 2.0-2.15 (m, 2H); 2.2-2.3 (m, 2H); 2.4 (s, 3H); 3.05-3.15 (m, 2H); 3.3-3.4 (m, 2H); 3.6-3.7 (m, 2H); 4.05 (s, 3H); 4.35 (t, 2H); 6.3 (s, 1H); 7.45 (d, 1H); 7.5 (s, 1H); 7.65 (s, 1H); 7.72 (s, 1H); 8.15 (d, 1H); 8.75 (s, 1H)
C) 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (130mg) (as preparation as described in the embodiment 9 initial substance parts) is with 3,4-dihydro-4-methyl-2H-1,4-benzoxazinyl-6-alcohol (83mg) (J.Org.Chem.1971,36 (1)) reaction, generate 6-methoxyl group-4-(4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl-6-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.85-2.0 (m, 2H); 2.0-2.15 (m, 2H); 2.25-2.35 (m, 2H); 2.83 (s, 3H); 3.05-3.15 (m, 2H); 3.3 (t, 2H); 3.4 (t, 2H); 3.7 (brm, 2H); 4.1 (s, 3H); 4.3 (t, 2H); 4.4 (t, 2H); 6.52 (d, 1H); 6.7 (s, 1H); 6.8 (d, 1H); 7.55 (s, 1H); 7.75 (s, 1H); 9.1 (s, 1H) embodiment 34
100 ℃ of heating 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (110mg, 0.34mmol) (as preparation as described in the initial substance part among the embodiment 10) and 5-oxyindole (55mg, 0.41mmol) containing potassium carbonate (70mg, 0.51mmol) DMF (1.5ml) in solution 2 hours. after the cooling, add entry, filter the collecting precipitation thing, water and ether washing successively, and then in the presence of phosphorus pentoxide vacuum drying, get 4-(indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (90mg, 64%).MS-ESI:419[MH]+ 1H NMR spectrum: (DMSOd 6) 1.35-1.5 (m, 2H); 1.8 (d, 2H); 1.95 (t, 2H); 1.7-2.0 (m, 1H); 2.2 (s, 3H); 2.85 (d, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 6.45 (s, 1H); 7.0 (d, 1H); 7.35 (s, 1H); 7.4-7.5 (m, 3H); 7.6 (s, 1H); 8.5 (s, 1H)
Elementary analysis: measured value C67.4 H6.5 N13.1C 24H 26N 4O 30.5H 2O value of calculation C67.4 H6.4 N13.1% embodiment 35
Adopt embodiment 34 described similar approach, make 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (110mg, 0.34mmol) (as preparation as described in the initial substance part among the embodiment 10) with 2,3-dimethyl-5-oxyindole (66mg, 0.41mmol) (Arch.Phrm.1972,305,159) reaction.Crude product is by the column chromatography purification, use ethanol/methylene (1/9) and 3M ammonia methanol solution/ethanol/methylene (5/15/80) eluting successively, get 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (60mg, 40%).MS-ESI:447[MH] +. 1H NMR spectrum: (DMSOd 6) 1.2-1.4 (m, 2H); 1.7 (d, 2H); 1.8 (t, 2H); 1.7-1.9 (m, 1H); 2.05 (s, 3H); 2.12 (s, 3H); 2.25 (s, 3H); 2.75 (d, 2H); 3.9 (s, 3H); 4.0 (d, 2H); 6.8 (d, 1H); 7.15 (s, 1H); 7.2 (d, 1H); 7.3 (s, 1H); 7.52 (s, 1H); 8.45 (s, 1H)
Elementary analysis: measured value C68.6 H6.9 N12.5C 26H 30N 4O 30.4H 2O value of calculation C68.8 H6.8 N12.4% embodiment 36
Utilize embodiment 34 described similar approach, make 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (110mg, 0.34mmol) (as preparation as described in the embodiment 9 initial substance parts) and 5-oxyindole (55mg, 0.41mmol) reaction.Crude product with methanol/ethyl acetate/dichloromethane (5/45/50) eluting, gets 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (70mg, 50%) by the aluminium oxide chromatogram purification.MS-ESI419[MH]+ 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.9-2.0 (m, 2H); 2.1 (m, 2H); 2.3 (t, 2H); 3.0-3.15 (m, 2H); 3.4 (t, 2H); 3.6-3.75 (m, 2H); 4.1 (s, 3H); 4.4 (t, 2H); 6.5 (s, 1H); 7.05 (d, 1H); 7.5 (s, 1H); 7.5-7.6 (m, 2H); 7.85 (s, 1H); 9.11 (s, 1H)
Elementary analysis: measured value C63.7 H6.4 N12.1C 24H 26N 4O 31.9H 2O value of calculation C63.7 H6.6 N12.4% embodiment 37
With 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (100mg, 0.31mmol) (as preparation as described in the preparation part of embodiment 10 initial substances) and 5-amino-2, (55mg, 0.34mmol) 70 ℃ of heating of the suspension in the isopropyl alcohol (6ml) that contains 5.5M hydrogen chloride/isopropyl alcohol liquid (60 μ l) are 30 minutes for the 3-dimethyl indole.After the cooling, the solid collected by filtration thing successively with isopropyl alcohol and ether washing, obtains 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline hydrochlorate (118mg, 74%) behind vacuum drying.MS-ESI:446[MH]+ 1H NMR spectrum: (DMSOd 6): 1.8-1.9 (m, 2H); 2.0 (d, 2H); 2.1-2.2 (m, 1H); 2.16 (s, 3H); 2.33 (s, 3H); 2.75 (br s, 3H); 2.95-3.05 (m, 2H); 3.5 (d, 2H); 4.0 (s, 3H); 4.07 (d, 2H); 7.25 (d, 1H); 7.4 (d, 1H); 7.42 (s, 1H); 7.52 (s, 1H); 8.25 (s, 1H); 8.75 (s, 1H); (10.0 br s, 1H); 10.9 (s, 1H); 11.25 (brs, 1H)
Elementary analysis: measured value C58.5 H6.8 N12.9C 26H 31N 5O 21H 2O1.9HCl value of calculation C58.6 H6.6 N13.1% embodiment 38
Utilize embodiment 37 described similar approach, make 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.31mmol) (preparing preparation as described in the part as embodiment 9 initial substances) and 5-amino-2,3-dimethyl indole (55mg, 0.34mmol) reaction.Obtain 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline hydrochlorate (114mg, 72%).MS-ESI:446[MH]+ 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.85-2.0 (m, 2H); 2.05-2.15 (m, 2H); 2.1 (s, 3H); 2.2 (s, 3H); 2.25-2.35 (m, 2H); 2.35 (s, 3H); 3.0-3.15 (m, 2H); 3.32-3.42 (m, 2H); 3.6-3.7 (m, 2H); 4.05 (s, 3H); 4.3 (t, 2H); 7.2 (d, 1H); 7.3 (s, 1H); 7.35 (d, 1H); 7.57 (s, 1H); 8.2 (s, 1H); 8.8 (s, 1H)
Elementary analysis: measured value C58.8 H7.0 N12.5C 26H 31N 5O1.9H 2O1.9HCl0.1 isopropyl alcohol value of calculation C58.6 H7.1 N12.9% embodiment 39
Application Example 38 described similar approach, make 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.31mmol) (preparing preparation as described in the part as embodiment 9 initial substances) and 5-amino-2-methyl indole (50mg, 0.34mmol), obtain 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline hydrochlorate (138mg, 89%).MS-ESI:432[MH]+ 1H NMR spectrum: (DMSOd 6) 1.8-1.9 (m, 2H); 2.0-2.1 (m, 2H); 2.15-2.35 (m, 2H); 2.4 (s, 3H); 3.0-3.1 (m, 2H); 3.2-3.3 (m, 2H); 3.5-3.6 (m, 2H); 4.0 (s, 3H); 4.32 (t, 2H); 6.2 (s, 1H); 7.2 (d, 1H); 7.3 (m, 2H); 7.65 (s, 1H); 8.25 (s, 1H); 8.75 (s, 1H); 10.75 (brs, 1H); 11.15 (s, 1H); 11.25 (brs, 1H)
Elementary analysis: measured value C58.9 H6.6 N13.5C 25H 29N 522.2HCl0.1 isopropyl alcohol value of calculation C58.7 H6.2 N13.5% embodiment 40
With 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.31mmol) (preparing preparation as described in the part as initial substance among the embodiment 9) and 7-hydroxyl-2,4-dimethyl quinoline (64mg, 0.36mmol) (Chem.Berichte, 1903,36,4016) containing potassium carbonate (86mg, 90 ℃ of heating of the mixture among DMF 0.62mmol) (3ml) 3 hours.After the cooling, mixture is poured in the silicagel column,, got 4-(2,4-dimethyl quinoline-7-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (50mg, 35%) with 2.5M ammonia methanol solution/dichloromethane (5/95) eluting.MS-ESI:459[MH]+ 1H NMR spectrum: (CDCl 3) 1.8 (br s, 4H); 2.2 (m, 4H); 2.55 (br s, 4H); 2.7 (2s, 6H); 2.68 (m, 2H); 4.05 (s, 3H); 4.3 (t, 2H); 7.15 (s, 1H); 7.35 (s, 1H); 7.45 (d, 1H); 7.6 (s, 1H); 7.9 (s, 1H); 8.05 (d, 1H); 8.6 (s, 1H)
Elementary analysis: measured value C70.4 H7.1 N12.1C 27H 30N 4O 30.2ether value of calculation C70.5 H6.8 N11.8% embodiment 41
Application Example 37 described similar approach, make 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (50mg, 0.155mmol) (as preparation as described in the initial substance part of embodiment 10) and 5-amino-2-methyl indole (0.171mmol) reaction, generate 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-(1-methyl piperidine-4-ylmethoxy) quinazoline hydrochlorate (72mg, quantitative).MS-ESI:432[MH]+ 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.5-1.7 (m, 2H); 2.05 (d, 2H); 2.1-2.2 (m, 1H); 2.45 (s, 3H); 2.8 (s, 3H); 3.05 (t, 2H); 3.5 (d, 2H); 4.0 (s, 3H); 4.1 (d, 2H); 6.2 (s, 1H); 7.2 (d, 1H); 7.32 (d, 1H); 7.4 (d, 1H); 7.6 (s, 1H); 8.2 (s, 1H); 8.85 (s, 1H)
Elementary analysis: measured value C53.9 H6.8 N12.4C 25H 29N 5O 226H 2O2.07HCl value of calculation C54.2 H6.6 N12.6% embodiment 42
90 ℃ of heating 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.31mmol) (as preparation as described in the initial substance part among the embodiment 9) and 7-hydroxy-2-methylquinoline (54mg, 0.34mmol) (J.Med.Chem.1998,41,4062) containing potassium carbonate (86mg, the suspension among DMF 0.62mmol) (3ml) 2 hours.After the cooling, mixture is assigned between ethyl acetate and the water.Tell organic layer, water, salt water washing, dry and remove volatile matter by evaporation.Residue is developed with minimum ether, filters and collects the final vacuum drying, thereby obtain 6-methoxyl group-4-(2-methylquinoline-7-base oxygen base)-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (95mg, 69%).MS-ESI:445[MH]+ 1H NMR spectrum: (CDCl 3) 1.8 (brs, 4H); 2.2 (m, 2H); 2.5 (br s, 4H); 2.7 (t, 2H); 2.8 (s, 3H); 4.1 (s, 3H); 4.3 (t, 2H); 7.3 (d, 1H); 7.35 (s, 1H); 7.45 (dd, 1H); 7.6 (s, 1H); 7.85 (d, 1H); 7.9 (s, 1H); 8.1 (d, 1H); 8.6 (s, 1H) embodiment 43
Adopt embodiment 42 described similar approach; make 4-chloro-6-methoxyl group-7-(1-(2-mesyl ethyl) piperidin-4-yl methoxyl group) quinazoline (156mg; 0.38mmol) (as preparation as described in the initial substance part among the embodiment 12) and 7-hydroxy-2-methylquinoline (66mg; 0.4mmol) (J.Med.Chem.1998; 41; 4062) reaction; obtain 6-methoxyl group-7-(1-(2-mesyl ethyl) piperidin-4-yl methoxyl group)-4-(2-methylquinoline-7-base oxygen base) quinazoline (166mg, 82%).MS-ESI:537[MH]+ 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.75-1.95 (m, 3H); 1.95-2.15 (m, 2H); 2.7 (s, 3H); 2.7-2.8 (m, 2H); 2.9-3.0 (m, 2H); 3.05 (s, 3H); 3.2-3.35 (m, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 7.4 (s, 1H); 7.45 (d, 1H); 7.55 (d, 1H); 7.65 (s, 1H); 7.8 (s, 1H); 8.05 (d, 1H); 8.35 (d, 1H); 8.55 (s, 1H)
Elementary analysis: measured value C62.2 H6.3 N10.4C 28H 32N 4O 5S0.35 ether 0.2DMF value of calculation C62.4 H6.4 N10.2% embodiment 44
90 ℃ of heating 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (50mg, 0.155mmol) (as preparation as described in the initial substance part among the embodiment 10) and 5-hydroxyl-2-Trifluoromethylquinocarboxylic (34mg, 0.17mmol) containing potassium carbonate (43mg, the suspension among DMF 0.31mmol) (1.5ml) 2 hours.After the cooling, mixture is assigned between ethyl acetate and the water.Tell organic layer, water, salt water washing, dry (MgSO 4) and remove volatile matter by evaporation.Residue is by the column chromatography purification, use methanol/ethyl acetate/dichloromethane (10/50/40), 2.5M ammonia methanol solution/ethyl acetate/dichloromethane (10/50/40) eluting successively, thereby obtain 6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline (35mg, 48%).MS-ESI:487[MH]+ 1H NMR spectrum: (DMSOd 6) 1.25-1.4 (m, 2H); 1.75 (d, 2H); 1.8 (t, 2H); 1.7-2.0 (m, 1H); 2.2 (s, 3H); 2.75 (d, 2H); 4.0 (s, 3H); 4.1 (d, 2H); 7.0 (s, 1H); 7.25 (d, 1H); 7.4 (s, 1H); 7.6 (d, 1H); 7.8 (s, 1H); 8.5 (s, 1H); 12.5 (s, 1H)
Elementary analysis: measured value C60.2 H5.8 N10.9C 25H 25F 3N 4O 30.7H 2O0.2 ether value of calculation C60.3 H5.6 N10.9%
Being prepared as follows of initial substance:
With (4-methoxyl group-2-aminomethyl phenyl)-carbamic acid-1, and 1-dimethyl ethyl ester (2g, 8.43mmol) anhydrous THF (25ml) solution of (J.Med.Chem.1996,39,5119) is cooled to-40 ℃, the adding s-butyl lithium (15ml, 19.5mmol).After stirring 15 minutes under this temperature, add N-methyl-N-methoxyl group trifluoroacetamide (1.32g, THF 8.43mmol) (20ml) solution in batches.-40 ℃ are continued to stir 1 hour, and warm then mixture is to room temperature.Mixture is poured in ether/1M hydrochloric acid.Tell organic layer, water, salt water washing, dry (magnesium sulfate) also steams and removes volatile matter.
Above-mentioned crude product (1.4g) is dissolved in dichloromethane (8ml), adds TFA (1.5ml).After the stirring at room 3 hours, vacuum is removed volatile matter.Crude product is assigned between dichloromethane and the water.Tell organic layer, water, salt water washing, dry (magnesium sulfate) also removes volatile matter by evaporation.Residue and then by the column chromatography purification, with ether/petroleum ether (1/9) eluting, 5-methoxyl group-2-trifluoro methyl indole (845mg, two step productive rates 47%). 1H NMR spectrum: (CDCl 3) 3.83 (s, 3H), 6.82 (s, 1H), 7.0 (dd, 1H), 7.1 (s, 1H), 7.3 (d, 1H), 8.15 (brs, 1H)
With 5-methoxyl group-2-trifluoro methyl indole (800mg, dichloromethane 3.7mmol) (6ml) solution is cooled to-15 ℃, add in batches the 1M Boron tribromide dichloromethane solution (7.44ml, 7.4mmol).Warm mixture stirred 45 minutes to room temperature.After being cooled to 0 ℃, add saturated aqueous solution of sodium bicarbonate (25ml).The mixture ethyl acetate extraction.Dry (magnesium sulfate) organic layer is also removed volatile matter by evaporation.Residue and then by the column chromatography purification, with the ethyl acetate/petroleum ether eluting.Steam except that behind the volatile matter, the gained solid is developed with pentane, filter also drying under vacuum, thereby obtain 5-hydroxyl-2-trifluoro methyl indole (290mg, 39%).MS-EI:201[M.]+ 1H NMR spectrum: (CDCl 3) 4.64 (s, 1H), 6.8 (s, 1H), 6.92 (dd, 1H), 7.1 (s, 1H), 7.3 (d, 1H), 8.3 (brs, 1H)
Elementary analysis: measured value C53.3 H2.9 N6.8C 9H 6F 3NO0.1H 2O value of calculation C53.3 H3.1 N6.9% embodiment 45
Adopt embodiment 44 described similar approach, make 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.3mmol) (as preparation as described in the initial substance part among the embodiment 9) and 5-hydroxyl-2-trifluoro methyl indole (75mg, 0.37mmol) (as preparation as described in the embodiment 44 initial substance parts) reaction, obtain 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline (105mg, 70%).MS-ESI:487[MH]+ 1H NMR spectrum: (CDCl 3) 1.8 (m, 4H); 2.1-2.3 (m, 2H); 2.55 (br s, 4H); 2.7 (t, 2H); 4.1 (s, 3H); 4.3 (t, 2H); 6.95 (s, 1H); 7.2 (dd, 1H); 7.35 (s, 1H); 7.5 (d, 1H); 7.55 (s, 1H); 7.6 (s, 1H); 8.6 (s, 1H); 8.8 (s, 1H)
Elementary analysis: measured value C61.7 H5.5 N11.5C 25H 25F 3N 4O 3Value of calculation C61.7 H5.2 N11.5% embodiment 46
Adopt embodiment 42 described similar approach, make 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (100mg, 0.31mmol) (as preparation as described in the initial substance part among the embodiment 10) and 7-hydroxy-2-methylquinoline (54mg, 0.34mmol) (J.Med.Chem.1998,41,4062) reaction obtains 6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy)-4-(2-methylquinoline-7-base oxygen base) quinazoline (86mg, 63%).MS-ESI:445[MH]+ 1H NMR spectrum: (CDCl 3) 1.4-1.6 (m, 2H); 1.95 (d, 2H); 2.05 (t, 2H); 1.9-2.1 (m, 1H); 2.35 (s, 3H); 2.8 (s, 3H); 2.95 (d, 2H); 4.1 (s, 3H); 4.15 (d, 2H); 7.3 (m, 2H); 7.45 (dd, 1H); 7.6 (s, 1H); 7.9 (d, 1H); 7.95 (s, 1H); 8.1 (d, 1H); 8.6 (s, 1H)
Elementary analysis: measured value C69.7 H6.5 N12.8C 26H 28N 4O 30.2H 2O value of calculation C69.7 H6.4 N12.5% embodiment 47
With 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (110mg, 0.34mmol) (as preparation as described in the embodiment 9 initial substance parts) and 2,3-dimethyl-5-oxyindole (66mg, 0.41mmol) (Arch.Pharm.1972,305,159) and potassium carbonate (70mg, 0.51mmol) heating of 100 ℃ of suspensions in DMF (1.5ml) is 2 hours.After the cooling, the chromatography purification residue is successively used ethanol/methylene (1/9) and 2.5M ammonia methanol solution/ethanol/methylene (5/10/85) eluting, gets 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (50mg, 33%).MS-ESI:447[MH]+ 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.9-2.0 (m, 2H); 2.05-2.15 (m, 2H); 2.15 (s, 3H); 2.3-2.4 (m, 2H); 2.4 (s, 3H), 3.05-3.15 (m, 2H); 3.35-3.45 (t, 2H); 3.7 (brs, 2H); 4.1 (s, 3H); 4.4 (t, 2H); 6.95 (d, 1H); 7.3 (s, 1H); 7.35 (d, 1H); 7.55 (s, 1H); 7.85 (s, 1H); 9.15 (s, 1H)
Elementary analysis: measured value C67.7 H6.8 N12.2C 26H 30N 4O 30.8H 2O value of calculation C67.8 H6.9 N12.2% embodiment 48
Adopt embodiment 32 described similar approach, make 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (1g, 3.33mmol) (as preparation as described in the initial substance part among the embodiment 1) and 5-hydroxy-2-methyl indole are (O.59mg, 0.4mmol) reaction, obtain 7-benzyloxy-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (1.25mg, 91%).MS-ESI:412[MH]+ 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H); 4.0 (s, 3H); 5.35 (s, 2H); 6.15 (s, 1H); 6.85 (s, 1H); 7.2-7.6 (m, 9H); 8.5 (s, 1H)
Elementary analysis: measured value C72.2 H5.1 N10.2C 25H 21N 3O 30.2H 2O value of calculation C72.3 H5.2 N10.1%
Initial substance is prepared as follows:
Under-45 ℃ of coolings, (25g adds Boron tribromide (32.5ml, dichloromethane 341mmol) (60m) solution in batches in dichloromethane 155mmol) (250ml) solution to 5-methoxyl group-2 methyl indole.-30 ℃ were stirred after 15 minutes, and warm mixture stirred 1 hour to room temperature.Add dichloromethane (300ml) in batches, mixture is cooled to 0 ℃.Add entry in batches, and regulate the pH to 6 of mixture with the 4N sodium hydroxide.Separate organic layer.The water layer dichloromethane extraction merges organic layer then, water, salt water washing, and dry (magnesium sulfate) also removes volatile matter by evaporation.Residue and then by the column chromatography purification, with ethyl acetate/dichloromethane (1/9, then 15/85) eluting, 5-hydroxy-2-methyl indole (21.2g, 93%). 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H); 5.95 (s, 1H); 6.5 (dd, 1H); 6.7 (s, 1H); 7.05 (d, 1H); 8.5 (s, 1H) embodiment 49
(0.2g, 0.5mmol) (as preparation as described in the embodiment 48) solution in the dichloromethane that contains 10% palladium-carbon (50mg) (5ml) and DMF (2ml) mixture is 2 hours with hydrogen treat 7-benzyloxy-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline under 1.8 atmospheric pressures.Filtering suspension liquid, and use methanol and washed with dichloromethane catalyst successively.Remove volatile matter in the filtrate by evaporation.Residue and then water development, and washing gained solid, 60 ℃ of vacuum dryings in the presence of phosphorus pentoxide, thus obtain 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (140mg, 89%).MS-ESI:322[MH]+ 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H); 4.0 (s, 3H); 6.15 (s, 1H); 6.9 (d, 1H); 7.2 (s, 1H); 7.25 (s, 1H); 7.3 (d, 1H); 7.6 (s, 1H); 8.4 (s, 1H) embodiment 50
100 ℃ of heating 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (150mg; 0.45mmol) and 5-hydroxyl-2-trifluoro methyl indole (109mg; 0.54mmol) (as preparation as described in the initial substance part among the embodiment 44) containing potassium carbonate (94mg, the suspension among DMF 0.67mmol) (1.5ml) 1 hour.After the cooling, filter the collecting precipitation thing,, get 6-methoxyl group-7-(3-mesyl propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline (195mg, 87%) behind the vacuum drying with the ether washing.MS-ESI:496[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.25-2.4 (m, 2H), 3.1 (s, 3H), 3.35 (t, 2H), 4.1 (s, 3H), 4.4 (t, 2H), 7.1 (s, 1H), 7.3 (d, 1H), 7.5 (s, 1H), 7.6 (d, 1H), 7.7 (s, 1H), 7.78 (s, 1H), 8.9 (s, 1H)
Being prepared as follows of initial substance:
To OXONE (E.I.du Pont de Nemours﹠amp; Co., the trade mark of Inc) add 3-(methyl mercapto)-1-propanol (5.3g, methanol 50mmol) (500ml) solution, this mixture of stirring at room 24 hours in water (150ml) solution (30g).The solids that filtering is settled out is removed methanol in the filtrate by evaporation then.Moist residue is saturated with sodium chloride, and (4 * 25ml) extract with dichloromethane.Then that moist residue reuse ammonium chloride is saturated, and with ethyl acetate (4 * 25ml) extractions.The united extraction thing, dry (magnesium sulfate) and steaming desolventize, thereby obtain 3-(mesyl)-1-propanol grease (610mg, 9%). 1H NMR spectrum: (CDCl 3) 2.10 (m, 2H); 2.96 (s, 3H); 3.20 (t, 2H); 3.80 (t, 2H) MS-ESI:139[MH] +
On the other hand, 3-(mesyl)-1-propanol can also be prepared as follows:
To 3-(methyl mercapto)-1-propanol (5ml, between adding in dichloromethane solution 48.6mmol) in batches-the chlorine benzylhydroperoxide (67%, 25g, 97.2mol).The precipitation separate out some-chlorobenzoic acid, remove by filter them.Evaporated filtrate, residue and then by the aluminium oxide purification, the dichloromethane that uses in order (100%), methylene chloride (95/5) eluting, thus obtain 3-(mesyl)-1-propanol grease (4.18g, 62%).
To 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (6g, 19.6mmol) add in dichloromethane (150ml) suspension of (as preparation as described in the initial substance part among the embodiment 12) triphenyl phasphine (8.9g, 35.2mmol).Then add in batches 3-(mesyl)-1-propanol (3.5g, 25.4mmol) and the diethylazodicarboxylate (5.55ml, 35.2mmol).In case reactant becomes homogeneous phase then reacts completely.Add silica gel, remove volatile matter by evaporation.The flash chromatography column top that places ethyl acetate (100%) pre-equilibration to cross in free-pouring powder.Use ethyl acetate (100%) and dichloromethane/ethyl acetate/methanol (60/35/5) eluting successively.Steam except that behind the volatile matter and obtain white solid 6-methoxyl group-7-(3-mesyl propoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (7.58g, 91%). 1H NMR spectrum: (CDCl 3) 1.2 (s, 9H); 2.4-2.5 (m, 2H); 3.0 (s, 3H); 3.25-3.35 (t, 2H); 5.95 (s, 1H); 7.1 (s, 1H); 7.65 (s, 1H); 8.2 (s, 1H)
With 6-methoxyl group-7-(3-mesyl propoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (7g 17mmol) is suspended in methanol, and adding 2M sodium hydroxide under continuous stirring (3.3ml, 6.6mmol).The afterreaction mixture became homogeneous phase in 15 minutes.Further stirring added entry (7ml) after 45 minutes, with the pH to 10 of 2M hydrochloric acid conditioned reaction mixture.Filter collecting precipitation thing (white solid), washing and in the presence of phosphorus pentoxide vacuum drying, thereby obtain 6-methoxyl group-7-(3-mesyl propoxyl group)-3,4-dihydroquinazoline-4-ketone (5g, 90%). 1H NMR spectrum: (DMSOd 6) 2.2-2.3 (m, 2H); 3.05 (s, 3H); 3.35 (t, 2H); 3.9 (s, 3H); 4.25 (t, 2H); 7.15 (s, 1H); 7.5 (s, 1H); 8.0 (s, 1H)
With 6-methoxyl group-7-(3-mesyl propoxyl group)-3, (3.6g 11.5mmol) is suspended in thionyl chloride (40ml) to 4-dihydroquinazoline-4-ketone.In atmosphere of hydrogen, add DMF (1.8ml).Reflux gained mixture 1.5 hours.Utilize toluene to carry out the several azeotropic distillation to remove thionyl chloride.Solid residue is suspended in ice/water, adds saturated solution of sodium bicarbonate and regulate mixture to pH7.The solid collected by filtration thing, washing is also dry in vacuum drying oven in the presence of phosphorus pentoxide, obtains 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (3.35g, 88%).Embodiment 51-52
Adopt the similar approach of embodiment 50, make 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (as preparation as described in the embodiment 50 initial substance parts) and suitable phenol reactant, generate the chemical compound described in the Table III.Table III
The embodiment sequence number Weight (mg) Productive rate % ?MS-ESI ?[MH] + ??????????Ar Note
????51 ??189 ??92 ??454 2-methylquinoline-7-base ????a
????52 ??175 ??90 ??428 Indole-5-base ????b
A) (150mg is 0.45mmol) with 7-hydroxy-2-methylquinoline (86.6mg, 054mmol) (J.Med.Chem.1998,41,4062) reaction for 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline.After the cooling, add entry, filter the collecting precipitation thing, water and ether washing successively obtains 6-methoxyl group-7-(3-mesyl propoxyl group)-4-(2-methylquinoline-7-base oxygen base) quinazoline behind the vacuum drying. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.2-2.35 (m, 2H), 2.95 (s, 3H), 3.1 (s, 3H), 3.35 (m, 2H), 4.05 (s, 3H), 4.4 (t, 2H), 7.5 (s, 1H), 7.7 (s, 1H), 7.95 (dd, 1H), 8.02 (d, 1H), 8.2 (s, 1H), 8.48 (d, 1H), 8.7 (s, 1H), 9.12 (d, 1H)
B) adopt the similar approach of note described in a); by 4-chloro-6-methoxyl group-7-(3-(mesyl) propoxyl group) quinazoline (150mg; 0.45mmol) and 5-oxyindole (72.4mg; 0.54mmol) reaction, obtain 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) (m, 2H), 3.1 (s, 3H), (t, 2H), 4.0 (s, 3H), 4.4 (t, 2H), 6.5 (s, 1H), 7.0 (dd, 1H), 7.4 (s, 1H), (m, 3H), 7.6 (s, 1H), 8.5 (s, 1H), 11.25 (s, 1H) embodiment 53 for 7.4-7.5 for 3.3-3.4 for 2.2-2.35
To 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (112mg, 0.35mmol) (as preparation as described in the embodiment 49) and N, N-dimethylethanolamine (62mg, 0.7mmol) add in the suspension in dichloromethane (2ml) in batches 0.5M triphenyl phasphine/dichloromethane and diisopropyl azo-2-carboxylic acid (150 μ l, 0.75mmol).After the stirring at room 2 hours, pour reactant mixture in the isolute  post (10g silica gel), with ethyl acetate/dichloromethane (1/1), methanol/ethyl acetate/dichloromethane (10/40/50), ethanol/methylene (10/90) and 3M ammonia methanol solution/ethanol/methylene (5/15/80)-successively eluting.Steam except that behind the volatile matter, residue is dissolved in minimum dichloromethane (about 3ml), add ether and petroleum ether (about 10ml).Filter and collect the precipitate that produces, get 7-(2-(N, N-dimethylamino) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (52mg, 38%) behind the vacuum drying.MS-ESI:393[MH] + 1H NMR spectrum: (DMSOd 6) 2.25 (s, 6H), 2.4 (s, 3H), 2.75 (t, 2H), 4.0 (s, 3H), 4.3 (1,2H), 6.15 (s, 1H), 6.87 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 7.5 (s, 1H) embodiment 54-56
Adopt embodiment 53 described similar approach, with the proper proportion quantitative response, produce the chemical compound described in the Table IV with suitable alcohol and 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (as preparation as described in the embodiment 49).Table IV
Figure A0080608501651
The embodiment sequence number Weight (mg) Productive rate % ?MS-ESI ?[MH] + ?????????R Note
????54 ??25 ??17 ??419 2-pyrrolidine-1-base oxethyl ????a
????55 ??112 ??74 ??433 1-methyl piperidine-3-ylmethoxy ????b
????56 ??115 ??72 ??456 2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl ????c
A) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 1-(2-hydroxyethyl) pyrrolidine (81mg) reaction obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-pyrrolidine-1-base oxethyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.65-1.8 (m, 4H), 2.4 (s, 3H), 2.6 (br s, 4H), 2.9 (t, 2H), 4.0 (s, 3H), 4.3 (t, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
B) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 1-methyl-3-piperidine carbinols (90mg) reaction obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-methyl piperidine-3-ylmethoxy) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.45-2.2 (m, 7H), 2.18 (s, 3H), 2.4 (s, 3H), 2.6 (brd, 1H), 2.85 (brd, 1H), 4.0 (s, 3H), 4.1 (d, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.25 (d, 1H), 7.3 (d, 1H), 7.35 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
C) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 2-(N-methyl-N-(4-pyridine radicals) amino) ethanol (106mg) (EP0359389) react, and obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 3.1 (s, 3H), 3.9 (t, 2H), 3.97 (s, 3H), 4.4 (t, 2H), 6.15 (s, 1H), 6.75 (d, 2H), 6.87 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.35 (s, 1H), 7.6 (s, 1H), 8.15 (d, 2H), 8.5 (s, 1H) embodiment 57-66
Adopt embodiment 53 described similar approach (just not needing the ammonia methanol solution in the column chromatography process), make suitable alcohol and 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (as preparation as described in the embodiment 49), generate the chemical compound described in the Table V with the proper proportion reaction.Table V
Figure A0080608501661
The embodiment sequence number Weight (mg) Productive rate % ?MS-ESI ?[MH] + ????R Note
???57 ??115 ??76 ??435 2-morpholino ethyoxyl ????a
???58 ??64 ??42 ??433 2-piperidino ethyoxyl ????b
???59 ??66 ??43 ??437 2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl ????c
???60 ??118 ??75 ??449 3-morpholino propoxyl group ????d
???61 ??101 ??68 ??424 2-(2-methoxy ethoxy) ethyoxyl ????e
???62 ??81 ??57 ??407 3-(N, N-dimethylamino) propoxyl group ????f
???63 ??160 ??92 ??497 3-(1,1-dioxo thiomorpholine generation) propoxyl group ????g
???64 ??121 ??83 ??417 2-(1H-1,2,4-triazol-1-yl) ethyoxyl ????h
????65 ??38 ??22 ??492 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl ????i
????66 ??80 ??48 ??479 2-(2-morpholino ethyoxyl) ethyoxyl ????j
A) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 4-(2-hydroxyethyl) morpholine (92mg) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 2.5-2.7 (m, 4H), 2.8 (t, 2H), 3.6 (t, 4H), 4.0 (s, 3H), 4.35 (t, 2H), 6.15 (s, 1H), 6.87 (dd, 1H), 7.25 (s, 1H), 7.32 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
B) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 1-(2-hydroxyethyl) piperidines (90mg) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-piperidino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H), 1.4-1.6 (m, 4H), 2.4 (s, 3H), 2.4-2.5 (m, 4H), 2.75 (t, 2H), 3.97 (s, 3H), 4.3 (t, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
C) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and reaction of 2-(N-(2-methoxy ethyl)-N-methylamino) ethanol (93mg) generates 6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H), 2.4 (s, 3H), 2.65 (t, 2H), 2.85 (t, 2H), 3.25 (s, 3H), 3.45 (t, 2H), 3.97 (s, 3H), 4.25 (t, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.32 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
Initial substance is prepared as follows:
Backflow 2-(methylamino) ethanol (5.4g, 72mmol), the 2-bromo-ethyl-methyl ether (10g, 72mmol) and triethylamine (10ml, 72mmol) mixture overnight in acetonitrile (70ml).After the cooling, filter solids, evaporated filtrate then.Residue is developed with ether.Separate ether layer, evaporation obtains 2-(N-(2-methoxy ethyl)-N-methylamino) ethanol (3g, 31%).MS-EI:134[MH]+ 1H NMR spectrum: (CDCl 3) 2.35 (s, 3H); 2.6 (t, 2H); 2.65 (t, 2H); 3.35 (s, 3H); 3.5 (t, 2H); 3.6 (t, 2H)
D) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 4-(3-hydroxypropyl) morpholine (102mg) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.1 (m, 2H), 2.4 (s, 3H), 2.45 (t, 2H), 2.45-2.6 (s, 4H), 3.6 (t, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.38 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
Initial substance is prepared as follows:
(75g, (94g, 1.08mol), 80 ℃ of reacting by heating things are 4 hours then dropwise to add morpholine in toluene 0.54mol) (750ml) solution to 3-bromo-1-propanol.Cooling mixture is to room temperature, the solids that filtering is separated out.Remove the volatile matter in the filtrate, and then gained grease is purified by distillation under 0.4-0.7mmHg, get colorless oil 4-(3-hydroxypropyl) morpholino (40g, 50%).B.p.68-70C (～0.5mmHg) 1H NMR spectrum: (DMSOd 6) 1.65-1.78 (m, 2H); 2.50 (t, 4H); 2.60 (t, 2H); 3.68 (t, 4H); 3.78 (t, 2H); 4.90 (brd, 1H)
E) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 2-(2-methoxy ethoxy) ethanol (84mg) reaction generates 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.42 (s, 3H), 3.27 (s, 3H), 3.5 (t, 2H), 3.65 (t, 2H), 3.85 (t, 2H), 4.0 (s, 3H), 4.32 (t, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
F) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and reaction of 3-(N, N-dimethylamino) propanol (72mg) generates 7-(3-N, N-dimethylamino propoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.0 (m, 2H), 2.17 (s, 6H), 2.4 (s, 3H), 3.98 (s, 3H), 4.22 (t, 2H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.35 (s, 1H), 7.6 (s, 1H), 8.47 (s, 1H)
G) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (135mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.0 (m, 2H), 2.38 (s, 3H), 2.65 (t, 2H), 2.9 (br s, 4H), 3.1 (brs, 4H), 3.96 (s, 3H), 4.25 (t, 2H), 6.12 (s, 1H), 6.85 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.37 (s, 1H), 7.56 (s, 1H), 8.46 (s, 1H)
H) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 2-(1H-1,2, the 4-triazol-1-yl) ethanol (79mg) (Ann.Phar.Fr.1977,35,503-508) reaction, generate 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1,2,4-triazol-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.42 (s, 3H), 3.96 (s, 3H), 4.62 (m, 2H), 4.75 (m, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.27 (s, 1H), 7.32 (d, 1H), 7.47 (s, 1H), 7.63 (s, 1H), 8.03 (s, 1H), 8.51 (s, 1H), 8.60 (s, 1H)
I) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and 2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethanol (132mg) (Arzneim.Forsch.1966,16,1557-1560) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.2-2.6 (m, 10H), 2.4 (s, 3H), 3.65 (t, 2H), 3.85 (t, 2H), 4.03 (s, 3H), 4.35 (m, 2H), 6.16 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.4 (s, 1H), 7.61 (s, 1H), 8.5 (s, 1H)
J) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline and reaction of 2-(2-morpholino ethyoxyl) ethanol (123mg) generates 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-morpholino ethyoxyl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.40 (s, 3H), 2.4-2.5 (m, 4H), 2.4-2.6 (m, 2H), 3.55 (t, 4H), 3.6 (t, 2H), 3.85 (t, 2H), 3.97 (brs, 3H), 4.15 (brs, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.48 (s, 1H)
Initial substance is prepared as follows:
To morpholine (2.58g, 30mmol) and potassium carbonate (5.5g, 40mmol) add in the mixture in acetonitrile (50ml) 2-(2-chloroethoxy) ethanol (1.25g, 10mmol).Reflux mixture 6 hours, stirring at room is 18 hours then.The filtering insoluble matter is removed volatile matter by evaporation from filtrate.Residue and then by the column chromatography purification, with methylene chloride (95/5, then 90/10, last 80/20) eluting, 2-(2-morpholino ethyoxyl) ethanol (600mg, 34%).MS-(EI): 175[M.] + 1H NMR spectrum: (CDCl 3) 2.5 (brs, 4H); 2.59 (t, 2H); 3.6-3.85 (m, 10H) embodiment 67
With 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (100mg, 0.29mmol), 5-hydroxy-2-methyl indole (53mg, 0.36mmol) (as preparation as described in embodiment 48 starting materials) and potassium carbonate (62mg, 0.44mol) 85 ℃ of heating of solution in DMF (2ml) 3 hours, then in 95 ℃ of reheat 2 hours.After the cooling, add ice/water (15ml), filter the collecting precipitation thing, dry under vacuum.Gained solid and then by the column chromatography purification, with methylene chloride (95/5) and methylene chloride/3M ammonia methanol solution (95/3/2) priority eluting, get 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (71mg, 54%).MS-ESI:447[MH] + 1H NMR spectrum: (DMSOd 6) 1.35-1.4 (m, 2H), 1.45-1.55 (m, 4H), 1.92-2.0 (m, 2H), 2.3-2.4 (m, 4H), 2.40 (s, 3H), 2.4-2.5 (m, 2H), 3.97 (s, 3H), 4.22 (t, 2H), 6.15 (s, 1H), 6.9 (d, 1H), 7.27 (s, 1H), 7.8 (d, 1H), 7.35 (s, 1H), 7.58 (s, 1H), 8.48 (s, 1H)
Initial substance is prepared as follows:
To 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (5g, 16.3mmol) (as preparation as described in the starting material among the embodiment 12), 3-bromo-1-propanol (2.21ml, 24.5mmol) and triphenyl phasphine (4.62g, 24.5mmol) add in the suspension in dichloromethane (50ml) in batches the diethylazodicarboxylate (3.9ml, 24.5mmol).After the stirring at room 2 hours, vacuum is removed volatile matter, residue and then by the column chromatography purification, use dichloromethane and methylene chloride (95/5) eluting successively, get 7-(3-bromine propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (6g, 86%).MS-ESI:427-429[MH] + 1H NMR spectrum: (DMSOd 6) 1.12 (s, 9H), 2.32 (t, 2H), 3.7 (t, 2H), 3.9 (s, 3H), 4.25 (t, 2H), 5.9 (s, 2H), 7.20 (s, 1H), 7.51 (s, 1H), 8.36 (s, 1H)
Elementary analysis: measured value C50.1 H5.4 N6.4C 18H 23BrN 2O 50.2H 2O value of calculation C50.2 H5.5 N6.5%
100 ℃ of heating 7-(3-bromine propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (2.89g, piperidines 6.78mmol) (10ml) solution 1 hour.After the cooling, vacuum is removed volatile matter.Residue is dissolved in dichloromethane, with saturated ammonium chloride and salt water washing.Dry (magnesium sulfate) organic layer, and remove volatile matter by evaporation.The vacuum drying residue, thus 6-methoxyl group-7-(3-piperidino propoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (2.4g, 83%) obtained.MS-ESI:432[MH] + 1H NMR spectrum: (DMSOd 6) 1.15 (s, 9H), 1.35-1.5 (m, 1H), 1.6-1.8 (m, 3H), and 1.8-1.9 (d, 2H), 2.2-2.3 (m, 2H), 2.95 (t, 2H), 3.25 (t, 2H), 3.55 (d, 2H), 335 (s, 3H), 4.25 (t, 2H), 5.94 (s, 2H), 7.24 (s, 1H), 7.56 (s, 1H), 8.46 (s, 1H)
Stirring at room 6-methoxyl group-7-(3-piperidino propoxyl group)-3-((new pentane acyloxy) methyl)-3, (2.35g, 5.45mmol) solution in 7M ammonia/methanol (50ml) spends the night 4-dihydroquinazoline-4-ketone.Vacuum is removed volatile matter, and residue is developed with ether, filters and use successively the washing of ether and ether/dichloromethane (1/1), gets 6-methoxyl group-7-(3-piperidino propoxyl group)-3,4-dihydroquinazoline-4-ketone (1.65g, 95%) behind the vacuum drying.MS-ESI:318[MH] + 1H NMR spectrum: (DMSOd 6) 1.3-1.4 (m, 2H), 1.4-1.55 (m, 4H), 1.85-1.95 (m, 2H), 2.35 (brs, 4H), 2.4 (t, 2H), 3.9 (s, 3H), 4.15 (t, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.9 (s, 1H)
Elementary analysis: measured value C63.5 H7.4 N13.1C 17H 23N 3O 30.2H 2O value of calculation C63.6 H7.4 N13.0%
Reflux 6-methoxyl group-7-(3-piperidino propoxyl group)-3, (1.5g, 4.7mmol) solution in the thionyl chloride that contains DMF (1.5ml) (15ml) is 3 hours for 4-dihydroquinazoline-4-ketone.After the cooling, vacuum is removed volatile matter.Residue is with the toluene azeotropic.The gained solids is assigned between dichloromethane and the sodium bicarbonate.Regulate the pH to 10 of water layer with the 6M sodium hydrate aqueous solution.Tell organic layer, use the salt water washing, dry (magnesium sulfate) also removes volatile matter by evaporation.Residue and then by the column chromatography purification, 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (1.21g, 76%).MS-ESI:336[MH] + 1H NMR spectrum: (DMSOd 6) (m, 2H), (m, 4H), (m, 2H), 2.4 (brs, 4H), 2.45 (t, 2H), 4.0 (s, 3H), 4.29 (t, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H) embodiment 68 for 1.9-2.05 for 1.5-1.6 for 1.35-1.45
Adopt embodiment 67 described similar approach, make 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (100mg) (as preparation as described in embodiment 67 starting materials) and 5-oxyindole (48mg, 0.36mmol) reaction, get 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (57mg, 45%).MS-ESI:433[MH] + 1H NMR spectrum: (DMSOd 6) 1.4 (br s, 2H), 1.45-1.6 (br s, 4H), 1.9-2.1 (m, 2H), 2.4 (br s, 4H), 2.45 (t, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.47 (s, 1H), 7.0 (d, 1H), 7.35 (s, 1H), 7.45 (s, 2H), 7.47 (d, 1H), 7.61 (s, 1H), 8.49 (s, 1H) embodiment 69
100 ℃ of heating 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (161mg, 0.5mmol) (as preparation as described in the embodiment 49), 4-(4-Methyl benzenesulfonyl oxygen ylmethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (222mg, 0.6mmol) (188mg, 1mmol) solution in DMF (1.6ml) is 2 hours for (as preparation as described in embodiment 10 starting materials) and potassium carbonate.After the cooling, add entry.Filter the collecting precipitation thing, washing, 60 ℃ of vacuum dryings in the presence of phosphorus pentoxide.The gained solid is developed with petroleum ether, filter and collect, with the washing of ether/petroleum ether (1/1) mixture, obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) quinazoline (200mg, 77%) behind the vacuum drying.MS-ESI:541[MNa] + 1H NMR spectrum: (DMSOd 6) 1.1-1.3 (m, 2H), 1.4 (s, 9H), 1.8 (d, 2H), 1.95-2.1 (m, 1H), 2.4 (s, 1H), 2.7-2.85 (br s, 2H), 3.95 (s, 3H), 4.05 (d, 2H), 6.12 (s, 1H), 6.85 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.35 (s, 1H), 7.55 (s, 1H), 8.45 (s, 1H) embodiment 70
(155mg, 0.3mmol) (as preparation as described in the embodiment 69) solution in the dichloromethane that contains TFA (1ml) (5ml) is 30 minutes for stirring at room 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) quinazoline.Vacuum is removed volatile matter, the residue water treatment, and be adjusted to pH12 with the 2M sodium hydroxide.The mixture dichloromethane extraction.Dry (magnesium sulfate) organic layer, volatile matter is removed in evaporation.Residue and then by the column chromatography purification is used dichloromethane/ethyl acetate/methanol (5/4/1) and methylene chloride (9/1) and 3M ammonia methanol solution/ethanol/methylene (5/15/80) eluting successively.Evaporation is dissolved in minimum dichloromethane with residue after removing and desolvating, and order adds ether and petroleum ether.Filter the collecting precipitation thing,, get 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (120mg, 96%) behind the vacuum drying with the ether washing.MS-ESI:419[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.5-1.7 (m, 2H), 2.05 (br d, 2H), 2.3-2.4 (m, 1H), 2.4 (s, 3H), 3.05 (t, 2H), 3.4 (d, 2H), 4.09 (s, 3H), 4.25 (d, 2H), 6.95 (dd, 1H), 7.35 (s, 1H), 7.4 (d, 1H), 7.6 (s, 1H), 7.85 (s, 1H), 9.15 (s, 1H) embodiment 71
To 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (726mg, 1.74mmolo) (as preparation as described in the embodiment 70) adding methoxyl group acetaldehyde (368mg in the solution in dichloromethane (15ml) and methanol (15ml) mixture, 3.47mol) (fresh distillation), then add again sodium triacetoxy borohydride (552mg, 2.6mol).After the stirring at room 1.5 hours, add saturated sodium bicarbonate.Vacuum is removed volatile matter, and residue is assigned between dichloromethane and the water.Tell organic layer, water, salt water washing, volatile matter is removed in dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with methylene chloride (80/20) eluting.Except that after desolvating, residue is developed with ether, filtered and collect, with the ether washing and in 60 ℃ of vacuum dryings, thereby obtain 6-methoxyl group-7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline (392mg, 47%).MS-ESI477[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.6-1.8 (m, 2H), 2.05 (brd, 2H), 2.15-2.3 (m, 1H), 2.4 (s, 3H), 3.05 (t, 2H), 3.3 (br s, 2H), 3.32 (s, 3H), 3.58 (d, 2H), 3.65 (br s, 2H), 4.05 (s, 3H), 4.18 (d, 2H), 6.2 (s, 0.5H (part exchange)), 6.92 (dd, 1H), 7.32 (s, 1H), 7.35 (d, 1H), 7.55 (s, 1H), 7.8 (s, 1H), 9.15 (s, 1H)
Elementary analysis: measured value C68.0 H6.8 N11.8C 27H 32N 4O 4Value of calculation C68.1 H6.8 N11.8%
Initial substance is prepared as follows:
40 ℃ are stirred 1,1,2-trimethoxy-ethane (90g, 750mmol) solution 1.5 hours in the water that contains 12N hydrochloric acid (3.75ml) (570ml).After the cooling, add solid sodium chloride, the mixture ether extraction.Dry (magnesium sulfate) organic layer.Distill organic layer then, collect 70-90 ℃ of fraction, obtain methoxyl group acetaldehyde (20.3g), this product is directly used in next step.Embodiment 72
To 7-(2-carboxy vinyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (75mg, 0.2mmol), triethylamine (40mg, 0.4mmol) and 1-(2-amino-ethyl) pyrrolidine (46mg, 0.4mmol) add in the solution in DMF (1.5ml) in batches the diphenylphosphine acyl azide (83mg, 0.3mmol).After the stirring at room 5 hours, mixture is assigned between ethyl acetate and the water.Tell organic layer, water and salt water washing, volatile matter is removed in dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification is with then dichloromethane/3M ammonia methanol solution (9/1) eluting of methylene chloride (9/1).Except that after desolvating; surplus solids is developed with ether, filters and collects, with ether washing and dry under vacuum; thereby obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((2-(2-pyrrolidine-1-base ethyl) carbamoyl) vinyl) quinazoline (25mg, 26%).MS-ESI:472[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.8-1.95 (m, 2H), 135-2.1 (m, 2H), 2.48 (s, 3H), 3.0-3.2 (m, 2H), 3.35 (t, 2H), 3.6 (t, 2H), 3.65 (br s, 2H), 4.11 (s, 3H), 6.18 (s, 0.5H, the part exchange), 6.95 (dd, 1H), 7.05 (d, 1H), 7.35 (s, 1H), 7.37 (d, 1H), 7.8 (s, 1H), 7.86 (d, 1H), 8.2 (s, 1H), 8.76 (s, 1H)
Initial substance is prepared as follows:
Under 5 ℃ of coolings, to 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline (320mg, 1mmol) (as preparation as described in embodiment 5 starting materials) in the dichloromethane that contains pyridine (2ml) (2ml) suspension, add trifluoromethanesulfanhydride anhydride (338mg, 1.2mmol).After finishing, warm mixture stirred 1 hour to room temperature.After volatile matter is removed in evaporation, residue is assigned between ethylacetate/ether and the water.Separate organic layer, use 0.5M hydrochloric acid, water, salt water washing successively, dry (magnesium sulfate) and evaporation get 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-(trifluoro-methanesulfonyl oxy) quinazoline (400mg, 88%).MS-ESI:453-455[MH] + 1H NMR spectrum: (DMSOd 6) 4.15 (s, 3H), 7.5 (d, 1H), 7.62 (t, 1H), 7.78 (d, 1H), 8.02 (s, 1H), 8.27 (s, 1H), 8.77 (s, 1H)
Under the argon atmospher, to 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-(trifluoro-methanesulfonyl oxy) quinazoline (136mg, 0.3mmol) DMF (1.5ml) solution in add triethylamine (33mg, 0.33mmol) and tert-butyl acrylate (77mg, 0.6mmol), then add again the diphenylphosphine acyl azide (3.4mg, 0.008mmol) and acid chloride (II) (1.7mg, 0.0075mmol).After finishing, use the argon cleaning reaction flask.Stirred the mixture 6 hours in 80-85 ℃.After the cooling, mixture is assigned between ethyl acetate and the water.Water layer is adjusted to pH6 with 2M hydrochloric acid.Tell organic layer, water and salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification is successively used diamino methane and dichloromethane/ether (95/5) eluting.After the solvent removed in vacuo, the gained solid is developed with pentane/ether, filtered and collect also drying under vacuum, thereby obtain 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-(2-(tertbutyloxycarbonyl) vinyl) quinazoline (63mg, 49%).MS-ESI:431[MH] + 1H NMR spectrum: (DMSOd 6) 1.51 (s, 9H), 4.07 (s, 3H), 6.87 (d, 1H), 7.45 (d, 1H), 7.6 (t, 1H), 7.7 (s, 1H), 7.75 (d, 1H), 7.91 (d, 1H), 8.39 (s, 1H), 8.65 (s, 1H)
Elementary analysis: measured value C61.1 H4.8 N6.6C 22H 20ClFN 2O 3Value of calculation C61.3 H4.7 N6.5%
Stirring at room 4-(4-chloro-2-fluorophenoxy)-(581mg, 1.31mmol) solution in dichloromethane/TFA mixture (2.5ml/1.5ml) is 1.5 hours for 6-methoxyl group-7-(2-(tertbutyloxycarbonyl) vinyl) quinazoline.After vacuum is removed volatile matter, residue is assigned within ethyl acetate and the water.Water layer is adjusted to pH3 with the 0.5M sodium hydroxide.Tell organic layer, water layer is further used ethyl acetate extraction.The organic layer salt water washing that merges, dry (magnesium sulfate) obtains 7-(2-carboxy vinyl)-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline (430mg, 85) after the evaporation. 1H NMR spectrum: (DMSOd 6) 4.08 (s, 3H), 6.9 (d, 1H), 7.45 (s, 1H), 7.6 (t, 1H), 7.70 (s, 1H), 7.73 (d, 1H), 7.95 (d, 1H), 8.39 (s, 1H), 8.66 (s, 1H)
To 7-(2-carboxy vinyl)-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline (105mg, 0.28mmol) and 5-hydroxy-2-methyl indole (82mg, 0.56mmol) add in (as preparation as described in embodiment 48 starting materials) suspension in DMSO (1.5ml) 1M HMDS sodium salt THF solution (0.84ml, 8.4mmol).After the stirring at room 2 hours, mixture is assigned within ethyl acetate and the water.Water layer is adjusted to pH3 with 2M hydrochloric acid.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with methylene chloride (being followed successively by 95/5,90/10 and 70/30) eluting, 7-(2-carboxy vinyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (75mg, 71%). 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 4.06 (s, 3H), 6.15 (s, 1H), 6.82 (d, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.68 (s, 1H), 7.84 (d, 1H), 8.25 (s, 1H), 8.55[s, 1H) embodiment 73
With 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (321mg, 1mmol) (as preparation as described in the embodiment 49), 1-bromo-3-chloropropane (120 μ l, 1.2mmol) and potassium carbonate (359mg, 2.6mmol) suspension in DMF (5ml) at room temperature stirs and spends the night.After adding entry, filter the collecting precipitation thing, washing, then in the presence of phosphorus pentoxide in 60 ℃ of dryings, thereby obtain 7-(3-chlorine propoxyl group)-6-methoxyl group-4-(the basic oxygen base of 2 methyl indole-5-) quinazoline (280mg, 70%).MS-FSI:398[MH] + 1H NMR spectrum: (DMSOd 6) (m, 2H), 2.4 (s, 3H), 3.85 (t, 2H), 4.0 (s, 3H), 4.32 (t, 2H), 6.15 (s, 1H), 6.88 (d, 1H), 7.27 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H) embodiment 74 for 2.2-3.35
(150mg, 0.38mmol) (as preparation as described in the embodiment 73) solution in 1-methyl piperazine (2ml) is 2 hours for 100 ℃ of heating 7-(3-chlorine propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline.After the cooling, mixture is assigned within ethyl acetate and 5% sodium bicarbonate aqueous solution.Tell organic layer, water and salt water washing, dry (magnesium sulfate) and evaporation.Residue so on the isolute post by column chromatography for separation, with methanol/ethyl acetate/dichloromethane (1/4/5, then 1/9/0) and 3M ammonia methanol solution/ethanol/methylene (5/10/80) eluting.After the solvent removed in vacuo, the gained solid is dissolved in minimum dichloromethane, adds ether/petroleum ether then.Filter the collecting precipitation thing, obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (55mg, 32%) behind the vacuum drying.MS-ESI:462[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD, 60 ℃) 2.2-2.3 (m, 2H), 2.4 (s, 3H), 2.9 (s, 3H), 3.4-3.5 (m, 4H), 3.5-3.8 (m, 6H), 4.07 (s, 3H), 4.4 (t, 2H), 6.95 (d, 1H), 7.35 (s, 1H), 7.4 (d, 1H), 7.55 (s, 1H), 7.8 (s, 1H), 8.95 (s, 1H) embodiment 75
To 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (160mg, 0.5mmol) add triphenyl phasphine (262mg in dichloromethane (5ml) suspension of (as preparation as described in the embodiment 49), 1mmol) and N, N-diethyl ethylene diamine (88mg, 0.75mmol), then add in batches the diethylazodicarboxylate (165 μ l, 1mmol).After the stirring at room 1 hour, vacuum is removed volatile matter.Residue and then by the column chromatography purification, use methylene chloride (95/5) and dichloromethane/3M ammonia methanol solution (90/10) eluting successively, get 7-(2-(N, N-diethylamino) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (147mg, 70%).MS-ESI 421[MH] + 1H NMR spectrum: (DMSOd 6) 1.0 (t, 6H), 2.41 (s, 3H), 2.6 (q, 4H), 2.88 (t, 2H), 3.97 (s, 3H), 4.24 (t, 2H), 6.14 (s, 1H) 6.89 (dd, 1H), 7.25 (s, 1H), 7.32 (d, 1H), 7.38 (s, 1H), 7.58 (s, 1H), 8.48 (s, 1H)
Elementary analysis: measured value C66.2 H6.9 N13.1C 24H 28N 4O 30.8H 2O value of calculation C66.3 H6.9 N12.9% embodiment 76
Adopt embodiment 75 described similar approach, make 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (321mg, 1mmol) (as preparation as described in the embodiment 49) and 2-((1-tertbutyloxycarbonyl) piperidin-4-yl oxygen base) ethanol (294mg, 1.2mmol) reaction, generate 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-((1-tertbutyloxycarbonyl) piperidin-4-yl oxygen base) ethyoxyl) quinazoline (420mg, 76%).MS-ESI:549[MH] + 1H NMR spectrum: (DMSOd 6) 1.4 (s, 9H), 1.3-1.5 (m, 2H), 1.7-1.9 (m, 2H), 2.38 (s, 3H), 3.0 (br t, 2H), 3.5-3.7 (m, 3H), 3.85 (m, 2H), 3.98 (s, 3H), 4.3 (t, 2H), 6.12 (s, 1H), 6.85 (d, 1H), 7.22 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.55 (s, 1H), 8.48 (s, 1H)
Initial substance is prepared as follows:
Under 0 ℃ of cooling, to 4,4-(ethylenedioxy) piperidines (adding tertbutyloxycarbonyl anhydride in the 1g, acetone/chloroform 7mmol) (3.5ml/3.5ml) solution (1.52g, 7mmol)/acetone (3.5ml).After the stirring at room 4 hours, vacuum is removed volatile matter.Residue is dissolved in ether, and with this diethyl ether solution water, salt water washing, the evaporation of dry (magnesium sulfate) back obtains 4, and 4-(ethylenedioxy)-1-tertiary butyloxycarbonyl phenylpiperidines (1.7g, quantitatively). 1H NMR spectrum: (CDCl 3): 1.46 (s, 9H), 1.65 (t, 4H), 3.5 (t, 4H), 3.97 (s, 4H)
Under 0 ℃ of cooling, to 4,4-(ethylenedioxy)-1-tertiary butyloxycarbonyl phenylpiperidines (100mg, 0.41mmol) THF (1.4ml) solution in add fresh distillatory boron trifluoride etherate (52 μ l, 0.41mmol), then add again sodium cyanoborohydride (38mg, 0.6mmol).After the stirring at room 6 hours, and adding boron trifluoride etherate (52 μ l) and sodium cyanoborohydride (26mg, 0.41mmol).After the stirred overnight at room temperature, mixture is assigned between ethyl acetate and the 2M sodium hydroxide.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification is used methylene chloride (95/5), methylene chloride/3M ammonia methanol solution (80/15/5) eluting successively, thereby is obtained 2-((1-tertbutyloxycarbonyl) piperidin-4-yl oxygen base) ethanol (42mg, 42%).MS-ESI:268[MNa] + 1H NMR spectrum: (CDCl 3) 1.48 (s, 9H), (m, 2H), (m, 2H), 2.0 (t, 1H), (m, 2H), 3.5 (m, 1H), 3.57 (t, 2H), (m, 4H) embodiment 77 for 3.7-3.9 for 3.05-3.15 for 8-1.9 for 1.5-1.6
(379mg, 0.69mmol) (as preparation as described in the embodiment 76) solution in the dichloromethane that contains TFA (2.5ml) (7ml) is 1.5 hours for stirring at room 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-((1-tertbutyloxycarbonyl) piperidin-4-yl oxygen base) ethylidene) quinazoline.After vacuum is removed volatile matter, residue is assigned between ethyl acetate and the water.Add solid sodium bicarbonate and 2N sodium hydroxide with the pH that regulates water layer to about 10.Organic layer water, saline wash successively, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters, ether washing and dry under vacuum, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl oxygen base) ethyoxyl) quinazoline (164mg, 53%). 1HNMR spectrum: (DMSOd 6) 1.2-1.4 (m, 2H), 1.8-1.9 (m, 2H), 2.47 (s, 3H), 2.4-2.5 (m, 2H), 2.9-3.0 (d, 2H), 3.3-3.5 (m, 1H), 3.95 (s, 2H), 4.0 (s, 3H), 4.35 (s, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.28 (s, 1H), 7.32 (d, 1H), 7.41 (s, 1H), 7.60 (s, 1H), 8.49 (s, 1H) MS-ESI:448[M.] +Embodiment 78
With 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (193mg, 0.6mmol) (as preparation as described in the embodiment 49), 4-(2-hydroxyl-oxethyl) pyridine (166mg, 1.2mmol), (J.Chem.Soc.Perkin II, 1987,1867) contain triphenyl phasphine (330mg, 1.26mmol) and diisopropyl azo-2-carboxylic acid (255mg, the solution stirring at room in dichloromethane 1.26mmol) (5ml) 2 hours.Filtering precipitate, order gets 6-methoxyl group-4-(methylindole-5-base oxygen base)-7-(2-(4-pyridyloxy) ethyoxyl) quinazoline (142mg, 54%) with ether and ethyl acetate development behind the vacuum drying. 1HNMR spectrum: (DMSOd 6) 2.40 (s, 3H), 3.97 (s, 3H), 4.52 (t, 2H), 4.58 (t, 2H), 6.14 (s, 1H), 6.89 (dd, 1H), 7.07 (d, 2H), 7.26 (s, 1H), 7.31 (d, 1H), 7.46 (s, 1H), 7.61 (s, 1H), 8.41 (d, 2H), 8.5 (s, 1H) MS-ESI:443[MH] +
Elementary analysis: measured value C66.6 H5.0 N12.5C 25H 22N 4O 40.12CH 2Cl 2Value of calculation C66.9 H5.0 N12.4% embodiment 79
(148mg, 0.31mmol) (as preparation as described in the embodiment 149) solution in the dichloromethane that contains TFA (1ml) (4ml) is 1 hour to stir 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-t-butoxycarbonyl amino) ethyoxyl) quinazoline.After vacuum is removed volatile matter, with residue with the toluene azeotropic.Then residue is dissolved in dichloromethane (3ml), the order add triethylamine (215 μ 1,1.5mmol) and mesyl chloride (48 μ l, 0.62mmol).After the stirring at room 1 hour, mixture is assigned between dichloromethane and the water.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification is with methylene chloride (99/1, then 97/3) eluting.Behind the evaporating solvent, solids washs and then vacuum drying with ether development, filtration, ether, thereby obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-mesyl amino) ethyoxyl) quinazoline (54mg, 38%). 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 2.93 (s, 3H), 3.0 (s, 3H), 3.62 (t, 2H), 4.0 (s, 3H), 4.38 (t, 2H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.26 (s, 1H), 7.3 (d, 1H), 7.43 (s, 1H), 7.61 (s, 1H), 8.49 (s, 1H) MS-ESI:457[MH] +Embodiment 80
(76mg, 0.17mmol) (as preparation as described in the embodiment 77) solution in acrylonitrile (0.5ml), dichloromethane (1ml) and methanol (1ml) spends the night stirring at room 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl oxygen base) ethyoxyl) quinazoline.After vacuum is removed volatile matter, residue is passed through the column chromatography purification, with methylene chloride (order is 98/2,95/5 and 90/10) eluting.Residue and then with the development of ethyl acetate and ether.Filter the gained solids, behind vacuum drying, obtain 7-(2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (73mg, 86%). 1H NMR spectrum: (DMSOd 6) 1.4-1.55 (m, 2H), 1.8-1.9 (m, 2H), 2.15 (t, 2H), 2.4 (s, 3H), 2.55 (t, 2H), 2.65 (t, 2H), 2.7-2.8 (m, 2H), 3.4-3.5 (m, 1H), 3.85 (m, 2H), 4.0 (s, 3H), 4.3 (t, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H) MS-ESI:502[MH] +
Elementary analysis: measured value C67.0 H6.2 N14.0C 28H 31N 5O 4Value of calculation C67.1 H6.2 N14.0% embodiment 81
95 ℃ of heating 4-chloro-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline (100mg, 0.31mmol) (as preparation as described in embodiment 9 starting materials), 6-oxyindole (50mg, 0.37mmol) and potassium carbonate (64mg, 0.466mmol) solution in DMF (1ml) is 4 hours.After the cooling, mixture dilutes with dichloromethane, pours silicagel column then into.Product is used dichloromethane, methylene chloride (80/20, follow 70/30 and 50/50) eluting successively.After steaming desolventized, precipitate was developed with ether, and filtration is also dry under vacuum, thereby obtained 6-methoxyl group-4-(indole-6-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (90mg, 69%). 1H NMR spectrum: (DMSOd 6) 1.85 (br s, 4H), 2.15-2.25 (m, 2H), 2.85-3.15 (m, 6H), 4.01 (s, 3H), 4.32 (t, 2H), 6.5 (s, 1H), 6.95 (dd, 1H), 7.32 (s, 1H), 7.4 (s, 2H), 7.6 (d, 1H), 7.6s (s, 1H), 8.52 (s, 1H) MS-ESI:419[MH] +Embodiment 82
To 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg, 0.34mmol), triphenyl phasphine (189mg, 0.72mol) and 3-pyrrolidine third-1-alcohol (89mg, 0.686mmol) (J.Org.Chem.1988,53,3164) add in the solution in dichloromethane (2.5ml) diisopropyl azo-2-carboxylic acid (146mg, 0.72mmol).After the stirred overnight at room temperature, filter solids.Filtrate is used ethyl acetate/dichloromethane (1/1), ethyl acetate/dichloromethane/methanol (4/5/1), methylene chloride (9/1) and 3N ammonia methanol solution/dichloromethane (1/9) eluting successively by the column chromatography purification.Except that after desolvating, residue is developed with ether, filter, and dry under vacuum, thus 4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (49mg, 35%) obtained. 1H NMR spectrum: (DMSOd 6) 1.8-2.0 (m, 2H), 2.0-2.15 (m, 2H), 2.2-2.32 (m, 2H), 2.41 (s, 3H), 3.0-3.2 (m, 2H), 3.4 (t, 2H), 3.6-3.7 (m, 2H), 4.35 (t, 2H), 6.2 (s, 1H), 6.95 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.5 (s, 1H), 7.57 (dd, 1H), 8.5 (d, 1H), 9.15 (s, 1H) MS-ESI:403[MH] +
Initial substance is prepared as follows:
(10ml, 96mmol) (368mg 16mmol), heated these mixture 30 minutes at 148 ℃ to middle adding sodium then to benzylalcohol.Add 7-fluoro-3,4-dihydroquinazoline-4-ketone (656mg, 4mmol) (J.Chme.Soc.section B 1967,449), the gained mixture in 24 hours reaction mixture of 148 ℃ of maintenances, is poured into gained solution in the water (170ml) thereafter, regulated aqueous mixture to pH3 with concentrated hydrochloric acid.Filter the collecting precipitation thing, water, ether washing, and dry under vacuum, thus white solid 7-benzyloxy-3 obtained, 4-dihydroquinazoline-4-ketone (890mg, 89%).M.p.267-269C 1H NMR spectrum: (DMSOd 6CF 3COOD) 5.32 (s, 2H); 7.25 (d, 1H); 7.32-7.52 (m, 6H); 8.12 (d, 1H); 8.99 (s, 1H) MS-ESI:252[MH] +
Elementary analysis: measured value C71.4 H4.9 N10.7C 15H 12N 2O 20.04H 2O value of calculation C71.2 H4.8 N11.1%
Reflux 7-benzyloxy-3, (11g is 43.6mmol) with the mixture of DMF (1ml) in thionyl chloride (100ml) 1.5 hours for 4-dihydroquinazoline-4-ketone.Steam to remove excessive thionyl chloride, and with residue with the toluene azeotropic.Then residue is assigned between dichloromethane and the water, adds saturated sodium bicarbonate aqueous solution and be approximately 9 until the pH of water layer.Separate organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation, thus obtain 7-benzyloxy-4-chloro-quinazoline (10.5g, 89%). 1H NMR spectrum: (DMSOd 6) 5.4 (s, 2H); 7.35-7.65 (m, 6H); 8.2 (d, 1H); 9.0 (s, 1H) MS-ESI:270[MH] +
80 ℃ of heating contain potassium carbonate (1.53g, 7-benzyloxy-4-chloro-quinazoline 11.1mmol) (2g, 7.4mmol), (1.3g, 8.9mmol) (as preparation as described in embodiment 48 starting materials) solution in DMF (20ml) is 3 hours for 5-hydroxy-2-methyl indole.After the cooling, the mixture distribution is poured in ice/water.Filtering precipitate washes with water and vacuum drying.The gained solid is dissolved in dichloromethane, carries out purification,, get 7-benzyloxy-4-(2 methyl indole-5-base oxygen base) quinazoline (2.28g, 81%) with ethyl acetate and dichloromethane (1/1) eluting by column chromatography.MS-ESI:382[MH] + 1H NMR spectrum: (DMSOd 6) 2.41 (s, 3H), 5.4 (s, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.4 (d, 1H), 7.4-7.5 (m, 4H), 7.55 (d, 2H), 8.32 (d, 1H), 8.6 (s, 1H).
To 7-benzyloxy-4-(2 methyl indole-5-base oxygen base) quinazoline (1.75g, in DMF 4.58mmol) (60ml) solution order add 10% palladium/carbon (200mg) and ammonium formate (4.34g, 69mmol).1 hour after-filtration mixture of stirring at room.Evaporated filtrate.Residue and then water development are filtered, with the ethyl acetate washing, and vacuum drying, thereby obtain 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (1.24g, 93%). 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.17 (s, 1H), 7.25-7.3 (m, 2H), 7.30 (d, 1H), 8.24 (d, 1H), 8.5 (s, 1H) embodiment 83-89
Adopt embodiment 82 described similar approach, make suitable alcohol and 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (as preparation as described in embodiment 82 starting materials) reaction, the chemical compound of describing in the Table VI under obtaining.Table VI
Figure A0080608501841
A) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 3-(mesyl)-1-propanol (95mg) (as preparation as described in embodiment 50 starting materials) reaction generates 7-(3-(mesyl) propoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.2-2.3 (m, 2H), 2.4 (s, 3H), 3.05 (s, 3H), 3.3-3.45 (m, 2H), 4.4 (t, 2H), 6.2 (s, 1H), 6.95 (dd, 1H), 7.38 (s, 1H), 7.4 (d, 1H), 7.5 (s, 1H), 7.6 (dd, 1H), 8.5 (d, 1H), 9.2 (s, 1H)
Elementary analysis: measured value C60.2 H5.3 N10.6C 21H 21N 3O 4S0.4DMF value of calculation C60.5 H5.4 N10.8%
B) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 4-(2-hydroxyethyl) morpholine (90mg) reaction generates 4-(2 methyl indole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6), CF 3COOD) 2.4 (s, 3H), 3.1-3.3 (m, 2H), 3.62 (d, 2H), 3.7-3.9 (m, 4H), 4.05 (d, 2H), 4.7 (t, 2H), 6.2 (s, 0.5H, part exchanges), 6.95 (dd, 1H), 7.35 (s, 1H), 7.39 (d, 1H), 7.6 (s, 1H), 7.65 (dd, 1H), 8.55 (d, 1H), 9.15 (s, 1H)
Elementary analysis: measured value C67.2 H6.0 N13.5C 23H 24N 4O 30.3H 2O value of calculation C67.4 H6.1 N13.7%
C) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 1-(3-hydroxypropyl) piperidines (98mg) reaction generates 4-(2 methyl indole-5-base oxygen base)-7-(3-piperidines-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.2-1.5 (m, 2H), 1.6-1.8 (m, 2H), 1.8-1.9 (m, 2H), 2.25-2.35 (m, 2H), 2.45 (s, 3H), 2.95 (t, 2H), 3.25-3.3 (m, 2H), 3.55 (d, 2H), 4.4 (t, 2H), 6.95 (dd, 1H), 7.4 (s, 1H), 7.45 (d, 1H), 7.5 (s, 1H), 7.6 (d, 1H), 8.55 (d, 1H), 9.15 (s, 1H)
D) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (133mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 4-(2 methyl indole-5-base oxygen base)-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.0 (m, 2H), 2.4 (s, 3H), 1.6-1.7 (m, 2H), 2.9 (br s, 4H), 3.1 (brs, 4H), 4.25 (t, 2H), 6.12 (s, 1H), 6.85 (d, 1H), 7.22 (s, 1H), 7.3 (d, 1H), 7.3-7.4 (m, 2H), 8.25 (d, 1H), 8.55 (s, 1H)
E) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 4-(3-hydroxypropyl) morpholine (100mg) (as preparation as described in embodiment 60 starting materials) reaction generates 4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H), 2.42 (s, 3H), 2.5 (t, 2H), 2.55 (t, 4H), 3.6 (t, 4H), 4.3 (t, 2H), 6.18 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.3-7.4 (m, 2H), 8.3 (d, 1H), 8.6 (s, 1H)
Elementary analysis: measured value C66.5 H6.2 N12.7C 24H 26N 4O 30.14CH 2Cl 20.7H 2O value of calculation C66.7 H6.4 N13.0%
F) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 1-(2-hydroxyethyl) piperidines (89mg) reaction generates 4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidines-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.4-1.5 (br s, 2H), 1.5-1.7 (brs, 4H), 2.42 (s, 3H), and 2.5-2.7 (brs, 4H), 2.8-3.0 (brs, 2H), 4.35 (brs, 2H), 6.18 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.4 (d, 1H), 7.42 (s, 1H), 8.3 (d, 1H), 8.6 (s, 1H)
Elementary analysis: measured value C69.0 H6.6 N13.4C 24H 26N 4O 20.8H 2O value of calculation C69.1 H6.7 N13.4%
G) 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg) and 2-(1H-1,2, the 4-triazol-1-yl) ethanol (78mg) (Ann.Phar.Fr.1977,35,503-508) reaction, generate 4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1,2,4-triazol-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 4.6 (m, 2H), 4.7 (m, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.28 (s, 1H), 7.3 (d, 2H), 7.4 (s, 1H), 8.02 (s, 1H), 8.3 (d, 1H), 8.6 (s, 1H), 8.65 (s, 1H)
Elementary analysis: measured value C63.7 H4.8 N21.5C 21H 18N 6O 20.5H 2O value of calculation C63.8 H4.8 N21.3% embodiment 90
Stirring at room 7-hydroxyl-4-(2 methyl indole-5-base oxygen base) quinazoline (423mg, 1.45mol) (as preparation as described in the embodiment 82 initial substance parts), triphenyl phasphine (685mg, 2.61mmol), 4-hydroxymethyl-1-tertiary butyloxycarbonyl phenylpiperidines (500mg, 2.32mmol) (528mg, 2.61mmol) solution in dichloromethane (18ml) spends the night for (as preparation as described in embodiment 10 starting materials) and diisopropyl azo-2-carboxylic acid.Then mixture is poured on the silicagel column, used eluent ethyl acetate.Behind the evaporating solvent, develop residue, filter and vacuum drying, thereby obtain 7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline (478mg, 68%) with ether. 1H NMR spectrum: (DMSOd 6) 1.3-1.4 (m, 2H), 1.42 (s, 9H), 1.85 (d, 2H), 2.0-2.1 (m, 1H), 2.42 (s, 3H), 2.7-2.9 (brs, 2H), 3.95-4.05 (m, 2H), 4.1 (d, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.33 (d, 1H), 7.38 (s, 1H), 7.35-7.4 (m, 1H), 8.3 (d, 1H), 8.6 (s, 1H) MS-ESI:489[MH] +
Elementary analysis: measured value C68.7 H6.7 N11.3C 28H 32N 4O 4Value of calculation C68.8 H6.6 N11.5% embodiment 91
To 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (124mg, 0.32mmol) dichloromethane (2.5ml) suspension in add triphenyl phasphine (179mg, 0.62811mol), 1-(2-hydroxyethyl) pyrrolidine (75mg, 0.65mmol), then add in batches the diisopropyl azo-2-carboxylic acid (134 μ l, 0.68mmol).After the stirred overnight at room temperature, mixture is poured on the silicagel column, use ethyl acetate/dichloromethane (1/1), ethyl acetate/dichloromethane/methanol (4/5/1) and methylene chloride (9/1) eluting successively.Except that after desolvating, solids is developed with ether, filter, and ether washing and vacuum drying, thus obtain 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(pyrrolidine-1-yl) ethyoxyl) quinazoline (51mg, 37%). 1H NMR spectrum: (DMSOd 6) 1.6-1.75 (m, 4H), 2.12 (s, 3H), 2.28 (s, 3H), 2.52 (br s, 4H), 3.85 (t, 2H), 3.93 (s, 3H), 4.25 (t, 2H), 6.8 (d, 1H), 7.17 (s, 1H), 7.22 (d, 1H), 7.33 (s, 1H), 7.54 (s, 1H), 8.43 (s, 1H)
Initial substance is prepared as follows:
Under-60 ℃ of coolings, to 2,3-dimethyl-5-methoxyl group indole (175mg, 1mmol) (J.Chem.Soc.1957, dropwise add in dichloromethane 3175-3180) (5ml) solution Boron tribromide (210 μ 1,2.2mmol).After finishing, warm mixture stirred 1 hour to room temperature.Add entry, regulate pH to 6 with the 2N sodium hydroxide then.The mixture ethyl acetate extraction separates organic layer thereafter, uses the salt water washing, and dry (magnesium sulfate) and evaporation get 2,3-dimethyl-5-oxyindole (124mg, 77%). 1H NMR spectrum: (DMSOd 6) 2.1 (s, 3H); 2.3 (8,3H); 6.5 (dd, 1H); 6.65 (d, 1H); 7.0 (d, 1H); 8.45 (s, 1H)
Under the blanket of nitrogen, to 2,3-dimethyl-5-oxyindole (643mg, add in DMF 4mmol) (10ml) solution potassium carbonate (690mg, 5mmol).After the stirring at room 15 minutes, add 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (1g, 3.33mmol) (as preparation as described in embodiment 1 starting material).90 ℃ of heating blends 2 hours, and then in 95 ℃ of heating 30 minutes.After the cooling, the mixture impouring is descended in the refrigerative water (100ml) at 5 ℃.Filtering precipitate, water, ether wash in proper order, and vacuum drying obtains 7-benzyloxy-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline (1.4g, 95%). 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H); 2.35 (s, 3H); 4.02 (s, 3H), 5.4 (s, 2H); 6.9 (dd, 1H); 7.22 (d, 1H); 7.3 (d, 1H); 7.35-7.6 (m, 6H); 7.65 (s, 1H); 8.5 (s, 1H)
Stirring at room contain ammonium formate (11gr, 174mmol) and the 7-benzyloxy-4-of 10% palladium-carbon (200mg) (2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline (2g, DMF 4.7mmol) (120ml) solution 2.5 hours.Filtering mixt, and vacuum evaporation filtrate.Residue and then with ether development, the solid collected by filtration thing, water, ether washing successively, behind 50 ℃ of vacuum dryings 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (1.1g, 69%). 1H NMR spectrum: (DMSOd 6) 2.1 (s, 3H); 2.32 (s, 3H); 3.97 (s, 3H); 7.85 (dd, 1H); 7.2 (bs, 2H); 7.25 (d, 1H); 7.58 (s, 1H); 8.4 (s, 1H) embodiment 92-106
Adopt embodiment 91 described similar approach, make suitable alcohol and 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (as preparation as described in embodiment 91 starting materials) reaction, the chemical compound described in the Table VII under generating.Table VII
Figure A0080608501891
Figure A0080608501892
* HPLC: condition 2 as previously mentioned).
A) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (124mg) and 2-(1H-1,2, the 4-triazol-1-yl) ethanol (74mg) (Ann.Phar.Fr.1977,35,503-508) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(1H-1,2,4-triazol-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.10 (s, 3H), 2.30 (s, 3H), 3.93 (s, 3H), 4.52 (m, 2H), 4.55-4.65 (m, 2H), 6.85 (d, 1H), 7.2 (s, 1H), 7.25 (d, 1H), 7.4 (d, 1H), 7.58 (s, 1H), 8.0 (s, 1H), 8.48 (s, 1H), 8.58 (s, 1H)
B) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (124mg) and 2-(2-methoxy ethoxy) ethanol (78mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.14 (s, 3H), 2.35 (s, 3H), 3H), (s, 3H), 3.5 (t, 2H), 3.65 (t, 2H), 3.85 (t, 2H), 4.0 (s, 3H), 4.32 (t, 2H), 6.9 (d, 1H), 7.25 (d, 1H), 7.28 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
C) 4-(2,3-dimethyl indole-5-base oxygen base)-and 7-hydroxyl-6-methoxyl group quinazoline (97mg) and N, N-diethyl ethylene diamine (68mg) reaction generates 7-(2-(N, the N-diethylamino) ethyoxyl)-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 1.05 (t, 6H), 2.15 (s, 3H), 2.35 (s, 3H), 2.6-2.7 (m, 4H), 2.92 (brs, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
D) 4-(2,3-dimethyl indole-5-base oxygen base)-and 7-hydroxyl-6-methoxyl group quinazoline (97mg) and N, N-dimethylethanolamine (52mg) reaction generates 7-(2-(N, the N-dimethylamino) ethyoxyl)-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 9H), 2.85 (br s, 2H), 4.0 (s, 3H), 4.35 (t, 2H), 6.87 (dd, 1H), 7.22 (s, 1H), 7.3 (d, 1H), 7.42 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
E) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 4-(2-hydroxyethyl) morpholine (59mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-morpholino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 3H), 3.25-3.4 (m, 2H), 3.65 (d, 2H), 3.7-3.8 (m, 4H), 4.0-4.1 (m, 2H), 4.1 (s, 3H), 4.7 (t, 2H), 6.95 (dd, 1H), 7.3 (s, 1H), 7.35 (d, 1H), 7.6 (s, 1H), 7.8 (s, 1H), 9.0 (s, 1H)
F) 4-(2,3-dimethyl indole-5-base oxygen base)-and 7-hydroxyl-6-methoxyl group quinazoline (97mg) and the reaction of 3-(N, N-dimethylamino) third-1-alcohol (60mg), generate 7-(3-(N, the N-dimethylamino) propoxyl group)-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H), 2.15 (s, 3H), 2.2 (s, 6H), 2.35 (s, 3H), 2.4 (t, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.9 (dd, 1H), 7.22 (d, 1H), 7.3 (d, 1H), 7.37 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
G) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 1-(2-hydroxyethyl)-2-Pyrrolidone (75mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(2-oxo-pyrrolidine-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.05 (m, 4H), 2.15 (s, 3H), 2.25 (t, 2H), 2.35 (s, 3H), 3.65 (t, 2H), 4.0 (s, 3H), 4.35 (t, 2H), 6.9 (d, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.45 (s, 1H), 7.62 (s, 1H), 8.5 (s, 1H)
H) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 2-(2-hydroxyethyl) piperidines (75mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-2-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.0-1.15 (m, 1H), 1.25-1.4 (m, 2H), 1.5 (brs, 1H), 1.65 (d, 1H), 1.7-1.8 (m, 1H), 1.8-1.9 (m, 2H), 2.15 (s, 3H), 2.35 (s, 3H), 2.5 (d, 1H), 2.6-2.7 (m, 1H), 2.9-3.0 (m, 1H), 4.0 (s, 3H), 4.2-4.35 (m, 2H), 6.88 (dd, 1H), 7.2 (s, 1H), 7.27 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
I) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 1-(2-hydroxyethyl) pyrrolidine-2,5-diketone (83mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-7-(2-(2,5-dioxo pyrrolidine-1-yl) ethyoxyl)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.12 (s, 3H), 2.35 (s, 3H), 2.68 (s, 4H), 3.85 (t, 2H), 3.95 (s, 3H), 4.35 (t, 2H), 6.88 (dd, 1H), 7.22 (s, 1H), 7.25 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
J) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 1-methyl-3-piperidine carbinols (75mg) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-3-ylmethoxy) quinazoline.
K) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 4-(3-hydroxypropyl) morpholine (75mg) (as preparation as described in the embodiment 60 initial substance parts) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group 7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H), 2.15 (s, 3H), 2.35 (s, 3H), 2.42 (br s, 4H), 2.5 (t, 2H), 3.6 (m, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 6.85 (dd, 1H), 7.25 (d, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H).
L) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 2-(N-(2-methoxy ethyl)-N-methylamino) ethanol (77mg) (as preparation as described in embodiment 59 starting materials) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 6H), 2.65 (t, 2H), 2.9 (t, 2H), 3.25 (s, 3H), 3.45 (t, 2H), 4.0 (s, 3H), 4.3 (t, 2H), 6.9 (dd, 1H), 722 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
M) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (112mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H), 2.15 (s, 3H), 2.35 (s, 3H), 2.7 (t, 2H), 2.95 (br s, 4H), 3.15 (br s, 4H), 4.0 (s, 3H), 4.29 (t, 2H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.61 (s, 1H), 8.5 (s, 1H)
N) 4-(2,3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 2-(4-pyridyloxy) ethanol (81mg) (J.Chem.Soc.Perkin Trans 2,1987,12,1867) reaction, generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(4-pyridyloxy) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 3H), 4.0 (s, 3H), 4.55 (m, 2H), 4.6 (m, 2H), 6.88 (dd, 1H), 7.08 (d, 2H), 7.22 (s, 1H), 7.28 (d, 1H), 7.48 (s, 1H), 7.6 (s, 1H), 8.42 (d, 2H), 8.5 (s, 1H), 10.78 (s, 1H)
O) 4-(2; 3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (97mg) and 3-(mesyl)-1-propanol (80mg) (as preparation as described in embodiment 50 starting materials) reaction; generate 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.8-1.9 (m, 2H), 2.15 (s, 3H), 2.25-2.35 (m, 2H), 2.35 (s, 3H), 3.0 (s, 3H), 4.02 (s, 3H), 4.35 (t, 2H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.7 (s, 1H), 8.52 (s, 1H) embodiment 107
Adopt embodiment 91 described similar approach, make 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 2-(2-methoxy ethoxy) ethanol (70mg) reaction, generate 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline (50mg, 42%). 1H NMR spectrum: (DMS0d 6) 3.3 (s, 3H), 3.5 (m, 2H), 3.65 (m, 2H), 3.85 (m, 2H), 4.02 (s, 3H), 4.35 (t, 2H), 6.58 (s, 1H), 7.0 (dd, 1H), 7.4 (s, 1H), 7.45 (brs, 2H), 7.47 (d, 1H), 7.61 (s, 1H), 8.5 (s, 1H) MS-ESI:410[MH]+
Initial substance is prepared as follows:
95 ℃ of heating contain potassium carbonate (2.75g, 7-benzyloxy 20mmol)-4-chloro-6-methoxyl group quinazoline (3g, 10mmol) (as preparation as described in the embodiment 1 initial substance part), (1.46g, 11mmol) mixture in DMF (30ml) is 2 hours for the 5-oxyindole.After the cooling, in mixture impouring water (100ml).Filtering precipitate, washing is 50 ℃ of vacuum dryings in the presence of phosphorus pentoxide subsequently.The gained solid is developed with ether, filters, and with ether washing and vacuum drying, thereby obtains 7-benzyloxy-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (3.5g, 88%). 1H NMR spectrum: (DMSOd 6) 4.02 (s, 3H), 5.4 (s, 2H), 6.5 (s, 1H), 7.0 (dd, 1H), 7.4-7.6 (m, 9H), 7.65 (s, 1H), 8.5 (s, 1H), 11.23 (s, 1H) MS-ESI:398[MH]+
Hydrogenation contains the 7-benzyloxy-4-of 10% palladium-carbon (2g) (indole-5-base oxygen base)-(8g, 20mmol) solution in DMF (50ml) and dichloromethane (100ml) stops until absorption of hydrogen 6-methoxyl group quinazoline under 1.8 atmospheric pressure.Filtering solution washs catalyst with DMF, then evaporated filtrate.Residue and then by the column chromatography purification is used dichloromethane, methylene chloride (95/5 and 90/10) eluting successively.Behind the evaporating solvent, develop residue, filter and vacuum drying, thereby obtain 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (2.7g with ether; 44%). 1H NMR spectrum: (DMSOd 6) 4.0 (s, 3H), 6.46 (s, 1H), 7.01 (dd, 1H), 7.2 (s, 1 H), 7.4-7.5 (m, 3H), 7.6 (s, 1H), 8.41 (s, 1H) embodiment 108-118
Adopt embodiment 107 described similar approach, make suitable alcohol and 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (as preparation as described in embodiment 107 starting materials) react the chemical compound that obtains down describing in the Table VII.Table VIII
Figure A0080608501971
R) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and N, N-diethyl ethylene diamine (68mg) reaction generates 7-(2-(N, N-diethylamino) ethyoxyl)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline.
S) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and N, N-dimethylethanolamine (52mg) reaction generates 7-(2-(N, N-dimethylamino) ethyoxyl)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.3 (s, 6H), 2.8 (t, 2H), 4.0 (s, 3H), 4.3 (t, 2H), 6.45 (s, 1H), 7.0 (dd, 1H), 7.4-7.5 (m, 4H), 7.6 (s, 1H), 8.5 (s, 1H)
T) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and the reaction of 3-(N, N-dimethylamino) third-1-alcohol (60mg) generates 7-(3-(N, N-dimethylamino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.05 (m, 2H), 2.21 (s, 6H), 2.45 (t, 2H), 4.02 (s, 3H), 4.25 (t, 2H), 6.47 (s, 1H), 7.0 (dd, 1H), 7.38 (s, 1H), 7.35-7.4 (m, 2H), 7.45 (d, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
U) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) with (2S)-2-(methylol)-1-crassitude (67mg) reaction, generate (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(1-methylpyrrolidin-2-yl) quinazoline.
V) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 3-(N, N-diethylamino)-1-propanol (76mg) reaction generates 7-(3-(N, N-ethylamino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 0.95 (t, 6H), 1.9-2.0 (m, 2H), 2.5 (m, 4H), 2.6 (t, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.48 (s, 1H), 7.0 (dd, 1H), 7.38 (s, 1H), 7.42-7.5 (m, 3H), 7.6 (s, 1H), 8.5 (s, 1H)
W) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 2-(2-hydroxyethyl) piperidines (75mg) reaction generates 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-2-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.45-1.75 (m, 3H), 1.75-1.85 (m, 2H), 2.0-2.1 (m, 1H), and 2.1-2.2 (m, 1H), 2.25-2.35 (m, 1H), 2.95 (t, 1H), 3.3-3.4 (m, 2H), 4.1 (s, 3H), 4.4-4.5 (m, 2H), 6.5 (s, 1H), 7.05 (dd, 1H), 7.45-7.6 (m, 4H), 7.75 (s, 1H), 9.0 (s, 1H)
X) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 1-(2-hydroxyethyl) piperidines (75mg) reaction generates 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.1-1.3 (m, 1H), 1.35-1.5 (m, 1H), 1.65-1.8 (m, 2H), 1.8-1.9 (m, 2H), 3.1 (t, 2H), 3.6 (d, 2H), 3.65 (t, 2H), 4.1 (s, 3H), 4.7 (t, 2H), 6.5 (d, 1H), 7.05 (dd, 1H), 7.45 (s, 1H), 7.5-7.55 (m, 2H), 7.61 (s, 1H), 7.8 (s, 1H), 9.0 (m, 1H)
Y) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 4-(3-hydroxypropyl) morpholine (84mg) (as preparation as described in the embodiment 60 initial substance parts) reaction generates 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.1 (m, 2H), 2.4 (br s, 4H), 2.5 (t, 2H), 3.6 (t, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 6.45 (s, 1H), 7.0 (dd, 1H), 7.4 (s, 1H), 7.4-7.45 (m, 2H), 7.47 (d, 1H), 7.6 (s, 1H), 8.5 (s, 1H)
Z) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 2-(N-(2-methoxy ethyl)-N-methylamino) ethanolamine (77mg) (as preparation as described in the embodiment 59 initial substance parts) reaction generates 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H), 2.65 (t, 2H), 2.9 (t, 2H), 3.25 (s, 3H), 3.45 (t, 2H), 4.0 (s, 3H), 4.3 (t, 2H), 6.45 (s, 1H), 7.05 (dd, 1H), 7.4-7.5 (m, 4H), 7.6 (s, 1H), 8.5 (s, 1H)
Aa) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (112mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H), 2.65 (m, 2H), 2.9 (brs, 4H), 3.15 (brs, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 6.5 (s, 1H), 7.0 (dd, 1H), 7.35-7.5 (m, 4H), 7.65 (s, 1H), 8.5 (s, 1H)
Bb) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (89mg) and 2-(4-pyridyloxy) ethanol (81mg) (J.Chem.Soc.Perkin Trans 2,1987,12,1867) reaction generates 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(4-pyridyloxy) ethyoxyl) quinazoline.Embodiment 119
90 ℃ of heating contain cesium carbonate (291mg, 0.894mmol) 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (200mg, 0.59mmol) (as preparation as described in the embodiment 67 initial substance parts), (96mg, 0.715mmol) solution in DMF (3ml) is 4 hours for the 6-oxyindole.After the cooling, the thin up mixture, filtering precipitate is washed and vacuum drying then.Gained solids and then by the column chromatography purification, with methylene chloride (90/10 is increased to 50/50) eluting, 4-(the basic oxygen base of indole-6-)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (240mg, 93%). 1H NMR spectrum: (DMSOd 6) 1.35-1.45 (m, 2H), 1.45-1.55 (m, 4H), 1.9-2.05 (m, 2H), 2.3-2.4 (m, 4H), 2.45 (t, 2H), 4.0 (s, 3H), 4.22 (t, 2H), 6.5 (s, 1H), 6.9 (dd, 1H), 7.3 (s, 1H), 7.35-7.40 (m, 2H), 7.55-7.65 (m, 2H), 8.5 (s, 1H) MS-ESI:433 [MH] +
Elementary analysis: measured value C68.4 H6.4 N12.8C 25H 28N 4O 30.4H 2O value of calculation C68.3 H6.6 N12.7% embodiment 120
90 ℃ of heating contain potassium carbonate (125mg; 0.91mmol) 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (200mg; 0.6mmol) (97mg, 0.73mmol) solution in DMF (3ml) is 2.5 hours for (as preparation as described in embodiment 50 starting materials) and 6-oxyindole.After the cooling, add entry.Filtering precipitate, washing and vacuum drying.Residue is developed with ether, filters, and ether washing and vacuum drying, thus obtain 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (130mg, 50%). 1H NMR spectrum: (DMSOd 6) 2.2-2.35 (m, 2H), 3.05 (s, 3H), 3.3 (m, 2H), 4.0 (s, 3H), 4.35 (t, 2H), 6.48 (s, 1H), 6.9 (dd, 1H) 7.3 (s, 1H), 7.4 (2s, 2H), 7.6 (d, 1H), 7.65 (s, 1H), 7.9 (s, 1H) MS-ESI:428[MH] +
Elementary analysis: measured value C56.2 H4.9 N9.3C 21H 21N 3O 5S1.1H 2O value of calculation C56.4 H5.2 N9.4% embodiment 121
Adopt embodiment 120 described similar approach, make 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (200mg, 0.59mmol) (as preparation as described in the embodiment 1 initial substance part) and 6-oxyindole (95mg, 0.71mmol) reaction, obtain 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (155mg, 60%). 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H), 2.4 (brs, 4H), 2.48 (t, 2H), 3.6 (t, 4H), 4.0 (s, 3H), 4.27 (t, 2H), 6.5 (s, 1H), 6.93 (dd, 1H), 7.3 (s, 1H), 7.4 (br s, 2H), 7.6 (d, 1H), 7.61 (s, 1H), 8.5 (s, 1H) MS-ESI:435[MH] +
Elementary analysis: measured value C62.0 H6.2 N12.1C 24H 26N 4O 41.6H 2O value of calculation C62.2 H6.4 N12.1% embodiment 122
(150mg, 0.31mmol) (as preparation as described in the embodiment 90) suspension in dichloromethane (2ml) and TFA (1.5ml) is 1 hour for stirring at room 7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline.After vacuum is removed volatile matter, with residue with the toluene azeotropic.Then residue is assigned between dichloromethane and the water, and regulates the pH to 11 of water layer.Tell organic layer, use the salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters, ether washing and vacuum drying, 4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (80mg, 67%). 1H NMR. spectrum: (DMSOd 6, CF 3COOD) 1.5-1.65 (m, 2H), 2.0 (d, 2H), 2.15-2.3 (m, 1H), 2.4 (s, 3H), 2.95 (t, 2H), 3.38 (d, 2H), 4.2 (d, 2H), 6.2 (s, 0.5H, the part exchange), 6.9 (dd, 1H), 7.35 (s, 1H), 7.4 (d, 1H), 7.5 (s, 1H), 7.58 (dd, 1H), 8.5 (d, 1H), 9.1 (s, 1H) MS-ESI:389[MH] +
Elementary analysis: measured value C68.9 H6.2 N13.7C 23H 24N 4O 20.2H 2O0.12CH 2Cl 2Value of calculation C69.0 H6.2 N13.9% embodiment 123
Adopt embodiment 71 described similar approach, make 4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (150mg, 0.386mmol) (as preparation as described in the embodiment 122) and methoxyl group acetaldehyde (83mg, 0.772mmol) (as preparation as described in embodiment 71 starting materials) reaction, obtain 7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline (80mg, 46%). 1H NMR spectrum: (DMSOd 6) 1.3-1.42 (m, 2H), 1.7-1.9 (m, 3H), 2.0 (t, 2H), 2.4 (s, 3H), 2.48 (t, 2H), 2.92 (d, 2H), 3.22 (s, 3H), 3.42 (t, 2H), 4.05 (d, 2H), 6.15 (s, 1H), 6.88 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.35 (s, 1H), 7.37 (d, 1H), 8.28 (d, 1H), 8.6 (s, 1H) MS-ESI:447[MH] +
Elementary analysis: measured value C68.4 H6.7 N12.2C 26H 30N 4O 30.5H 2O value of calculation C68.6 H6.9 N12.3% embodiment 124
To 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (120mg; 0.37mmol) (as preparation as described in the embodiment 49) and 3-(ethylsulfonyl)-1-propanol (74mg; 0.48mmol) at dichloromethane (3.5ml) and triphenyl phasphine (176mg; 0.67mmol) in solution in add in batches the diethylazodicarboxylate (117mg, 0.67mmol).After the stirring at room 2 hours, pour residue into silicagel column, use ethyl acetate/dichloromethane (1/1) and methylene chloride (97/3, follow 95/5) eluting successively.After the solvent removed in vacuo, residue is developed with ether, filters and vacuum drying, gets 7-(3-(ethylsulfonyl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (93mg, 55%). 1H NMR spectrum: (DMSOd 6) 1.25 (t, 3H), 2.2-2.3 (m, 2H), 2.4 (s, 3H), 3.2 (q, 2H), 3.3 (t, 2H), 4.0 (s, 3H), 4.35 (t, 2H), 6.15 (s, 1H), 6.9 (dd, 1H), 7.28 (s, 1H), 7.32 (d, 1H), 7.4 (s, 1H), 7.62 (s, 1H), 8.5 (s, 1H) MS-ESI:456[MH] +Elementary analysis: measured value C 60.3 H 5.6 N 9.2C 23H 25N 3O 5S value of calculation C 60.6 H 5.5 N 9.2%
Initial substance is prepared as follows:
Stirring at room contains 3-chloroperoxybenzoic acid (5g, ethylmercapto group propanol 20mmol) (1.2g, dichloromethane 10mmol) (30ml) solution 30 minutes.Filtering precipitate is used washed with dichloromethane, then filtrate is poured on the alumina column, uses dichloromethane, methylene chloride (95/5 and 90/10) eluting successively.Except that after desolvating, residue is dissolved in dichloromethane, dry (magnesium sulfate) and evaporation get 3-(ethylsulfonyl)-1-propanol (1.05g, 69%). 1H NMR spectrum: (DMSOd 6) 1.25 (t, 3H), 1.75-1.9 (m, 2H), 3.0-3.2 (m, 4H), 3.5 (q, 2H), 4.7 (t, 1H) MS-ESI:153 [MH] +Embodiment 125
Adopt embodiment 124 described similar approach; make 4-(2; 3-dimethyl indole-5-base oxygen base)-7-hydroxyl-6-methoxyl group quinazoline (120mg; 0.36mol) (as preparation as described in the embodiment 91 initial substance parts) and 3-(ethylsulfonyl)-1-propanol (71mg; 0.46mmol) (as preparation as described in embodiment 124 starting materials) reaction; generate 4-(2,3-dimethyl indole-5-base oxygen base)-7-(3-ethylsulfonyl propoxyl group)-6-methoxyl group quinazoline (96mg, 57%). 1H NMR spectrum: (DMSOd 6) 1.25 (t, 3H), 2.15 (s, 3H), 2.2-2.3 (m, 2H), 2.35 (s, 3H), 3.2 (q, 2H), 3.3 (t, 2H), 4.02 (s, 3H), 4.35 (t, 2H), 6.9 (dd, 1H), 7.22 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.63 (s, 1H), 8.51 (s, 1H) MS-ESI:470[MH] +Elementary analysis: measured value C 60.6 H 6.0 N 8.8C 24H 27N 3O 5S0.4H 2O value of calculation C 60.5 H 5.9 N 8.8% embodiment 126
Adopt embodiment 124 described similar approach, make 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (128mg, 0.4mol) (as preparation as described in the embodiment 49) and 4-(2-hydroxyethyl)-(1-tertbutyloxycarbonyl) piperidines (119mg, 0.52mmol) react and spend the night, generate 7-(2-(1-tertbutyloxycarbonyl piperidin-4-yl) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (34mg, 16%). 1H NMR spectrum: (DMSOd 6) 1.05-1.2 (m, 2H), 1.42 (s, 9H), 1.62-1.85 (m, 5H), 2.42 (s, 3H), 2.62-2.82 (m, 2H), 3.9-4.0 (m, 2H), 4.0 (s, and 3H) 4.25 (t, 2H), 6.17 (s, 1H), 6.9 (dd, 1H), 7.3 (d, 1H), 7.32 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H) MS-ESI:533[MH] +Elementary analysis: measured value C 67.8 H 6.9 N 10.5C 30H 36N 4O 5Value of calculation C 67.7 H 6.8 N 10.5%
Initial substance is prepared as follows:
Hydrogenation contains 4-(2-hydroxyethyl) pyridine (1.8g, acetic acid 14.6mol) (15ml) solution 20 hours of platinum oxide (200mg) under 3.3-4 atmospheric pressure.After the filtration, evaporated filtrate and with twice of toluene azeotropic.Residue adds solid sodium hydroxide and regulates pH to 13 with the development of 2N sodium hydroxide.Vacuum is removed volatile matter, and then develops residue with ether, filters, and obtains 2-(piperidin-4-yl)-1-ethanol (860mg, 46%) behind washed with dichloromethane and vacuum drying. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.3-1.5 (m, 4H), 1.6-1.7 (m, 1H), 1.7-1.9 (d, 2H), 1.75 (t, 2H), 3.25 (d, 2H), 3.55 (t, 2H)
Stirring at room contains two carbonic acid tert-butyl ester acid anhydrides (1.4g, 2-6.4mol) (piperidin-4-yl)-1-ethanol (830mg, DMF 6.4mmo1) (5ml) solution 48 hours.After vacuum is removed volatile matter, residue is assigned between ether and the water.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation get 4-(2-hydroxyethyl)-(1-tertbutyloxycarbonyl) piperidines (1g, 68%). 1H NMR spectrum: (DMSOd 6) (m, 2H), (m, 3H), 1.4 (s, 9H), 1.6 (d, 2H), (brs, 2H), 3.45 (dd, 2H), 3.9 (d, 2H), 4.35 (t, 1H) embodiment 127 for 2.5-2.8 for 1.3-1.6 for 0.9-1.1
Adopt embodiment 121 described similar approach, make 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (160mg, 0.47mol) (as preparation as described in the embodiment 1 initial substance part) and 6-hydroxy-2-methyl indole (84mg, 0.57mmol) (Eur.J.Med.Chem.1975,10,187) reaction generates 6-methoxyl group-4-(2 methyl indole-6-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline (157mg, 73%). 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.25-2.35 (m, 2H), 2.38 (s, 3H), 3.15 (t, 2H), 3.35 (t, 2H), 3.5 (d, 2H), 3.68 (t, 2H), 4.0 (d, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 6.18 (s, 1H), 6.9 (d, 1H), 7.22 (s, 1H), 7.45 (d, 1H), 7.52 (s, 1H), 7.8 (s, 1H), 9.05 (s, 1H) MS-ESI:449[MH] +Elementary analysis: measured value C 66.4 H 6.4 N 12.4C 25H 28N 4O 40.2H 2O value of calculation C 66.4 H 6.3 N 12.4% embodiment 128
Adopt and similar method as described in synthetic 4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (as implementing preparation as described in 122), use 7-(2-(1-tertbutyloxycarbonyl piperidin-4-yl) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (400mg, 0.75mmol) (as preparation as described in the embodiment 126), obtain 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl) ethyoxyl) quinazoline (284mg, 87%). 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.3-1.5 (m, 2H), 1.8-2.0 (m, 5H), 2.4 (s, 3H), 2.9 (t, 2H), 3.3 (d, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 6.2 (s, 1H), 6.95 (dd, 1H), 7.35 (s, 1H), 7.37 (d, 1H), 7.52 (s, 1H), 7.8 (s, 1H), 9.1 (s, 1H) MS-ESI:433[MH] +Embodiment 129
Under 0 ℃ of cooling, to 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol), triphenyl phasphine (107mg, 0.4mmol), (E)-4-(pyrrolidine-1-yl) but-2-ene-1-alcohol (40mg, 0.28mmol) in the suspension in DMF (0.4ml) and the dichloromethane (1.5ml), add in batches the diethylazodicarboxylate (65 μ l, 0.4mmol).Warm reactant mixture is to room temperature, and stirring is spent the night.Mixture is poured on the silicagel column, with dichloromethane, methylene chloride (98/2), dichloromethane/3N ammonia methanol solution (95/5 and 90/10) sequentially eluting, get 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-((E)-4-(pyrrolidine-1-yl) but-2-ene-1-base oxygen base) quinazoline (51mg, 55%). 1H NMR spectrum: (DMSOd 6) 1.6-1.7 (m, 4H), 2.15 (s, 3H), 2.3 (s, 3H), 2.4 (brs, 4H), 3.1 (d, 2H), 3.97 (s, 3H), 4.7 (d, 2H), 5.8-6.0 (m, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (d, 1H), 7.55 (s, 1H), 7.87 (s, 1H), 8.3 (s, 1H), 9.4 (s, 1H), 10.62 (s, 1H) MS-ESI:458[MH] +
Initial substance is prepared as follows:
Under 0 ℃ of cooling, to 2-butyne-1, the 4-glycol (10g, 116mmol) add in the agitating solution in toluene (15ml) and pyridine (10.3ml) in batches thionyl chloride (9.3ml, 128mmol).Stirring at room mixture 3.5 hours is then in the impouring frozen water.Use the ether extraction mixture, subsequently organic layer is washed in proper order with saturated sodium bicarbonate aqueous solution and saline, dry (magnesium sulfate) also removes volatile matter by evaporation.Residue and then by the column chromatography purification, with petroleum ether/ethyl ether (7/3) eluting, 4-neoprene-2-alkynes-1-alcohol (4.74g, 39%). 1H NMR spectrum: (CDCl 3) 1.68 (t, 1H); 4.18 (d, 2H); 4.33 (d, 2H)
(4.74g, (7.8ml, 94mmol), 60 ℃ stirred the mixture 1 hour dropwise to add pyrrolidine in toluene 45mmol) (40ml) solution to 4-neoprene-2-alkynes-1-alcohol.Steam and remove volatile matter, and the chromatography purification residue, with methylene chloride (96/4) eluting, get 4-(pyrrolidine-1-yl) fourth-2-alkynes-1-alcohol (4.3g, 69%). 1H NMR spectrum: (CDCl 3) 1.82 (t, 4H); 2.63 (t, 4H); 3.44 (t, 2H), 4.29 (t, 2H)
(2.35g 62mmol) dropwise adds 4-(pyrrolidine-1-yl) fourth-2-alkynes-1-alcohol (4.3g, THF 31mmol) (20ml) solution, and in 60 ℃ of following heated and stirred mixture 2 hours in the suspension in anhydrous THF (8ml) to lithium aluminium hydride reduction.Cooling mixture to 5 ℃ dropwise adds 2M sodium hydrate aqueous solution (28ml).Filter the gained suspension, from filtrate, remove volatile matter by evaporation.Residue is dissolved in the dichloromethane/ethyl acetate mixed liquor, and dry (magnesium sulfate) and steaming desolventize.Residue and then by the aluminum oxide column chromatography purification, with methylene chloride (97/3) eluting, (E)-4-(pyrrolidine-1-yl) but-2-ene-1-alcohol (3.09g, 70%). 1H NMR spectrum: (CDCl 3) 1.82 (m, 4H); 2.61 (m, 4H); 3.17 (m, 2H); 4.13 (s, 2H); 5.84 (m, 2H)
Reflux contains the 4-chloro-6-methoxyl group-7-benzyloxy quinazoline (7g of 6.2N hydrogen chloride isopropyl alcohol liquid (380 μ l), 23mmol) (as preparation as described in the embodiment 1 initial substance part) and 5-amino-2,3-dimethyl indole (4.5g, 28mmol) solution in isopropyl alcohol (90ml) is 3 hours, thereafter stirred overnight at room temperature.Mixture is developed with ether, and the filtration solids with ether washing and vacuum drying, gets 7-benzyloxy-4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group quinazoline (10.5g, quantitative). 1H NMR spectrum: (DMSOd 6) 2.16 (s, 3H), 2.33 (s, 3H), 4.0 (s, 3H), 5.34 (s, 2H), 7.2 (d, 1H), 7.32 (d, 1H), 7.35-7.55 (m, 7H), 8.2 (s, 1H), 8.7 (s, 1H), 10.9 (s, 1H), 11.15 (s, 1H) MS-ESI:425[MH]+
(10g, (20g is 326mmol) with 10% palladium-carbon (1g) 22mmol) to add ammonium formate in the solution in DMF (100ml) and methanol (300ml) to 7-benzyloxy-4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group quinazoline.After the stirring at room 3 hours, add ammonia (120ml).Filtering precipitate, washing and vacuum drying.Residue also passes through the column chromatography purification with ethyl acetate and ether development, filtration thereafter, vacuum drying, with ethanol/methylene (5/95, follow 10/90) eluting, get 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (5.5g, 75%). 1H NMR spectrum: (DMSOd 6) 2.2 (s, 3H), 2.35 (s, 3H), 3.97 (s, 3H), 7.0 (s, 1H), 7.22 (d, 1H), 7.3 (d, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.28 (s, 1H), 9.35 (s, 1H), 10.2 (br s, 1H), 10.62 (s, 1H) MS-ESI:335[MH] +Embodiment 130-145
Adopt embodiment 129 described similar approach, make 4-(2,3-dimethyl indole-5-base is amino)-(68mg, 0.2mmol) (as preparation as described in embodiment 129 starting materials) and suitably alcohol reaction generate the chemical compound of the red description of Table I X to 7-hydroxyl-6-methoxyl group quinazoline.Table I X
Figure A0080608502081
Figure A0080608502091
A) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) and 3-(5-methyl-[1,2,4]-and triazol-1-yl] third-1-alcohol (40mg) reaction, generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-(5-methyl isophthalic acid H-[1,2,4]-and triazol-1-yl) propoxyl group) quinazoline.
Initial substance is prepared as follows:
Under the argon atmospher, in alcohol sodium solution (by sodium (4.6g) and ethanol (250ml) prepared fresh), add 1,2, and the 4-triazole (13.8g, 200mmol).Fully the dissolving after, dropwise add 3-bromine third-1-alcohol (18ml, 200mmol).Backflow mixture 18 hours leaches solid then, uses washing with alcohol.Evaporated filtrate, residue and then by the column chromatography purification, with methylene chloride (9/1) eluting, 3-(1,2, the 4-triazol-1-yl) third-1-alcohol (22.8g, 90%). 1H NMR spectrum: (CDCl 3): 2.12 (m, 2H); 2.6 (brs, 1H); 3.65 (t, 2H); 4.35 (t, 2H); 7.95 (s, 1H); 8.1 (s, 1H)
To 3-(1,2, the 4-triazol-1-yl) third-1-alcohol (7g, in DMF 55mmol) (70ml) solution order add t butyldimethylsilyl chloride (9.1g, 60mmol), DMAP (336mg, 2.7mmol) and imidazoles (4.5gr, 66mmol).After the stirred overnight at room temperature, vacuum is removed volatile matter, thereafter residue is assigned between water and the ethylacetate/ether.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with dichloromethane/ether (6/4) eluting, 3-(t-butyldimethylsilyloxy base)-1-(1,2, the 4-triazol-1-yl) propane (11.1g, 84%).MS-EI:242[MH]+ 1H NMR spectrum: (CDCl 3) 0.25 (s, 6H); 0.9 (s, 9H); 2.05 (m, 2H); 3.52 (t, 2H); 4.25 (t, 2H); 7.9 (s, 1H); 8.02 (s, 1H)
In 45 minutes, (7g 29mmol) adds 2.5M n-BuLi (17.4ml) in-70 ℃ of cooling solutions of DMF to 3-(t-butyldimethylsilyloxy base)-1-(1,2, the 4-triazol-1-yl) propane.-70 ℃ were stirred after 90 minutes, and the adding methyl iodide (3.6ml, 58mmol).After the stirring at room 2 hours, in mixture impouring saturated ammonium chloride.Mixture is then with ether and ethyl acetate dilution.Separate organic layer, wash in proper order with sodium thiosulfate, saline, dry (magnesium sulfate) and evaporation, thus obtain 3-(t-butyldimethylsilyloxy base)-1-(5-methyl-[1,2,4]-triazol-1-yl) propane (7.3g, 98%).MS-EI:256[MH]+ 1H NMR spectrum: (CDCl 3) 0.25 (s, 6H); 0.85 (s, 9H); 2.0 (, 2H); 2.4 (s, 3H); 3.52 (t, 2H); 4.15 (t, 2H); 7.72 (s, 1H)
(10.4g adds 3-(t-butyldimethylsilyloxy base)-1-(5-methyl-[1,2,4]-triazol-1-yl) propane (7.2g, methanol 28mmol) (30ml) solution in methanol 280mmol) (110ml) solution to ammonium fluoride.Backflow mixture 4.5 hours.After the cooling, add silica gel (100g), and vacuum is removed volatile matter.Residue is added on the silicagel column,, gets 3-(5-methyl-[1,2,4]-triazol-1-yl) third-1-alcohol (3.65g, 92%) with dichloromethane/ethyl acetate (1/1) mixture, methylene chloride (9/1) mixture sequentially eluting.MS-ESI:142[MH]+ 1H NMR spectrum: (CDCl 3) 2.05 (m, 2H); 2.5 (s, 3H); 3.62 (t, 2H); 4.25 (t, 2H); 7.8 (s, 1H) b) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) with 2-(N-(2-methoxy ethyl)-N-methylamino) ethanol (38mg) (as preparation as described in embodiment 59 starting materials) reaction, generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 6H), 2.65 (t, 2H), 2.85 (t, 2H), 3.25 (s, 3H), 3.45 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 7.15 (s, 1H), 7.22 (s, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.3 (s, 1H), 9.4 (s, 1H), (10.62 s, 1H) c) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2-(1-Methylimidazole .-2-yl) ethanol (36mg) (EP 06751112A1), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(1-Methylimidazole .-2-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.32 (s, 3H), 3.2 (t, 2H), 3.7 (s, 3H), 3.95 (s, 3H), 4.45 (t, 2H), 6.8 (s, 1H), 7.05 (s, 1H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.88 (s, 1H), 8.32 (s, 1H), 9.4 (s, 1H), (10.62 s, 1H) d) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 1-(3-hydroxypropyl)-4-methyl piperazine (45mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.0 (m, 2H), 2.15 (2s, 6H), 2.0-2.9 (m, 8H), 2.32 (s, 3H), 2.45 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 7.1 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.3 (s, 1H), 9.4 (s, 1H), 10.62 (s, 1H)
Initial substance is prepared as follows:
To the 1-methyl piperazine (29ml, dropwise add in ethanol 26mmol) (200ml) solution 3-bromine third-1-alcohol (20ml, 20mmol).The adding potassium carbonate (83gr, 60mmol), backflow mixture 20 hours.After the cooling, leach solids, thereafter evaporated filtrate.Residue is developed with ether, filters and evaporation.The surplus residue of institute so under about 0.2mmHg in 60-70 ℃ of distillation, obtain 1-(3-hydroxypropyl)-4-methyl piperazine (17g, 53%). 1H NMR spectrum: (CDCl 3) 1.72 (m, 2H); 2.3 (s, 3H); 2.2-2.8 (m, 8H); 2.6 (t, 2H); 3.8 (t, 2H); 5.3 (brs, 1H) e) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (55mg) (as preparation as described in the embodiment 5 initial substance parts) reaction, generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.0 (m, 2H), 2.5 (s, 9H), 2.65 (t, 2H), 2.9 (brs, 4H), 3.15 (brs, 4H), 3.95 (s, 3H), 4.25 (t, 2H), 7.2 (s, 1H), 7.85 (s, 1H), 8.0 (dd, 1H), 8.15 (d, 1H), 8.2 (s, 1H), 8.45 (s, 1H), 9.6 (s, 1H), 10.95 (s, 1H) f) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2-(N-methyl-N-(4-pyridine radicals) amino) ethanol (43mg) (EP 0359389), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.35 (s, 3H), 3.07 (s, 3H), 3.85 (t, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 6.7 (d, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.15 (d, 2H), 8.3 (s, 1H), 9.4 (s, 1H), (10.65 s, 1H) g) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2-furancarbinol (28mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-furyl methoxyl group) quinazoline.H) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) and 2-N, N-dimethylethanolamine (25mg) reaction, generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(N, N-dimethylamino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.25 (s, 6H), 2.32 (s, 3H), 2.72 (t, 2H), 3.95 (s, 3H), 4.2 (t, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.32 (s, 1H), 9.4 (s, 1H), (10.6 s, 1H) i) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 1-(2-hydroxyethyl) pyrrolidine (33mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(pyrrolidine-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.65-1.75 (m, 4H), 2.15 (s, 3HH), 2.35 (s, 3H), 2.55-2.65 (m, 4H), 2.9 (t, 2H), 3.95 (s, 3H), 4.25 (t, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.32 (s, 1H), 9.4 (s, 1H), (10.62 s, 1H) j) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2,2'-ethylenedioxybis(ethanol). monomethyl ether (47mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(2-(2-methoxy ethoxy) ethyoxyl) ethyoxyl) quinazoline.K) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) with 5,5-dimethyl-1,3-diox-2-ethanol (46mg) reaction, and generation 7-(2-(5,5-dimethyl-1,3-diox-2-yl) ethyoxyl)-4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 0.7 (s, 3H), 1.15 (s, 3H), 2.05-2.1 (m, 2H), 2.1 (s, 3H), 2.6 (s, 3H), 3.42 (d, 2H), 3.57 (d, 2H), 4.0 (s, 3H), 4.22 (t, 2H), 4.7 (t, 1H), 7.2 (s, 1H), 7.82 (s, 1H), 8.0 (dd, 1H), 8.17 (d, 1H), 8.3 (s, 1H), 8.45 (s, 1H), 9.6 (s, 1H), 10.95 (s, 1H) l) 4-(2,3-dimethyl indole-5-base is amino)-(68mg 0.2mmol) with 1-(2-hydroxyethyl) piperidines (37mg) reaction, generates 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline to 7-hydroxyl-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H), 1.45-1.6 (m, 4H), 2.15 (s, 3H), 2.35 (s, 3H), 2.45 (brs, 4H), 2.75 (t, 2H), 3.95 (s, 3HH), 4.25 (t, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.3 (s, 1H), 9.4 (s, 1H), (10.62 s, 1H) m) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2-(N-methyl-N-(pyridazine-4-yl) amino) ethanol (44mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(N-methyl-N-(pyridazine-4-yl) amino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.32 (s, 3H), 3.1 (s, 3H), 3.9 (s, 3H), 3.95 (t, 2H), 4.35 (t, 2H), 6.85 (dd, 1H), 7.15 (s, 1H), 7.20 (d, 1H), 7.28 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.3 (s, 1H), 8.58 (d, 1H), 8.9 (d, 1H), 9.4 (s, 1H), 10.62 (s, 1H)
Initial substance is prepared as follows:
Reflux 4-bromo-3, (1.11g, 5mmol) (0.75g, 10mmol) solution in isopropyl alcohol (10ml) is 30 minutes for (J.Chem.Soc., Perkin Trans I, 1974,696) and 2-(methylamino) ethanol for 6-two chloro-pyridazines.Evaporation removes and desolvates, and residue is assigned between dichloromethane and the water, and regulates the pH to 9 of water layer with solid carbonic acid potassium.Tell organic layer, use the salt water washing, dry (magnesium sulfate) and steaming desolventize.Residue and then with ether development filters and collects and vacuum drying, thus 2-(N-(3,6-dichloro-pyridazine-4-yl)-N-methylamino) ethanol (1g, 90%). 1H NMR spectrum: (CDCl 3) 2.1 (brs, 1H); 3.09 (s, 3H); 3.71 (t, 2H); 3.93 (t, 2H); 6.8 (s, 1H) MS-ESI:221[MH] +
Under 3 atmospheric pressures, (N-(3 with 2-, 6-dichloro-pyridazine-4-yl)-and the N-methylamino) (444mg 2mmol) stirred in atmosphere of hydrogen 4 hours with the mixture of 10% palladium carbon catalyst (150mg) in ethanol (15ml), methanol (5ml) and ammonia (15ml) ethanol.Filtration catalizer, evaporation removes and desolvates then.Residue is dissolved in dichloromethane, the filtering insoluble matter, and remove solvent in the filtrate by evaporation.Residue and then by the neutral aluminum oxide column chromatography purification is with diamino methane/methanol (95/5, then 90/10) eluting.The development of gained refined products reuse petroleum ether, the solid collected by filtration product obtains 2-(N-methyl-N-(pyridazine-4-yl) amino) ethanol (275mg, 91%) behind the vacuum drying. 1H NMR spectrum: (CDCl 3) 3.06 (s, 3H); 3.57 (t, 2H); 3.89 (t, 2H); 6.52 (dd, 1H); 8.48 (d, 1H); 8.54 (d, 1H) MS-ESI:153[MH] +N) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 2-(2-morpholino ethyoxyl) ethanol (50mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(2-morpholino ethyoxyl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.18 (s, 3H), 2.35 (s, 3H), 2.35-2.45 (m, 4H), 2.45-2.5 (m, 2H), 3.5-3.55 (m, 4H), 3.65 (t, 2H), 3.8-3.85 (m, 2H), 3.95 (s, 1H), 4.25 (m, 2H), 7.15 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.55 (s, 1H), 7.85 (s, 1H), 8.3 (s, 1H), 9.4 (s, 1H), 10.62 (s, 1H)
Initial substance is prepared as follows:
To morpholine (2.58g, 30mmol) and potassium carbonate (5.5g, 40mmol) add in the mixture in acetonitrile (50ml) 2-(2-chloroethoxy) ethanol (1.25g, 10mmol).Reflux mixture 6 hours, and then in stirring at room 18 hours.The filtering insoluble matter, and by evaporating from filtrate except that desolvating.Residue and then by the column chromatography purification adopts methylene chloride (according to 95/5,90/10,80/20 order) eluting, 2-(2-morpholino ethyoxyl) ethanol (600mg, 34%). 1H NMR spectrum: (CDCl 3) 2.5 (brs, 4H); 2.59 (t, 2H); 3.6-3.85 (m, 10H) MS-(EI): 175[M.] +O) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 3-(2-hydroxyethyl) pyridine (35mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(2-(3-pyridine radicals) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H), 2.32 (s, 3H), 3.15 (t, 2H), 3.95 (s, 3H), 4.4 (t, 2H), 7.2 (s, 1H), 7.22 (d, 1H), 7.3 (dd, 1H), 7.35 (dd, 1H), 7.55 (s, 1H), 7.8 (d, 1H), 7.85 (s, 1H), 8.32 (s, 1H), 8.45 (dd, 1H), 8.6 (s, 1H), 9.4 (s, 1H), (10.68 s, 1H) p) 4-(2,3-dimethyl indole-5-base is amino)-7-hydroxyl-6-methoxyl group quinazoline (68mg, 0.2mmol) react with 1-(3-hydroxypropyl) pyrrolidin-2-one (41mg), generate 4-(2,3-dimethyl indole-5-base is amino)-6-methoxyl group-7-(3-(2-oxo-pyrrolidine-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.9-2.05 (m, 4H), 2.12 (s, 3H), 2.15-2.3 (m, 2H), 2.6 (s, 3H), 3.3-3.45 (m, 4H), 4.0 (s, 3H), 4.15 (t, 2H), 7.15 (s, 1H), 7.82 (s, 1H), 8.0 (dd, 1H), 8.17 (d, 1H), 8.3 (s, 1H), 8.45 (s, 1H), 9.6 (s, 1H), 10.95 (s, 1H) embodiment 146
Adopt embodiment 121 described similar approach, make 4-chloro-6-methoxyl group-7-(3-pyrrolidino propoxyl group) quinazoline (150mg, 0.47mmol) (as preparation as described in embodiment 9 starting materials) and 6-hydroxy-2-methyl indole (83mg, 0.56mol) (Eru.J.Med.Chem.1975,10,187) reaction generates 6-methoxyl group-4-(2 methyl indole-6-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (170mg, 85%). 1H NMR spectrum: (DMSOd 6) 1.65-1.8 (m, 4H), 1.95-2.05 (m, 2H), 2.42 (s, 3H), 2.5 (brs, 1H), 2.6 (t, 2H), 4.0 (s, 3H), 4.27 (t, 2H), 6.2 (s, 1H), 6.85 (dd, 1H), 7.2 (s, 1H), 7.4 (s, 1H), 7.45 (d, 1H), 7.6 (s, 1H), 8.5 (s, 1H) MS-ESI:433[MH] +Elementary analysis measured value C 68.3 H 6.4 N 12.8C 25H 28N 4O 30.4H 2O value of calculation C 68.3 H 6.6 N 12.7% embodiment 147
Adopt and embodiment 123 described similar methods, use 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl) ethyoxyl) quinazoline (120mg, 0.28mmol), obtain 7-(2-(1-(2-methoxy ethyl) piperidin-4-yl) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (55mg, 40%). 1H NMR spectrum: (DMSOd 6) 1.15-1.3 (m, 2H), 1.4-1.55 (m, 1H), 1.65-1.8 (m, 4H), 1.95 (t, 2H), 2.4 (s, 3H), 2.42 (t, 2H), 2.85 (d, 2H), 3.25 (s, 3H), 3.42 (t, 2H), 4.0 (s, 3H), 4.22 (t, 2H), 6.15 (s, 1H), 6.85 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.38 (s, 1H), 7.59 (s, 1H), 8.5 (s, 1H) .MS-ESI:491[MH] +Elementary analysis measured value C 65.3 H 7.1 N 10.9C 28H 34N 4O 41.3H 2O value of calculation C 65.4 H 7.2 N 10.9% embodiment 148
Adopt and the described similar method of embodiment 120 OR, 121 PER PP, make 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (160mg, 0.48mmol) (as preparation as described in embodiment 1 starting material) with 1,2-dimethyl-5-oxyindole (92mg, 0.57mol) (Tetrahedron 1994,50,13433) reaction, generate 4-(1,2-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (163mg, 74%). 1H NMR spectrum: (DMSOd 6) 1.95-2.1 (m, 2H), 2.4 (brs, 4H), 2.45 (s, 3H), 2.5 (t, 2H), 3.65 (t, 4H), 3.75 (s, 3H), 4.0 (s, 3H), 4.25 (t, 2H), 6.25 (s, 1H), 6.95 (dd, 1H), 7.3 (s, 1H), 7.38 (s, 1H), 7.45 (d, 1H), 7.6 (s, 1H), 8.5 (s, 1H) MS-ESI:463[MH] +Elementary analysis measured value C 67.2 H 6.5 N 12.1C 26H 30N 4O 4Value of calculation C 67.5 H 6.5 N 12.1% embodiment 149
Adopt embodiment 124 described similar approach, make 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (2.3g, 7.16mmol) (as preparation as described in the embodiment 49) and (N-methyl-N-tertbutyloxycarbonyl) ethanolamine (1.51g, 8.6mmol) reaction, generate 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-t-butoxycarbonyl amino) ethyoxyl) quinazoline (1.93g, 56%). 1H NMR spectrum: (DMSOd 6) 1.4 (s, 9H), 2.4 (s, 3H), 2.90 (s, 3H), 3.65 (t, 2H), 4.0 (s, 3H), 4.35 (t, 2H), 6.15 (s, 1H), 6.8 (dd, 1H), 7.28 (s, 1H), 7.35 (d, 1H), 7.42 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H); MS-ESI:479[MH] +Elementary analysis measured value C 65.0 H 6.4 N 11.7C 26H 30N 4O 5S value of calculation C 65.3 H 6.3 N 11.7% embodiment 150
Stirring at room contains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-t-butoxycarbonyl amino) ethyoxyl) quinazoline of TFA (12ml), and (550mg, 1.15mmol) (as preparation as described in the embodiment 149) solution in dichloromethane (10ml) is 3 hours.After the solvent removed in vacuo, residue is assigned between dichloromethane and the sodium bicarbonate.Regulate the pH to 11 of water layer with the 2N sodium hydroxide.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters and vacuum drying, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methylamino) ethyoxyl) quinazoline (356mg, 82%). 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H), 2.5 (s, 3H), 2.9 (t, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 6.25 (s, 1H), 6.9 (dd, 1H), 7.25 (s, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 8.5 (s, 1H), 11.0 (s, 1H) MS-ESI:379[MH]+elementary analysis measured value C 64.6 H 5.8 N 14.2C 21H 22N 4O 30.7H 2O value of calculation C 64.5 H 6.0 N 14.3% embodiment 151
To contain chloroacetonitrile (114mg, 1.5mmol), potassium carbonate (346mg, 2.5mmol) and potassium iodide (50mg, 0.3mmol) and 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (419mg, 1mmol) mixture of (as preparation as described in the embodiment 70) and DMF (6ml) at room temperature stirs and spends the night.With in the mixture impouring water, leach precipitate then, wash with water and vacuum drying.Residue and then by the column chromatography purification, with dichloromethane, methylene chloride (98/2 and 95/5) sequentially eluting.After the solvent removed in vacuo, the development of residue reuse ether is filtered, ether washing and vacuum drying, thus obtain 7-((1-cyano methyl) piperidin-4-yl methoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (304mg, 66%). 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.6-1.8 (m, 2H), 2.05-2.2 (d, 2H), 2.2-2.3 (m, 1H), 2.45 (s, 3H), 3.2 (t, 2H), 3.65 (d, 2H), 4.1 (s, 3H), 4.22 (d, 2H), 4.6 (s, 2H), 6.2 (s, 0.5H,
The part exchange), 6.9 (dd, 1H), 7.35 (s, 1H), 7.4 (d, 1H), 7.55 (s, 1H), 7.8 (s, 1H), 9.1 (s, 1H) MS-ESI:458[MH] +Elementary analysis measured value C 67.6 H 6.1 N 15.2C 26H 27N 5O 30.2H 2O value of calculation C 67.7 H 6.0 N 15.2% embodiment 152
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (360mg; 1.00mmol), potassium carbonate (215mg; 1.56mmol) and 5-oxyindole (147mg; 1.10mmol) mixture in DMF (8.0ml) 5 hours, be cooled to room temperature thereafter.Steam to remove and desolvate, residue is by silica gel chromatography, with methanol (2.5-5%)/dichloromethane eluting.Gained solid re-crystallizing in ethyl acetate is filtered and is washed with ether, obtains 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (77mg, 17%). 1H NMR spectrum: (DMSOd 6) 2.07 (m, 2H), 2.78 (s, 3H), 2.87 (s, 3H), 3.25 (t, 2H), 3.97 (s, 3H), 4.23 (t, 2H), 6.43 (brs, 1H), 6.96 (dd, 1H), 7.32 (s, 1H), 7.41 (m, 3H), 7.59 (d, 1H), 8.48 (s, 1H) and 11.17 (s, 1H) MS (ESI): 457 (MH) +Elementary analysis measured value C 57.5 H 5.3 N 12.0C 22H 24N 4O 5S value of calculation C 57.9 H 5.3 N 12.3%
Initial substance is prepared as follows:
The described similar method of initial substance among employing and the synthetic embodiment 5, use 4-bromo-2-fluorophenol to substitute 4-chloro-2-fluorophenol, to make 4-(4-bromo-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline with mode like 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline ditosylate salt.
Under the blanket of nitrogen, stirring at room 4-(4-bromo-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline (9.64g, 26.4mmol) and triphenyl phasphine (20.9g, 79.8mmol) mixture in dichloromethane (240ml) is 30 minutes.Add successively 3-(N-tertbutyloxycarbonyl)-Propanolamine (6.26g, 35.8mmol) and the diethylazodicarboxylate (12.4ml, 13.7g, 78.7mmol).Stirred reaction mixture 2 hours.Evaporation removes and desolvates then, and residue is dissolved in acetonitrile (250ml).Concentrate gained solution to half of initial volume, cooling thereafter.Filter gained crystalline solid,, obtain 4-(4-bromo-2-fluorophenoxy)-7-(3-(N-t-butoxycarbonyl amino) propoxyl group)-6-methoxyl group quinazoline (10.0g, 73%) after the drying with the ether washing. 1H NMR spectrum: (DMSOd 6) 1.37 (s, 9H), 1.94 (t, 2H), 3.13 (q, 2H), 3.97 (s, 3H), 4.21 (t, 2H), 6.89 (brs, 1H), 7.38 (s, 1H), 7.43-7.53 (m, 2H), 7.57 (s, 1H), 7.78 (dd, 1H) and 8.55 (s, 1H) MS (ESI): 522 (MH) +Elementary analysis measured value C 52.1 H 4.7 N 7.9C 23H 25N 3BrFO 5Value of calculation C 52.3 H 4.9 N 8.0%
With 4-(4-bromo-2-fluorophenoxy)-7-(3-(N-t-butoxycarbonyl amino) propoxyl group)--(5.46g 10.5mmol) is dissolved in trifluoroacetic acid (75ml) to the methoxyl group quinazoline, and 85 ℃ were heated 1.5 hours.Cooling gained solution, and steam and remove excessive trifluoroacetic acid.Residue is used ammonia (0.88) solution-treated then, and (3 * 150ml) extract, and filter by phase separation paper with dichloromethane.Steam to remove and desolvate, get 7-(the amino propoxyl group of 3-)-4-(4-bromo-2-fluorophenoxy)-6-methoxyl group quinazoline (4.42g, 100%). 1H NMR spectrum: (DMSOd 6) 1.87 (m, 2H), 2.73 (t, 2H), 3.98 (s, 3H), 4.26 (t, 2H), 7.40 (s, 1H), 7.50 (m, 2H), 7.55 (s, 1H), 7.78 (dd, 1H) and 8.55 (s, 1H) MS (ESI): 422 (MH) +
With 7-(the amino propoxyl group of 3-)-4-(4-bromo-2-fluorophenoxy)-6-methoxyl group quinazoline (2.71g, 6.4mmol) and triethylamine (1.1ml, 0.80g, 7.9mmol) solution in dichloromethane (15ml) is with mesyl chloride (0.53ml, 0.79g, 6.9mmol) dichloromethane (10ml) solution-treated, and under blanket of nitrogen stirring at room 18 hours.Steam then and remove dichloromethane, add THF (4ml).Gained solution is handled (to pH8) with saturated aqueous solution of sodium bicarbonate; vigorous stirring 30 minutes, filtering precipitate is washed and drying then; thereby obtain 4-(4-bromo-2-fluorophenoxy)-6-methoxyl group-7-(3-(N-mesyl amino) propoxyl group) quinazoline (2.98g, 93%). 1H NMR spectrum: (DMSOd 6) 2.01 (m, 2H), 2.90 (s, 3H), 3.15 (t, 2H), 3.96 (s, 3H), 4.25 (t, 2H), 7.06 (s, 1H), 7.40 (s, 1H), 7.49 (m, 2H), 7.56 (s, 1H), 7.78 (dd, 1H) and 8.54 (s.1H) MS (ESI): 500/502 (MH) +
With 4-(4-bromo-2-fluorophenoxy)-6-methoxyl group-7-(3-(N-mesyl amino) propoxyl group) quinazoline (1.0g; 2mmol) be dissolved in DMF (10ml); (60% mineral oil disperses thing, and 0.11g 2.7mmol) handles and stirred 30 minutes under blanket of nitrogen with sodium hydride.(0.16ml 2.6mmol), stirred the mixture 18 hours to add methyl iodide.Evaporation removes and desolvates, and residue is water-soluble again, and (3 * 30ml) extract with dichloromethane.Organic solution is water, salt water washing then, and dry (magnesium sulfate) also is evaporated to dried.Crude product and then by the silica gel chromatography purification, with methanol (2.5-5%)/dichloromethane eluting, 4-(4-bromo-2-fluorophenoxy)-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (0.86g, 83%). 1H NMR spectrum: (DMSOd 6) 2.06 (m, 2H), 2.78 (s, 3H), 2.87 (s, 3H), 3.24 (t, 2H), 3.97 (s, 3H), 4.23 (t, 2H), 7.39 (s, 1H), 7.48 (m, 2H), 7.55 (s, 1H), 7.78 (dd, 1H) and 8.54 (s, 1H) MS (ESI): 514/516 (MH) +
(4.70g 9.1mmol) is dissolved in 2N aqueous hydrochloric acid solution (85ml), and during reflux 1 with 4-(4-bromo-2-fluorophenoxy)-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline.After the cooling, carefully pour solution into (to pH 8) in the saturated aqueous solution of sodium bicarbonate, vigorous stirring 30 minutes.Filter the precipitate produced and in addition dry.Then filter cake is absorbed and form suspension in the acetone, filter, the ether washing is also dry, thereby obtains 6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline-4-one (3.23g, 88%). 1H NMR:(DMSOd 6) 2.02 (m, 2H), 2.77 (s, 3H), 2.86 (s, 3H), 3.22 (t, 2H), 3.86 (s, 3H), 4.13 (t, 2H), 7.09 (s, 1H), 7.42 (s, 1H), 7.95 (s, 1H) and 12.02 (s, 1H) MS (ESI): 342 (MH) +
(2.24g 6.6mmol) is dissolved in thionyl chloride (25ml), handles with DMF (5) with 6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline-4-one.Reflux gained solution is 1 hour then, then is cooled to room temperature.Excessive thionyl chloride is removed in evaporation, subsequently with toluene azeotropic (3x).Residue is with saturated aqueous solution of sodium bicarbonate alkalization (to pH8), and then with twice of ethyl acetate extraction.With gained organic solution water, salt water washing, dry (magnesium sulfate) and be evaporated to driedly obtains 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (1.90g, 80%). 1H NMR spectrum: (DMSOd 6) 2.08 (m, 2H), 2.78 (s, 3H), 2.88 (s, 3H), 3.24 (t, 2H), 3.98 (s, 3H), 4.26 (t, 2H), 7.37 (s, 1H), 7.42 (s, 1H) and 8.86 (s, 1H) MS (ESI): 360 (MH) +Embodiment 153
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (360mg; 1.00mmol) (as preparation as described in embodiment 152 starting materials), potassium carbonate (215mg; 1.56mmol) and 5-hydroxy-2-methyl indole (162mg; 1.10mmol) mixture in DMF (8.0ml) 5 hours, cool to room temperature thereafter.Evaporation removes and desolvates, and residue is passed through silica gel chromatography, with methanol (2.5-5%)/dichloromethane eluting.Gained solid and then use re-crystallizing in ethyl acetate filters and with the ether washing, thereby obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (166mg, 35%). 1H NMR spectrum: (DMSOd 6) 2.06 (m, 2H), 2.38 (s, 3H), 2.79 (s, 3H), 2.89 (s, 3H), 3.24 (t, 2H), 3.96 (s, 3H), 4.21 (t, 2H), 6.11 (brs, 1H), 6.87 (dd, 1H), 7.23 (d, 1H), 7.30 (d, 1H), 7.35 (s, 1H), 7.57 (s, 1H), 8.46 (s, 1H) and 10.98 (s, 1H) MS (ESI): 471 (MH) +Elementary analysis measured value C 58.3 H 5.6 N 11.7C 23H 26N 4O 5S value of calculation C 58.7 H 5.6 N 11.9% embodiment 154
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (150mg; 0.42mmol) (as preparation as described in embodiment 152 starting materials), potassium carbonate (90mg; 0.63mmol) and 7-hydroxyquinoline (67mg; 0.46mmol) mixture in DMF (5.0ml) 2 hours, cool to room temperature thereafter.Evaporation removes and desolvates, and residue is absorbed in the 2N sodium hydrate aqueous solution.Leach precipitate, drying is dissolved in dichloromethane again and filters gained solution by phase separation paper.Evaporated filtrate is to doing then.Gained solid and then use the acetonitrile recrystallization filters and with the ether washing, thereby obtains 6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (122mg, 63%). 1H NMR spectrum: (DMSOd 6) 2.09 (m, 2H), 2.79 (s, 3H), 2.90 (s, 3H), 3.26 (t, 2H), 3.99 (s, 3H), 4.26 (t, 2H), 7.39 (s, 1H), 7.54 (dd, 1H), 7.56 (dd, 1H), 7.60 (s, 1H), 7.91 (d, 1H), 8.09 (d, 1H), 8.44 (d, 1H), 8.55 (s, 1H) and 8.93 (dd, 1H) MS (ESI): 469 (MH) +Elementary analysis measured value C 58.6 H 5.1 N 11.9C 23H 24N 4O 5S value of calculation C 59.0 H 5.2 N 12.0% embodiment 155
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (150mg; 0.42mmol) (as preparation as described in embodiment 152 starting materials), potassium carbonate (90mg; 0.63mmol) and 7-hydroxy-4-methyl quinoline (71mg; 0.46mmol) (Chem.Berich.1967; 100; 2077) mixture in DMF (5.0ml) is 2 hours, thereafter cool to room temperature.The DMF solvent is removed in evaporation, and residue is absorbed in the 2N sodium hydrate aqueous solution.Leach precipitate, drying is dissolved in dichloromethane again and filters gained solution by phase separation paper.Evaporated filtrate is to doing then.Gained solid and then use the acetonitrile recrystallization filters and with the ether washing, thereby obtains 6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group)-4-(4-methylquinoline-7-base oxygen base) quinazoline (84mg, 42%). 1H NMR spectrum: (DMSOd 6) 2.09 (m, 2H), 2.71 (s, 3H), 2.79 (s, 3H), 2.89 (s, 3H), 3.25 (t, 2H), 3.98 (s, 3H), 4.25 (t, 2H), 7.37 (s, 1H), 7.38 (d, 1H), 7.61 (dd, 1H), 7.63 (s, 1H), 7.89 (d, 1H), 8.20 (d, 1H), 8.54 (s, 1H) and 8.76 (d, 1H) MS (ESI): 483 (MH) +Elementary analysis measured value C 59.1 H 5.3 N 11.5C 24H 26N 4O 5S value of calculation C 59.1 H 5.0 N 12.0% embodiment 156
100 ℃ are stirred (R, S)-4-chloro-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (90mg, 0.28mmol) (as preparation as described in embodiment 7 starting materials), potassium carbonate (60mg, 0.44mmol) and 7-hydroxyl-4-Trifluoromethylquinocarboxylic (65mg, 0.31mmol) (Ukr.Khim.Zh. (Russ.Ed) Vol.59, N.4, pp 408-411, preparation described in 1993) mixture in DMF (2ml) is 6 hours, thereafter cool to room temperature.The DMF solvent is removed in evaporation, residue is dissolved in ethanol/methylene (1/1), and is adsorbed onto on the silica gel.Crude mixture is passed through silica gel chromatography, with/methanol/0.880 ammonia (95/5/1) eluting, product obtain after with the acetonitrile recrystallization (R, S)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(4-Trifluoromethylquinocarboxylic-7-base oxygen base) quinazoline (58mg, 42%). 1H NMR spectrum: (DMSOd 6100 ℃) 1.24 (m, 1H), 1.59 (m, 1H), 1.70 (m, 1H), 1.83 (m, 1H), 2.05 (m, 2H), 2.17 (m, 1H), 2.24 (s, 3H), 2.64 (dt, 1H), 2.84 (dd, 1H), 4.05 (s, 3H), 4.18 (d, 2H), 7.43 (s, 1H), 7.69 (s, 1H), 7.87 (dd, 1H), 7.96 (d, 1H), 8.18 (s, 1H), 8.25 (dd, 1H), 8.59 (s, 1H) and 9.16 (d, 1H) MS (ESI): 499 (MH) +Elementary analysis measured value C 62.2 H 5.1 N 11.0C 26H 25N 4F 3O 3Value of calculation C 62.6 H 5.1 N 11.2% embodiment 157
100 ℃ are stirred (R, S)-4-chloro-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (150mg, 0.46mmol) (as preparation as described in embodiment 7 starting materials), potassium carbonate (106mg, 0.77mmol) and 3-fluoro-7-hydroxyquinoline (119mg, 0.73mmol) mixture in DMF (5ml) 2 hours, cool to room temperature thereafter.Evaporation removes and desolvates, and residue is handled with 1.0N sodium hydrate aqueous solution (30ml), stirs then 30 minutes.The solid collected by filtration crude product, and wash with water.The gained solid is dissolved in dichloromethane, filters by phase separation paper.Evaporation removes desolvates, solid residue and then use the acetonitrile recrystallization, (R, S)-4-(the basic oxygen base of 3-fluorine quinoline-7-)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (83mg, 40%). 1H NMR spectrum: (DMSOd 6) 1.11 (m, 1H), 1.50 (m, 1H), 1.64 (m, 1H), 1.84 (m, 3H), 2.10 (m, 1H), 2.15 (s, 3H), 2.62 (d, 1H), 2.83 (d, 1H), 4.00 (s, 3H), 4.08 (d, 2H), 7.38 (s, 1H), 7.62 (s, 1H), 7.68 (dd, 1H), 7.97 (d, 1H), 8.10 (d, 1H), 8.34 (dd, 1H), 8.54 (s, 1H) and 8.97 (d, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 66.2 H 5.6 N 12.3C 25H 25N 4FO 30.2H 2O value of calculation C 66.4 H 5.7 N 12.4%
Initial substance 3-fluoro-7-hydroxyquinoline is prepared as follows:
(300mg, 1.55mmol) (as Tetrahedron, Vol.52, No.9, pp.3223-3228, preparation described in 1996) is dissolved in thionyl chloride (3ml), handles with DMF (1), and reflux 1 hour with 3-fluoro-7-methoxy quinoline-2 (1H)-ketone.Excessive thionyl chloride is removed in evaporation, and with a residue and a toluene-azeotropic (3x).Residue alkalizes to pH8 with saturated aqueous solution of sodium bicarbonate, and (3 * 200ml) extract to use ethyl acetate then.Organic solution water and salt water washing, subsequent drying (magnesium sulfate), and be evaporated to dried, thereby obtain 2-chloro-3-fluoro-7-methoxy quinoline (320mg, 97%). 1H NMR spectrum: (CDCl 3) 3.95 (s, 3H), 725 (dd, 1H), 7.37 (d, 1H), 7.67 (d, 1H) and 7.78 (d, 1H) MS (ESI): 212 (MH) +
With 2-chloro-3-fluoro-7-methoxy quinoline (310mg, 1.47mmol), (310mg, 0.4ml 3.07mmol) stirred in atmosphere of hydrogen 24 hours under atmospheric pressure with the mixture of 10% palladium-active carbon (50mg) in dehydrated alcohol (5ml) triethylamine.Then by the diatomite filtration mixture.The kieselguhr methanol wash is removed solvent in the merging filtrate by evaporation then.Crude product with 10% ethyl acetate/isohexane eluting, gets 3-fluoro-7-methoxy quinoline (130mg, 54%) by the silica gel chromatography purification. 1H NMR spectrum: (CDCl 3) 3.96 (and s, 3H), 7.24 (dd, 1H), 7.44 (d, 1H), 7.66 (d, 1H) and 7.73 (dd, 1H) and 8.76 (d, 1H) MS (ESI): 178 (MH) +
Under the blanket of nitrogen, (130mg 0.74mmol) is dissolved in dichloromethane (2ml), handles with Boron tribromide (4ml, 1.0M dichloromethane solution) with 3-fluoro-7-methoxy quinoline.Stirring at room reactant mixture 24 hours then slowly adds the excessive methanol cessation reaction.Further stirred gained solution 2 hours, be evaporated to dried 3-fluoro-7-hydroxyquinoline then, this product need not into-goes on foot purification and can directly use.MS(ESI)：164(MH) +。Embodiment 158
100 ℃ are stirred (R, S)-4-chloro-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (240mg, 0.75mmol) (as preparation as described in embodiment 7 starting materials), potassium carbonate (160mg, 1.16mmol) and 3-fluoro-7-hydroxy-2-methylquinoline (150mg, 0.85mmol) mixture in DMF (6ml) 5 hours, cool to room temperature thereafter.Evaporation removes and desolvates, and residue is handled with 1.0N sodium hydrate aqueous solution (30ml), stirs then 30 minutes.The solid collected by filtration crude product, and wash with water.The gained solid is dissolved in dichloromethane, filters by phase separation paper.Evaporation removes desolvates, solid residue and then use the acetonitrile recrystallization, 4-(the basic oxygen base of 3-fluoro-2-methylquinoline-7-)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline (71mg, 21%). 1H NMR spectrum: (DMSOd 6) 1.11 (m, 1H), 1.68 (m, 5H), 2.10 (m, 1H), 2.20 (s, 3H), 2.64 (m, 4H), 2.87 (d, 1H), 3.98 (s, 3H), 4.09 (d, 2H), 7.37 (s, 1H), 7.57 (dd, 1H), 7.60 (s, 1H), 7.86 (d, 1H), 8.02 (d, 1H), 8.20 (d, 1H) and 8.53 (s, 1H) MS (ESI): 463 (MH) +Elementary analysis measured value C 66.4 H 6.1 N 11.8C 26H 27N 4FO 30.4H 2O value of calculation C 66.5 H 6.0 N 11.9%
Initial substance is prepared as follows:
Under-78 ℃, to copper bromide (I) (570mg, 4.0mmol) and methyl-magnesium-bromide (3.0M diethyl ether solution, 2.7ml, 8mmol) add the 2-chloro-3-fluoro-7-methoxy quinoline be dissolved among the anhydrous THF (1ml) (210mg, 1mmol) (as preparation as described in embodiment 157 starting materials) in the mixed liquor in anhydrous THF (20ml).-78 ℃ stirred the mixture 1 hour, were warmed to room temperature then, further stirred 18 hours.Add ammonium chloride saturated aqueous solution and 5N sodium hydrate aqueous solution (pH12), and extract product with ethyl acetate (3x).Organic solution water, salt water washing, dry (magnesium sulfate) and be evaporated to dried, 3-fluoro-7-methoxyl group-2-methylquinoline (0.17g, 91%). 1H NMR spectrum: (CDCl 3) 2.70 (d, 3H), 3.94 (s, 3H), 7.17 (dd, 1H), 7.37 (d, 1H) and 7.61 (m, 2H) MS (ESI): 192 (MH) +
Under the blanket of nitrogen, (0.16g 0.85mmol) is dissolved in dichloromethane (4ml), and (4ml, 1.0M dichloromethane solution 4.0ml) are handled with Boron tribromide solution with 3-fluoro-7-methoxyl group-2-methylquinoline.Stirring at room reaction 24 hours slowly adds excessive methanol then.Further stirred gained solution 2 hours, be evaporated to thereafter dried, 3-fluoro-7-hydroxy-2-methylquinoline.This product need not to be further purified and directly uses.MS (ESI): 178 (MH) +Embodiment 159
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (400mg, 1.19mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (255mg, 1.84mmol) and 7-hydroxyquinoline (180mg, 1.32mmol) mixture in DMF (10ml) 4 hours, cool to room temperature thereafter.Handle the gained mixture with 1.0N sodium hydrate aqueous solution (30ml), stirred then 1 hour.The solid collected by filtration crude product also washes with water.Subsequently the gained solid is dissolved in diamino methane, filters by phase separation paper.Evaporation removes to desolvate and obtains solid residue, and then gets 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline (0.27g, 52%) with the acetonitrile recrystallization. 1H NMR spectrum: (DMSOd 6) 1.37 (m, 2H), 1.51 (m, 4H), 1.95 (m, 2H), 2.32 (m, 4H), 2.42 (t, 2H), 3.98 (s, 3H), 4.23 (t, 2H), 7.38 (s, 1H), 7.56 (m, 2H), 7.62 (s, 1H), 7.91 (d, 1H), 8.09 (d, 1H), 8.44 (d, 1H), 8.54 (s, 1H) and 8.91 (dd, 1H) MS (ESI): 445 (MH) +Elementary analysis measured value C 70.9 H 6.3 N 12.7C 26H 28N 4O 3Value of calculation C 70.3 H 6.3 N 12.6% embodiment 160
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (360mg; 1.00mmol) (as preparation as described in embodiment 152 starting materials), potassium carbonate (215mg; 1.56mmol) and 2; 3-dimethyl-5-oxyindole (177mg; 1.10mmol) (Arch.Pharm.1972; 305,159) mixture in DMF (8.0ml) is 5 hours, thereafter cool to room temperature.Evaporation removes and desolvates, and residue is passed through silica gel chromatography, with methanol (2.5%)/dichloromethane eluting.The gained solid filters with t-butyl methyl ether/acetonitrile recrystallization, obtains 4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (201mg, 42%) after the ether washing. 1H NMR spectrum: (DMSOd 6) 2.07 (m, 2H), 2.12 (s, 3H), 2.31 (s, 3H), 2.79 (s, 3H), 2.89 (s, 3H), 3.25 (t, 2H), 3.97 (s, 3H), 4.23 (t, 2H), 6.86 (dd, 1H), 7.20 (d, 1H), (7.25 d, 1 H), 7.35 (s, 1H), 7.58 (s, 1H), 8.46 (s, 1H) and 11.17 (s, 1H) MS (ESI): 485 (MH) +Elementary analysis measured value C 59.5 H 5.8 N 11.4C 24H 28N 4O 5S value of calculation C 59.5 H 5.8 N 11.6% embodiment 161
60 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (322mg, 1.00mmol) (as preparation as described in the embodiment 49), potassium carbonate (414mg, 3.00mmol) and epibromohydrin (274mg, 2.00mmol) mixture in DMF (7.0ml) 2 hours, cool to room temperature thereafter.Evaporation removes and desolvates, and residue is dissolved in dichloromethane (10ml).(48 μ l 0.6mmol) handle, and at room temperature stirred 24 hours with morpholine to get the separatory that waits of this solution of 5ml.Evaporation removes and desolvates, and uses water treatment and vigorous stirring 30 minutes.Filtering precipitate, washing and dry.The gained solid suspension is also stirred in acetone, filter, ether washing after drying gets 7-(2-hydroxyl-3-morpholino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (127mg, 27%). 1H NMR spectrum: (DMSOd 6) 2.38 (s, 3H), 2.45 (m, 6H), 3.57 (t, 4H), 3.95 (s, 3H), 4.03-4.14 (m, 2H), 4.23 (m, 1H), 4.95 (s, 1H), 6.12 (s, 1H), 6.86 (dd, 1H), 7.23 (d, 1H), 7.29 (d, 1H), 7.37 (s, 1H), 7.57 (s, 1H), 8.47 (s, 1H) and 10.98 (s, 1H) MS (ESI): 465 (MH) +Elementary analysis measured value C 62.7 H 5.9 N 11.5C 25H 28N 4O 50.7H 2O value of calculation C 62.9 H 6.2 N 11.7% embodiment 162
70 ℃ of heating 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (100g, 0.27mmol) and piperidines (79 μ l, 0.8mmol) mixture in DMF (4ml) is 24 hours.Evaporation removes and desolvates, with residue acetonitrile recrystallization.Filter solids, ether washing after drying gets 7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (80mg, 65%). 1H NMR spectrum: (DMSOd 6) 1.35 (m, 2H), 1.51 (m, 4H), 2.39 (m, 9H), 3.96 (s, 3H), 4.08 (m, 2H), 4.21 (dd, 1H), 4.86 (brs, 1H), 6.11 (s, 1H), 6.87 (dd, 1H), 7.23 (d, 1H), 7.29 (d, 1H), 7.37 (s, 1H), 7.56 (s, 1H), 8.45 (s, 1H) and 10.98 (s, 1H) MS (ESI): 464 (MH) +Elementary analysis measured value C 66.2 H 6.4 N 11.9C 26H 30N 4O 40.4H 2O value of calculation C 66.5 H 6.6 N 11.9%
Initial substance is prepared as follows:
60 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (1.89g, 5.90mmol) (as preparation as described in the embodiment 49), potassium carbonate (2.43g, 17.6mmol) and epibromohydrin (1.61g, 11.7mmol) mixture in DMF (40ml) 2 hours, be cooled to room temperature thereafter.The filtering inorganic insoluble substance, and by evaporating except that desolvating.Residue and then with ether development filters, and further washs after drying with ether, 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (1.97g, 89%). 1H NMR spectrum: (DMSOd 6) 2.38 (s, 3H), 2.76 (m, 1H), 2.90 (t, 1H), 3.43 (m, 1H), 3.97 (s, 3H), 4.04 (m, 1H), 4.57 (dd, 1H), 6.11 (s, 1H), 6.86 (dd, 1H), 7.27 (m, 2H), 7.38 (s, 1H), 7.59 (s, 1H), 8.46 (s, 1H) and 10.92 (s, 1H) MS (ESI): 378 (MH) +Embodiment 163
70 ℃ of heating 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg, 0.27mmol) (67 μ l, 0.8mmol) mixture in DMF (4ml) is 24 hours for (as preparation as described in the starting material among the embodiment 162) and pyrrolidine.Evaporation removes and desolvates, and residue is passed through silica gel chromatography, with methylene chloride/0.880 ammonia (100/8/1) eluting.Evaporate relevant fraction to doing, then a small amount of dichloromethane of residue reuse is handled, after high vacuum dry, obtain white foam thing 7-(2-hydroxyl-3-pyrrolidine-1-base propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (44mg, 37%). 1H NMR spectrum: (DMSOd 6) 1.69 (brs, 4H), 2.38 (s, 3H), 2.50 (m, 6H), 3.97 (s, 3H), 4.07 (m, 2H), 4.21 (dd, 1H), 4.96 (brs, 1H), 6.11 (s, 1H), 6.g6 (dd, 1H), 7.23 (d, 1H), 7.29 (d, 1H), 7.35 (s, 1H), 7.56 (s, 1H), 8.46 (s, 1H) and 10.98 (s, 1H) MS (ESI): 450 (MH) +Elementary analysis measured value C 65.5 H 6.3 N 11.8C 25H 28N 4O 40.4H 2O value of calculation C 65.9 H 6.4 N 12.3% embodiment 164
70 ℃ of heating 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg, 0.27mmol) (100 μ l, 0.8mmol) mixture in DMF (4ml) is 24 hours for (as preparation as described in the embodiment 162 initial substance parts) and diethylamine.Evaporation removes and desolvates, and residue is passed through silica gel chromatography, with diamino methane/methanol/0.880 ammonia (100/8/1) eluting.Evaporate relevant fraction to doing, then a small amount of dichloromethane of residue reuse is handled, after high vacuum dry, obtain white foam thing 7-(3-(N, N-diethylamino)-2-hydroxyl propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (55mg, 46%). 1H NMR spectrum: (DMSOd 6) 0.96 (t, 6H), 2.38 (s, 3H), 2.52 (m, 6H), 3.96 (s, 3H), 3.97 (m, 1H), 4.09 (m, 1H), 4.23 (dd, 1H), 4.84 (brs, 1H), 6.12 (s, 1H), 6.88 (dd, 1H), 7.24 (d, 1H), 7.29 (d, 1H), 7.36 (s, 1H), 7.56 (s, 1H), 8.45 (s, 1H) and 10.98 (s, 1H) MS (ESI): 452 (MH) +Elementary analysis measured value C 66.2 H 6.7 N 12.4C 25H 30N 4O 4Value of calculation C 66.6 H 6.7 N 12.4% embodiment 165
70 ℃ of heating 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg, 0.27mmol) (200 μ l, 1.8mmol) mixture in DMF (4ml) is 24 hours for (as preparation as described in embodiment 162 starting materials) and N methyl piperazine.Evaporation removes and to desolvate then, and with acetonitrile recrystallization residue.Solid collected by filtration, ether washing after drying obtain 7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (41mg, 32%). 1H NMR spectrum: (DMSOd 6): 2.11 (s, 3H), 2.29 (m, 4H), 2.40 (s, 3H), 2.47 (m, 6H), 3.96 (s, 3H), 4.07 (m, 2H), 4.20 (dd, 1H), 4.89 (d, 1H), 6.11 (s, 1H), 6.87 (dd, 1H), 7.23 (d, 1H), 7.29 (d, 1H), 7.35 (s, 1H), 7.58 (s, 1H), 8.46 (s, 1H) and 10.98 (s, 1H) MS (ESI): 479 (MH) +Elementary analysis measured value C 64.4 H 6.5 N 14.4C 26H 31N 5O 40.3H 2O value of calculation C 64.7 H 6.6 N 14.5% embodiment 166
70 ℃ of heating 7-(2, the 3-glycidoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (100mg, 0.27mmol) (100 μ l, 0.8mmol) mixture in DMF (4ml) is 24 hours for (as preparation as described in embodiment 162 starting materials) and 2-aminopropane..Evaporation removes and desolvates then, and residue passed through silica gel chromatography, with methylene chloride/0.880 ammonia (100/8/1) eluting, get 7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (18mg, 16%). 1H NMR spectrum: (DMSOd 6) 1.00 (d, 6H), 2.40 (s, 3H), 2.56-2.78 (m, 3H), 3.97 (m, 4H), 4.07-4.28 (m, 2H), 5.04 (m, 1H), 6.12 (s, 1H), 6.88 (dd, 1H), 7.22-7.33 (m, 2H), 7.38 (s, 1H), 7.58 (s, 1H), 8.48 (s, 1H) and 10.98 (s, 1H) MS (ESI): 437 (MH) +Embodiment 167
95 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (168mg, 0.5mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (276mg, 2.0mmol) and 5-hydroxyl-6-trifluoro methyl indole (110mg, 0.55mmol) and the mixture of DMA (4.0ml) 1.5 hours, be cooled to room temperature thereafter.Filter reaction mixture, and vacuum evaporation filtrate.Residue by silica gel chromatography, with methylene chloride/0.880 ammonia (89/10/1) eluting, is obtained the part refined oil.This grease further by high-efficiency column chromatograph (18 amino silane reverse phase silica gel) purification, with acetonitrile/water/trifluoroacetic acid (60/39.8/0.2) eluting, is obtained a grease, and then is dissolved in diamino methane again, and wash with saturated aqueous solution of sodium bicarbonate.The evaporation dichloromethane layer obtains 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(6-trifluoro methyl indole-5-base oxygen base) quinazoline (62mg, 25%). 1H NMR spectrum: (DMSOd 6) 1.45 (m, 2H), 1.60 (m, 4H), 2.13 (m2H), 2.44 (m, 4H), 2.56 (m, 2H), 4.04 (s, 3H), 4.27 (t, 2H), 6.63 (brs, 1H), 7.33 (s, 1H), 7.40 (t, 1H), 7.61 (s, 1H), 7.67 (s, 1H), 7.75 (s, 1H) and 8.60 (m, 2H) MS (ESI): 501 (MH) +Elementary analysis measured value C 62.0 H 5.6 N 10.6C 26H 27F 3N 4O 30.35H 2O, value of calculation C 61.6 H 5.5 N 11.0%
Initial substance is prepared as follows:
Under room temperature, the vigorous stirring, in nitrogen atmosphere to benzylalcohol (10.8g, add in DMA 100mmol) (100ml) solution in batches sodium hydride (1.8g, the 60% oil content thing that looses, 45mmol).Be warming to 45 ℃ of reactions 30 minutes, cooling mixture is to room temperature then, and (11.3g in DMA 50mmol) (30ml) agitating solution, keeps temperature to be lower than 10 ℃ between charge period dropwise to be added to 2-chloro-5-nitro-trifluoromethylbenzene.25 ℃ stirred the mixture 1 hour, used the acetic acid acidify then, and evaporation obtains a yellow solid.This residue is dissolved in dichloromethane, washes with water, then dry (magnesium sulfate) and evaporation.Residue is suspended in the mixed liquor of hexane (70ml) and ether (10ml), leaches the solid that is produced and obtain 2-benzyloxy-5-nitro-trifluoromethylbenzene (6.6g, 49%). 1H NMR spectrum: (CDCl 3) 5.33 (s, 2H), 7.13 (d, 1H), 7.31-7.43 (m, 5H), 8.35 (dd, 1H), 8.52 (d, 1H)
With potassium tert-butoxide (3.94g, 35.4mmol) being dissolved in dry DMF (15ml), (3.5g is 16.1mmol) with 4-chlorphenyl acetonitrile (2.96g for 30 minutes adding 2-benzyloxy-5-nitro-trifluoromethylbenzenes, 17.7mmol) mixture in DMF (20ml), keeping temperature between charge period is-15 ℃.-10 ℃ stirred the mixture 1 hour, poured into then in the 1M hydrochloric acid (150ml), and (2 * 100ml) extract product with dichloromethane.Dry (magnesium sulfate) organic extract, and then,, get 5-benzyloxy-2-nitro-4-(trifluoromethyl) benzene acetonitrile (5.2g, 77%) with dichloromethane/hexane (1/1) eluting by silica gel chromatography. 1H NMR spectrum: (CDCl 3) 4.30 (s, 2H), 5.38 (s, 2H), 7.25 (s, 1H), 7.33-7.50 (m, 5H) and 8.51 (s, 1H) MS (ESI): 335 (M-H) -
(2.22g 6.6mmol) is dissolved in ethanol (45ml), water (5ml) and the acetic acid (0.32ml), utilizes the hydrogenation 2 hours under 1 atmospheric pressure of 10% palladium-carbon then with 5-benzyloxy-2-nitro-4-(trifluoromethyl) benzene acetonitrile.Filtration catalizer, evaporated filtrate obtain 5-hydroxyl-6-trifluoro methyl indole (1.12g, 84%). 1H NMR spectrum: (CDCl 3) 4.48 (s, 1H), 6.48 (m, 1H), 7.14 (s, 1H), 7.32 (t, 1H), 7.57 (s, 1H) and 8.20 (brs, 1H) MS (ESI): 200 (M-H) -Embodiment 168
95 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (200mg, 0.6mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (248mg, 1.8mmol) and 5-hydroxyl-6-methoxyl group indole (127mg, 0.78mmol) mixture in DMA (4.0ml) is 2.5 hours.Reaction mixture is to room temperature, filtering reaction and vacuum evaporation filtrate.Residue passes through silica gel chromatography, with methylene chloride/0.880 ammonia (89/10/1) eluting, and with ether development gained grease, thereby obtain 4-(6-methoxyl group indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group)-quinazoline (106mg, 38%). 1H NMR spectrum: (DMSOd 6) 1.38 (m, 2H), 1.47 (m, 4H), 1.95 (m, 2H), 2.32 (m, 4H), 2.40 (m, 2H), 3.66 (3H, s), 3.97 (s, 3H), 4.28 (t, 2H), 6.35 (brs, 1H), 7.06 (s, 1H), 7.24 (t, 1H), 7.34 (s, 1H), 7.36 (s, 1H), 7.55 (s, 1H) and 8.41 (s, 1H) MS (ESI): 463 (MH) +Elementary analysis measured value C 65.2 H 6.8 N 11.2C 26H 30N 4O 41.0H 2O, 0.3 ether value of calculation C, 64.9 H, 7.0 N 11.1%
5-hydroxyl-6-methoxyl group indole raw material is prepared as follows:
Under 25 ℃, 1 atmospheric pressure, in methanol (10ml), utilize 10% palladium-carbon (50mg) hydrogenation 5-benzyloxy-6-methoxyl group indole (253mg, 1.0mmol) 2 hours.Filtration catalizer, evaporated filtrate obtain 5-hydroxyl-6-methoxyl group indole (141mg, 87%). 1H NMR spectrum: (CDCl 3) 3.92 (s, 3H), 5.40 (s, 1H), 6.42 (br s, 1H), 6.87 (s, 1H), 7.07 (m, 1H), 7.13 (s, 1H), 7.93 (brs, 1H) MS (ESI): 162 (M-H) -Embodiment 169
85 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (200mg, 0.595mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (411mg, 2.98mmol) and 4-oxyindole (103mg, 0.774mmol) mixture in DMA (2.0ml) 3 hours, be cooled to room temperature thereafter.Filter reaction mixture, evaporated filtrate obtain a solid residue.And then with residue by silica gel chromatography, use to contain the dichloromethane gradient eluting that 0%, 2%, 4%, 10% methanol closes ammonia, 4-(indole-4-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (131mg, 51%). 1H NMR spectrum: (DMSOd 6) 1.39 (m, 2H), 1.50 (m, 4H), 1.98 (t, 2H), 2.35 (m, 4H), 2.40 (t, 2H), 3.98 (s, 3H), 4.25 (t, 2H), 6.10 (t, 1H), 6.90 (d, 1H), 7.15 (t, 1H), 7.30 (t, 1H), 7.35 (d, 1H), 7.38 (s, 1H), 7.62 (s, 1H), 8.45 (s, 1H) and 11.29 (s, 1H) MS (ESI): 433 (MH) +M.p.80-82 ℃ of embodiment 170
85 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (200mg, 0.595mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (411mg, 2.98mmol) and 3-hydroxycarbazole (142mg, 0.774mmol) mixture in DMA (2.0ml) 3 hours, be cooled to room temperature thereafter.Filter reaction mixture, evaporated filtrate obtain a solid residue.And then with residue by silica gel chromatography, use to contain the dichloromethane gradient eluting that 0%, 2%, 4%, 10% methanol closes ammonia, 4-(9H-carbazole-3-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (212mg, 74%). 1H NMR spectrum: (DMSOd 6) 1.39 (m, 2H), 1.50 (m, 4H), 2.35 (m, 4H), 2.40 (t, 2H), 3.98 (s, 3H), 4.25 (t, 2H), 7.05 (dd, 1H), 7.15 (t, 1H), 7.35 (t, 1H), 7.38 (s, 1H), 7.40 (s, 1H), 7.50 (d, 1H), 7.60 (s, 1H), 8.10 (d, 1H), 8.15 (d, 1H), 8.55 (s, 1H) and 11.33 (s, 1H) MS (ESI): 483 (MH) +Embodiment 171
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (84mg, 0.24mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (162mg, 1.18mmol) and 7-chloro-5-oxyindole-2-carboxylic acid, ethyl ester (62mg, 0.26mmol) mixture in DMA (2.0ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and evaporated filtrate.Residue and then pass through silica gel chromatography, use contains the dichloromethane gradient eluting of 2.5%, 5%, 10% methanol, and then with the dichloromethane eluting that contains 2% ammonia, get 4-(7-chloro-2-(ethoxy carbonyl) indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (78mg, 63%). 1H NMR spectrum: (DMSOd 6) 1.30 (t, 3H), 1.40 (m, 2H), 1.50 (m, 4H), 1.98 (t, 2H), 2.35 (m, 4H), 2.40 (t, 2H), 3.98 (s, 3H), 4.25 (t, 2H), 4.30 (q, 2H), 7.15 (m, 1H), 7.18 (s, 1H), 7.60 (s, 1H), 8.40 (s, 1H) and 12.60 (s, 1H) MS (ESI): 539 (MH) +Elementary analysis measured value C 61.2 H 5.9 N 10.3C 28H 31ClN 4O 50.5H 2O value of calculation C 61.4 H 5.9 N 10.2%
Initial substance is prepared as follows:
(2.719g 14mmol), cools off this suspension to-5 ℃ to add 2-chloro-4-aminoanisole in 0.8M aqueous hydrochloric acid solution (15ml).Add sodium nitrite (1.063g, water 15.4mmol) (3ml) solution.Add sodium acetate after finishing and regulate pH to 4-5.In another flask, will be-5 ℃ of refrigerative acetoacetic acid ethyl-α-ethyl ester (2.18ml, ethanol 15.4mmol) (15ml) solution potassium hydroxide (864mg, water 15.4mmol) (3ml) solution-treated, then reuse ice (4g) processing down.The diazol that in second kind of solution, adds the beginning preparation then rapidly, and under-5 ℃, stirred 4 hours, be warmed to room temperature thereafter.(3 * 100ml) extract, and dry (magnesium sulfate) organic solution is filtered and solvent removed in vacuo obtains an orange with ethyl acetate with mixture.Then this grease is dissolved in ethanol (35ml), and on flask, disposes reflux condenser.Dropwise add concentrated sulphuric acid (35ml), and under no external heat situation, cause reactant to reflux thus.Agitating solution 1 hour, evaporation removes and desolvates then.Residue is absorbed in the water, and (3 * 100ml) extract to use ethyl acetate thereafter.Salt water washing organic solution, dry (magnesium sulfate), filtration and evaporation get a brown oil.This rough oil product and then by silica gel chromatography, with the dichloromethane eluting, 7-chloro-5-methoxyl group indole-2-carboxylic ethyl ester (125mg, 4%). 1H NMR spectrum: (CDCl 3) 1.40 (t, 3H), 3.98 (s, 3H), 4.40 (q, 2H), 6.60 (d, 1H), 7.05 (d, 1H), 7.15 (s, 1H) and 9.10 (s, 1H) MS (ESI): 254 (MH) +
Under-78 ℃, (add Boron tribromide (1.07ml in the 82mg, dichloromethane 0.323mmol) (5ml) solution to 7-chloro-5-methoxyl group indole-2-carboxylic ethyl ester, 1.0M DCM solution, 1.07mmol), and, be warmed to ambient temperature overnight then in-78 ℃ of stirring reactions 30 minutes.Carefully add entry, and regulate pH to 6-7 by adding the 2M sodium hydroxide.The mixture ethyl acetate (2 * 50ml) extract, salt water washing organic solution, and also evaporation of dry (magnesium sulfate), filtration gets orange solids 7-chloro-5-oxyindole-2-carboxylic acid, ethyl ester (55mg, 71%). 1H NMR spectrum: (DMSOd 6) 1.38 (t, 3H), 4.35 (q, 2H), 6.60 (d, 1H), 6.95 (d, 1H), 7.10 (d, 1H), 9.80 (s, 1H) and 11.80 (s, 1H) MS (ESI): 238 (MH) -Embodiment 172
100 ℃ are stirred 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (1.5g, 4.99mmol) (as preparation as described in embodiment 1 starting material), potassium carbonate (2.07g, 15mmol) with 2,3-dimethyl-5-oxyindole (1.21g, 7.5mmol) (Arch.Pharm.1972,305,159) mixture in DMF (75ml) is 2 hours, is cooled to room temperature thereafter.Filter reaction mixture and evaporated filtrate.Solid residue and then by silica gel chromatography, with 2.5% ethanol/methylene eluting, 7-benzyloxy-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline (976mg, 46%). 1H NMR spectrum: (CDCl 3) 2.10 (s, 3H), 2.30 (s, 3H), 3.98 (s, 3H), 5.30 (s, 2H), 6.85 (dd, 1H), 7.20 (d, 1H), 7.25 (d, 1H), 7.40 (m, 6H), 7.60 (s, 1H), 8.40 (s, 1H) and 10.74 (s, 1H) MS (ESI): 426 (MH) +Embodiment 173
Stirring at room 7-benzyloxy-4-(2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline (912mg, 2.14mmol) (as preparation as described in the embodiment 172), Bis(tert-butoxycarbonyl)oxide (1.871g, 8.56mmol) and 4-dimethylamino naphthyridine (70mg, 5mol%) mixture overnight in acetonitrile (40ml).Evaporating solvent then, and residue is dissolved in ethyl acetate.Organic solution 2N hydrochloric acid washed twice, and then use the salt water washing.Thereafter dry (magnesium sulfate) organic layer filters and evaporation, gets yellow solid 7-benzyloxy-4-(1-tertbutyloxycarbonyl-2,3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline (1.108g, 99%). 1H NMR spectrum: (CDCl 3) 1.70 (s, 9H), 2.08 (s, 3H), 2.50 (s, 3H), 4.10 (s, 3H), 5.35 (s, 2H), 7.15 (dd, 1H), 7.38 (m, 6H), 7.60 (s, 1H), 8.20 (d, 1H) and 8.60 (s, 1H) MS (ESI): 526 (MH) +Embodiment 174
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol) (as preparation as described in embodiment 1 starting material), potassium carbonate (106g, 0.77mmol) and 2-hydroxyquinoline (111mg, 0.76mmol) mixture in DMF (7.5ml) 5 hours, be cooled to room temperature thereafter.With 1.0N sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.Reactant mixture ethyl acetate extraction three times, water and salt water washing extract then.The dried over mgso organic extract filters and evaporates to remove and desolvates.Residue and then pass through silica gel chromatography, with methylene chloride (95/5) eluting, gained solid and then with ether development filters and dry, get 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-2-base oxygen base)-quinazoline (33mg, 11%). 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H), 2.38 (m, 4H), 2.48 (t, 2H), 3.58 (m, 4H), 3.98 (s, 3H), 4.26 (t, 2H), 7.41 (s, 1H), 7.52 (d, 1H), 7.58 (s, 1H), 7.64 (t, 1H), 7.78 (m, 1H), 7.88 (d, 1H), 8.06 (d, 1H), 8.56 (d, 1H) and 8.57 (s, 1H) MS (ESI): 447 (MH) +Elementary analysis measured value C 66.8 H 5.9 N 12.4C 25H 26N 4O 40.2H 2O value of calculation C 66.7 H 5.9 N 12.4% embodiment 175
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (225mg, 0.67mmol) (as preparation as described in embodiment 1 starting material), potassium carbonate (106g, 0.77mmol) and 5-hydroxyquinoline (111mg, 0.77mmol) mixture in DMF (7.5ml) 5 hours, be cooled to room temperature thereafter.With 1.0N sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.Leach the precipitate that is produced, washing and of short duration air-dry.Moist solids is dissolved in dichloromethane, filters and vacuum evaporation filtrate by phase separation paper.Residue and then with ether development filters and dry, 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-5-base oxygen base)-quinazoline (178mg, 59%). 1H NMR spectrum: (DMSOd 6) 1.98 (m, 2H), 2.39 (m, 4H), 2.48 (t, 2H), 3.59 (t, 4H), 4.01 (s, 3H), 4.28 (t, 2H), 7.42, (s, 1H), 7.50 (m, 1H), 7.59 (d, 1H), 7.74 (s, 1H), 7.87 (t, 1H), 8.02 (d, 1H), 8.20 (m, 1H), 8.44 (s, 1H) and 8.96 (m, 1H) MS (ESI): 447 (MH) +Elementary analysis measured value C 66.2 H 5.7 N 12.4C 25H 26N 4O 40.4H 2O value of calculation C 66.2 H 6.0 N 12.4% embodiment 176
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (200mg, 0.57mmol), potassium carbonate (106mg, 0.77mmol) and the 7-hydroxyquinoline (111mg, 0.76mmol) mixture in DMF (7ml) is 5 hours, is cooled to room temperature thereafter.With 1.0N sodium hydrate aqueous solution (40ml) reaction mixture, and stirred for several minute at room temperature.Reactant mixture ethyl acetate extraction four times, water and salt water washing organic extract then.With the dried over mgso organic extract, filter and evaporate to remove and desolvate.Residue and then with the development of ether/isohexane filters and dry, 6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group)-4-(quinoline-7-base oxygen base)-quinazoline (102mg, 39%). 1H NMR spectrum: (DMSOd 6) 1.96 (m, 2H), 2.15 (s, 3H), 2.35 (m, 8H), 2.46 (t, 2H), 3.99 (s, 3H), 4.24 (t, 2H), 7.39 (s, 1H), 7.56 (m, 1H), 7.61 (m, 1H), 7.62 (s, 1H), 7.92 (d, 1H), 8.10 (d, 1H), 8.44 (d, 1H), 8.54 (s, 1H) and 8.92 (m, 1H) MS (ESI): 460 (MH) +Elementary analysis measured value C 67.2 H 6.2 N 15.0C 26H 29N 5O 30.3H 2O value of calculation C 67.2 H 6.4 N 15.1%
Initial substance is prepared as follows:
With triethylamine (4.6ml, 33mmol) and p-toluenesulfonyl chloride (3.2g, 17mmol) handle 1-(3-hydroxypropyl)-4-methyl piperazine (2.4g, 15mmol) dichloromethane (60ml) solution of (as preparation as described in embodiment 133 starting materials), and at room temperature stirring 2 hours.Gained solution is used saturated aqueous solution of sodium bicarbonate and water washing successively, and filter by phase separation paper.Vacuum evaporation filtrate obtains grease 3-(4-methyl-piperazine-1-yl) propyl group-4-tosylate, places crystallization (3.7g, 78%) subsequently.MS(ESI)：313(MH) +。
Stir down, and reflux 2-amino-4-benzyloxy-5-methoxy benzamide (J.Med.Chem.1977, vol 20,146-149,10g, 0.04mol) (7.4g, 0.05mol) the mixture in the Zai diox (100ml) is 24 hours with Gold reagent.In reactant mixture, add sodium acetate (3.02g, 0.037mol) and acetic acid (1.65ml 0.029mol), further heated 3 hours.Evaporating mixture adds entry in residue, leach solids then, and washing is also dry.The acetic acid recrystallization gets 7-benzyloxy-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (8.7g, 84%).
Stir down, reflux 7-benzyloxy-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (2.82g, 0.01mol), the mixture of thionyl chloride (40ml) and DMF (0.28ml) 1 hour.Evaporating mixture, and then, obtain 7-benzyloxy-4-chloro-6-methoxyl group quinazoline hydrochlorate (3.45g) with the toluene azeotropic.
To 7-benzyloxy-4-chloro-6-methoxyl group quinazoline hydrochlorate (506mg, add in pyridine 1.5mmol) (8ml) solution 4-chloro-2-fluoro-phenol (264mg, 1.8mmol), this mixture of reflux 45 minutes.Evaporation removes and to desolvate then, and residue is assigned among ethyl acetate and the water.Organic layer 0.1M HCl, water and salt water washing, dry (magnesium sulfate) and evaporation remove desolvates.Solid residue with the petroleum ether development, filters and collects crude product thereafter, and by purification by flash chromatography, with dichloromethane/ether (9/1) eluting, gets paste solid 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline (474mg, 77%).M.p.179-180 ℃ 1H NMR spectrum: (DMSOd 6) 3.99 (s, 3H); 5.36 (s, 2H); 7.35-7.5 (m, 4H); 7.55-7.65 (m, 5H); 7.72 (d, 1H); 8.6 (s, 1H) MS-ESI:411[MH] +Elementary analysis: measured value C 63.38 H 4.07 N 6.78C 22H 16ClFN 2O 30.06H 2O 0.05CH 2Cl 2Value of calculation C 63.64 H 3.93 N 6.73%
Reflux 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyl group quinazoline (451mg, TFA 1.1mmol) (4.5ml) solution 3 hours.The mixture dilution with toluene, volatile matter is removed in evaporation then.Residue and then with dichloromethane development filters and collects, through ether washing final vacuum drying, 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline (320mg, 90%). 1H NMR spectrum: (DMSOd 6) 4.0 (s, 3H); 7.27 (s, 1H); 7.43 (dd, 1H); 7.56 (t, 1H); 7.57 (s, 1H); (7.72 dd, 1 H); 8.5 (s, 1H) MS-ESI:321[MH] +
90 ℃ of trifluoroacetate (3.2g that stir 4-(4-chloro-2-fluorophenoxy)-7-hydroxyl-6-methoxyl group quinazoline, 7.4mmol), potassium carbonate (6.1g, 44.2mmol) and 3-(4-methyl isophthalic acid-piperazinyl) propyl group-4-tosylate (3.0g, 9.6mmol) mixture in DMF (60ml) 5 hours, be cooled to room temperature thereafter.Reactant mixture is poured in the water (700ml), used ethyl acetate extraction 5 times.The extract water that merges, saturated aqueous solution of sodium bicarbonate, water and saturated brine washing.The dried over mgso ethyl acetate solution filters and solvent removed in vacuo, gained residue and then by silica gel chromatography, with methylene chloride/0.880 ammonia (100/8/1) eluting.Merge relevant fraction, vacuum evaporation obtains a residue.With the development of latter's reuse ether, filter and drying, get 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (1.64g, 48%). 1H NMR spectrum: (DMSOd 6) 1.95 (m, 2H), 2.14 (s, 3H), 2.35 (m, 8H), 2.44 (t, 2H), 3.96 (s, 3H), 4.22 (t, 2H), 7.38 (s, 1H), 7.40 (m, 1H), 7.54 (m, 2H), 7.68 (m, 1H) and 8.55 (s, 1H) MS (ESI): 461 (MH) +Elementary analysis measured value C 59.6 H 5.7 N 12.2C 23H 26ClFN 4O 3Value of calculation C 59.9 H 5.7 N 12.2%
(2.6g, 5.6mmol), 95 ℃ were stirred this mixture 2 hours to handle 4-(4-chloro-2-fluorophenoxy)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline with 2.0N aqueous hydrochloric acid solution (45ml).Cooling mixture adds solid sodium bicarbonate alkalization, then by with the toluene azeotropic removal of water.Residue and then by silica gel chromatography, with methylene chloride/0.880 ammonia (50/8/1) eluting, 6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group)-3,4-dihydroquinazoline-4-ketone (1.8g, 96%).MS(ESI)：333(MH) +。
With 6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group)-3, (2.15g 6.48mmol) is suspended among thionyl chloride (25ml) and the DMF (0.18ml) 4-dihydroquinazoline-4-ketone, and refluxes and stirred 2 hours.The vacuum evaporation thionyl chloride, with residue with twice of toluene azeotropic.And then residue is water-soluble, with sodium bicarbonate aqueous solution alkalization, and with dichloromethane extraction aqueous solution 4 times.The organic extract water and the salt water washing that merge are filtered by phase separation paper then.Vacuum evaporation filtrate, residue with methylene chloride/0.880 ammonia (100/8/1) eluting, obtains a solid by silica gel chromatography.The development of latter's reuse small amount of acetone is filtered and drying, gets 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (1.2g, 5396).This product need not to be further purified and directly uses.MS(ESI)：351(MH) +。Embodiment 177
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline (200mg, 0.64mmol), potassium carbonate (102mg, 0.74mmol) and the 7-hydroxyquinoline (107mg, 0.74mmol) mixture in DMSO (5ml) is 5 hours, is cooled to room temperature thereafter.In mixture impouring water, extract twice with washed with dichloromethane and with 10/1 methylene chloride/methanol mixture.Extract water and salt water washing, dried over mgso is filtered and vacuum evaporation filtrate.Residue and then pass through silica gel chromatography, with methylene chloride/0.880 ammonia (100/8/1) eluting, obtain a grease, and then by developing crystallization with ether, get 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(quinoline-7-base oxygen base)-quinazoline (148mg, 55%). 1H NMR spectrum: (DMSOd 6) 3.25 (s, 3H), 3.50 (t, 2H), 3.60 (t, 2H), 3.80 (t, 2H), 4.00 (s, 3H), 4.30 (t, 2H), 7.40 (s, 1H), 7.55 (m, 1H), 7.60 (m, 1H), 7.65 (s, 1H), 7.90 (d, 1H), 8.10 (d, 1H), 8.40 (m, 1H), 8.50 (s, 1H) and 8.90 (m, 1H) MS (ESI): 422 (MH) +Elementary analysis measured value C 65.8 H 5.2 N 10.0C 23H 23N 3O 5Value of calculation C 65.6 H 5.5 N 10.0%
Initial substance is prepared as follows:
Under 0 ℃ of cooling, to 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (1.2g, 3.9mmol) (as preparation as described in embodiment 12 starting materials), triphenyl phasphine (1.44g, 5.5mmol) and 2-(2-methoxy ethoxy) ethanol (653 μ l, 5.5mmol) dropwise add in the mixture in dichloromethane (70ml) diethylazodicarboxylate (864 μ l, 5.5mmol).Stirring at room gained mixture 1.5 hours, evaporation removes and desolvates then.Residue and then by the column chromatography purification is with ethyl acetate/dichloromethane (50/50, then 80/20) eluting.Gained is purified solid suspension in ether, filter and collect, get 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (1.70g, 100%) behind the vacuum drying. 1H NMR spectrum: (DMSOd 6) 1.13 (s, 9H); 3.26 (s, 3H); 3.5 (m, 2H); 3.65 (m, 2H); 3.85 (m, 2H); 3.91 (s, 3H); 4.3 (m, 2H); 5.9 (s, 2H); 7.2 (s, 1H); 7.5 (s, 1H); 8.4 (s, 1H)
To 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-3-((new pentane acyloxy) methyl)-3, (2.26g 5.5mmol) adds saturated methanol and closes ammonia (20ml) 4-dihydroquinazoline-4-ketone in the solution in ethanol (40ml) and dichloromethane (15ml) mixed liquor.Stirring at room mixture 24 hours further adds methanol and closes ammonia (20ml).Thereafter stirred the mixture under room temperature 24 hours, volatile matter is removed in evaporation then again.Residue is developed with ether, filters and collects, and vacuum drying gets 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-3,4-dihydroquinazoline-4-ketone (975mg, 78%). 1H NMR spectrum: (DMSOd 6) 3.25 (s, 3H); 3.45 (t, 2H); 3.6 (t, 2H); 3.8 (t, 2H); 3.9 (s, 3H); 4.2 (t, 2H); 7.15 (s, 1H); 7.45 (s, 1H); 8.0 (s, 1H) MS-EI:294[M] +
60 ℃ of heating 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-3, (930mg, 3.16mmol) solution in thionyl chloride (15ml) and DMF (150 μ l) is 1.5 hours for 4-dihydroquinazoline-4-ketone.Cooling mixture, and by evaporating and removing volatile matter with methylbenzene azeotropic.Residue is dissolved in dichloromethane, add 5% sodium bicarbonate aqueous solution to the pH of water layer be 8.Tell organic layer, use the salt water washing, dry (magnesium sulfate) and evaporation remove desolvates.Residue and then by purification by flash chromatography, with eluent ethyl acetate, 4-chloro-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline (863mg, 87%). 1H NMR spectrum: (DMSOd 6) 3.24 (s, 3H); 3.47 (m, 2H); 3.62 (m, 2H); 3.84 (t, 2H); 4.01 (s, 3H); 4.25 (t, 2H); 7.41 (s, 1H); 7.49 (s, 1H); 8.88 (s, 1H) embodiment 178
Under 25 ℃, to 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (168mg, 0.5mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (207mg, 1.5mmol), 3-methyl-5-oxyindole (88mg, 0.6mmol) (Can.J.Chem.1964,42,514) and in the mixture of DMA (2.0ml) led to nitrogen 5 minutes.100 ℃ were stirred this mixture 3 hours then, were cooled to room temperature subsequently, filtered and vacuum evaporation filtrate.Residue and then by silica gel chromatography closes ammonia (7M) (90/10) eluting with methylene chloride, 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (155mg, 69%). 1H NMR spectrum: (DMSOd 6) 1.37 (m, 2H), 1.50 (m, 4H), 1.95 (m, 2H), 2.2 1 (s, 3H), 2.34 (m, 4H), 2.42 (t, 2H), 3.96 (s, 3H), 4.22 (t, 2H), 6.95 (dd, 1H), 7.16 (s, 1h), 7.35 (m, 3H), 7.58 (s, 1H), 8.48 (s, 1H) and 10.82 (s, 1H) MS (ESI): 447 (MH) +Elementary analysis measured value C 68.2 H 6.8 N 12.6C 26H 30N 4O 30.5H 2O, value of calculation C 68.5 H 6.8 N 12.3%
Embodiment 179
Adopt embodiment 178 described similar approach, use 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (as preparation as described in embodiment 9 starting materials), obtain 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (154mg, 79%). 1H NMR spectrum: (DMSOd 6) 1.68 (m, 4H), 1.97 (m, 2H), 2.22 (s, 3H), 2.43 (m, 4H), 2.55 (t, 2H), 3.96 (s, 3H), 4.22 (t, 2H), 6.93 (dd, 1H), 7.16 (s, 1H), 7.35 (m, 3H), 7.58 (s, 1H), 8.48 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 433 (MH) +M.p.75-77 ℃ of embodiment 180
Adopt embodiment 178 described similar approach, use 4-chloro-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline, obtain 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(2-piperidino ethyoxyl) quinazoline (156mg, 80%). 1H NMR spectrum: (DMSOd 6) 1.38 (m, 2H), 1.50 (m, 4H), 2.24 (s, 3H), 2.73 (t, 2H), 3.96 (s, 3H), 4.28 (t, 2H), 6.93 (dd, 1H), 7.16 (s, 1H), 7.32 (d, 1H), 7.37 (m, 2H), 7.58 (s, 1H), 8.47 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 433 (MH) +Elementary analysis measured value C 67.0 H 6.5 N 13.0C 25H 28N 4O 30.75H 2O value of calculation C 67.3 H 6.6 N 12.6%
Initial substance is prepared as follows:
To 7-hydroxyl-6-methoxyl group-4-phenoxy group quinazoline (1.0g, 3.73mmol) (as preparation as described in embodiment 1 starting material) and potassium carbonate (2.6g, 18.8mmol) adding 1-(2-chloroethyl) piperidine hydrochlorate (0.83g in DMF (30ml), 4.5mmol), and 110 ℃ of heating blends 2.5 hours are placed cooling thereafter.The filtering insoluble matter, and remove volatile matter in the filtrate by evaporation.Residue and then by the column chromatography purification, with methylene chloride (9/1) eluting, 6-methoxyl group-4-phenoxy group-7-(2-piperidino ethyoxyl) quinazoline (1.2g, 85%). 1H NMR spectrum: (DMSOd 6) 1.38 (m, 2H); 1.50 (m, 4H); 2.4-2.5 (m, 4H); 2.75 (t, 2H); 3.95 (s, 3H); 4.27 (t, 2H); 7.30 (m, 3H); 7.40 (s, 1H); 7.46 (m, 2H); 7.54 (s, 1H); 8.52 (s, 1H) MS-ESI:380[MH] +
(1.15g 3.0mmol) with the mixture of 2M hydrochloric acid (20ml) 2 hours, places cooling thereafter for 90 ℃ of heating 6-methoxyl group-4-phenoxy group-7-(2-piperidino ethyoxyl) quinazolines.Mixture neutralizes with solid sodium bicarbonate, and uses dichloromethane extraction.Tell organic facies, it is removed volatile matter by phase separation paper and evaporation, obtain solid product (230mg).Regulate the pH to 10 of water, filter and collect the precipitate that is produced, washing and dry obtains second batch of product (220mg).Merge product and obtain 6-methoxyl group-7-(2-piperidino ethyoxyl)-3,4-dihydroquinazoline-4-ketone (450mg, 50%).MS-ESI：304[MH] +。
Reflux 6-methoxyl group-7-(2-piperidino ethyoxyl)-3, (440mg 1.45mmol), the mixture of thionyl chloride (15ml) and DMF (3) 3 hours, places cooling to 4-dihydroquinazoline-4-ketone then.The evaporation remove excessive thionyl chloride, and with residue with the toluene azeotropic, thereby obtain 4-chloro-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline hydrochlorate crude product (640mg).
4-chloro-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline hydrochlorate is suspended in dichloromethane (100ml) and the saturated aqueous solution of sodium bicarbonate (5ml), then vigorous stirring 10 minutes at room temperature.Separate each layer, and dry (magnesium sulfate) organic layer, evaporation thereafter obtains a white solid thing.This solid with methanol (2.5ml) development, is leached the gained solid,, obtain 4-chloro-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline (0.36g) after the drying with the cold methanol washing.Embodiment 181
Adopt embodiment 178 described similar approach; use 4-chloro-6-methoxyl group-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (as preparation as described in embodiment 152 starting materials); obtain 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-(N-methyl-N-mesyl amino) propoxyl group) quinazoline (104mg, 49%). 1H NMR spectrum: (DMSOd 6) 2.08 (m, 2H), 2.22 (s, 3H), 2.80 (s, 3H), 2.88 (s, 3H), 3.27 (t, 2H), 3.97 (s, 3H), 4.22 (t, 2H), 6.95 (dd, 1H), 7.17 (s, 1H,), 7.35 (m, 3H), 7.59 (s, 1H), 8.48 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 471 (MH) +Elementary analysis measured value C 57.0 H 5.6 N 11.4C 23H 26FN 4O 5S 0.5H 2O, value of calculation C 57.5 H 5.7 N 11.7% embodiment 182
95 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (218mg, 0.68mmol) (as preparation as described in embodiment 9 starting materials), 5-hydroxyl-1H-pyrrolo-[2,3-b] pyridine (100mg, 0.75mmol) and potassium carbonate (280mg, 2.0mmol) mixture in DMF (4ml) 6 hours, be cooled to room temperature thereafter.With 1.0N sodium hydrate aqueous solution reaction mixture, and stirred for several minute at room temperature.Leach the precipitate that is produced, washing, the air-dry crude product that obtains, and then by the column chromatography purification, with methylene chloride/880 ammonia (100/8/1) eluting.Merge relevant fraction, vacuum evaporation obtains the white solid thing.It is added on the post, use methylene chloride (4/1) solvent elution, the white solid that obtains and then develop with acetone, filter and drying, obtain 6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group)-4-(1H-pyrrolo-[2,3-b] pyridine-5-base oxygen base) quinazoline (50mg, 18%).M.p.184.0-185.5 ℃ 1H NMR spectrum: (DMSOd 6) 1.70 (m, 4H), 1.99 (m, 2H), 2.46 (m, 4H), 2.58 (t, 2H), 4.00 (s, 3H), 4.26 (t, 2H), 6.48 (t, 1H), 7.36 (s, 1H), 7.55 (t, 1H), 7.60 (s, 1H), 7.92 (d, 1H), 8.19 (d, 1H), 8.50 (s, 1H) and 11.78 (brs, 1H) MS (ESI): 420 (MH) +Elementary analysis measured value: C 63.9 H 5.9 N 16.1C 23H 25N 5O 30.7H 2O value of calculation: C 63.9 H 6.2 N 16.2%.
Initial substance is prepared as follows:
In inert atmosphere, stir 5-methoxyl group-1H-pyrrolo-[2,3-b] pyridine (210mg, 1.42mmol) (heterocyclic 50, (2), 1065-1080, (1999)) suspension in dichloromethane (10ml), dropwise add the dichloromethane solution (4.3ml of 1.0M Boron tribromide, 4.3mmol), stirring at room gained mixture overnight.The pH to 6 of Dropwise 5 N sodium hydrate aqueous solution conditioned reaction mixture, further then thin up.With obtained aqueous solution for several times with ethyl acetate extraction, the united extraction thing, water, salt water washing successively, and use dried over mgso.Vacuum is removed ethyl acetate solvent, and residue and then by the column chromatography purification with methylene chloride (95/5) eluting, obtains a white solid thing.This solid is developed with ether, filtered and drying, get 5-hydroxyl-1H-pyrrolo-[2,3-b] pyridine (108mg, 57%).M.p.206-209 ℃ 1H NMR spectrum: (DMSOd 6) 6.25 (s, 1H), 7.27 (s, 1H), 7.33 (s, 1H), 7.82 (s, 1H), 9.00 (s, 1H) and 11.20 (s, 1H) MS (ESI): 135 (MH) +Embodiment 183
Under 25 ℃, to 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (168mg, 0.5mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (345mg, 5.0mmol), (106mg, logical nitrogen is 5 minutes 0.6mmol) and in the mixture of DMA (2.0ml) for 5-hydroxyl-2-indole-carboxylic acid.100 ℃ were stirred this mixture 3 hours then, were cooled to room temperature subsequently, filtered and vacuum evaporation filtrate.Residue and then by octadecylsilane reverse phase silica gel purification, with acetonitrile/water/trifluoroacetic acid (30/69.8/0.2-50/49.8/0.2 gradient liquid) eluting.Product further by silica gel chromatography, closes ammonia (7M) (90/10) eluting with methylene chloride, gets 4-(2-carboxyl indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (85mg, 36%). 1H NMR spectrum: (DMSOd 6) 1.43 (m, 2H), 1.56 (m, 4H), 2.04 (m, 2H), 2.59 (m, 6H), 3.97 (s, 3H), 4.24 (t, 2H), 7.01 (s, 1H), 7.11 (dd, 1H), 7.36 (s, 1H), and 7.4g (m, 2H), 7.58 (s, 1H), 8.48 (s, 1H) and 11.53 (brs, 1H) MS (ESI): 477 (MH) +Embodiment 184
With 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (0.15g; 0.45mmol) (as preparation as described in embodiment 50 starting materials), potassium carbonate (94mg; 0.68mmol) and 7-hydroxyquinoline (79mg; 0.54mmol) be suspended in dry DMF (1.5ml), be heated to 90 ℃ of reactions and spend the night.Add the entry postprecipitation and separate out chemical compound.Filter the collecting precipitation thing, washing and in the presence of phosphorus pentoxide vacuum drying, thereby obtain 6-methoxyl group-7-(3-mesyl propoxyl group)-4-(the basic oxygen base of quinoline-7-) quinazoline (161mg, 81%). 1H NMR spectrum: (DMSOd 6) 2.26 (m, 2H); 3.08 (s, 3H); 3.35 (m, 2H); 4.03 (s, 3H); 4.38 (m, 2H); 7.45 (s, 1H); 7.60 (m, 1H); 7.65 (m, 1H); 7.70 (s, 1H); 7.95 (d, 1H); 8.15 (d, 1H); 8.46 (d, 1H); 8.60 (s, 1H); 8.95 (d, 1H) MS (ESI): 440[MH] +Embodiment 185-188
Adopt embodiment 184 described similar approach, (0.15g, 0.45mmol) (as preparation as described in embodiment 50 starting materials) and suitable phenol reactant generate the chemical compound in the Table X to make 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline.Table X
Figure A0080608502471
A) use 4-chloro-7-hydroxyquinoline (96mg), obtain 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.24 (m, 2H); 3.04 (s, 3H); 3.35 (m, 2H); 3.99 (s, 3H); 4.32 (m, 2H); 7.42 (s, 1H); 7.64 (s, 1H); 7.80 (d, 2H); 8.04 (d, 1H); 8.29 (d, 1H); 8.55 (s, 1H); 8.87 (d, 1H) b) uses 5-hydroxy-2-methyl indole (80mg), obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.24 (m, 2H); 2.40 (s, 3H); 3.05 (s, 3H); 3.35 (m, 2H); 4.0 (s, 3H); 4.32 (m, 2H); 6.13 (s, 1H); 6.88 (d, 1H); 7.25 (d, 1H); 7.32 (d, 1H); 7.39 (s, 1H); 7.60 (s, 1H); 8.50 (s, 1H) c) uses 5-hydroxy-2-methyl benzothiazole (90mg), obtains 6-methoxyl group-4-(2-methyl isophthalic acid, 3-benzothiazole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.24 (m, 2H); 2.28 (s, 3H); 3.05 (s, 3H); 3.35 (m, 2H); 4.0 (s, 3H); 4.32 (m, 2H); 7.36 (d, 1H); 7.41 (s, 1H); 7.65 (s, 1H); 7.87 (d, 1H); 8.11 (d, 1H); 8.53 (s, 1H) d) uses 2,7-dihydroxy naphthlene (87mg) obtains 4-(7-hydroxyl-2-naphthoxy)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.24 (m, 2H); 3.05 (s, 3H); 3.35 (m, 2H); 3.98 (s, 3H); 4.32 (m, 2H); 7.06 (d, 1H); 7.12 (s, 1H); 7.18 (d, 1H); 7.40 (d, 1H); 7.59 (m, 2H); 7.85 (m, 2H); 8.55 (d, 1H); 9.8 (brs, 1H) embodiment 189
Under room temperature, the nitrogen atmosphere, to 2-chloro-5-hydroxy benzo imidazoles (191mg, 0.75mmol) in the part of DMF (3ml), add sodium hydride (60mg, 1.5mmol).Add 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-yl) methoxyl group quinazoline (200mg, 0.62mmol) (as preparation as described in embodiment 10 starting materials), 100 ℃ of these mixture of heating 2 hours after 10 minutes.Find not complete reaction thus add again 2-chloro-5-hydroxy benzo imidazoles (30mg, 0.12mmol) and sodium hydride (11mg, 0.28mmol).Continue heating 1 hour.Use ethyl acetate and ammonium chloride saturated aqueous solution post processing, then dry (magnesium sulfate) organic facies, evaporating solvent obtains crude product.Utilize methylene chloride that the latter is adsorbed on the aluminium oxide, and then, use methylene chloride (98: 2) as eluant by the neutral alumina purification by flash chromatography.Evaporating solvent and with ether development, thus 4-(2-chloro-1H-benzimidazole-6-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (46mg, 16%) obtained. 1H NMR spectrum: (DMSOd 6+ TFA) 1.60 (m, 2H); 2.05 (d, 2H); 2.15 (m, 1H); 2.80 (s, 3H); 3.05 (m, 2H); 3.55 (m, 2H); 4.05 (s, 3H); 4.15 (d, 2H); 7.20 (dd, 1H); 7.50 (dd, 2H); 7.65 (d, 1H); 7.70 (s, 1H); 8.80 (s, 1H) MS (ESI): 454[MH] +
Initial substance is prepared as follows:
Under the argon atmospher, with 2-chloro-5-methoxyl group benzo imidazoles (0.3g 1.64mmol) is suspended in dichloromethane (20ml), then add Boron tribromide (233 μ l, 2.46mmol).Stirring at room reactant mixture 2 hours.Evaporating solvent, and the gained powder is added in the methanol (30ml) in batches.Add silica gel, and evaporating solvent.Then the gained powder is placed the silicagel column top, use methylene chloride (95/5) eluted product.Evaporating solvent and with ether development, thus 2-chloro-5-hydroxy benzo imidazoles (440mg, 99%) obtained.Embodiment 190
Adopt embodiment 189 described similar approach, make 4-chloro-6-methoxyl group-7-(1-methyl piperidine-1-yl) methoxyl group quinazoline (as preparation as described in embodiment 10 starting materials) and 5-hydroxy-2-methyl benzimidazole (200mg, 0.62mmol) reaction, pass through 10g silica gel ISOLUTE column purification after the post processing, use dichloromethane successively, methylene chloride (95/5) and the saturated methanol of dichloromethane/ammonia (95/5) eluting, get 6-methoxyl group-4-(2-methyl isophthalic acid H-benzimidazole-6-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (68mg, 25%). 1H NMR spectrum: (DMSOd 6+ TFA) 1.60 (m, 2H); 2.10 (m, 2H); 2.20 (m, 1H); 2.80 (s, 3H); 2.85 (s, 3H); 3.05 (m, 2H); 3.50 (m, 2H); 4.05 (s, 3H); 4.15 (d, 2H); 7.50 (s, 1H); 7.55 (d, 1H); 7.70 (s, 1H); 7.85 (d, 1H); 7.90 (d, 1H); 8.65 (s, 1H) MS (ESI): 434[MH] +
Initial substance is prepared as follows:
4-methoxyl group-1, the free alkali of 2-phenylenediamine dihydrochloride (10g) obtains by its mixture with ethyl acetate and saturated aqueous solution of sodium bicarbonate is shaken.Organic facies is used salt water washing, drying (magnesium sulfate) and evaporating solvent then.With the dark grease of gained (6.08g 50mmol) is dissolved in toluene (60ml), sequentially add right-toluenesulfonic acid (60mg) and triethly orthoacetate (9.15ml, 50mmol).Heating blends to 110 ℃ is till no ethanol distillates.Rotary evaporation is removed residual toluene, and residue and then by purification by flash chromatography uses methylene chloride (95/5) as eluant.The dark grease of gained is developed with ether, and the solid collected by filtration thing gets 5-methoxyl group-2-tolimidazole (4.15g, 51%). 1H NMR composes (DMSOd 6+ TFA) 2.75 (s, 3H); 3.g5 (s, 3H); 7.15 (dd, 1H); 7.25 (s, 1H); 7.70 (d, 1H)
Synthetic 2-described similar method of chloro-5-hydroxy benzo imidazoles among employing and the embodiment 189, make 5-methoxyl group-2-tolimidazole (4.0g, 25mmol) with Boron tribromide (7ml, 74mmol) reaction in dichloromethane (150ml), through post processing and flash chromatography (using methylene chloride 90/10) afterwards, obtain 5-hydroxy-2-methyl benzimidazole (4.4g, 76%). 1H NMR composes (DMSOd 6) 2.70 (s, 3H); 6.95 (dd, 1H); 7.00 (d, 1H); 7.55 (d, 1H) embodiment 191
Under the argon atmospher, with 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (200mg, 0.62mmol) (as preparation as described in embodiment 10 starting materials) be suspended in DMF (3ml).Add 3-cyano group-7-hydroxyquinoline (116mg, 0.68mmol) and potassium carbonate (129mg, 0.93mmol), 95 ℃ of reacting by heating mixture 90 minutes.After being cooled to room temperature, the diluted mixture that adds methylene chloride thing, and pour ISOLUTE silicagel column top into.Dichloromethane, methylene chloride (95/5) and the saturated methanol of dichloromethane/ammonia (95/5) eluting use in order.Evaporating solvent, solids is developed with ether, thereby obtains 4-(3-cyano quinolines-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (244mg, 86%). 1H NMR spectrum: (DMSOd 6+ TFA) 1.60 (m, 2H); 2.10 (m, 3H); 2.85 (s, 3H); 3.05 (m, 2H); 3.55 (m, 2H); 4.05 (s, 3H); 4.20 (d, 2H); 7.55 (s, 1H); 7.80 (s, 1H); 7.85 (dd, 1H); 8.15 (s, 1H); 8.3 (d, 1H); 8.85 (s, 1H); 9.20 (s, 1H); 9.25 (s, 1H) MS (ESI): 456[MH] +456
Initial substance is prepared as follows:
Between 60 ℃ of heating-(50g is 407mmol) with ethoxy methylene diethyl malonate (102g, 407mmol) 20 minutes for aminoanisole.Add diphenyl ether (270ml) then, be warming up to 240 ℃ in 30 minutes.Distillate the ethanol that is produced.Continue heating 1 hour under this temperature, reaction mixture to 120 ℃ adds the heptane diluted reaction mixture this moment then, at room temperature places subsequently and spends the night.Filter and collect the brown solid thing, after methanol and ether washing, obtain 7-methoxyl group 4-oxo-1,4-dihydroquinoline-3-carboxylic acid, ethyl ester (45g, 45%).Repeat twice of this reaction. 1H NMR spectrum: (DMSOd 6) 1.25 (t, 3H); 3.85 (s, 3H); 4.20 (q, 2H); 6.95 (d, 1H); 7.00 (s, 1H); 8.05 (d, 1H); 8.50 (s, 1H)
To 7-methoxyl group-4-oxo-1, (58g adds phosphoryl chloride phosphorus oxychloride (88ml) in 235mmol) to 4-dihydroquinoline-3-carboxylic acid, ethyl ester, then reflux mixture 45 minutes under anhydrous condition.To be cooled to room temperature, the evaporation phosphoryl chloride phosphorus oxychloride, and solid residue is added in batches in the mixture of ammonia (150ml) and ice (200g).This hydrolysing step needs external refrigeration, and needs the further ammonia that adds to be approximately 8 to keep pH.The water dichloromethane extraction, water and salt water washing organic facies thereafter, dry (magnesium sulfate) and be concentrated into about 300ml.Add pentane (400ml), filter and collect the precipitate that is produced.Obtain 4-chloro-3-ethoxy carbonyl-7-methoxy quinoline (45.5g, 73%) behind the vacuum drying. 1H NMR spectrum: (DMSOd 6) 1.40 (t, 3H); 4.00 (s, 3H); 4.45 (q, 2H); 7.45 (dd, 1H); 7.55 (d, 1H); 8.30 (d, 1H); 9.10 (s, 1H)
(43g 162mmol) is dissolved in acetic acid (250ml), utilizes 10% palladium-carbon (1.5g), and hydrogenation is 8 hours under atmospheric pressure with 4-chloro-3-ethoxy carbonyl-7-methoxy quinoline.Pass through the Celite pad filtration catalizer then, and evaporating solvent.The residue thin up is adjusted to pH7-8 with saturated aqueous solution of sodium bicarbonate.The solid collected by filtration thing, washing, vacuum drying in the presence of phosphorus pentoxide gets cream-coloured powder 3-ethoxy carbonyl-7-methoxy quinoline (33mg, 88%) then. 1H NMR spectrum: (DMSOd 6) 1.40 (t, 3H); 3.95 (s, 3H); 4.40 (q, 2H); 7.35 (dd, 1H); 7.50 (d, 1H); 8.15 (d, 1H); 8.90 (d, 1H); 9.25 (d, 1H)
Adding 3-ethoxy carbonyl-7-methoxy quinoline in the saturated methanol solution of ammonia (28g, 120mmol).These 2 weeks of suspension of stirring at room in the glass pressure container.Filter and collect the white solid thing,, get 3-carbamoyl-7-methoxy quinoline (21g, 86%) with methanol wash and vacuum drying. 1H NMR composes (DMSOd 6) 3.95 (s, 3H); 7.35 (dd, 1H); 7.45 (d, 1H); 7.60 (brs, 1H); 8.00 (d, 1H); 8.20 (brs, 1H); 8.75 (s, 1H); 9.25 (s, 1H)
Under the argon atmospher, (4g 20mmol) is suspended in anhydrous methylene chloride (60ml) with 3-carbamoyl-7-methoxy quinoline.(2.25ml, 32mmol), cooling mixture dropwise added oxalyl chloride (2.08ml, dichloromethane 24mmol) (20ml) solution then to-78 ℃ in 1 hour to add anhydrous dimethyl sulfoxide.Finished back 15 minutes, (8.3ml 60mmol), and continue to stir these heterogeneous reaction mixture 1 hour at-78 ℃, was warming up to room temperature then dropwise to add triethylamine again.Remove by filter unreacting material, dilute with water filtrate, and then reuse ethyl acetate extraction.Merge organic facies, salt water washing, dry (magnesium sulfate) and evaporating solvent.Residue and then by purification by flash chromatography uses methylene chloride (97/3) eluting.The gained solids obtains 3-cyano group-7-methoxy quinoline (1.47g, 40%) with development behind vacuum drying. 1H NMR composes (DMSOd 6) 4.00 (t, 3H); 7.40 (dd, 1H); 7.50 (d, 1H); 8.00 (d, 1H); 8.95 (s, 1H); 9.10 (d, 1H)
With 3-cyano group-7-methoxy quinoline (380mg 2.1mmol) is suspended in benzene (10ml), add aluminum chloride (826mg, 6.2mmol), reflux gained mixture 30 minutes.(275mg 2.1mol), further stirred the gained mixture 2 hours to add aluminum chloride again.Evaporating solvent is added to gained bottle green solid in the ice, uses ethyl acetate extraction.Salt water washing organic facies, dry (magnesium sulfate) and evaporation.Find still to contain some aluminum salt in the gained solid, press then and describedly remove them.Solids is dissolved in dichloromethane (200ml), with saturated solution of sodium bicarbonate vigorous stirring 1 hour together.Filter water and collect product, vacuum drying in the presence of phosphorus pentoxide gets 3-cyano group-7-cyano quinolines (238mg, 6896) then. 1H NMR composes (DMSOd 6) 7.25 (d, 1H); 7.30 (d, 1H); 7.95 (d, 1H); 8.85 (d, 1H); 9.00 (d, 1H) embodiment 192
(110mg adds TFA (0.3ml) in (3ml) solution 0.2mmol), stirring at room mixture 1 hour to quinazoline to 6-methoxyl group-7-(3-morpholino propoxyl group)-4-((1-tertbutyloxycarbonyl-1,2,3,4-tetrahydroquinoline-6-yl) oxygen base).Evaporating solvent, residue grease dilutes with dichloromethane, regulates pH to 9 with saturated solution of sodium bicarbonate then.Organic facies water, salt water washing, dry (magnesium sulfate) filters and evaporating solvent, gets 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(1,2,3,4-tetrahydroquinoline-6-base oxygen base) quinazoline (84mg, 93%). 1H NMR spectrum: (CDCl 3) 1.95 (m, 2H); 2.15 (m, 2H); 2.45 (m, 4H); 2.60 (t, 2H); 2.80 (t, 2H); 3.35 (t, 2H); 3.75 (m, 4H); 3.90 (brs, 1H); 4.05 (s, 3H); 4.30 (t, 2H); 6.55 (d, 1H); 6.85 (m, 2H); 7.30 (s, 1H); 7.55 (s, 1H); 8.65 (s, 1H) MS (ESI): 451[MH] +Elementary analysis: measured value C 66.4 H 6.9 N 12.4C 2H 1N 1O 11HCl, 2H 2O value of calculation C 66.7 H 6.7 N 12.4%.
Initial substance is prepared as follows:
(1g 6.9mmol) is dissolved in methanol, utilizes (276mg) hydrogenation 24 hours of platinum oxide (IV) under 3 atmospheric pressures with the 6-hydroxyquinoline.Catalyst removes by filter by Celite pad, and evaporating solvent.The residual solids thing washs with ether, gets 6-hydroxyl-(1,2,3,4)-tetrahydroquinoline (698mg, 68%). 1H NMR spectrum: (DMSOd 6) 1.75 (m, 2H); 2.60 (m, 2H); 3.05 (m, 2H); 4.90 (brs, 1H); 6.30 (m, 3H); 8.25 (brs, 1H)
Under the argon atmospher, (250mg 1.7mmol) is suspended in acetone (1ml) and the chloroform (1ml) with 6-hydroxyl-(1,2,3,4)-tetrahydroquinoline.(365mg, acetone soln 1.7mmol) then add THF (2ml) and separate with hydrotropy dropwise to add the tertbutyloxycarbonyl anhydride.The stirring at room reactant mixture spends the night, and evaporating solvent is assigned to residue among ethyl acetate and the water, and water, saline wash organic facies in succession then, and dry (magnesium sulfate) filters and evaporating solvent.Gained natural gum thing and then by purification by flash chromatography uses methylene chloride (97/3) eluting.Evaporating solvent obtains brown foams 6-hydroxyl-4-(1-tertbutyloxycarbonyl-1,2,3,4-tetrahydroquinoline (344mg, 82%). 1H NMR spectrum: (DMSOd 6) 1.50 (m, 9H); 1.90 (m, 2H); 2.70 (t, 2H); 3.65 (t, 2H); 4.75 (brs, 1H); 6.55 (d, 1H); 6.65 (dd, 1H); 7.45 (d, 1H)
Under the argon atmospher, at potassium carbonate (61mg, 0.44mmol) and 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (100mg, 0.3mmol) (as preparation as described in embodiment 1 starting material) exist down, with 6-hydroxyl 4-(1-tertbutyloxycarbonyl-1,2,3, (82mg 0.32mmol) is dissolved in anhydrous dimethyl formamide to the 4-tetrahydroquinoline.60 ℃ of heating did not react after 2 hours.(12mg, 0.3mmol), 120 ℃ of reacting by heating mixture are 90 minutes then to add sodium hydride.In cooling mixture impouring water and ethyl acetate.Organic facies water, salt water washing, dry (magnesium sulfate), filtration and evaporating solvent.Residue and then by purification by flash chromatography uses methylene chloride (97/3) as solvent earlier.Evaporating solvent obtains white solid 6-methoxyl group-7-(3-morpholino propoxyl group)-4-((1-tertbutyloxycarbonyl-1,2,3,4-tetrahydroquinoline-6-yl) oxygen base) quinazoline (115mg, 71%). 1H NMR spectrum: (DMSOd 6) 1.55 (s, 9H); 1.95 (m, 2H); 2.15 (m, 2H); 2.50 (m, 4H); 2.60 (t, 2H); 2.85 (t, 2H); 2.75 (m, 6H); 4.05 (s, 3H); 4.30 (t, 2H); 7.00 (m, 2H); 7.35 (s, 1H); 7.55 (s, 1H); 7.80 (d, 1H); 8.65 (s, 1H) embodiment 193
Adopt embodiment 192 described similar approach, make 4-(1-tertbutyloxycarbonyl-2,3-dihydro-indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (169mg, 0.32mmol) react with TFA (1ml), after post processing and purification, obtain 4-(2,3-dihydro-1H-indole-5-yl) oxygen base-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (124mg, 91%). 1H NMR spectrum: (CDCl 3) 1.90 (br, 4H); 2.30 (br, 2H); 2.70 (br d, 6H); 3.10 (t, 2H); 3.65 (t, 2H); 4.05 (s, 3H); 4.30 (t, 2H); 6.70 (d, 1H); 6.80 (dd, 1H); 7.00 (s, 1H); 7.30 (s, 1H); 7.55 (s, 1H); 8.65 (s, 1H) MS (ESI): 421[MH] +
Initial substance is prepared as follows:
In argon atmosphere, (2g 15mmol) is dissolved in methanol (60ml) with the 5-oxyindole.Add sodium cyanoborohydride (1.89g, 30mmol) and boron trifluoride etherate (4.2ml, 33mmol), this mixture of reflux 3 hours, cool to room temperature then.Evaporating solvent is assigned to residue between ethyl acetate and the water.Add ammonia and regulate pH to 10, use more amount ethyl acetate extraction water thereafter.The organic facies water, the salt water washing that merge, dry (magnesium sulfate), filtration and evaporating solvent.Residue and then by purification by flash chromatography uses methylene chloride (95/5) as solvent.Evaporating solvent obtains pale solid 5-hydroxyl-2,3-dihydro-1H-indole (1.45g, 73%). 1H NMR spectrum: (DMSOd 6+ TFA) 3.15 (t, 2H); 3.70 (t, 2H); 6.75 (dd, 1H); 6.85 (d, 1H); 7.30 (d, 1H)
With 5-hydroxyl-2, (1.5g 11.1mmol) is suspended in the mixture of acetone (7ml), chloroform (7ml) and THF (6ml) 3-dihydro-1H-indole.Dropwise add tertbutyloxycarbonyl anhydride (2.42g, THF 11mmol) (7ml) solution.The stirring at room reactant mixture spends the night, and evaporating solvent is assigned to residue between ethyl acetate and the water, and water, saline wash organic facies in succession then, dry (magnesium sulfate), filtration and evaporating solvent.Residual solids and then by purification by flash chromatography uses methylene chloride (95/5) as solvent.Evaporating solvent obtains pale solid 5-hydroxyl-(1-tertbutyloxycarbonyl)-2,3-indoline (2.28g, 87%). 1H NMR spectrum: (CDCl 3) 3.05 (t, 2H); 3.95 (brs, 2H); 4.70 (brs, 1H); 6.60 (d, 1H); 6.65 (s, 1H); 7.70 (brs, 1H)
Under the argon atmospher, (22mg 0.56mmol) is suspended in anhydrous dimethyl formamide with sodium hydride.Add 5-hydroxyl-(1-tertbutyloxycarbonyl)-2,3-indoline (131mg, 0.56mmol), then add 4-chloro-6-methyl-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (150mg, 0.47mmol) (as preparation as described in embodiment 9 starting materials) after 10 minutes.110 ℃ of reacting by heating mixture 3 hours, then cool to room temperature and be assigned to ethyl acetate and water among.Organic facies water, salt water washing, dry (magnesium sulfate), filtration and evaporating solvent.Residue and then by purification by flash chromatography uses and is initiated with methylene chloride (90/10), finally is the polarity increase solvent mixture eluting of the saturated methanol of methylene chloride/ammonia (80/15/5).Evaporating solvent obtains white solid 4-(1-tertbutyloxycarbonyl-2,3-dihydro-indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (178mg, 73%). 1H NMR spectrum: (DMSOd 6) 1.60 (s, 9H); 1.80 (m, 4H); 2.20 (m, 2H); 2.55 (m, 4H); 2.70 (t, 2H); 3.15 (t, 2H); 4.05 (brs, 5H); 4.30 (t, 2H); 7.00 (d, 1H); 7.05 (s, 1H); 7.30 (s, 1H); 7.55 (s, 1H); 7.90 (brs, 1H); 8.60 (s, 1H) embodiment 194
Adopt embodiment 192 described similar approach, make 4-(1-tertbutyloxycarbonyl-2,3-dihydro-indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (191mg, 0.37mmol) react with TFA (1ml), after post processing and purification, obtain 4-(2,3-dihydro-1H-indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (103mg, 67%). 1H NMR spectrum: (CDCl 3) 1.65 (m, 2H); 2.00 (m, 3H); 2.25 (m, 2H); 2.45 (s, 3H); 3.10 (m, 4H); 3.65 (t, 2H); 4.05 (s, 3H); 4.10 (d, 2H); 6.70 (d, 1H); 6.85 (dd, 1H); 7.0 (s, 1H); 7.25 (s, 1H); 7.55 (s, 1H); 8.60 (s, 1H) MS (ESI): 421[MH] +
Initial substance is prepared as follows:
Adopt embodiment 193 described similar approach, make 4-chloro-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (150mg, 0.47mmol) (as preparation as described in embodiment 10 starting materials) and 5-hydroxyl-(1-tertbutyloxycarbonyl)-2,3-indoline (132mg, 0.56mmol) (as preparation as described in embodiment 193 starting materials) reaction, after post processing and purification, obtain white solid 4-(1-tertbutyloxycarbonyl-2,3-indoline-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (197mg, 81%). 1H NMR spectrum: (CDCl 3) 1.50 (brs, 11H); 2.00 (m, 5H); 2.30 (s, 3H); 2.90 (d, 2H); 3.15 (t, 2H); 4.05 (brs, 7H); 7.05 (brs, 2H); 7.30 (s, 1H); 7.55 (s, 1H); 7.95 (brs, 1H); 8.60 (s, 1H) embodiment 195
To 4-chloro-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline (250mg, 0.78mmol) add Anhydrous potassium carbonate (320mg in DMF (10ml) suspension of (as preparation as described in embodiment 180 starting materials), 2.30mmol) and 7-hydroxyquinoline (135mg, 0.94mmol), 90 ℃ of heating reflux reaction things 1 hour.Cool off reactant then to room temperature, add the 1N sodium hydrate aqueous solution.Filter the precipitate that is produced, water and washing with acetone, suction dried obtains white solid 6-methoxyl group-7-(2-piperidino ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline (248mg, 0.58mmol, 75%). 1H NMR spectrum: d H(300MHz, CDCl 3): 1.5 (2H, m; NCH 2CH 2CH 2), 1.6 (4H, m; 2 * NCH 2CH 2), 2.6 (4H, t; 2 * NCH 2); 2.9 (2H, t; NCH 2), 4.1 (3H, s; OCH 3), 4.3 (2H, t; OCH 2), 7.3 (1H, s; ArH), 7.4 (1H, dd; ArH), 7.5 (1H, dd; ArH), 7.6 (1H, s; ArH), 7.9 (1H, d; ArH), 8.0 (1H, d; ArH), 8.2 (1H, d; ArH), 8.6 (1H, s; ArH) and 8.9 (1H, dd; ArH) m/z (ESP+) 431 (MH +, 100%) and embodiment 196
To 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (1.82g, 6.1mmol) add potassium carbonate (2.50g in DMF (50ml) suspension of (as preparation as described in embodiment 1 starting material), 18.1mmol) and the 7-hydroxyquinoline (1.06g, 7.3mmol), 90 ℃ of heating reflux reaction things 4 hours.With in the reactant impouring 1N sodium hydrate aqueous solution, filter the precipitate that is produced then, washing, and suction dried.Further in vacuum drying oven, obtain Off-white solid 7-benzyloxy-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline (1.50g, 3.7mmol, 60%) after the drying. 1H NMR spectrum: d H(300MHz, DMSO-d 6): 4.0 (3H, s; OCH 3), 5.4 (2H, s; OCH 2), 7.3-7.7 (9H, m; 9 * ArH), 7.9 (1H, brs; ArH), 8.1 (1H, d; ArH), 8.4 (1H, d; ArH), 8.5 (1H, s; ArH) and 8.9 (1H, d; ArH) implement 197
(1.50g, 3.70mmol) trifluoroacetic acid (50ml) solution of (as preparation as described in the embodiment 196) is 150 minutes for reflux 7-benzyloxy-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline.The vacuum concentration reactant is used ammonium hydroxide saturated aqueous solution neutralization reactant then.Filter the precipitate that is produced, suction dried behind washing with acetone, thus obtain white solid 7-hydroxyl-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline (0.90g, 2.82mmol, 76%). 1H NMR spectrum: d H(300MHz, DMSO-d 6): 4.0 (3H, s; OCH 3), 7.1 (1H, s; ArH), 7.3-7.4 (3H, m; 3 * ArH), 7.9 (1H, brs; ArH), 8.1 (1H, d; ArH), 8.4-8.5 (2H, d; 2 * ArH) and 8.9 (1H, d; ArH) m/z (ESP+) 320 (MH +, 100%) and embodiment 198
To 7-hydroxyl-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline (450mg, 1.40mmol) add Anhydrous potassium carbonate (773mg in DMF (50ml) suspension of (as preparation as described in the embodiment 197), 5.60mmol) and 4-(2-hydroxyethyl) morpholine (335mg, 1.80mmol), heating reflux reaction thing 2 hours.Vacuum evaporation DMF, and residue is assigned between dichloromethane and the 1N sodium hydrate aqueous solution.(3 * 200ml) extract mixture, dry (magnesium sulfate) and vacuum concentration with dichloromethane.Crude product filters gained solid and suction dried with hexane/ether development, thereby obtains bright brown solid 6-methoxyl group-7-(2-morpholino ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline (430mg, 1.00mmol, 71%). 1H NMR spectrum: d H(300MHz, CDCl 3): 2.7 (4H, t; 2 * NCH 2); 3.0 (2H, t; NCH 2), 3.7 (4H, t; 2 * OCH 2), 4.1 (3H, s; OCH 3), 4.4 (2H, t; OCH 2), 7.2 (1H, s; ArH), 7.4 (1H, dd; ArH), 7.5 (1H, dd; ArH), 7.6 (1H, s; ArH), 7.9 (1H, d; ArH), 8.0 (1H, brs; ArH), 8.2 (1H, d; ArH), 8.6 (1H, s; ArH) and 8.9 (1H, dd; ArH) m/z (ESP+) 433 (MH +, 100%) and elementary analysis measured value C 65.0 H 5.6 N 12.6C 24H 24N 4O 40.5H 2O value of calculation C 65.3 H 5.7 N 12.7% embodiment 199
To 7-hydroxyl-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline (100mg, 0.31mmol) (as preparation as described in the embodiment 197) and (S)-(+)-5-(methylol)-2-Pyrrolidone (101mg, 0.47mmol) add triphenyl phasphine (244mg in the solution in dichloromethane (10ml), 0.93mmol) and DEAD (0.15ml, 162mg, 0.93mmol), the stirring at room reactant spends the night.Reactant mixture is directly poured in the 2g SCX ion exchange column, with dichloromethane, methylene chloride (4/1), methylene chloride/ammonium hydroxide (20/5/1) sequentially eluting.The suitable fraction of vacuum concentration, and residue developed with ether, filter the solids that is produced, obtain yellow solid (5S)-6-methoxyl group-7-(5-oxo-pyrrolidine-2-ylmethoxy)-4-(quinoline-7-base oxygen base) quinazoline (55mg after the suction dried, 0.13mmol, 43%). 1H NMR spectrum: d H(300MHz, CDCl 3): 2.3-2.5 (4H, m; 2x ketopyrrolidine-CH 2), 4.0-4.1 (4H, m; Ketopyrrolidine CH; OCH 3), 4.2-4.3 (2H, m; OCH 2), 6.1 (1H, brs; NH), 7.3 (1H, s; ArH), 7.4 (1H, dd; ArH), 7.5 (1H, dd; ArH), 7.9 (1H, d; ArH), 8.0 (1H, brs; ArH), 8.2 (1H, d; ArH), 8.6 (1H, s; ArH) and 8.9 (1H, dd; ArH) m/z (ESP+) 417 (MH +, 100%) and embodiment 200
To 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (100mg, 0.31mmol) order adds potassium carbonate (124mg in DMF (10ml) solution of (as preparation as described in embodiment 9 starting materials), 0.9mmol, 3eq.) and 2-hydroxycarbazole (66mg, 0.36mmol, 1.2eq.), 100 ℃ of reacting by heating things 4 hours.Vacuum is removed DMF, and residue is dissolved in dichloromethane, places on the 2g SCX ion exchange column.Use dichloromethane, 20% ethanol/methylene, 20% ethanol/methylene+3% ammonium hydroxide eluting successively, obtain the brown solid crude product.Further use silica gel bonded elution chromatography purification, use dichloromethane-15% ethanol/methylene+1% ammonium hydroxide eluting, then develop with ether, obtain white solid 4-(9H-carbazole-2-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (31mg, 22%). 1H NMR spectrum: d H(300MHz, DMSO-d 6) 1.7 (4H, m; 2x pyrrolidine-CH 2), 2.0 (2H, t; OCH 2CH 2), 2.5 (4H, m; 2x pyrrolidine-NCH 2) 2.6 (2H, t; NCH 2), 4.0 (3H, s; OCH 3), 4.2 (2H, t; OCH 2), 7.1 (1H, br d; ArH), 7.2 (1H, t; ArH), 7.3-7.4 (3H, m; 3 * ArH), 7.5 (1H, brd; ArH), 7.6 (1H, s; ArH), 8.1-8.2 (2H, m; 2 * ArH), 8.5 (1H, s; ArH), 11.3 (1H, s; Carbazole NH) m/z (ESP+) 469 (MH +, 100%) and embodiment 201
Under 4 ℃ of coolings, to 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg, 0.32mmol), ((N-(3 for 2-, 6-dichloro-pyridazine-4-yl)-and the N-methyl) amino) ethanol (107mg, 0.48mmol) (as preparation as described in embodiment 142 starting materials), triphenyl phasphine (168mg, 0.64mmol) adding diethylazodicarboxylate (101 μ l, dichloromethane 0.64mmol) (0.4ml) solution in the solution among dichloromethane (1ml) and the DMF (0.5ml).4 ℃ stirred the mixture 12 hours, then stirred overnight at room temperature.Filtering precipitate, with ether washing, vacuum drying then, thus obtain 7-(2-((N-(3,6-dichloro-pyridazine-4-yl)-N-methyl) amino) ethyoxyl)-4-(indole-5-base is amino)-6-methoxyl group quinazoline (72mg, 44%).MS-ESI:510-512[MH] + 1H NMR spectrum: (DMSOd 6) 3.12 (s, 3H); 3.85 (s, 3H); (4.1 t, 2H)); 4.45 (t, 2H); 6.45 (s, 1H); 7.2 (s, 1H); 7.3 (s, 1H); 7.35 (m, 2H); 7.42 (d, 1H); 7.8 (s, 1H); 7.85 (s, 1H); 8.35 (s, 1H); 9.45 (s, 1H)
Initial substance is prepared as follows:
To contain 5N hydrogen chloride/isopropyl alcohol liquid (260 μ l, 1.6mmol) 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (5g, 16.6mmol) (as preparation as described in embodiment 1 starting material), (2.4g, 18.2mmol) solution in isopropyl alcohol (60ml) refluxed 90 minutes the 5-amino indole.The cooling final vacuum is removed volatile matter.Residual solids is developed with isopropyl alcohol, filters, and then washs in proper order with isopropyl alcohol and ether, and vacuum drying obtains 7-benzyloxy-4-(indole-5-base is amino)-6-methoxyl group quinazoline hydrochlorate (6.9g, 96%). 1H NMR spectrum: (DMSOd 6) 4.05 (s, 3H); 5.35 (s, 2H); 6.5 (s, 1H); 7.3 (d, 1H); 7.4-7.65 (m, 9H); 7.8 (s, 1H); 8.3 (s, 1H); 8.7 (s, 1H)
Stirring at room contain ammonium formate (22gr, 347mmol) and the 7-benzyloxy-4-of 10% palladium-carbon (1g) (indole-5-base is amino)-(10g, 23.1mmol) solution in methanol (300ml) and DMF (100ml) spends the night 6-methoxyl group quinazoline hydrochlorate.By the diatomite filtration reaction solution, with DMF, methanol wash successively, evaporated filtrate.And then residue is dissolved in 2mM ammonia (300ml), stirred 15 minutes.Filter solids, water, ethyl acetate are washed with ether successively, 50 ℃ of vacuum dryings 2 days.Residual solids column chromatography purification is with ethanol/methylene (1/9) eluting.Vacuum is removed volatile matter, and solids placed 70 ℃ of dryings of vacuum 2 days, obtains 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (6.8g, 97%).MS-ESI:307[MH]+ 1H NMR spectrum: (DMSOd 6) 3.98 (s, 3H); 6.42 (s, 1H); 7.0 (s, 1H); 7.3-7.45 (m, 3H); 7.85 (s, 2H); 8.28 (s, 1H); 9.35 (s, 1H); 10.25 (brs, 1H); 11.05 (s, 1H) embodiment 202-204
Adopt embodiment 201 described similar approach, use the chemical compound described in the synthetic Table X I of 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (as preparation as described in embodiment 201 starting materials).Table X I
The embodiment sequence number Weight (mg) Productive rate % MS-ESI [MH] + Note ????R
A) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline and reaction of 2-(N-methyl-N-(4-pyridine radicals) amino) ethanol (73mg) (EP 0359389) generates 4-(indole-5-base is amino)-6-methoxyl group-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 3.08 (s, 3H); 3.9 (t, 2H); 3.95 (s, 3H); 4.35 (t, 2H); 6.45 (s, 1H); 6.75 (d, 2H); 7.15 (s, 1H); 7.35 (m, 2H); 7.4 (d, 1H); 7.85 (s, 1H); 7.9 (s, 1H); 8.15 (d, 2H); 8.38 (s, 1H); 9.45 (s, 1H) b) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline and 3-hydroxymethylpyridine (53mg) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-((3-pyridine radicals) methoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 4.0 (s, 3H); 5.35 (s, 2H); 6.42 (s, 1H); 7.3-7.55 (m, 5H); 7.8-8.0 (m, 3H); 8.4 (s, 1H); 8.6 (d, 1H); 8.75 (s, 1H); 9.5 (s, 1H) c) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline and 5-(2-hydroxyethyl)-4-methylthiazol (69mg) reaction, generate 4-(indole-5-base is amino)-6-methoxyl group-7-(2-(4-methyl isophthalic acid, 3-thiazole-5-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.45 (s, 3H); 3.32 (t, 2H); 3.95 (s, 3H); 4.32 (t, 2H); 6.45 (s, 1H); 7.15 (s, 1H); 7.3-7.45 (m, 3H); 7.85 (s, 1H); 7.9 (s, 1H); 8.35 (s, 1H); 8.85 (s, 1H); 9.45 (s, 1H) embodiment 205
Under 4 ℃ of coolings, to 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (102mg, 0.32mmol), 4-(3-hydroxypropyl) morpholine (70mg, 0.48mmol) (as preparation as described in embodiment 60 starting materials), triphenyl phasphine (168mg, 0.64mmol) adding diethylazodicarboxylate (101 μ l, dichloromethane 0.64mmol) (0.4ml) solution in the solution among dichloromethane (1ml) and the DMF (0.5ml).4 ℃ stirred the mixture 12 hours, then stirred overnight at room temperature.Pour mixture into silicagel column (IST post , 10g silica gel), with dichloromethane (15ml), 5% ethanol/methylene (45ml), 5% methanol (ammonia is saturated)/dichloromethane (30ml), 10% methanol (ammonia is saturated)/dichloromethane (45ml), 15% methanol (ammonia is saturated)/dichloromethane (30ml) sequentially eluting.Evaporation contains expect and the fraction of product obtains 6-methoxyl group-4-(2 methyl indole-5-base amino)-7-(3-morpholino propoxyl group) quinazoline (63mg, 44%).MS-ESI:448[MH] + 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H); 2.4 (s, 3H); 2.3-2.6 (m, 6H); 3.6 (t, 4H); 3.95 (s, 3H); 4.2 (t, 2H); 6.12 (s, 1H); 7.12 (s, 1H); 7.3 (brs, 2H); 7.7 (s, 1H); 7.85 (s, 1H); 8.35 (s, 1H); 9.4 (s, 1H)
Initial substance is prepared as follows:
Hydrogenation contains the 2-methyl-5-nitro indole of 10% palladium-carbon (128mg), and (1g, 5.7mmol) solution in ethanol (25ml) and THF (25ml) stops until absorption of hydrogen.Filtering mixt, evaporated filtrate obtain 5-amino-2-methyl indole (830mg, quantitative). 1H NMR spectrum: (DMSOd 6) 2.3 (s, 3H): 4.3 (brs, 2H); 5.8 (s, 1H); 6.35 (d, 1H); 6.55 (s, 1H); 6.95 (d, 1H); 10.35 (brs, 1H)
Adopt and the described similar method of synthetic embodiment 201 initial substances, make 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (2g, 6.6mmol) (as preparation as described in embodiment 1 starting material) and 5-amino-2-methyl indole (1.078,7.3mmol) reaction, generate 7-benzyloxy-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline hydrochlorate (2.9g, quantitative).MS-ESI:411[MH]+ 1H NMR spectrum: (DMSOd 6) 2.41 (s, 3H); 4.01 (s, 3H); 5.33 (s, 2H); 6.18 (s, 1H); 7.25 (d, 1H); 7.3-7.7 (m, 8H); 8.3 (s, 1H); 8.7 (s, 1H); 11.1 (s, 1H); 11.4 (s, 1H)
The described similar method of initial substance among employing and the synthetic embodiment 201, make 7-benzyloxy-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline hydrochlorate (2.87g, 6.4mmol) and ammonium formate (6g, 9.6mmol) reaction, generate 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (1.91g, 93%).MS-ESI:321[MH]+ 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H); 3.95 (s, 3H); 6.12 (s, 1H); 7.0 (s, 1H); 7.25 (s, 1H); 7.7 (s, 1H); 7.85 (s, 1H); 83 (s, 1H); 9.35 (s, 1H); 10.2 (brs, 1H); 10.9 (s, 1H) embodiment 206-207
Adopt embodiment 205 described similar approach, use the chemical compound described in the synthetic Table X II of 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (as preparation as described in the initial substance among the embodiment 205).Table X II
Figure A0080608502641
Figure A0080608502642
A) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (98mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (93mg) (as preparation as described in the starting material among the embodiment 5) reaction, generate 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H); 2.4 (s, 3H); 2.7 (t, 2H); 2.95 (m, 4H); 3.15 (m, 4H); 3.95 (s, 3H); 4.2 (t, 2H); 6.15 (s, 1H); 7.18 (s, 1H); 7.28 (m, 2H); 7.7 (s, 1H); 7.85 (s, 1H); 8.35 (s, 1H); 9.4 (s, 1H) b) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (98mg) and 1-(2-hydroxyethyl) piperidines (62mg) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-(2-piperidino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.4 (m, 2H); 1.45-1.6 (m, 4H); 2.42 (s, 3H); 2.45 (brs, 4H); 2.75 (t, 2H); 3.95 (s, 3H); 4.25 (t, 2H); 6.15 (s, 1H); 7.15 (s, 1H); 7.25 (brs, 2H); 7.7 (s, 1H); 7.88 (s, 1H); 8.35 (s, 1H); 9.4 (s, 1H) embodiment 208
Adopt embodiment 205 described similar approach, make 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg, 0.32mmol) (as preparation as described in embodiment 201 starting materials) and 3-(1,2, the 3-triazol-1-yl) propane-1-alcohol (61mg, 0.48mmol) reaction, (indole-5-base is amino)-(3-(1 for 6-methoxyl group-7-to generate 4-, 2, the 3-triazol-1-yl) propoxyl group) quinazoline (56mg, 42%).MS-ESI:416[MH] + 1H NMR spectrum: (DMSOd 6) 2.4 (m, 2H); 4.0 (s, 3H); 4.2 (t, 2H); 4.65 (t, 2H); 6.45 (s, 1H); 7.15 (s, 1H); 7.35 (m, 2H); 7.42 (d, 1H); 7.75 (s, 1H); 7.88 (s, 1H); 7.9 (s, 1H); 8.2 (s, 1H); 8.38 (s, 1H); 9.42 (s, 1H)
Initial substance is prepared as follows:
90 ℃ of heating contain pyridine (50) 1,2,3-triazoles, and (5g, 72.4mmol) (7.8ml, 72.4mmol) mixture is 4 hours with ethyl acrylate.After the cooling, vacuum is removed volatile matter, and then residue is passed through the column chromatography purification,, obtains (1H-1,2,3-triazol-1-yl) ethyl propionate (8.96g, 73%) with dichloromethane/ether eluting. 1H NMR spectrum: (CDCl 3) 1.25 (t, 3H); 2.95 (t, 2H); 4.15 (q, 2H); 4.7 (t, 2H); 7.65 (s, 1H); 7.7 (s, 1H)
Under 0 ℃ of cooling, (3g dropwise adds (1H-1,2,3-triazol-1-yl) ethyl propionate (8.96g, THF 53mmol) (50ml) solution in THF 79mmol) (250ml) suspension to lithium aluminium hydride reduction.5 ℃ were stirred after 1 hour, and room temperature restir mixture is 1 hour then.Then at 0 ℃ of following cooling mixture, and dropwise add 4N sodium hydroxide (30ml).Filtering mixt, solids washs in proper order with THF, ethyl acetate.Dry (magnesium sulfate) filtrate and evaporation.Residue and then by the column chromatography purification, with methylene chloride (94/6) eluting, 3-(1,2,3-triazoles-1-yl) third-1-alcohol (6.2g, 92%). 1H NMR spectrum: (CDCl 3): 2.1-2.2 (m, 3H); 3.65 (m, 2H); 4.6 (t, 2H); 7.6 (s, 1H); 7.72 (s, 1H) embodiment 209-216
Adopt the similar approach of describing among the embodiment 208, use the chemical compound described in the synthetic Table X III of 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (as preparation as described in the starting material among the embodiment 201).Table X III
Figure A0080608502672
A) 7-hydroxyl-4-(indole-5-base amino)-6-methoxyl group quinazoline (98mg) and 2-(N-(2-methoxy ethyl)-N-methylamino) ethanol (64mg) (as preparation as described in embodiment 59 starting materials) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-(2-(N-(2-methoxy ethyl)-N-methylamino) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H); 2.68 (t, 2H); 2.82 (t, 2H); 3.25 (s, 3H); 3.5 (t, 2H); 3.97 (s, 3H); 4.22 (t, 2H), 6.45 (s, 1H); 7.18 (s, 1H); 7.3-7.45 (m, 3H); 7.88 (m, 2H); 8.35 (s, 1H); 9.42 (s, 1H) b) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 1-(3-hydroxypropyl) pyrrolidine-2,5-diketone (76mg) reaction, generate 7-(3-(2,5-dioxo pyrrolidine-1-yl) propoxyl group)-4-(indole-5-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.05 (m, 2H); 2.65 (s, 3H); 3.6 (t, 2H); 3.98 (s, 2H); 4.15 (t, 2H); 6.45 (s, 1H); 7.1 (s, 1H); 7.3-7.45 (m, 3H); 8.7 (s, 1H); 8.8 (s, 1H); 8.35 (s, 1H); 9.45 (s, 1H)
Initial substance is prepared as follows:
Backflow contains potassium carbonate, and ((5g, 50.5mmol) (6.85ml, 76mmol) solution in acetonitrile (80ml) spends the night the 5-diketone with 3-N-Propyl Bromide-1-alcohol for 14g, pyrrolidine 100mmol)-2.After the cooling, filtering mixt and evaporated filtrate.Residue is dissolved in dichloromethane, and then by the column chromatography purification, with ethyl acetate/petroleum ether (4/1) eluting.After the evaporation volatile matter, under about 0.1mm Hg,, obtain 1-(3-hydroxypropyl) pyrrolidine-2,5-diketone (2.6g, 34%) in 100-125 ℃ of distillation leftover. 1H NMR spectrum: (CDCl 3) 1.8 (m, 2H); 2.52 (t, 1H); 2.78 (s, 4H); 3.58 (q, 2H); 3.7 (t, 2H) c) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (93mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-4-(indole-5-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H); 2.7 (t, 2H); 2.95 (brs, 4H); 3.15 (brs, 4H); 3.97 (s, 3H); 4.2 (t, 2H); 6.45 (s, 1H); 7.2 (s, 1H); 7.3-7.5 (m, 3H); 7.9 (2s, 2H); 8.35 (s, 1H); 9.42 (s, 1H) d) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 3-((4-methyl-4H-1,2,4-triazole-3-yl) third-1-alcohol (83mg) reaction sulfenyl), generate 4-(indole-5-base is amino)-6-methoxyl group-7-(3-((4-methyl-4H-1,2,4-triazole-3-yl) sulfenyl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.22 (m, 2H); 3.3 (m, 2H); 3.65 (s, 3H); 3.95 (s, 3H); 4.25 (t, 2H); 6.45 (s, 1H); 7.15 (s, 1H); 7.3-7.45 (m, 3H); 7.88 (s, 1H); 8.0 (s, 1H); 8.35 (s, 1H); 8.58 (s, 1H); 9.45 (s, 1H)
Initial substance is prepared as follows:
40 ℃ of heating contain potassium carbonate (1.57g, 4-methyl-4-H-1 14mmol), 2, (1.72g, 15mmol) (1.39g, 10mmol) solution in DMF (10ml) is 30 minutes with 3-N-Propyl Bromide-1-alcohol for 4-triazole-3-mercaptan.Then mixture is assigned among saturated ammonium chloride and the ethyl acetate.The evaporation water layer is to doing, residue and then develop with ethyl acetate and dichloromethane.Filter formed suspension, dry (magnesium sulfate) filtrate and evaporation.Residue column chromatography purification with methylene chloride (9/1) eluting, gets 3-((4-methyl-4H-1,2,4-triazole-3-yl) sulfenyl) propane-1-alcohol (510mg, 30%). 1H NMR spectrum: (CDCl 3) 2.02 (m, 2H); 3.45 (t, 2H); 3.55 (s, 3H); 3.75 (t, 2H); 8.15 (s, 1H) e) 7-hydroxyl-4-(indole-5-base amino)-6-methoxyl group quinazoline (98mg) and 1-(3-hydroxypropyl)-4-methyl piperazine (76mg) (as preparation as described in embodiment 133 starting materials) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H); 2.2 (s, 3H); 2.25-2.55 (m, 10H); 4.0 (s, 3H); 4.2 (t, 2H); 6.45 (s, 1H); 7.15 (s, 1H); 7.35 (m, 2H); 7.42 (d, 1H); 7.88 (brs, 2H); 8.38 (s, 1H); 9.42 (s, 1H) f) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 2-methyl cellosolve (37mg) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-(2-methoxy ethoxy) quinazoline. 1H NMR spectrum: (DMSOd 6) 3.4 (s, 3H); 3.75 (t, 2H); 3.98 (s, 3H); 4.38 (t, 2H); 6.45 (s, 1H); 7.18 (s, 1H); 7.35 (m, 2H); 7.42 (d, 1H); 7.85 (s, 1H); 7.9 (s, 1H); 8.38 (s, 1H); 9.5 (s, 1H) g) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 2-(2-methoxy ethoxy) ethanol (58mg) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 3.3 (s, 3H); 3.5 (t, 2H); 3.65 (t, 2H); 3.85 (t, 2H); 4.0 (s, 3H); 4.28 (t, 2H); 6.45 (s, 1H); 7.18 (s, 1H); 7.35 (m, 2H); 7.45 (d, 1H); 7.88 (s, 1H); 7.9 (s, 1H); 8.35 (s, 1H); 9.45 (s, 1H) h) 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg) and 1-(2-hydroxyethyl) piperidines (62mg) reaction generates 4-(indole-5-base is amino)-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.3-1.6 (m, 6H); 2.5 (brs, 4H); 2.7 (t, 2H); 3.98 (s, 3H); 4.25 (t, 2H); 6.45 (s, 1H); 7.18 (s, 1H); 7.35 (m, 2H); 7.42 (d, 1H); 7.9 (brs, 2H); 8.38 (s, 1H); 9.42 (s, 1H) embodiment 217-223
Adopt the similar approach of describing among the embodiment 205, use the chemical compound described in 7-hydroxyl-4-(indole-6-base is amino)-synthetic Table X IV of 6-methoxyl group quinazoline.
Initial substance is prepared as follows:
The described similar method of initial substance among use and the preparation embodiment 201, (500mg 3mmol) generates 6-amino indole (395mg, quantitative) to hydrogenation 6-nitroindoline. 1H NMR spectrum: (DMSOd 6) 6.41 (s, 1H); 6.6 (ad, 1H); 6.63 (s, 1H); 7.0 (t, 1H); 7.4 (d, 1H); 7.87 (brs, 1H)
The described similar method of initial substance among employing and the preparation embodiment 201, make 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (2.5g, 8.3mmol) (as preparation as described in embodiment 1 starting material) and 6-amino indole (1.5g, 11.4mmol) reaction, generate 7-benzyloxy-4-(indole-6-base is amino)-6-methoxyl group quinazoline hydrochlorate (3.18g, 89%).MS-ESI:397[MH]+ 1H NMR spectrum: (DMSOd 6) 4.02 (s, 3H); 5.35 (s, 2H); 6.5 (s, 1H); 7.25 (dd, 1H); 7.35-7.6 (m, 5H); 7.63 (d, 1H); 7.72 (s, 1H); 8.3 (s, 1H); 8.75 (s, 1H); 11.3 (brs, 1H)
Adopt the described similar approach of initial substance among the preparation embodiment 201, with ammonium formate (655mg, 10.4mmol) handle 7-benzyloxy-4-(indole-6-base is amino)-6-methoxyl group quinazoline hydrochlorate, generate 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (162mg, 76%).MS-ESI:307[MH]+ 1H NMR spectrum: (DMSOd 6) 4.0 (s, 3H); 6.4 (s, 1H); 7.0 (s, 1H); 7.3 (m, 2H); 7.5 (d, 1H); 7.85 (s, 1H); 8.0 (s, 1H); 8.35 (s, 1H); 9.35 (s, H); 11.05 (s, 1H) Table X IV
Figure A0080608502721
A) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 3-(1,2, the 3-triazol-1-yl) propane-1-alcohol (61mg) (as preparation as described in embodiment 208 starting materials) reaction, (indole-6-base is amino)-(3-(1 for 6-methoxyl group-7-to generate 4-, 2, the 3-triazol-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.42 (t, 2H); 4.02 (s, 3H); 4.2 (t, 2H); 4.62 (t, 2H); 6.42 (s, 1H); 7.15 (s, 1H); 7.3 (m, 2H); 7.55 (d, 1H); 7.75 (s, 1H); 7.92(s, 1H); 8.02 (s, 1H); 8.2 (s, 1H); 8.42 (s, 1H); 9.45 (s, 1H) b) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 3-(1,1-dioxo thiomorpholine generation)-1-propanol (93mg) (as preparation as described in embodiment 5 starting materials) reaction, generate 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-4-(indole-6-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.0 (m, 2H); 2.7 (t, 2H); 2.95 (brs, 4H); 3.12 (brs, 4H); 4.0 (s, 3H); 4.2 (t, 2H); 6.42 (s, 1H); 7.2 (s, 1H); 7.3 (m, 2H); 7.55 (d, 1H); 7.9 (s, 1H); 8.02 (s, 1H); 8.42 (s, 1H); 9.48 (s, 1H) c) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 3-((4-methyl-4H-1,2,4-triazole-3-yl) propane-1-alcohol (83mg) (as preparation as described in the starting material among the embodiment 212) reaction sulfenyl), generate 4-(indole-6-base is amino)-6-methoxyl group-7-(3-((4-methyl-4H-1,2,4-triazole-3-yl) sulfenyl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.22 (t, 2H); 3.3 (t, 2H); 3.6 (s, 3H); 4.0 (s, 3H); 4.28 (t, 2H); 6.4 (s, 1H); 7.18 (s, 1H); 7.3 (m, 2H); 7.53 (d, 1H); 7.9 (s, 1H), 8.02 (s, 1H); 8.42 (s, 1H); 8.58 (s, 1H); 9.45 (s, 1H) d) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 1-(2-hydroxyethyl) piperidines (62mg) reaction generates 4-(indole-6-base is amino)-6-methoxyl group-7-(2-piperidino ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.3-1.6 (m, 6H); 2.5 (brs, 4H); 2.75 (t, 2H); 4.0 (s, 3H); 4.25 (t, 2H); 6.42 (s, 1H); 7.2 (s, 1H); 7.3 (m, 2H); 7.55 (d, 1H); 7.9 (s, 1H); 8.02 (s, 1H); 8.42 (s, 1H): 9.45 (s, 1H) e) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 1-(3-hydroxypropyl) pyrrolidine (62mg) reaction generates 4-(indole-6-base is amino)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline.
Initial substance is prepared as follows:
Backflow contains potassium carbonate, and (145g, (50g, 0.7mol) (66.15g, 0.7mol) solution in acetonitrile (11) is 20 hours with 3-chloropropane-1-alcohol for pyrrolidine 1.05mol).After the cooling, filtering mixt, and solids washed with acetonitrile, evaporated filtrate then.Residue is in approximately 70mmHg, 130 ℃ of distillations down, thereby obtains 1-(3-hydroxypropyl) pyrrolidine (62.1g, 69%).MS-ESI:130[MH]+ 1H NMR spectrum: (CDCl 3) 1.6-1.8 (m, 6H); 2.55 (brs, 4H); 2.75 (t, 2H); 3.85 (t, 2H); 5.2-5.8 (brs, 1H) f) (indole-6-base is amino)-((N-(2 with 3-for 6-methoxyl group quinazoline (98mg) for 7-hydroxyl-4-, 6-dimethyl-4-pyridine radicals)-and the N-methyl) amino) propane-1-alcohol (93mg) reaction, generate 7-(3-((N-(2,6-dimethyl-4-pyridine radicals)-N-methyl) amino) propoxyl group)-4-(indole-6-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.08 (m, 2H); 2.22 (s, 6H); 2.95 (s, 3H); 3.6 (t, 2H); 4.05 (s, 3H); 4.15 (t, 2H); 6.35 (s, 2H); 6.42 (s, 1H); 7.15 (s, 1H); 7.3 (m, 2H); 7.55 (d, 1H); 7.92 (s, 1H); 8.02 (s, 1H); 8.4 (s, 1H); 9.45 (s, 1H)
Initial substance is prepared as follows:
140 ℃ of heating contain 2N ether solution of hydrogen chloride (10) 4-chloro-2, and (2.12g, 15mmol) (4g, 45mmol) solution in is 1 hour with 3-(N-methylamino)-propane-1-alcohol for the 6-lutidines.Add water (10ml) diluted mixture thing, pour into then in the suspension of magnesium sulfate (125g) in ethyl acetate (200ml).Filtering mixt.Evaporated filtrate, and develop residue with ether.Filter the solid that is produced, vacuum drying obtains 3-((N-(2,6-dimethyl-4-pyridine radicals)-N-methyl) amino) propane-1-alcohol (1.76g, 61%).MS-EI:194[M.]+ 1H NMR spectrum: (CDCl 3) 1.75-1.95 (m, 2H); 2.4 (s, 6H); 3.0 (s, 3H); 3.48 (t, 2H); 3.7 (t, 2H); 6.25 (s, 2H) g) 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) and 3-hydroxy-methyl pyridine (53mg) reaction generates 4-(indole-6-base is amino)-6-methoxyl group-7-((3-pyridine radicals) methoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 4.02 (s, 3H); 5.35 (s, 2H); 6.42 (s, 1H); 7.22-7.4 (m, 3H); 7.5 (m, 1H); 7.55 (d, 1H); 7.95 (s, 1H); 7.97 (d, 1H); 8.0 (s, 1H); 8.42 (s, 1H); 8.6 (d, 1H); 8.78 (s, 1H); 9.5 (s, 1H) embodiment 224
Adopt the similar approach of describing among the embodiment 208, make 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline (98mg, 0.32mmol) (as preparation as described in the starting material among the embodiment 201) with (E)-4-(pyrrolidine-1-yl) but-2-ene-1-alcohol (68mg, 0.48mmol) (as preparation as described in embodiment 129 starting materials) reaction.Evaporation contains expect and residue is developed with the isopropyl alcohol (1ml) that contains 6.2N isopropanol solution of hydrogen chloride (100 μ l) after the fraction of product.After the stirring at room 10 minutes, add ether (500 μ l).Filtering precipitate with the ether washing for several times, gets 4-(indole-5-base is amino)-6-methoxyl group-7-((E) 4-(pyrrolidine-1-yl) but-2-ene-1-base oxygen base) quinazoline hydrochlorate (14mg, 10%).MS-ESI:430[MH] + 1H NMR spectrum: (DMSOd 6) 1.85-2.7 (brs, 4H); 2.95-3.1 (brs, 2H); 3.0 (m, 2H); 3.4-3.5 (m, 2H); 3.8 (d, 2H); 4.0 (s, 3H); 4.8 (d, 2H); 6.0-6.3 (m, 2H); 6.5 (%, 1H); 7.2-7.539 (m, 4H); 7.75 (s, 1H); 8.25 (s, 1H); 8.8 (brs, 1H) embodiment 225
Processing 7-hydroxyl-4-as described below (indole-5-base amino)-6-methoxyl group quinazoline (as preparation as described in embodiment 201 starting materials).After chromatogram purification and evaporating solvent, residue is developed in isopropyl alcohol (1ml) solution that contains 6.2N hydrogen chloride/isopropyl alcohol (100 μ l).After the stirring at room 10 minutes, add ether (500 μ l).Filter solids, obtain 7-hydroxyl-4-(indole-5-base is amino)-6-methoxyl group quinazoline hydrochlorate behind the vacuum drying.
Adopt the similar approach of describing among the embodiment 224, use the chemical compound described in 7-hydroxyl-4-(indole-5-base is amino)-synthetic Table X V of 6-methoxyl group quinazoline hydrochlorate.Table X V
Figure A0080608502761
A) (indole-5-base is amino)-((N-(2 with 3-for 6-methoxyl group quinazoline hydrochlorate (98mg) for 7-hydroxyl-4-, 6-dimethyl-4-pyridine radicals)-and the N-methyl) amino) propane-1-alcohol (93mg) (as preparation as described in the starting material among the embodiment 222) reaction, generate 7-(3-((N-(2,6-dimethyl-4-pyridine radicals)-N-methyl) amino) propoxyl group)-4-(indole-5-base is amino)-6-methoxyl group quinazoline. 1H NMR spectrum: (DMSOd 6) 2.2 (m, 2H); 2.5 (2brs, 6H); 3.2 (s, 3H); 3.8 (t, 2H); 4.1 (s, 3H); 4.25 (t, 2H); 6.52 (s, 1H); 6.75 (brs, 1H); 6.9 (brs, 1H); 7.35 (dd, 1H); 7.45 (brs, 2H); 7.5 (d, 1H); 7.8 (s, 1H); 8.4 (s, 1H); 8.75 (s, 1H) embodiment 226
Adopt the similar approach of describing among the embodiment 224, make 7-hydroxyl-4-(indole-6-base amino)-6-methoxyl group quinazoline (as preparation as described in the starting material among the embodiment 217) (98mg, 0.32mmol) and 4-(3-hydroxypropyl) morpholine (70mg, 0.48mmol) (as preparation as described in embodiment 60 starting materials) reaction, obtain 4-(indole-6-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline hydrochlorate (26mg, 19%).MS-ESI:434[MH] + 1H NMR spectrum: (DMSOd 6), CF 3COOD) 2.35 (m, 2H); 3.15 (m, 2H); 3.3 (t, 2H); 3.52 (d, 2H); 3.8 (t, 2H); 4.0 (d, 2H); 4.1 (s, 3H); 4.3 (t, 2H); (6.5 s, 0.5H, part exchange); 7.3 (d, 1H); 7.4 (s, 1H); 7.45 (s, 1H); 7.65 (d, 1H); 7.75 (s, 1H); 8.3 (s, 1H); 8.75 (s, 1H) embodiment 227-229
Adopt embodiment 226 described similar approach, use the chemical compound of describing among the synthetic Table X VI of 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (as preparation as described in the starting material among the embodiment 217).Table X VI
Figure A0080608502772
A) (reaction of (N-methyl-N-(4-pyridine radicals) amino) ethanol (73mg) (EP 0359389A1) generates 4-(indole-6-base is amino)-6-methoxyl group-7-(2-((N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline hydrochlorate to 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg) with 2-. 1H NMR spectrum: (DMSOd 6) 3.3 (s, 3H); 4.0 (s, 3H); 4.18 (t, 2H); 4.45 (t, 2H); 6.5 (s, 1H); 7.35 (d, 1H); 7.35-7.5 (m, 4H); 7.62 (d, 1H); 7.75 (s, 1H); 8.3 (d, 2H); 8.4 (s, 1H); 8.75 (s, 1H) b) 7-hydroxyl-4-(indole-6-base amino)-6-methoxyl group quinazoline (98mg) with (E)-4-(pyrrolidine-1-yl) but-2-ene-1-alcohol (68mg, 0.48mmol) (as preparation as described in the starting material among the embodiment 129) reaction, generate 4-(indole-6-base is amino)-6-methoxyl group-7-((E)-4-(pyrrolidine-1-yl) but-2-ene-1-base oxygen base) quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd 6) 1.8-2.1 (m, 4H); 2.9-3.1 (m, 2H); 3.4-3.5 (brs, 2H); 3.87 (d, 2H); 4.05 (s, 3H); 4.9 (d, 2H); 6.1 (m, 1H); 6.3 (m, 1H); 6.5 (s, 1H); 7.25 (d, 1H); 7.45 (m, 2H); 7.65 (d, 1H); 7.75 (s, 1H); 8.3 (s, 1H); 8.8 (s, 1H) c) 7-hydroxyl-4-(indole-6-base amino)-6-methoxyl group quinazoline (98mg) and 1-(3-hydroxypropyl)-4-methyl piperazine (76mg) (as preparation as described in the starting material among the embodiment 133) reaction generates 4-(indole-6-base is amino)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline hydrochlorate.Embodiment 230
Adopt the similar approach of describing among the embodiment 224, make 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (102mg, 0.32mmol) (as preparation as described in the starting material among the embodiment 205) and 1-(3-hydroxypropyl)-glyoxal ethyline (67mg, 0.48mmol) (EP 0060696A1) reaction, obtain 6-methoxyl group-7-(3-(glyoxal ethyline-1-yl) propoxyl group)-4-(2 methyl indole-5-base is amino) quinazoline hydrochlorate (53mg, 3796).MS-ESI:443[MH] + 1H NMR spectrum: (DMSOd 6) 2.42 (s, 3H); 2.62 (s, 3H); 4.03 (s, 3H); 4.3 (t, 2H); 4.35 (t, 2H); 6.2 (s, 1H); 7.22 (d, 1H); 7.35 (d, 1H); 7.45 (s, 1H); 7.6 (dd, 1H); 7.65 (dd, 1H); 7.7 (s, 1H); 8.35 (s, 1H); 8.75 (s, 1H) embodiment 231-235
Adopt embodiment 224 described similar approach, use 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (102mg, 0.32mmol) chemical compound of describing among (as preparation as described in the starting material among the embodiment 205) synthetic Table X VII.Table X VII
Figure A0080608502791
A) ((N-(2 with 3-for quinazoline (102mg) for 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino), 6-dimethyl-4-pyridine radicals)-and the N-methyl) amino) third-1-alcohol (93mg) (as preparation as described in the starting material among the embodiment 222) reaction, generate 7-(3-((N-(2,6-dimethyl-4-pyridine radicals)-N-methyl) amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.2 (m, 2H); 2.4 (s, 6H); 2.45 (s, 3H); 3.15 (s, 3H); 3.75 (t, 2H); 4.02 (s, 3H); 4.25 (t, 2H); 6.2 (s, 1H); 6.72 (brs, 1H); 6.85 (brs, 1H); 7.2 (dd, 1H); 7.3-7.4 (m, 2H); 7.62 (s, 1H); 8.3 (s, 1H); 8.7 (s, 1H) b) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base amino) quinazoline (102mg) with (E)-4-(pyrrolidine-1-yl) but-2-ene-1-alcohol (68mg, 0.48mmol) (as preparation as described in the starting material among the embodiment 129) reaction, generate 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-((E)-4-(pyrrolidine-1-yl) but-2-ene-1-base oxygen base) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.8-2.1 (m, 4H); 2.4 (s, 3H); 2.9-3.1 (m, 2H); 3.4-3.6 (m, 2H); 3.9 (d, 2H); 4.05 (s, 3H); 4.9 (d, 2H); 6.1 (m, 1H); 6.2 (s, 1H); 63 (d, t, 1H); 7.2 (m, 1H); 7.37 (d, 1H); 7.4 (s, 1H); 7.32 (s, 1H); 8.3 (s, 1H); 8.75 (s, 1H) c) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (102mg) and 3-((4-methyl-4H-1,2,4-triazole-3-yl) propane-1-alcohol (83mg) (as preparation as described in the starting material among the embodiment 212) reaction sulfenyl), generate 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-(3-((4-methyl-4H-1,2,4-triazole-3-yl) sulfenyl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.25 (m, 2H); 2.45 (s, 3H); 3.35 (t, 2H); 3.65 (s, 3H); 4.05 (s, 3H); 4.35 (t, 2H); 6.2 (s, 1H); 7.2 (d, 1H); 7.35 (s, 1H); 7.37 (d, 1H); 7.62 (s, 1H); 8.25 (s, 1H); 8.75 (s, 1H); 8.9 (s, 1H) d) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base amino) quinazoline (102mg) and 1-(3-hydroxypropyl)-4-methyl piperazine (76mg) (as preparation as described in the starting material among the embodiment 133) reaction generates 6-methoxyl group-4-(2 methyl indole-5-base is amino)-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline.E) 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base is amino) quinazoline (102mg) and 2-(2-methoxy ethoxy) ethanol synthesis generates 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(2 methyl indole-5-base is amino) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.45 (s, 3H); 3.28 (s, 3H); 3.5 (t, 2H), 3.65 (t, 2H); 3.9 (t, 2H); 4.02 (s, 3H); 4.33 (t, 2H); 6.2 (s, 1H); 7.2 (d, 1H); 7.4 (m, 2H); 7.63 (s, 1H); 8.28 (s, 1H); 8.73 (s, 1H) embodiment 236
90 ℃ of stirrings contain cesium carbonate (282mg, 0.86mmol) 4-chloro-6-methoxyl group-7-((1-cyano methyl piperidin-4-yl) methoxyl group) quinazoline (200mg, 0.58mmol) (85mg, 0.63mmol) solution in DMF (3ml) is 90 minutes with the 5-oxyindole.After the cooling, in mixture impouring water (25ml).Filtering precipitate, vacuum drying and by reversed-phase silica gel column chromatography purification (KromaSil  C18), with methanol (1% acetic acid) (1/1) eluting.Merge to contain and expect the fraction of product, evaporation obtains 7-((1-cyano methyl) piperidin-4-yl methoxyl group)-4-(the basic oxygen base of indole-5-)-6-methoxyl group quinazoline (44mg, 17%).MS-ESI:444[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.7 (m, 2H); 2.15 (d, 2H); 2.2-2.35 (m, 1H); 3.20 (t, 2H); 3.65 (d, 2H); 4.1 (s, 3H); 4.25 (d, 2H); 4.62 (s, 2H); (6.5 s, 0.5H, part exchange); 7.1 (dd, 1H); 7.5 (s, 1H); 7.5-7.6 (m, 3H); 7.85 (s, 1H); 9.1 (s, 1H)
Initial substance is prepared as follows:
Under 0 ℃ of cooling, to 6-methoxyl group-7-(piperidin-4-yl methoxyl group)-3-((new pentane acyloxy) methyl)-3, (34g 84mmol) adds the 1N sodium hydroxide in the water slurry of (as preparation as described in the starting material among the embodiment 12) and reaches 8 until the pH of mixture 4-dihydroquinazoline-4-keto hydrochloride.With chloroform extraction gained solution, and dry (magnesium sulfate) organic layer, filter and evaporation, thereby obtain 6-methoxyl group-7-(piperidin-4-yl methoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (29g).
To 6-methoxyl group-7-(piperidin-4-yl methoxyl group)-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (28.9g, 72%) with hydration formaldehyde 12M (11.95ml, 141mmol) in the solution of methanol/THF (1/1) in (580ml), add in batches sodium cyanoborohydride (5.7g, 86mmol).After the stirring at room 90 minutes, vacuum is removed volatile matter, and residue is assigned between dichloromethane and the water.Tell organic layer, dry (magnesium sulfate) and evaporation.Residue is dissolved in the saturated methanol of ammonia (500ml).Stirring at room gained mixture 36 hours.Vacuum is removed volatile matter.Residue with ether/dichloromethane mixture development, is filtered ether washing and vacuum drying.The gained solids is dissolved in thionyl chloride (180ml), adds DMF (1.8ml).80 ℃ were stirred after 75 minutes, and vacuum is removed volatile matter.Residue with toluene azeotropic twice, is assigned to the gained solids among dichloromethane and the water then, regulates the pH to 9 of water layer with the 2N sodium hydroxide.Dry (magnesium sulfate) organic layer and evaporation.Residue and then by the aluminum oxide column chromatography purification, use dichloromethane, dichloromethane/ethyl acetate (70/30, then 50/50), ethyl acetate and ethyl acetate/methanol (80/20) sequentially eluting, 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (11.2g) (identical) and 4-chloro-6-methoxyl group-7-((1-(cyano methyl) piperidin-4-yl) methoxyl group) quinazoline (2.55g) with the initial substance of preparation among the embodiment 10.MS-ESI:347[MH] + 1H NMR spectrum: (DMSOd 6) 1.42 (m, 2H); 1.85 (d, 2H); 1.8-1.9 (m, 1H); 2.2 (t, 2H); 2.85 (d, 2H); 3.75 (s, 2H); 4.05 (s, 3H); 4.15 (d, 2H); 7.42 (s, 1H); 7.5 (s, 1H); 8.9 (s, 1H) embodiment 237
95 ℃ are stirred 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (2gr, 6.22mmol) (as preparation as described in embodiment 10 starting materials) and 4-fluoro-5-hydroxy-2-methyl indole (1.23g, 7.46mmol) solution in DMF (30ml) [wherein contain potassium carbonate (1.28g, 9.33mmol)] 2 hours.After the cooling, vacuum is removed volatile matter, develops residue with ether, filters and vacuum drying.Gained residue and then by the column chromatography purification is with ethanol/methylene (1/9), the saturated ethanol/methylene of methanol/ammonia (20/1/79, then 20/5/75) sequentially eluting.Merge to contain and expect that the fraction of product is also evaporated.The gained solid is developed with methanol, filters and vacuum drying, gets 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (1.95g, 69%).MS-ESI：451[MH] +。 1H NMR composes (DMSOd 6) 1.4 (m, 2H); 1.8 (d, 2H); 1.7-1.9 (m, 1H); 1.9 (t, 2H); 2.2 (s, 3H); 2.45 (s, 3H); 2.8 (d, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 6.25 (s, 1H); 7.0 (dd, 1H); 7.2 (d, 1H); 7.4 (s, 1H); 7.62 (s, 1H); 8.5 (s, 1H) elementary analysis: measured value C 64.2 H 6.5 N 11.7C 25H 27FN 4O 30.91 methanol 0.08CH 2Cl 20.1H 2O value of calculation C 63.9 H 6.4 N 11.5%
Initial substance is prepared as follows:
Under-15 ℃ of coolings, (9.9g, 58mmol) (10.7g 64mmol) adds potassium tert-butoxide (14.3g, DMF 127mmol) (124ml) in the solution in DMF (50ml) with 4-chlorophenoxy acetonitrile to 2-fluoro-4-Nitroanisole.-15 ℃ are stirred after 30 minutes, in the cold hydrochloric acid of mixture impouring 1N.The mixture ethyl acetate extraction.With organic layer 1N sodium hydroxide, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with the dichloromethane eluting.Merge to contain and expect and the fraction of product evaporate thereafter.Residue is dissolved in the ethanol (180ml) and acetic acid (24ml) that contains 10% palladium-carbon (600mg), and this mixture of hydrogenation is 2 hours under 3 atmospheric pressures.Filtering mixt, and vacuum is removed volatile matter.And then residue is assigned among ethyl acetate and the water.Tell organic layer, wash successively, dry (magnesium sulfate) and evaporation with saturated sodium bicarbonate, saline.Residue and then by the column chromatography purification with the dichloromethane eluting, obtains 1/2 mixture (5.64g, 59%) of 4-fluoro-5-methoxyl group indole and 6-fluoro-5-methoxyl group indole. 1H NMR spectrum: (DMSOd 6) 3.85 (s, 3H); (6.38 s, 1H, 6-fluorine); 6.45 (s, 1H; The 4-fluorine); 6.9-7.4 (m, 3H)
Stirring at room 4-fluoro-5-methoxyl group indole and 6-fluoro-5-methoxyl group indole (1/2) (496mg, 3mmol), (720mg, 3.3mmol) solution in acetonitrile (12ml) [wherein contain DMAP (18mg, 0.15mmol)] is 24 hours for Bis(tert-butoxycarbonyl)oxide.Vacuum is removed volatile matter then.Residue is dissolved in ethyl acetate, wash successively with 1N hydrochloric acid, water, saline, dry (magnesium sulfate) and evaporation obtain 4-fluoro-5-methoxyl group-1-tertbutyloxycarbonyl indole and 6-fluoro-5-methoxyl group-1-tertbutyloxycarbonyl indole mixture (1/2) (702mg, 88%). 1H NMR spectrum: (DMSOd 6) 1.65 (s, 9H); 3.9 (s, 3H): 6.6 (d, 1H, 6-fluorine); (6.72 d, 1H, 4-fluorine); (7.2 t, 1H, 6-fluorine); (7.4 d, 1H, 4-fluorine); (7.62 d, 1H, 6-fluorine); (7.68 d, 1H, 4-fluorine); (7.78 s, 1H, 4-fluorine); (7.85 s, 1H, 6-fluorine).
Under-65 ℃ of coolings, to 4-fluoro-5-methoxyl group-1-tertbutyloxycarbonyl indole and 6-fluoro-5-methoxyl group-1-tertbutyloxycarbonyl indole (1/2) (8.1g, 30.5mmol) add in the solution in THF (100ml) tert-butyl lithium (1.7M) (23ml, 35.7mmol).-70 ℃ were stirred after 4 hours, and (8.66g, 61mmol), warm mixture is to room temperature to add methyl iodide.Add entry, then with gained mixture ether extraction.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation are directly used in next step then.
Above-mentioned crude product is dissolved in dichloromethane (100ml), adds TFA (25ml).After the stirring at room 1 hour, vacuum is removed volatile matter.Residue is dissolved in ethyl acetate, washs organic layer successively, dry (magnesium sulfate) and evaporation with 1N sodium hydroxide, water, saline.Residue and then by the column chromatography purification with ethyl acetate/petroleum ether (3/7) eluting, obtains 6-fluoro-5-methoxyl group-2 methyl indole (1.6g) and 4-fluoro-5-methoxyl group-2 methyl indole (0.8g, 48%).6-fluoro-5-methoxyl group-2 methyl indole: MS-ESI:180[MH] + 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H); 3.8 (s, 3H); 6.05 (s, 1H); 7.1 (s, 1H); 7.12 (s, 1H); 10.8 (s, 1H) 4-fluoro-5-methoxyl group-2 methyl indole: MS-ESI:180[MH] + 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H); 3.8 (s, 3H); 6.15 (s, 1H); 6.9 (t, 1H); 7.05 (d, 1H); 11.0 (s, 1H)
Under-30 ℃ of coolings, (709mg adds Boron tribromide (2.18g, dichloromethane 8.7mmol) (1ml) solution in dichloromethane 3.95mmol) (9ml) solution to 4-fluoro-5-methoxyl group-2 methyl indole.After the stirring at room 1 hour, mixture is poured in the water, diluted with dichloromethane.Regulate the pH to 6 of water layer.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with ethyl acetate/petroleum ether (3/7) eluting, 4-fluoro-5-hydroxy-2-methyl indole (461mg, 70%).M8-E8I:166[MH] + 1H NMR spectrum: (DMSOd 6) 2.35 (s, 3H); 6.05 (s, 1H); 6.65 (dd, 1H); 6.9 (d, 1H); 8.75 (s, 1H); 10.9 (s, 1H) 13C NMR spectrum: (DMSOd 6) 13.5; 94,0; 106,0; 112; 118.5 (d); 132 (d); 136 (d); 136.5; 142.5 (d)
On the other hand, 4-fluoro-5-hydroxy-2-methyl indole can also be prepared as follows:
Keeping temperature to be lower than under 15 ℃ the situation, to the sodium hydride under 10 ℃ of coolings (5.42g, 226mmol) (wash with pentane in advance)/THF add in (100ml) suspension ethyl acetoacetate (29.4g, 226mmol).After finishing, further stirred the mixture 15 minutes, be cooled to 5 ℃ then.Add 1,2,3-three fluoro-4-Nitrobenzol (20g, THF 113mmol) (150ml) solution keeping temperature to be lower than under 5 ℃ the situation.Warm then mixture stirred 24 hours to room temperature.Vacuum is removed volatile matter, and residue is assigned in ethyl acetate and the 2N aqueous hydrochloric acid solution.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue is dissolved in concentrated hydrochloric acid (650ml) and acetic acid (600ml), and this mixture 15 hours refluxes.After the cooling, vacuum is removed volatile matter, and then residue is assigned among sodium bicarbonate aqueous solution (5%) and the ethyl acetate.Organic layer sodium bicarbonate, water, salt water washing, dry (magnesium sulfate) and evaporation.At last residue is passed through the column chromatography purification,, get 3-acetyl group methyl isophthalic acid, 2-two fluoro-4-Nitrobenzol (17.5g, 72%) with ethyl acetate/petroleum ether (75/25) eluting. 1H NMR spectrum: (CDCl 3) 2.4 (s, 3H); 4.25 (s, 2H); 7.25 (dd, 1H); 8.0 (dd, 1H)
Stirring at room contains the 3-acetyl group methyl isophthalic acid of Montmorillonitum K10 (1g) and trimethyl orthoformate (5ml), 2-two fluoro-4-Nitrobenzol (500mg, dichloromethane 2.3mmol) (5ml) solution 24 hours.Filter solids,, obtain 1,2-two fluoro-3-(2,2-dimethoxy propyl group)-4-Nitrobenzol (534mg, 88%) with washed with dichloromethane and evaporated filtrate. 1H NMR spectrum: (CDCl 3) 1.2 (s, 3H); 3.2 (s, 6H); 3.52 (s, 2H); 7.18 (dd, 1H); 7.6 (m, 1H)
To benzylalcohol (221mg, add in DMA 2.05mmol) (1.5ml) solution 60% sodium hydride (82mg, 2.05mmol).Stirring at room mixture 1 hour.Add 1,2-two fluoro-3-(2,2-dimethoxy propyl group)-4-Nitrobenzol (534mg, the 2.05mmol) solution in DMA (1.5ml), stirring at room gained mixture 3 hours.Use 1N hydrochloric acid (10ml) diluted mixture thing then, and use ethyl acetate extraction.The evaporation organic layer is dissolved in THF (2ml) with residue, adds 6N hydrochloric acid (0.3ml).Stirring at room mixture 1 hour, solvent removed in vacuo thereafter.Residue is assigned among ethyl acetate and the water.Tell organic layer, use the salt water washing, dry (magnesium sulfate) and evaporation.Solids is developed with ether, filters, and ether washing and vacuum drying get 3-acetyl group methyl isophthalic acid-benzyloxy-2-fluoro-4-Nitrobenzol (350mg, 56%). 1H NMR spectrum: (CDCl 3) 2.35 (s, 3H); 4.25 (s, 2H); 5.25 (s, 2H); 7.0 (dd, 1H); 7.32-7.5 (m, 5H); 8.0 (dd, 1H)
Hydrogenation contains the 3-acetyl group methyl isophthalic acid-benzyloxy-2-fluoro-4-Nitrobenzol of 10% palladium-carbon (30mg) (300mg, 0.99mmol) solution in ethanol (10ml) and acetic acid (1ml) is 2 hours under 2 atmospheric pressures.Filtering mixt and evaporated filtrate.Residue is dissolved in ethyl acetate, and with sodium bicarbonate aqueous solution, salt water washing organic layer, evaporation obtains 4-fluoro-5-hydroxy-2-methyl indole.Residue and then by the column chromatography purification, with ethyl acetate/petroleum ether (3/7) eluting, 4-fluoro-5-hydroxy-2-methyl indole (63mg, 30%).Analytical data as above.
Other method is that 4-fluoro-5-methoxyl group-2 methyl indole can also be prepared as follows:
Under 5 ℃ of coolings, to 1, (16.2g 62mmol) adds Feldalat NM (by sodium (1.71g) and methanol (35ml) prepared fresh) in methanol (200ml) solution of (preparation as mentioned above) to 2-two fluoro-3-(2,2-dimethoxy propyl group)-4-Nitrobenzol.Warm mixture stirred 3 days to room temperature.Vacuum is removed volatile matter, and residue is assigned within ethyl acetate and the 2N hydrochloric acid (1ml).Concentrate organic layer to the 100ml cumulative volume, add THF (100ml) and 6N hydrochloric acid (25ml).Mixture at room temperature stirred 1 hour.Vacuum is removed volatile matter then, and residue is assigned among ethyl acetate and the water.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with ethyl acetate/petroleum ether (3/7) eluting, 3-acetyl group methyl-2-fluoro-1-methoxyl group-4-Nitrobenzol (12.7g, 90%).MS-ESI:250[MNa]+ 1H NMR spectrum: (CDCl 3) 2.38 (s, 3H); 4.0 (s, 3H); 4.25 (s, 2H); 7.0 (dd, 1H); 8.05 (d, 1H)
To 3-acetyl group methyl-2-fluoro-1-methoxyl group-4-Nitrobenzol (11.36g adds 4M ammonium acetate solution (700ml) in acetone 50mmol) (200ml) solution, then dropwise add titanium trichloride solution (15% aqueous solution, 340ml).This mixture of stirring at room 10 minutes is used the ether extraction mixture then.Organic layer washs in proper order with 0.5N sodium hydroxide, water, saline, and dry (magnesium sulfate) and vacuum are removed volatile matter.Residue and then by the column chromatography purification, with the dichloromethane eluting, 4-fluoro-5-methoxyl group-2 methyl indole (8.15g, 90%). 1H NMR spectrum: (DMSO) 2.35 (s, 3H); 3.8 (s, 3H); 6.1 (s, 1H); 6.85 (dd, 1H); 7.02 (d, 1H)
Use Boron tribromide cracking 4-fluoro-5-methoxyl group-2 methyl indole as mentioned above, obtain 4-fluoro-5-hydroxy-2-methyl indole.Embodiment 238
Adopt the similar approach of describing among the embodiment 237, make 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (1.65g, 4.89mmol) (as preparation as described in the starting material among the embodiment 67) and 4-fluoro-5-hydroxy-2-methyl indole (970mg, 5.88mmol) (as preparation as described in embodiment 237 starting materials) reaction, obtain 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (1.9g, 83%).MS-ESI:465[MH] + 1H NMR spectrum: (DMSOd 6) 1.4 (brs, 2H); 1.5 (m, 4H); 1.95 (m, 2H); 2.25-2.5 (m, 6H); 2.45 (s, 3H); 4.0 (s, 3H); 4.25 (t, 2H); 6.25 (s, 1H); 7.0 (dd, 1H); 7.15 (d, 1H); 7.4 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H) embodiment 239
Adopt the similar approach of describing among the embodiment 237, make 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (106mg, 0.30mmol) (as preparation as described in the starting material among the embodiment 176) and 4-fluoro-5-hydroxy-2-methyl indole (60mg, 0.36mmol) (as preparation as described in embodiment 237 starting materials) reaction, obtain 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (100mg, 70%).MS-ESI:480[MH] + 1H NMR spectrum: (DMSOd 6) 2.0 (t, 2H); 2.15 (s, 3H); 2.45 (s, 3H); 2.2-2.6 (m, 10H); 4.02 (s, 3H); 4.25 (t, 2H); 6.25 (s, 1H); 7.0 (dd, 1H); 7.18 (d, 1H); 7.4 (s, 1H); 7.62 (s, 1H); 8.5 (s, 1H) embodiment 240
Adopt the similar approach of describing among the embodiment 237, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (2g, 6.22mmol) (as preparation as described in the starting material among the embodiment 9) and 4-fluoro-5-hydroxy-2-methyl indole (1.23g, 7.46mmol) (as preparation as described in embodiment 237 starting materials) reaction, obtain 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (1.41g, 50%).MS-ESI:451[MH]+ 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.0 (m, 2H); 2.41 (s, 3H); 2.5 (brs, 4H); 2.6 (t, 2H); 4.0 (s, 3H); 4.25 (t, 2H); 6.25 (s, 1H); 7.0 (dd, 1H); 7.2 (d, 1H); 7.4 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H) elementary analysis: measured value C 63.3 H 6.4 N 11.9C 25H 27FN 4O 31.08H 2O; 0.16: methanol value of calculation C 63.6 H 6.3 N 11.8% embodiment 241
90 ℃ of heating 4-chloro-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline (300mg, 0.9mmol) and 4-fluoro-5-oxyindole (162mg, 1mmol) (as preparation as described in embodiment 242 starting materials) solution in DMF (4.5ml) [wherein contain potassium carbonate (185mg, 1.3mmol)] is 1 hour.After the cooling, filtering mixt, and wash solids with DMF.Evaporated filtrate passes through the column chromatography purification with residue, with dichloromethane, ethanol/methylene (1/99), the saturated ethanol/methylene of ammonia (2/98) sequentially eluting then.Merge and contain expection product fraction, evaporation thereafter.With ether development gained solids, filtration, ether washing and vacuum drying, get 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline (282mg, 69%).MS-ESI:451[MH]+ 1H NMR spectrum: (DMSOd 6) 1.2-1.3 (m, 2H); 1.4-1.55 (m, 1H); 1.7-1.9 (m, 6H); 2.15 (s, 3H); 2.75 (d, 2H); 4.0 (s, 3H); 4.3 (t, 2H); 6.55 (s, 1H); 7.1 (dd, 1H); 7.3 (d, 1H); 7.4 (s, 1H); 7.5 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H); 11.5 (s, 1H)
Initial substance is prepared as follows:
To refrigerative 4-(2-hydroxyethyl)-(1-tertbutyloxycarbonyl) piperidines (12.9g under-5 ℃, 56mmol) (as preparation as described in embodiment 126 starting materials) solution in t-butyl methyl ether (120ml) [wherein contains 1,4-diazabicylo [2.2.2] octane (9.8g, dropwise add toluene sulfochloride (14.5gr 87mmol)], t-butyl methyl ether 76mmol) (120ml) keeps temperature to be lower than 0 ℃ between charge period.After finishing, warm mixture stirred 1 hour to room temperature.Mixture is poured in the petroleum ether (240ml).Filter formed precipitate, use petroleum ether.Evaporated filtrate is dissolved in ether with residue then.Wash ether layer in succession with 0.5N hydrochloric acid, saturated sodium bicarbonate, dry (magnesium sulfate) and evaporation obtain 4-(2-(4-Methyl benzenesulfonyl oxygen base) ethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (20.9g, 97%). 1N NMR spectrum: (CDCl 3) 0.95-1.05 (m, 4H); 1.45 (s, 9H); 1.4-1.6 (m, and 3H) 2.45 (s, 3H); 2.62 (t, 2H); 3.9-4.1 (m, 2H); 4.1 (t, 2H); 7.35 (d, 2H); 7.8 (d, 2H)
To contain 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (7g, 23mmol) (as preparation as described in the starting material among the embodiment 12), 4-(2-(4-Methyl benzenesulfonyl oxygen base) ethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (11.4g, 30mmol) and potassium carbonate (6.32g, 100 ℃ of DMF 46mmol) (70ml) suspensions stirred 3 hours.After the cooling, vacuum is removed volatile matter, then residue is assigned among ether and the water.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Gained solid and then with pentane development filters and vacuum drying, 7-(2-(1-tertbutyloxycarbonyl piperidin-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (10.5g, 88%).MS-ESI:540[MNa] + 1H NMR spectrum: (CDCl 3) 1.2 (s, 9H); 1.15-1.25 (m, 2H); 1.48 (s, 9H); 1.65-1.75 (m, 1H); 1.7 (d, 2H); 1.9 (dd, 2H); 2.72 (t, 2H); 4.0 (s, 3H); 4.0-4.2 (m, 2H); 4.2 (t, 2H); 5.95 (s, 2H); 7.1 (s, 1H); 7.65 (s, 1H); 8.2 (s, 1H)
Stirring at room contains 7-(2-(1-tertbutyloxycarbonyl piperidin-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3 of TFA (25ml), and 4-dihydroquinazoline-4-ketone (10.5g, 20mmol)/dichloromethane (100ml) solution 1 hour.Add entry (50ml) and dichloromethane (100ml), regulate the pH to 8 of water layer then with sodium bicarbonate.Separate organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development, and filter formed solids, behind vacuum drying, obtain 7-(2-(piperidin-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (8.3g, 100%). 1H NMR spectrum: (CDCl 3) 1.2 (s, 9H); 1.65 (m, 2H); 1.9 (brs, 2H); 1.8-1.9 (m, 1H); 2.0 (d, 2H); 2.9 (t, 2H); 3.45 (d, 2H); 4.0 (s, 3H); 4.2 (t, 2H); 5.95 (s, 2H); 7.1 (s, 1H); 7.65 (s, 1H); 8.2 (s, 1H)
To 7-(2-(piperidin-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (6g 14.4mmol) successively adds 37% formalin (2.2ml in the solution in methanol (30ml) and dichloromethane (60ml) to 4-dihydroquinazoline-4-ketone; 28.9mmol) and acetic acid (990 μ l; 17.3mmol).Add in batches the triacetic acid sodium borohydride (4.6g, 21.6mmol).After the stirring at room 1 hour, vacuum is removed volatile matter, then residue is assigned among water (50ml) and the dichloromethane (50ml).Regulate the pH to 7 of water layer, water, salt water washing, dry (magnesium sulfate) and evaporation.The gained solids is developed with ether, filters, and ether washing and vacuum drying get 7-(2-(1-methyl piperidine-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (4.2g, 68%).MS-ESI:432[MH] + 1H NMR spectrum: (CDCl 3) 1.22 (s, 9H); 1.68 (brs, 3H); (1.9 m, 4H); 2.32 (brs, 2H); 2.52 (s, 3H); 3.18 (d, 2H); 4.0 (s, 3H); 4.2 (t, 2H); 5.95 (s, 2H); 7.1 (s, 1H); 7.65 (s, 1H); 8.2 (s, 2H)
Stirring at room 7-(2-(1-methyl piperidine-4-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (4.2g, 9.7mmol) solution in the saturated methanol of ammonia (150ml) spends the night 4-dihydroquinazoline-4-ketone.Vacuum is removed volatile matter, and develops residue with ether.Filter formed solids, behind ether washing and vacuum drying, obtain 7-(2-(1-methyl piperidine-4-yl) ethyoxyl)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (3.12g, 100%).MS-ESI:318[MH] + 1H NMR spectrum: (DMSOd 6) 1.3 (m, 2H); 1.58 (brs, 1H); 1.72 (dd, 2H); 1.8 (d, 2H); 2.4 (s, 3H); 2.2-2.45 (m, 2H); 3.0 (brs, 2H); 3.85 (s, 3H); 4.15 (t, 2H); 7.15 (s, 1H); 7.45 (s, 1H); 8.0 (s, 1H)
Backflow 7-(2-(1-methyl piperidine-4-yl) ethyoxyl)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (3.1g, thionyl chloride 9.8mmol) (40ml) solution (wherein containing 400 μ lDMF) 4 hours.After the cooling, vacuum is removed volatile matter.Residue is assigned between dichloromethane and the water, regulates the pH to 11 of water layer with solid sodium bicarbonate and ammonia.Separate organic layer, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters, and with ether washing and dry under vacuum, thereby obtains 4-chloro-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline (1.83g, 54%).MS-ESI:336[MH] + 1H NMR spectrum: (CDCl 3) 1.4-1.7 (m, 3H); 1.8 (d, 2H); 1.9 (dd, 2H); 2.05 (t, 2H); 2.35 (s, 3H); 2.95 (d, 2H); 4.05 (s, 3H); 4.25 (t, 2H); 7.3 (s, 1H); 7.4 (s, 1H); 8.88 (s, 1H) embodiment 242
95 ℃ are stirred 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (213mg, 0.662mmol) (as preparation as described in embodiment 10 starting materials) and 6-fluoro-5-oxyindole (120mg, 0.794mmol) solution in DMF (3ml) [wherein also contain potassium carbonate (137mg, 0.994mmol)] 3.5 hours.After the cooling, in mixture impouring water.Filtering mixt, and wash the gained solids with water.Solids is dissolved in dichloromethane.Dry (magnesium sulfate) organic layer, evaporation then.Residue and then with the development of ether/ethyl acetate filters the solids that forms, and obtains 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (135mg, 46%) behind the vacuum drying.MS-ESI:437[MH] + 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H); 1.8 (d, 2H); 1.9 (t, 2H); 1.7-1.9 (m, 1H); 2.17 (s, 3H); 2.8 (d, 2H); 4.0 (s, 3H); 4.1 (d, 2H); 6.48 (br s, 1H); 7.38 (d, 1H); 7.4 (s, 1H); 7.42 (t, 1H); 7.58 (d, 1H); 7.6 (s, 1H); 8.5 (s, 1H) elementary analysis measured value C 65.0 H 5.8 N 12.7C 24H 25FN 4O 30.4H 2O value of calculation C 65.0 H 5.9 N 12.6%
Initial substance is prepared as follows:
Backflow contain 2-fluoro-4-nitrophenol (15gr, 95.5mmol), benzyl bromide a-bromotoluene (18g, 105mmol), acetone (125ml) and potassium carbonate (26.5gr, mixture 190mmol) 2 hours.Remove volatile matter, then residue is assigned within 2N hydrochloric acid and the ethyl acetate.Separate organic layer, water and salt water washing, dry (magnesium sulfate) and vacuum are removed volatile matter.The residual solids thing is developed with petroleum ether, thereby obtains 2-fluoro-4-nitro-benzyloxy benzene (23g, 97%). 1H NMR spectrum: (CDCl 3) 53 (s, 2H); 7.1 (t, 1H); 7.35-7.55 (m, 5H); 8.0 (m, 2H)
To refrigerative potassium tert-butoxide (1.72g under-30 ℃, 15.4mmol dropwise add 2-fluoro-4-nitro-benzyloxy benzene (1.73g in)/DMF (15ml) solution, 7mmol) (1.29g, 7.7mmol), holding temperature is lower than-25 ℃ between charge period with 4-chlorophenoxy acetonitrile.After finishing ,-20 ℃ stirred the mixture 30 minutes, then in the mixture of cold hydrochloric acid of impouring 1N and ether.Separate organic layer, wash in proper order, then dry (magnesium sulfate) with 1N sodium hydroxide, water, saline.Vacuum is removed volatile matter, and then residue is passed through the column chromatography purification, with dichloromethane/petroleum ether (3/1) eluting, gets 3-cyano methyl-2-fluoro-4-nitro benzyloxy benzene and 5-cyano methyl-2-fluoro-4-nitro benzyloxy benzol mixture (1.2g, 60%). 1H NMR spectrum: (DMSOd 6) 4.22 (s, 2H, the isomers of 3-cyano methyl); (4.3 s, 2H, the isomer of 5-cyano methyl); (5.32 s, 2H, the isomer of 5-cyano methyl); (5.36 s, 2H, the isomer of 3-cyano methyl); 7.3-7.7 (m, 6H); (8.1 d, 1H, the isomer of 3-cyano methyl); (8.2 d, 1H, the isomer of 5-cyano methyl).
Hydrogenation 3-cyano methyl under 3 atmospheric pressures-2-fluoro-4-nitro benzyloxy benzene and 5-cyano methyl-2-fluoro-4-nitro benzyloxy benzol mixture (23g, 80.4mmol) solution [wherein containing 10% palladium-carbon (600mg)] in ethanol (220ml) and acetic acid (30ml), stop until absorption of hydrogen.Filtering mixt, vacuum evaporation filtrate then.Residue and then by using the column chromatography purification of Prochrom  equipment with dichloromethane/petroleum ether (20/80) eluting, obtains 4-fluoro-5-oxyindole (2.48g) and 6-fluoro-5-oxyindole (3.5g).4-fluoro-5-oxyindole: 1H NMR spectrum: (DMSOd 6) 6.32 (s, 1H); 6.75 (dd, 1H); 7.0 (d, 1H); 7.28 (dd, 1H); 8.8 (brs, 1H); 11.05 (brs, 1H) 6-fluoro-5-oxyindole: 1H NMR spectrum: (DMSOd 6) 6.25 (s, 1H); 7.0 (d, 1H); 7.12 (d, 1H); 7.2 (dd, 1H); 9.0 (brs, 1H) embodiment 243
95 ℃ are stirred 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (213mg, 0.662mmol) (as preparation as described in embodiment 10 starting materials) and 4-fluoro-5-oxyindole (120mg, 0.794mmol) (as preparation as described in the starting material among the embodiment 242) solution in DMF (3ml) [wherein contain potassium carbonate (137mg, 0.994mmol)] 3 hours.After the cooling, mixture is assigned among ethyl acetate and the water.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then develop with cold diethyl ether.Filter solids, get 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline (77mg, 26%) behind the vacuum drying.MS-ESI:437[MH] + 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.8 (d, 2H); 1.9 (t, 2H); 1.7-1.95 (m, 1H); 2.2 (s, 3H); 2.8 (d, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 6.55 (s, 1H); 7.1 (t, 1H); 7.3 (d, 1H); 7.4 (s, 1H); 7.48 (t, 1H); 7.62 (s, 1H); 8.5 (s, 1H) elementary analysis measured value C 64.8 H 5.8 N 12.6C 24H 25FN 4O 30.4H 2O value of calculation C 65.0 H 5.9 N 12.6% embodiment 244
95 ℃ of stirrings contain potassium carbonate (137mg, 0.994mmol) 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (282mg, 0.662mmol), (120mg, 0.794mmol) (as preparation as described in the starting material among the embodiment 242) mixture in DMF (3ml) is 3 hours for 6-fluoro-5-oxyindole.After the cooling, in residue impouring water (12ml), regulate pH to 8.The mixture ethyl acetate extraction.Separate organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then pass through C 18Preparation of silica gel column chromatography purification, with 60% methanol/ammonium carbonate solution (the 2g ammonium carbonate/liter, use CO 2Saturated) eluting.Merge to contain and expect and the fraction of product evaporate then.The gained solid is filtered in the development of residue reuse ether, and vacuum drying gets 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (147mg, 48%).MS-ESI:466[MH] + 1H NMR, spectrum: (DMSOd 6, CF 3COOD) 2.3-2.4 (m, 2H); 3.0 (s, 3H); 3.2-3.9 (m, 8H); 3.5 (t, 2H); 4.1 (s, 3H); 4.4 (t, 2H); 6.52 (d, 1H); 7.45 (d, 1H); 7.48 (s, 1H); 7.6 (s, 1H); 7.65 (d, 1H); 7.82 (s, 1H); 9.0 (s, 1H) elementary analysis measured value C 62.1 H 6.4 N 14.2C 25H 28FN 5O 30.9H 2O value of calculation C 62.3 H 6.2 N 14.5%
Initial substance is prepared as follows:
Under 5 ℃ of coolings, to 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (29g, 94.7mmol) add triphenyl phasphine (37.1g in (as preparation as described in the starting material among the embodiment 12) suspension in dichloromethane (280ml), 141.6mmol), then dropwise add 3-bromo-1-propanol (12.8ml, 141.6mmol) and the diethylazodicarboxylate (2.4ml, 141.6mmol).After the stirring at room 2 hours, vacuum is removed volatile matter, residue and then by the column chromatography purification, with methylene chloride (98/2) eluting.Merge to contain and expect the fraction of product, evaporation is then developed the residual solids thing with ether, filtration, ether washing and vacuum drying, get 7-(3-bromine propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (37.22g, 92%).MS-ESI:427-429[MH]+ 1H NMR spectrum: (DMSOd 6) 1.18 (s, 9H); 2.32 (m, 2H); 3.7 (t, 2H); 3.92 (s, 3H); 4.28 (t, 2H); 5.95 (s, 2H); 7.2 (s, 1H); 7.5 (s, 1H); 8.4 (s, 1H)
100 ℃ are stirred 7-(3-bromine propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, and (36.7g, 86mmol) suspension in 1-methyl piperazine (370ml) is 90 minutes for 4-dihydroquinazoline-4-ketone.After vacuum is removed volatile matter, residue is assigned in dichloromethane and the aqueous ammonium chloride solution.Separate organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Solids is developed with ether, filters, and ether washing and vacuum drying get 7-(3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (31.9g, 83%).MS-ESI:447[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.15 (s, 9H); 2.25 (t, 2H); 2.5 (s, 3H); 3.45 (t, 2H); 3.2-4.0 (m, 8H); 3.9 (s, 3H); 4.25 (t, 2H); 5.95 (s, 2H); 7.22 (s, 1H); 7.55 (s, 1H); 8.6 (s, 1H)
Stirring at room 7-(3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (31.8g, 71.3mmol) suspension in the saturated methanol of ammonia spends the night 4-dihydroquinazoline-4-ketone.Vacuum is removed volatile matter then.Residual solids is filtered with the ether development that contains about 10% dichloromethane, with the ether washing that contains about 10% dichloromethane, vacuum drying then, get 7-(3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (22.63g, 95%).MS-ESI:333[MH]+ 1H NMR spectrum: (DMSOd 6) 1.92 (m, 2H); 2.15 (s, 3H); 2.2-2.5 (m, 10H); 3.88 (s, 3H); 4.15 (t, 2H); 7.1 (s, 1H); 7.45 (s, 1H); 7.98 (s, 1H)
Backflow 7-(3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-3, (22.6g, 68mmol) solution in the thionyl chloride that contains DMF (5ml) (300ml) is 2 hours for 4-dihydroquinazoline-4-ketone.After the cooling, vacuum is removed volatile matter, and residue and toluene is twice of azeotropic together.Residual solids is dissolved in dichloromethane, adds entry then.Cooling mixture to 0 ℃, the pH value of water layer is adjusted to 7 with the solid carbonic acid hydrogen salt earlier, and then is elevated to 10 with the 6N sodium hydroxide.Separate organic layer, with the water layer dichloromethane extraction.Use salt water washing organic layer then, dry (magnesium sulfate) filters and vacuum is removed volatile matter.Residue and then with ether development filters, ether washing and vacuum drying, 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (16.3g, 68%).MS-ESI:351-353[MH]+ 1H NMR spectrum: (DMSOd 6) 1.98 (t, 2H); 2.18 (s, 3H); 2.45 (t, 2H); 2.22-2.5 (m, 8H); 4.05 (s, 3H); 4.28 (t, 2H); 7.4 (s, 3H); 7.45 (s, 1H); 8.9 (s, 1H) embodiment 245
Adopt the similar approach of describing among the embodiment 243, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (213mg, 0.662mmol) (as preparation as described in the starting material among the embodiment 9) and 6-fluoro-5-oxyindole (120mg, 0.794mmol) (as preparation as described in the starting material among the embodiment 242) containing potassium carbonate (137mg, 0.993mmol) DMF (3ml) in the reaction, generate 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (154mg, 53%).MS-ESI:437[MH] + 1H NMR spectrum: (DMSOd 6) 1.7-1.8 (m, 4H); 2.0-2.1 (m, 2H); 2.48 (brs, 4H); 2.6 (t, 2H); 4.02 (s, 3H); 4.3 (t, 2H); 6.5 (s, 1H); 7.4 (d, 1H); 7.4 (s, 1H); 7.45 (t, 1H); 7.6 (d, 1H); 7.62 (s, 1H); 8.52 (s, 1H) elementary analysis measured value C 65.4 H 6.0 N 12.9C 24H 25HN 4O 30.2H 2O value of calculation C 65.5 H 5.8 N 12.7% embodiment 246
To containing potassium iodide (99mg, 0.6mmol) 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (500mg, 1.2mmol) order adds 4-(2-chloroethyl) morpholine hydrochloride (134mg in (as preparation as described in the embodiment 70) solution in methanol (11.5ml), 0.72mmol) and sodium bicarbonate (151mg, 1.8mmol).Reflux to stir after 1 hour, add again 4-(2-chloroethyl) morpholine hydrochloride (134mg, 0.72mmol) and sodium bicarbonate (151mg, 1.8mmol).Reflux and stir after 1 hour, cooling mixture, and filtering precipitate are used methanol, water washing successively, after obtaining, the phosphorus pentoxide drying obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-morpholino ethyl) piperidin-4-yl methoxyl group) quinazoline (470mg, 73%).MS-ESI:532[MH] + 1H NMR spectrum: (DMSOd 6) 1.3-1.45 (m, 2H); 1.8 (d, 2H); 1.7-1.9 (m, 1H); 2.0 (t, 2H); 2.3-2.45 (m, 8H); 2.4 (s, 3H); 2.95 (d, 2H); 3.6 (t, 4H); 4.0 (s, 3H); 4.08 (d, 2H); 6.18 (s, 1H); 6.9 (dd, 1H); 7.3 (s, 1H); 7.35 (d, 1H); 7.4 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H); 11.05 (s, 1H) elementary analysis measured value C 65.3 H 7.1 N 12.6C 30H 32N 5O 40.6H 2O 0.6 methanol value of calculation C 65.4 H 7.3 N 12.5% embodiment 247
Figure A0080608502981
With 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (1.76g, 5.47mmol) (as preparation as described in the starting material among the embodiment 9), 4-fluoro-5-oxyindole (0.992g, 6.57mmol) (as preparation as described in embodiment 242 starting materials) solution in DMF (25ml) [wherein contain potassium carbonate (1.14g, 8.21mmol)] is 95 ℃ of heating 1 hour down.After the cooling, filtering mixt also washs with DMF.Evaporated filtrate by the column chromatography purification, uses methanol/(1/9), ethanol/methylene/methanol (containing ammonia) (16/80/4) sequentially eluting with residue, merges to contain expect and the fraction of product evaporate thereafter.Residue and then again by column chromatography repurity, with methylene chloride (80/20-40/60) gradient elution.Merging contains expection product fraction and is evaporated.Residue is developed with cold methanol, filters the solids that forms, and ether washing and vacuum drying get 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (1.24g, 52%).MS-ESI:437[MH] + 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.0 (m, 2H); 2.45 (brs, 4H); 2.6 (t, 2H); 4.05 (s, 3H); 4.28 (t, 2H); 6.58 (s, 1H); 7.1 (t, 2H); 7.35 (d, 1H); 7.4 (s, 1H); 7.5 (t, 1H); 7.65 (s, 1H); 8.52 (s, 1H) elementary analysis measured value C 65.3 H 5.9 N 12.6C 24H 25FN 4O 30.19 methanol, 0.17H 2O value of calculation C 65.2 H 5.9 N 12.6% embodiment 248
95 ℃ of heating contain potassium carbonate (137mg, 0.993mmol), 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (222mg, 0.662mmol) (120mg, 0.794mmol) (as preparation as described in embodiment 242 starting materials) mixture in DMF (3ml) is 3.5 hours for (as preparation as described in embodiment 67 starting materials) and 6-fluoro-5-oxyindole.After the cooling, mixture is poured in the water, used ethyl acetate extraction.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters and vacuum drying, 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (139mg, 46%).MS-ESI:451[MH] + 1H NMR spectrum: (DMSOd 6) 1.35-1.45 (m, 2H); 1.45-1.6 (m, 4H); 2.0 (m, 2H); 2.35 (brs, 4H); 2.42 (t, 2H); 4.05 (s, 3H); 4.25 (t, 2H); 6.5 (s, 1H); 7.4 (d, 1H); 7.42 (s, 1H); 7.44 (t, 1H); 7.6 (d, 1H); 7.65 (s, 1H); 8.5 (s, 1H) elementary analysis measured value C 65.9 H 6.2 N 12.3C 25H 22FN 4O 30.3H 2O value of calculation C 65.9 H 6.1 N 12.3% embodiment 249
Adopt embodiment 244 described similar approach, 95 ℃ of heating 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (407mg, 1.21mmol) (as preparation as described in the starting material among the embodiment 67), 4-fluoro-5-oxyindole (220mg, 1.45mmol) (as preparation as described in the starting material among the embodiment 242) and potassium carbonate (251mg, 1.82mmol) mixture in DMF (6ml) 90 minutes, obtain 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (367mg, 67%) behind the purification.MS-ESI:451[MH] + 1H NMR spectrum: (DMSOd 6) 1.35-1.45 (m, 2H); 1.55 (m, 4H); 2.0 (m, 2H); 2.38 (brs, 4H); 2.45 (t, 2H); 4.02 (s, 3H); 4.25 (t, 2H); 6.55 (s, 1H); 7.12 (dd, 1H); 7.32 (d, 1H); 7.4 (s, 1H); 7.5 (s, 1H); 7.65 (s, 1H); 8.52 (s, 1H) elementary analysis measured value: C 66.0 H 6.2 N 12.4C 25H 27FN 4O 30.2H 2O value of calculation: C 66.1 H 6.1 N 12.3%. embodiment 250
Adopt embodiment 248 described similar approach, make 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (268mg, 0.833mmol) (as preparation as described in embodiment 9 starting materials) and 6-fluoro-5-hydroxy-2-methyl indole (165mg, 1mmol) containing potassium carbonate (173mg, 1.25mmol) DMF (3.5ml) in the reaction, generate 4-(6-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (215mg, 57%).MS-ESI:451[MH] + 1H NMR spectrum: (DMSOd 6) 1.65-1.8 (brs, 4H); 2.02 (m, 2H); 2.4 (s, 3H); 2.48 (brs, 4H); 2.6 (t, 2H); 4.02 (s, 3H); 4.3 (t, 2H); 6.18 (s, 1H); 7.25 (d, 1H); 7.4 (s, 1H); 7.45 (d, 1H); 7.6 (s, 1H); 8.5 (s, 1H) elementary analysis measured value C 65.6 H 6.1 N 12.2C 25H 27FN 4O 30.4H 2O value of calculation C 65.6 H 6.1 N 12.2%
Initial substance is prepared as follows:
(1.23g 6.86mmol) adds Boron tribromide (3.78g, dichloromethane 15.1mmol) (2ml) solution in dichloromethane (15ml) solution of (as preparation as described in the starting material among the embodiment 237) to 6-fluoro-5-methoxyl group-2 methyl indole under-30 ℃ of coolings.After the stirring at room 90 minutes, in mixture impouring ice, dilute with dichloromethane.The pH to 6. that regulates water layer separates organic layer then, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with ethyl acetate/petroleum ether (8/2) eluting, 6-fluoro-5-hydroxy-2-methyl indole (905mg, 80%).MS-ESI:166[MH] + 1H NMR spectrum: (DMSOd 6) 2.3 (s, 3H); 5.95 (s, 1H); 6.9 (d, 1H); 7.0 (d, 1H); 8.85 (s, 1H); 10.6 (s, 1H) 13C NMR spectrum: (DMSOd 6) 13.3; 97.4 (d); 98.3; 105.5; 124.5; 128.8 (d); 135.6; 138.5 (d); 148.3 (d).Embodiment 251
Figure A0080608503011
95 ℃ of stirrings contain 4-chloro-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (232mg, 0.662mmol) (as preparation as described in the starting material in embodiment 176 or 244), 4-fluoro-5-oxyindole (120mg, 0.794mmol) (as preparation as described in embodiment 242 starting materials), DMF (3ml) and potassium carbonate (137mg, mixture 1mmol) 3 hours.After the cooling, in residue impouring water (12ml), use ethyl acetate extraction.Organic layer water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by anti-phase C 18The column chromatography purification, with methanol/ammonium carbonate (the 2g ammonium carbonate/liter, use CO 2Saturated) (60/40, thereafter 70/30) eluting.Merge and contain expection product fraction, evaporation then.Residue is dissolved in ethyl acetate, and dry (magnesium sulfate) and vacuum are removed volatile matter.Residue and then the development of reuse ether are filtered and vacuum drying, get 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline (130mg, 42%).MS-ESI:466[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.3-2.4 (m, 2H); 2.97 (s, 3H); 3.2-4.1 (m, 8H); 3.5 (t, 2H); 4.07 (s, 3H); 4.4 (t, 2H); 6.6 (d, 1H); 7.15 (t, 1H); 7.38 (d, 1H); 7.5 (d, 1H); 7.6 (s, 1H); 7.82 (s, 1H); 8.95 (s, 1H) elementary analysis measured value C 64.4 H 6.1 N 15.0C 25H 26FN 5O 3Value of calculation C 64.5 H 6.1 N 15.0% embodiment 252
With 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (600mg, 1.43mmol) (as preparation as described in the embodiment 70), 1-(2-chloroethyl)-pyrrolidine (292mg, 1.72mmol) mixture in methanol (14ml) [wherein also contains sodium carbonate (262mg, 4.3mmol) and potassium iodide (48mg, 0.29mmol)] 50 ℃ stirred 20 hours.After the cooling, vacuum is removed volatile matter.Residue and then by anti-phase C 18Preparation HPLC purification, with methanol/ammonium carbonate solution (the 2g ammonium carbonate/liter, use CO 2Saturated) (60/40, follow 70/30) eluting.Merge and contain expection product fraction, vacuum is removed volatile matter then.Residue reuse ether development subsequently, filter formed solids, behind ether washing and vacuum drying, get 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-(pyrrolidine-1-yl) ethyl)-piperidin-4-yl methoxyl group) quinazoline (102mg, 20%).MS-ESI:516[MH] + 1H NMR spectrum: (DMSOd 6) 1.3-1.5 (m, 2H); 1.6-1.75 (m, 4H); 1.8 (d, 2H); 1.7-1.9 (m, 1H); 1.95 (t, 2H); 2.45 (s, 3H); 2.4-2.5 (m, 5H); 2.95 (d, 2H); 3.35 (d, 2H); 4.0 (s, 3H); 4.1 (d, 2H); 6.18 (s, 1H); 6.9 (d, 1H); 7.25 (s, 1H); 7.35 (d, 1H); 7.38 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H); 11.05 (s, 1H) elementary analysis measured value C 68.6 H 7.2 N 13.3C 30H 37N 5O 30.5H 2O value of calculation C 68.7 H 7.3 N 13.4% embodiment 253
90 ℃ of stirrings contain potassium carbonate (67mg, 0.487mmol), 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (110mg, 0.325mmol) (59mg, 0.39mmol) (as preparation as described in embodiment 242 starting materials) mixture in DMF (1.8ml) is 2 hours for (as preparation as described in the starting material among the embodiment 1) and 6-fluoro-5-oxyindole.After the cooling, add entry.Separate formed solids, develop with methanol then.Add entry, filter the solids that produces, washing and vacuum drying get 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (55mg, 41%).MS-ESI:453[MH] + 1H NMR spectrum: (DMSOd 6) 1.95-2.05 (m, 2H); 2.45 (br s, 4H-); 2.5 (t, 2H); 3.62 (t, 4H); 4.02 (s, 3H); 4.3 (t, 2H); 6.5 (s, 1H); 7.4 (d, 1H); 7.45 (s, 1H); 7.47 (t, 1H); 7.58 (d, 1H); 7.62 (s, 1H); 8.5 (s, 1H) elementary analysis measured value C 61.6 H 5.5 N 11.9C 24H 25FN 4O 40.8H 2O value of calculation C 61.7 H 5.7 N 12.0% embodiment 254
Under 10 ℃ of coolings, to 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (183mg, 0.6mmol) (as preparation as described in the starting material among the embodiment 107), triphenyl phasphine (235mg, 0.89mmol) and 4-(2-hydroxyethyl) morpholine (93mg, 0.72mol) add in the solution in dichloromethane (4ml) diethylazodicarboxylate (140 μ l, 0.89mmol).After the stirring at room 3 hours, place mixture overnight for 5 ℃.Mixture is poured on the silicagel column, with dichloromethane, ethanol/methylene (2/98), 3N ammonia methanol solution/dichloromethane (2/98) sequentially eluting.Merge and contain expection product fraction, evaporation obtains 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-morpholino ethyoxyl) quinazoline (137mg, 55%).MS-ESI:421[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 3.30 (t, 2H); 3.65 (d, 2H); 3.7-3.8 (m, 4H); 4.05 (d, 2H); 4.1 (s, 3H); 4.7 (t, 2H); 6.5 (s, 1H); 7.05 (dd, 1H); 7.4-7.6 (m, 3H); 7.65 (s, 1H); 7.82 (s, 1H); 9.0 (s, 1H) embodiment 255-257
Adopt and similar method described in the embodiment 254, use 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (183mg, 0.6mmol) chemical compound among (as preparation as described in the starting material among the embodiment 107) preparation Table X VIII.Table X VIII
Figure A0080608503031
A) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (183mg, 0.6mmol) react with 1-(2-hydroxyethyl) pyrrolidine (82mg), generate 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(pyrrolidine-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6) 1.72 (brs, 4H); 2.6 (brs, 4H); 2.9 (t, 2H); 4.0 (s, 3H); 4.3 (t, 2H); 6.48 (s, 1H); 7.0 (dd, 1H); 7.4-7.5 (m, 3H); 7.6 (s, 1H); 8.5 (s, 1H); 11.3 (brs, 1H) b) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (183mg, 0.6mmol) react with 4-(2-hydroxyethyl)-1-methyl piperazine (103mg), generate 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(4-methyl piperazine-1-yl) ethyoxyl) quinazoline. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.5 (s, 3H); 3.35 (t, 2H); 3.65 (d, 2H); 3.7-3.8 (m, 4H); 4.05 (d, 2H); 4.1 (s, 3H); 4.7 (t, 2H); 7.05 (dd, 1H); 7.45 (s, 1H); 7.5-7.6 (m, 2H); 7.65 (s, 1H); 7.82 (s, 1H); 9.0 (s, 1H)
Initial substance is prepared as follows:
To the 1-methyl piperazine (1.26g, 13mmol) with potassium carbonate (5.0g, 36mmol) dropwise add in the mixture in dehydrated alcohol (150ml) ethylene bromohyrin (2.36g, 19mmol), and reflux mixture 18 hours.Cooling mixture then, the filtering precipitate is also removed the solvent evaporates thing by evaporation.Residue and then handle with acetone/dichloromethane, the filtering insoluble matter is removed solvent in the filtrate by evaporation, obtains bright brown oil 4-(2-hydroxyethyl)-1-methyl piperazine (870mg, 48%). 1H NMR spectrum: (CDCl 3) 2.18 (s, 3H); 2.3-2.7 (brm, 8H); 2.56 (t, 2H); 3.61 (t, 2H) MS-ESI:145[MH] +C) 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (183mg, 0.6mmol) with 1-(3-hydroxypropyl)-4-methyl piperazine (113mg) (as preparation as described in the starting material among the embodiment 133) reaction, generate 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline. 1H NMR spectrum: (DMSOd 6) 2.15 (s, 3H); 2.3-2.4 (brs, 4H); 2.5-2.6 (m, 4H); 2.8 (t, 2H); 4.0 (s, 3H); 4.35 (t, 2H); 6.45 (s, 1H); 7.0 (dd, 1H); 7.4-7.5 (m, 4H); 7.62 (s, 1H); 8.5 (s, 1H) embodiment 258
(4-fluoro-2 methyl indole-5-base oxygen base)-(570mg, 1.12mmol) solution in the saturated methanol of ammonia (7ml) spends the night 6-methoxyl group quinazoline stirring at room (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-4-.Vacuum is removed volatile matter then, and residue is passed through the column chromatography purification, with dichloromethane/contain ammonia methanol solution (approximately 3N) eluting, (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group quinazoline (390mg; 75%).MS-ESI:467[MH]+ 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.85-2.0 (m, 2H); 2.0-2.15 (m, 2H); 2.42 (s, 3H); 3.15 (m, 2H); 3.4 (d, 2H); 3.65 (m, 2H); 4.1 (s, 3H); 4.32 (d, 2H); 4.4 (m, 1H); 7.05 (dd, 1H); 7.22 (d, 1H); 7.6 (s, 1H); 7.85 (s, 1H); 9.02 (s, 1H)
Initial substance is prepared as follows:
60 ℃ of stirrings contain 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (1.2g, 3.91mmol) (as preparation as described in embodiment 12 starting materials) and 2-(R)-(-)-(+)-2,3-Epoxy-1-propanol tosylate (1.25g, 5.47mmol) and potassium carbonate (1.61g, DMF 11.7mmol) (10ml) suspension 4 hours.After the cooling, filtering mixt also washs solids with DMA.Evaporated filtrate is assigned to residue between ethyl acetate and the ammonia then.Tell organic layer, water, salt water washing, dry (magnesium sulfate) and evaporation.Residue and then by the column chromatography purification, with eluent ethyl acetate.Merge and contain expection product fraction, evaporation obtains (2R)-7-(oxirane-2-ylmethoxy)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (1.21g, 85%).MS-ESI:363[MH] + 1H NMR spectrum: (DMSOd 6) 1.12 (s, 9H); 2.75 (m, 1H); 2.9 (t, 1H); 3.4 (m, 1H); 3.93 (s, 3H); 4.0 (dd, 1H); 4.52 (dd, 1H); 5.9 (s, 2H); 7.2 (s, 1H); 7.52 (s, 1H); 8.35 (s, 1H)
Backflow (2R)-7-(oxirane-2-ylmethoxy)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (1.1g, 3mmol) (216mg, 3mmol) solution in chloroform (15ml) is 11 hours with pyrrolidine for 4-dihydroquinazoline-4-ketone.Vacuum is removed volatile matter then, residue and then by the column chromatography purification, with methylene chloride (85/15, follow 70/30) eluting, get (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3-((oxy acid methyl neopentyl)-3,4-dihydroquinazoline-4-ketone (1.18g, 90%). 1H NMR spectrum: (DMSOd 6) 1.15 (s, 9H); 1.7 (brs, 4H); 2.48 (m, 1H); 2.5 (brs, 4H); 2.65 (dd, 1H); 3.9 (s, 3H); 4.0 (brs, 1H); 4.05 (dd, 1H); 4.18 (dd, 1H); 4.95 (brs, 1H); 5.9 (s, 2H); 7.2 (s, 1H); 7.5 (s, 1H); 8.35 (s, 1H)
((oxy acid methyl neopentyl)-3, (778mg, 1.8mmol) solution in the saturated methanol of ammonia (20ml) is 24 hours for 4-dihydroquinazoline-4-ketone for stirring at room (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3-.Vacuum is removed volatile matter then.Residue is developed with ether, and filters this residue, with ether washing and vacuum drying, gets (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3 then, and 4-dihydroquinazoline-4-ketone (800mg, quantitatively). 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.92 (m, 2H); 2.05 (m, 2H); 3.15 (m, 2H); 3.35 (d, 2H); 3.62 (m, 2H); 3.98 (s, 3H); 4.18 (d, 2H); 4.32 (m, 1H); 7.35 (s, 1H); 7.6 (s, 1H); 9.2 (s, 1H)
Stirring at room (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3, (803mg, 2.51mmol) (1.2ml, 12.5mmol) mixture in is 1 hour at acetic anhydride for 4-dihydroquinazoline-4-ketone.(360 μ l 20mmol), continue to stir 90 minutes to add entry.Then mixture is assigned among sodium bicarbonate aqueous solution and the dichloromethane.Separate organic layer, use the salt water washing, dry (magnesium sulfate) and evaporation.Residue and then with ether development filters and vacuum drying, thereby obtains (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (595mg, 65%).MS-ESI:362[MH]+ 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.05 (s, 3H); 2.5 (brs, 4H); 2.72 (m, 2H); 3.9 (s, 3H); 4.3 (m, 2H); 5.25 (m, 1H); 7.2 (s, 1H); 7.45 (s, 1H); 8.0 (s, 1H)
80 ℃ of heating (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-3, (556mg, 1.54mmol) solution in thionyl chloride (6ml) and DMF (3) is 4 hours for 4-dihydroquinazoline-4-ketone.Vacuum is removed volatile matter then.Residue is dissolved in dichloromethane, with sodium bicarbonate aqueous solution, salt water washing organic layer, dry (magnesium sulfate) and evaporation, thus (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-4-chloro-6-methoxyl group quinazoline (530mg, 90%) obtained. 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.05 (s, 3H); 2.55 (brs, 4H); 2.75 (brs, 2H); 4.02 (s, 3H); 4.35-4.5 (m, 2H); 5.3 (m, 1H); 7.4 (s, 1H); 7.5 (s, 1H); 7.9 (s, 1H)
90 ℃ of stirrings contain (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-4-chloro-6-methoxyl group quinazoline (530mg, 1.4mmol) and 4-fluoro-5-hydroxy-2-methyl indole (277mg, 1.68mmol) (290mg, 2.1mmol) suspension in DMF (8ml) is 2 hours for (as preparation as described in the starting material among the embodiment 237) and potassium carbonate.After the cooling, vacuum is removed volatile matter, and then with residue by the column chromatography purification, with methylene chloride (95/5) eluting, get (2R)-7-(2-acetoxy-3-(pyrrolidine-1-yl) propoxyl group)-4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group quinazoline (580mg, 81%). 1H NMR spectrum: (DMSOd 6) 1.7 (brs, 4H); 2.05 (s, 3H); 2.4 (s, 3H); 2.52 (brs, 4H); 2.65-2.82 (m, 2H); 4.0 (s, 3H); 4.4 (m, 2H); 5.3 (m, 1H); 6.25 (s, 1H); 7.0 (dd, 1H); 7.18 (d, 1H); 7.48 (s, 1H); 7.62 (s, 1H); 8.5 (s, 1H) embodiment 259
80 ℃ of heating 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (61mg, 0.19mmol) (30mg, 0.23mmol) solution in isopropyl alcohol (2ml) [wherein containing 6.2N hydrogen chloride isopropyl alcohol liquid (33 μ l)] is 6 hours for (as preparation as described in embodiment 9 starting materials) and 5-amine indole.After the cooling, filtering precipitate with ether washing and vacuum drying, gets 4-(indole-5-base is amino)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline hydrochlorate (80mg, 72%).MS-ESI:418[MH] + 1H NMR spectrum: (DMSOd 6, CF 3COOD) 1.9 (m, 2H); 2.05 (m, 2H); 2.3 (m, 2H); 3.1 (m, 2H); 3.4 (t, 2H); 3.65 (m, 2H); 4.05 (s, 3H); 4.35 (t, 2H); (6.5 s, 0.5H, part exchange); 7.3 (d, 1H); 7.4 (s, 1H); 7.45 (s, 1H); 7.55 (d, 1H); 7.8 (s, 1H); 8.25 (s, 1H); 8.8 (s, 1H) embodiment 260-265
Adopt and similar method described in the embodiment 259, use 5-amino indole (30mg, 0.23mmol) chemical compound of describing among the synthetic Table X IX.Table X IX
Figure A0080608503081
A) 4-chloro-6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline (78mg) (as preparation as described in embodiment 12 starting materials) and the reaction of 5-amino indole generate 4-(indole-5-base is amino)-6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group) quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd6) 1.65-1.8 (m, 2H); 2.05 (d, 2H); 2.2 (brs, 1H); 3.1 (brs, 2H); 3.2 (s, 3H); 3.5 (brs, 2H); 3.6 (d, 2H); 3.8 (m, 2H); 4.05 (s, 3H); 4.] (d, 2H); 6.5 (s, 1H); 7.3 (d, 1H); 7.42 (m, 2H); 7.5 (d, 1H); 7.8 (s, 1H); 8.4 (s, 1H); 8.7 (s, 1H); 11.15 (brs, 1H); 11.32 (s, 1H) .11.5 (s, 1H) .b) 4-chloro-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline (61mg) (as preparation as described in embodiment 10 starting materials) and the reaction of 5-amino indole generate 4-(indole-5-base is amino)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd 6) 1.6-1.8 (m, 2H); 2.02 (d, 2H); 2.15 (brs, 1H); 2.75 (s, 3H); 3.0 (brs, 2H); 3.45 (d, 2H); 4.02 (s, 3H); 4.1 (d, 2H); 6.5 (s, 1H); 7.3 (d, 1H); 7.4 (m, 2H); 7.5 (d, 1H); 7.8 (s, 1H); 8.3 (s, 1H); 8.7 (s, 1H); 10.4 (brs, 1H); 11.3 (s, 1H)
There is (being produced by protonated effect) another kind of form piperidine ring (being approximately parent compound 20%) in the 4.3ppm place at detected bimodal showing in the NMR spectrum.C) 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (64mg) (as preparation as described in embodiment 1 starting material) and the reaction of 5-amino indole generate 4-(indole-5-base is amino)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline hydrochlorate. 1H NMR composes (DMSOd 6CF 3COOD): 2.35 (m, 2H); 3.15 (t, 2H); 3.3 (t, 2H); 3.57 (d, 2H); 3.8 (m, 2H); 4.02 (d, 2H); 4.03 (s, 3H); 4.3 (t, 2H); 6.5 (d, 1H); 7.3 (dd, 1H); 7.4 (s, 1H); 7.45 (s, 1H); 7.52 (d, 1H); 7.8 (s, 1H); G.25 (s, 1H); 8.78 (s; 1H) d) 4-chloro-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline (62mg) (as preparation as described in embodiment 50 starting materials) react under 6.2N hydrogen chloride/isopropyl alcohol liquid (4 μ l) with the 5-amino indole, generation 4-(the basic amino of indole-5-)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.2-2.4 (m, 2H); 3.07 (s, 3H); 3.35 (t, 2H); 4.05 (s, 3H); 4.35 (t, 2H); (6.5 d, 0.5H, part exchange); 7.2-7.35 (m, 2H); 7.45 (s, 1H); 7.5 (d, 1H); 7.8 (s, 1H); 8.2 (s, 1H); 8.75 (s, 1H) e) 4-chloro-7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group quinazoline (58mg) reacts in the presence of 6.2N hydrogen chloride/isopropyl alcohol liquid (4 μ l) with the 5-amino indole, generates 4-(indole-5-base is amino)-7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 4.03 (s, 3H); 4.65 (t, 2H); 4.8 (t, 2H); (6.5 d, 1H, part exchange); 7.30 (d, 1H); 7.4 (s, 1H); 7.45 (s, 1H); 7.52 (d, 1H); 7.75 (s, 1H); 7.8 (s, 1H); 7.9 (s, 1H); 8.25 (s, 1H); 8.75 (s, 1H); 9.25 (s, 1H)
Initial substance is prepared as follows:
Under 5 ℃, to 7-hydroxyl-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (612mg, 2mmol) (as preparation as described in embodiment 12 starting materials), 2-(imidazoles-1-yl) ethanol (280mg, 2.5mmol) (J.Med.Chem.1993,25,4052-4060) and triphenyl phasphine (655mg, 2.5mmol) dropwise add in the suspension in dichloromethane (10ml) diethylazodicarboxylate (435mg, 2.5mmol).5 ℃ stirred the mixture 10 minutes, and the room temperature restir is 1 hour then.Mixture is directly poured on the silicagel column,, got 7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group-3-((new pentane acyloxy) methyl)-3,4-dihydroquinazoline-4-ketone (640mg, 80%) with methylene chloride (95/5) eluting. 1H NMR spectrum: (CDCl 3) 1.19 (s, 9H); 3.98 (s, 3H); 4.34 (m, 2H); 4.45 (m, 2H); 5.94 (s, 2H); 7.02 (s, 1H); 7.07 (s, 1H); 7.11 (s, 1H); 7.64 (s, 1H); 7.67 (s, 1H); 8.17 (s, 1H) MS-ESI:423[MNa] +Elementary analysis: measured value C 58.3 H 6.4 N 13.9C 20H 24N 4O 50.7H 2O value of calculation C 58.2 H 6.2 N 13.6%
Stirring at room 7-(2-imidazoles-1-yl) ethyoxyl)-and 6-methoxyl group-3-((new pentane acyloxy) methyl)-3, (640mg 1.6mmol) closes solution 15 hours in the ammonia (10ml) at saturated methanol to 4-dihydroquinazoline-4-ketone.Volatile matter is removed in evaporation then, and residual solids is developed with ether, filters and collects and vacuum drying, gets 7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group-3,4-dihydroquinazoline-4-ketone (412mg, 90%). 1H NMR spectrum: (DMSOd 6) 3.89 (s, 3H); 4.4-4.5 (m, 4H); 6.9 (s, 1H); 7.16 (s, 1H); 7.28 (s, 1H); 7.47 (s, H); 7.7 (s, 1H); 7.99 (s, 1H) MS-ESI:287[MH] +Elementary analysis: measured value C 57.8 H 5.2 N 19.3C 14H 14N 4O 30.3H 2O value of calculation C 57.7 H 5.1 N 19.2%
Reflux 7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group-3, and 4-dihydroquinazoline-4-ketone (412mg, 1.44mmol), the mixture of thionyl chloride (5ml) and DMF (0.2ml) 1 hour.Use the dilution with toluene mixture then, and remove volatile matter by evaporation.Residue is suspended in dichloromethane, is cooled to 0 ℃, add sodium bicarbonate aqueous solution.Filter and collect the precipitate that produces, obtain 4-chloro-7-(2-(imidazoles-1-yl) ethyoxyl)-6-methoxyl group quinazoline (258mg, 59%) behind the vacuum drying. 1H NMR spectrum: (DMSOd 6) 4.01 (s, 3H); 4.47 (m, 2H); 4.53 (m, 2H); 6.89 (s, 1H); 7.27 (s, 1H); 7.41 (s, 1H); 7.49 (s, 1H); 7.70 (s, 1H); 8.88 (s, 1H) MS-ESI:327[MNa] +F) 4-chloro-6-methoxyl group-7-(3-(1H-1,2, the 4-triazol-1-yl) propoxyl group) quinazoline (61mg) reacts in the presence of 6.2N hydrogen chloride/isopropyl alcohol liquid (4 μ l) with the 5-amino indole, generate 4-(indole-5-base is amino)-6-methoxyl group-7-(3-(1H-1,2, the 4-1-yl) propoxyl group) the quinazoline hydrochlorate. 1H NMR spectrum: (DMSOd 6, CF 3COOD) 2.5 (m, 2H); 4.0 (s, 3H); 4.3 (t, 2H); 4.6 (t, 2H); (6.52 d, 0.5H partly exchanges); 7.3 (s, 1H); 7.35 (d, 1H); 7.45 (s, 1H); 7.55 (d, 1H); 7.8 (s, 1H); 8.16 (s, 1H); 8.66 (s, 1H); 8.77 (s, 1H); 9.43 (s, 1H) embodiment 266
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (144mg, 0.43mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (91mg, 0.66mmol) and 3-fluoro-7-hydroxyquinoline (77mg, 0.47mmol) (as preparation as described in embodiment 157 starting materials) mixture in DMF (3ml) 2 hours, be cooled to room temperature thereafter.Evaporation reaction mixture is to doing, and silica gel column chromatography gained residue is with ethanol/methylene/ammonia (0.880) (5/100/1) eluting.Merge relevant fraction, be evaporated to the dried 4-of obtaining (3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (87mg, 44%). 1H NMR spectrum: (DMSOd 6) 1.37 (m, 2H); 1.49 (m, 4H); 1.96 (m, 2H); 2.34 (m, 4H); 2.43 (t, 2H); 4.00 (s, 3H); 4.23 (t, 2H); 7.38 (s, 1H); 7.62 (s, 1H); 7.69 (dd, 1H); 8.00 (d, 1H); 8.12 (d, 1H); 8.34 (dd, 1H); 8.54 (s, 1H); 8.98 (d, 1H) MS (ESI): 463 (MH) +Embodiment 267
100 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (218mg, 0.68mmol) (as preparation as described in embodiment 9 starting materials), potassium carbonate (138mg, 1.13mmol) and 3-fluoro-7-hydroxyquinoline (117mg, 0.72mmol) (as preparation as described in embodiment 157 starting materials) mixture in DMF (4.5ml) 4 hours, be cooled to room temperature thereafter.Evaporation reaction mixture is extremely done, and residue is dissolved in dichloromethane, water, salt water washing, thereafter dry (magnesium sulfate).The evaporation organic fraction is extremely done, and then with acetonitrile recrystallization residue, obtains 4-(3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (86mg, 28%). 1H NMR spectrum: (DMSOd 6) 1.90 (m, 2H); 2.00 (m, 2H); 2.27 (m, 2H); 3.02 (m, 2H); 3.32 (m, 2H); 3.59 (m, 2H); 4.00 (s, 3H); 4.33 (t, 2H); 7.43 (s, 1H); 7.62 (s, 1H); 7.70 (dd, 1H); 7.99 (d, 1H); 8.11 (d, 1H); 8.35 (dd, 1H); 8.54 (s, 1H); 8.97 (d, 1H) MS (ESI): 449 (MH) +Embodiment 268
95 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (280mg, 0.87mmol) (as preparation as described in the embodiment 49), potassium carbonate (370mg, 2.68mmol) and 4-(1-methyl-2-oxo-piperidine-4-yl) methyl-4-tosylate (260mg, 0.87mmol) mixture in DMF (8ml) 4 hours, be cooled to room temperature thereafter.Use the acetone diluted reactant mixture, filter and vacuum evaporation filtrate, products therefrom and then by the column chromatography purification, with methylene chloride/0.88 ammonia (100/8/1) eluting.Merge relevant fraction, vacuum evaporation obtains a grease, obtains 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-methyl-2-oxo-piperidine-4-ylmethoxy) quinazoline (66mg, 17%) after ether development crystallization.M.p.250-251C 1H NMR spectrum: (DMSO-d 6) 1.66 (m, 1H), 2.10 (m, 2H), 2.40 (s, 3H), 2.50 (m, 2H), 2.84 (s, 3H), 3.34 (m, 2H), 3.99 (s, 3H), 4.12 (d, 2H), 6.12 (s, 1H), 6.86 (m, 1H), 7.25 (d, 1H), 7.30 (d, 1H), 7.38 (s, 1H), 7.59 (s, 1H), 8.48 (s, 1H) and 10.98 (brs, 1H) .MS (ESI): 447 (MH) +Elementary analysis measured value C 66.8 H 5.9 N 12.4C 25H 26N 4O 40.2H 2O value of calculation C 66.7 H 5.9 N 12.5%
Initial substance is prepared as follows:
With triethylamine (187mg, 1.85mmol) and p-toluenesulfonyl chloride (176mg, 0.92mmol) handle 4-methylol-1-methyl-2-piperidones (120mg in succession, 0.84mmol) (Yakugaku Zasshi 88, (5), 573-582, (1968)) dichloromethane solution, and stirring at room gained mixture overnight.Use the dichloromethane diluted reaction mixture then, and use sodium bicarbonate aqueous solution, water and salt water washing in succession.With the dichloromethane solution dried over mgso, filter and vacuum evaporation filtrate, obtain a dark oily residue.The latter for several times so that shift out product from insoluble matter, merges cleaning mixture with the ether washing, and vacuum evaporation obtains bright brown oily 4-(1-methyl-2-oxo-piperidine-4-yl) methyl-4-tosylate (130mg, 52%).This product need not to be further purified direct use.MS (ESI): 298 (MH) +And impurity.Embodiment 269
70 ℃ of stirring (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.79mmol) and 1-methyl piperazine (0.26ml, 2.38mmol) mixture in DMF (10ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and then residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, methylene chloride/0.88 ammonia (100/8/1)), vacuum evaporation obtains (2R)-7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (344mg, 91%). 1H NMR spectrum: (DMSO-d 6) 2.10 (s, 3H), 2.4 (m, 13H), 3.98 (s, 3H), 4.06 (m, 3H), 4.90 (brs, 1H), 6.12 (s, 1H), 6.85 (dd, 1H), 7.3 (m, 2H), 7.58 (s, 1H), 8.42 (s, 1H) and 10.98 (brs, 1H) MS (ESI): 478 (MH) +Elementary analysis measured value C 61.3 H 6.3 N 13.8C 26H 30N 4O 40.2H 2O.0.5 dichloromethane value of calculation C 61.9 H 6.2 N 13.4%
Initial substance is prepared as follows:
60 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (300mg, 0.93mmol) (as preparation as described in the embodiment 49), potassium carbonate (385mg, 2.79mmol) and (2R)-(-)-(+)-2,3-Epoxy-1-propanol tosylate (426mg, 2.79mmol) mixture in DMF (15ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and vacuum evaporation filtrate.Residue and then be dissolved in dichloromethane washs with saturated solution of sodium bicarbonate.Dry then (magnesium sulfate) organic layer filters and solvent removed in vacuo, obtains a yellow solid.The development of latter's reuse ether is filtered and drying, obtains yellow solid (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (185mg, 53%). 1H NMR spectrum: (DMSOd 6) 2.40 (s, 3H), 2.75 (m, 1H), 2.90 (m, 1H), 3.40 (m, 1H), 3.98 (s, 3H), 4.05 (m, 1H), 4.60 (m, 1H), 6.15 (s, 1H), 6.85 (dd, 1H), 7.30 (m, and 2H) 7.40 (s, 1H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.98 (s, 1H) MS (ESI): 378 (MH) +Embodiment 270
70 ℃ of stirring (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.79mmol) (as preparation as described in embodiment 269 starting materials) and diethylamine (0.25ml, 2.38mmol) mixture in DMF (10ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and then residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, methylene chloride/0.88 ammonia (100/8/1)), obtain (2R)-7-(3-(N, the N-diethylamino)-2-hydroxyl propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (288mg, 81%). 1H NMR spectrum: (DMSO-d 6) 0.95 (t, 6H), 2.10 (s, 3H), 2.4 (m, 6H), 3.98 (s, 3H), 4.14 (m, 3H), 4.84 (brs, 1H), 6.12 (s, 1H), 6.85 (dd, 1H), 7.3 (m, 3H), 7.58 (s, 1H), 8.42 (s, 1H) and 10.98 (brs, 1H) MS (ESI): 448 (MH) +Elementary analysis measured value C 64.3 H 6.6 N 12.0C 25H 30N 4O 40.4 dichloromethane value of calculation C 64.0 H 6.4 N 11.6% embodiment 271
Stirring at room 7-benzyloxy-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (7.76g, 18.9mmol), (17.82g is 282mmol) with the mixture of 10% palladium-carbon (800mg) in DMF (350ml) 1 hour for ammonium formate.Catalyst passes through the kieselguhr filtering, and uses the DMF washing leaching cake.Solvent removed in vacuo together stirred residue and saturated solution of sodium bicarbonate 2 hours.Filter this suspension then, washing and dry gets 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (5.49g, 91%). 1H NMR spectrum: (DMSO-d 6) 220 (s, 3H), 3.98 (s, 3H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.20 (s, 1H), 7.35 (m, 3H), 7.58 (s, 1H), 8.40 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 322 (MH) +
Initial substance is prepared as follows:
75 ℃ are stirred 7-benzyloxy-4-chloro-6-methoxyl group quinazoline (7.859g, 26.1mmol) (as preparation as described in embodiment 1 starting material), potassium carbonate (18.03g, 130mmol) with 5-hydroxy-3-methyl indole (5.00g, 34.0mmol) (Journal of Organic Chemistry1993,58,3757) mixture in DMA (600ml) is 2 hours, is cooled to room temperature thereafter.Filter reaction mixture, and vacuum evaporation filtrate.Rough solids and then by silica gel chromatography, with 2.5% methanol/97.5% dichloromethane eluting, 7-benzyloxy-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (7.791g, 73%). 1H NMR spectrum: (CDCl 3) 2.30 (s, 3H), 4.10 (s, 3H), 5.36 (s, 2H), 7.04 (m, 2H), 7.43 (m, 8H), 7.62 (s, 1H), 8.02 (s, 1H) and 8.60 (s, 1H) MS (ESI): 412 (MH) +Embodiment 272
80 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (800mg, 2.49mmol) (as preparation as described in the embodiment 271), potassium carbonate (687mg, 4.98mmol) and 1-chloro-3-morpholino propane (448mg, 2.74mmol) (as preparation as described in embodiment 1 starting material) mixture in DMF (20ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.88 (100/8/1)).Product obtains 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline (570mg, 51%) behind ethyl alcohol recrystallization. 1H NMR spectrum: (DMSO-d 6) 1.98 (m, 2H), 2.20 (s, 3H), 2.40 (t, 4H), 2.50 (m, 2H), 3.60 (t, 4H), 3.98 (s, 3H), 4.20 (t, 2H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 64.2 H 6.0 N 11.8C 25H 28N 4O 40.7H 2O 0.7 ethanol value of calculation C 64.2 H 6.9 N 1l.4% embodiment 273
80 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (800mg, 2.49mmol) (as preparation as described in embodiment 271 starting materials), potassium carbonate (1.031g, 7.47mmol) and 4-(2-chloroethyl) morpholine hydrochloride (510mg, 2.74mmol) mixture in DMF (25ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)).Product obtains 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline (510mg, 47%) behind ethyl alcohol recrystallization. 1H NMR spectrum: (DMSO-d 6) 2.20 (s, 3H), 2.55 (t, 4H), 2.80 (t, 2H), 3.60 (t, 4H), 3.98 (s, 3H), 4.30 (t, 2H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 2H), 7.40 (s, 1H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 64.1 H 6.3 N 12.2C 24H 26N 4O 40.4H 2O 0.8 ethanol value of calculation C 64.3 H 6.1 N 11.7% embodiment 274
80 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (1.00g, 3.11mmol) (as preparation as described in embodiment 271 starting materials), potassium carbonate (1.288g, 9.33mmol) and 4-(4-Methyl benzenesulfonyl oxygen ylmethyl)-1-tertiary butyloxycarbonyl phenylpiperidines (1.264g, 3.42mmol) (as preparation as described in embodiment 10 starting materials) mixture in DMF (35ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and solvent removed in vacuo.Residue and then pass through silica gel chromatography, with 5% methanol/95% dichloromethane eluting, and, thereby obtain 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) quinazoline (1.011g, 63%) with the product ethyl alcohol recrystallization. 1H NMR spectrum: (DMSO-d 6) 1.3 (m, 4H) 1.42 (s, and 9H) 1.90 (d, 2H), 2.10 (m, 1H), 2.28 (s, 3H), 2.80 (m, 2H), 3.98 (s, 3H), 4.08 (d, 2H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 519 (MH) +Embodiment 275
75 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (600mg, 1.87mmol) (as preparation as described in embodiment 271 starting materials), potassium carbonate (773mg, 5.60mmol) and 3-(1,1-dioxo thiomorpholine generation) propoxyl group tosylate (1.296g, 3.74mmol) mixture overnight in DMF (30ml), be cooled to room temperature thereafter.Filter reaction mixture and solvent removed in vacuo.Residue and then by silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)).Product obtains 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (525mg, 56%) behind ethyl alcohol recrystallization. 1H NMR spectrum: (DMSO-d 6) 1.98 (m, 2H), 2.17 (s, 3H), 2.65 (t, 2H), 2.90 (t, 4H), 3.10 (t, 4H), 3.98 (s, 3H), 4.25 (t, 2H), 6.95 (dd, 1H), 7.15 (s, 1H), 7.30 (d, 1H), 7.35 (m, 2H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 497 (MH) +Elementary analysis: measured value C 58.4 H 5.5 N 11.1C 25H 28N 4O 5S 0.8H 2O value of calculation C 58.8 H 5.8 N 11.0% embodiment 276
(1.290g, 2.49mmol) (as preparation as described in the embodiment 274) mixture in 25% trifluoroacetic acid/75% dichloromethane solution (75ml) is 2 hours for stirring at room 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(1-tertbutyloxycarbonyl piperidin-4-yl methoxyl group) quinazoline.Solvent removed in vacuo then, remaining buff jelly is developed with strong aqua ammonia.Leach the gained solid, drying obtains 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (648mg, 62%). 1H NMR spectrum: (DMSO-d 6) 1.35 (m, 2H), 1.80 (m, 2H), 2.05 (m, 1H), 2.10 (s, 3H), 2.70 (m, 2H), 3.10 (m, 2H), 3.98 (s, 3H), 4.05 (d, 2H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.34 (m, 3H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 419 (MH) +Embodiment 277
Stirring at room 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline (460mg, 1.10mmol) (0.38ml, 6.05mmol) mixture in methanol (5ml) is 24 hours for (as preparation as described in the embodiment 276), triethylamine (5ml) and chloroacetonitrile.Solvent removed in vacuo then, residue and then by the column chromatography purification, use gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), and with product acetonitrile recrystallization, thereby obtain 7-(1-cyano methyl piperidin-4-yl methoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (178mg, 35%). 1H NMR spectrum: (DMSO-d 6) 1.40 (m, 2H), 1.80 (m, 4H), 2.20 (m, 4H), 2.81 (m, 2H), 3.65 (s, 2H), 3.98 (s, 3H), 4.05 (d, 2H), 6.98 (dd, 1H), 7.15 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.83 (brs, 1H) MS (ESI): 458 (MH) +Elementary analysis: measured value C 66.3 H 6.1 N 14.8C 26H 27N 5O 30.7H 2O value of calculation C 66.4 H 6.1 N 14.9% embodiment 278
60 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (1.35g, 4.2mmol) (as preparation as described in embodiment 271 starting materials), potassium carbonate (1.74g, 12.6mmol) and (2R)-(-)-(+)-2,3-Epoxy-1-propanol tosylate (1.92g, 8.4mmol) mixture overnight in DMF (25ml), be cooled to room temperature thereafter.Filter reaction mixture and solvent removed in vacuo.Residue is dissolved in dichloromethane, washs with saturated solution of sodium bicarbonate.Dry then) magnesium sulfate (organic layer), filter and solvent removed in vacuo, obtain a solids.And then develop the latter with ether, and leach formed solid, obtain (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (842mg, 53%) after the drying. 1H NMR spectrum: (DMSO-d 6) 2.20 (s, 3H), 2.80 (m, 1H), 2.90 (m, 1H), 3.42 (m, 1H), 3.98 (s, 3H), 4.02 (m, 1H), 4.60 (m, 1H), 6.98 (dd, 1H), 7.18 (s, 1H) 7.35 (m, 3H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.82 (s, 1H) MS (ESI): 378 (MH) +Embodiment 279
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.65mmol) (as preparation as described in the embodiment 278) and piperidines (0.2ml, 2.04mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, 1%0.880 saturated ammonia/10% methanol/89% dichloromethane), thereby obtain (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (237mg, 78%). 1H NMR spectrum: (DMSO-d 6) 1.38 (m, 2H), 1.50 (m, 4H), 2.34 (m, 9H), 3.98 (s, 3H), 4.16 (m, 3H), 4.85 (brs, 1H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 464 (MH) +Elementary analysis: measured value C 66.3 H 6.6 N 12.1C 26H 30N 4O 40.5 methanol value of calculation C 66.5 H 6.7 N 11.7% embodiment 280
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.65mmol) (as preparation as described in the embodiment 278) and pyrrolidine (0.17ml, 2.04mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (257mg, 88%). 1H NMR spectrum: (DMSO-d 6) 1.65 (m, 4H), 1.98 (m, 2H), 2.20 (s, 3H), 2.50 (m, 2H), 2.62 (m, 2H), 3.98 (s, 3H), 4.17 (m, 3H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 449 (MH) +Elementary analysis: measured value C 64.1 H 6.4 N 12.6C 25H 28N 4O 41.0H 2O value of calculation C 64.4 H 6.5 N 12.0% embodiment 281
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and 1-methyl piperazine (0.31ml, 2.78mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (352mg, 80%). 1H NMR spectrum: (DMSO-d 6) 2.10 (s, 3H), 2.20 (s, 3H), 2.40 (m, 10H), 3.98 (s, 3H), 4.13 (m, 3H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 478 (MH) +Elementary analysis: measured value C 61.6 H 6.4 N 14.4C 26H 31N 5O 41.0H 2O.0.25 methanol value of calculation C 61.6 H 6.8 N13.9% embodiment 282
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and morpholine (0.24ml, 2.78mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (methane dioxide, 5% methanol/95% dichloromethane, the methanol/saturated ammonia in dihydro methane/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-morpholino propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (398mg, 93%). 1H NMR spectrum: (DMSO-d 6) 2.20 (s, 3H), 2.44 (m, 6H), 3.48 (t, 4H), 3.98 (s, 3H), 4.13 (m, 3H), 4.98 (brs, 1H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 465 (MH) +Elementary analysis: measured value C 58.5 H 6.0 N 11.2C 25H 28N 4O 52.5H 2O. value of calculation C 58.9 H 6.5 N 11.0% embodiment 283
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and 2.0M decil alcoholic solution (4.60ml, 9.30mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-dimethylamino propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (308mg, 78%). 1H NMR spectrum: (DMSO-d 6) 2.10 (m, 9H), 2.20 (m, 2H), 3.98 (s, 3H), 4.13 (m, 3H), 4.98 (brs, 1H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 423 (MH) +Elementary analysis: measured value C 65.5 H 6.2 N 13.2C 23H 20N 4O 4Value of calculation C 65.4 H 6.2 N 13.3% embodiment 284
60 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and diethylamine (0.29ml, 2.78mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, and residue passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-((N, the N-diethylamino) propoxyl group))-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (338mg, 81%). 1H NMR spectrum: (DMSO-d 6) 0.95 (t, 6H), 2.11 (s, 3H), 2.40 (m, 6H), 3.98 (s, 3H), 4.13 (m, 3H), 4.84 (brs, 1H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 451 (MH) +Elementary analysis: measured value C 64.4 H 6.6 N 12.0C 25H 30N 4O 41.0H 2O. value of calculation C 64.1 H 6.9 N 12.0% embodiment 285
100 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and 2-aminopropane. (0.29ml, 4.65mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, residue is passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (307mg, 75%). 1H NMR spectrum: (DMSO-d 6) 0.98 (d, 6H), 2.20 (s, 3H), 2.55-2.80 (m, 3H), 3.98 (s, 3H), 4.02-4.20 (m, 3H), 4.98 (brs, 1H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.30-7.40 (m, 3H), 7.60 (s, 1H), 8.42 (s is 1H) with 10.82 (brs, 1H) MS (ESI): 437 (MH) +Elementary analysis: measured value C 63.3 H 6.3 N 12.4C 24H 28N 4O 41.0H 2O. value of calculation C 63.4 H 6.7 N 12.3% embodiment 286
130 ℃ of stirring (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (350mg, 0.93mmol) (as preparation as described in the embodiment 278) and diisopropylamine (0.78ml, 5.58mmol) mixture in DMF (10ml) 24 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, residue is passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, the saturated ammonia in ethanol/methylene/0.880 (100/8/1)), thereby obtain (2R)-7-(2-hydroxyl-3-((N, the N-diisopropyl) propoxyl group amino))-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (398mg, 93%). 1H NMR spectrum: (DMSO-d 6) 0.98 (d, 12H), 2.20 (s, 3H), 2.72 (m, 2H), 3.00 (m, 2H), 3.98 (s, 3H), 4.11 (m, 3H), 6.98 (dd, 1H), 7.18 (s, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 8.42 (s, 1H) and 10.82 (brs, 1H) MS (ESI): 479 (MH) +Elementary analysis: measured value C 65.4 H 6.8 N 11.3C 27H 3N 4O 40.8H 2O. value of calculation C 55.8 H 7.2 N 11.4% embodiment 287
70 ℃ of heating (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (0.12ml, 0.84mmol) mixture in DMF (5ml) is 3 hours for (as preparation as described in the embodiment 278) and 4-(3-aminopropyl) morpholine.Solvent removed in vacuo is absorbed in dichloromethane with residue then, and then washes with water, dry (magnesium sulfate), filtration and evaporation.The gained residue passes through silica gel chromatography again, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, 20% methanol close ammonia (7M)/80% dichloromethane), thereby obtain (2R)-7-(2-hydroxyl-3-(3-morpholino propyl group amino) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (67mg, 46%). 1H NMR spectrum: (DMSO-d 6) 1.28 (m, 2H), 2.30 (t, 4H), 2.56 (t, 2H), 2.650 (m, 4H), 3.55 (t, 4H), 3.98 (s, 3H), 4.15 (m, 3H), 6.42 (s, 1H), 6.98 (dd, 1H), 7.42 (m, 4H), 7.60 (s, 1H), 8.45 (s, 1H) and 11.19 (brs, 1H) MS (ESI): 508 (MH) +Elementary analysis: measured value C 59.7 H 6.6 N 13.4C 27H 33N 5O 51.8H 20 value of calculation C, 60.1 H, 6.8 N, 13.0% embodiment 288
Heating (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (132mg, 0.84mmol) ℃ reaction of the mixture to 70 in DMF (5ml) is 3 hours for (as preparation as described in the embodiment 278) and 1-(3-aminopropyl)-4-methyl piperazine.Solvent removed in vacuo is absorbed in dichloromethane with residue then, and then washes with water, dry (magnesium sulfate), filtration and evaporation.Gained residue and then pass through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, 20% methanol close ammonia (7M)/80% dichloromethane), thereby obtain (2R)-7-(2-hydroxyl-3-(3-(4-methyl piperazine-1-yl) propyl group amino) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (44mg, 31%). 1H NMR spectrum: (DMSO-d 6) 1.55 (m, 2H), 2.10 (s, 3H), 230 (t, 8H), 2.62 (m, 6H), 3.98 (s, 3H), 4.12 (m, 3H), 6.42 (s, 1H), 6.98 (dd, 1H), 7.42 (m, 4H), 7.60 (s, 1H), 8.45 (s, 1H) and 11.19 (brs, 1H) MS (ESI): 521 (MH) +Elementary analysis: measured value C 61.3 H 7.3 N 16.1C 28H 36N 6O 41.6H 2O value of calculation C 61.2 H 7.2 N 16.3% embodiment 289
Heating (2R)-6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (70mg, 0.19mmol) (74mg, 0.58mmol) ℃ reaction of the mixture to 60 in DMF (5ml) is 3 hours for (as preparation as described in the embodiment 278) and 1-(3-aminopropyl) pyrrolidine.Solvent removed in vacuo then, residue is passed through silica gel chromatography, gradient elution (dichloromethane, 5% methanol/95% dichloromethane, 20% methanol close ammonia (7M)/80% dichloromethane), thereby obtain (2R)-7-(2-hydroxyl-3-(3-(pyrrolidine-1-yl) propyl group amino) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline (64mg, 68%). 1H NMR spectrum: (DMSO-d 6) 1.60 (m, 6H), 2.25 (m, 4H), 2.60 (m, 4H), 3.08 (m, 2H), 3.98 (s, 3H), 4.12 (m, 3H), 6.42 (s, 1H), 6.98 (dd, 1H), 7.34 (m, 4H), 7.58 (s, 1H), 8.42 (s, 1H) and 11.80 (brs, 1H) MS (ESI): 492 (MH) +Embodiment 290
90 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (380mg, 1.13mmol) (as preparation as described in the embodiment 67 initial substance parts), potassium carbonate (469mg, 3.4mmol), 4-bromo-5-oxyindole (240mg, 1.13mmol) and the mixture of DMA (4.0ml) 3 hours, be cooled to room temperature thereafter.Filter reaction mixture and vacuum evaporation filtrate.Residue column chromatography purification uses methylene chloride to close ammonia (7M) (95/5) eluting, obtains a grease.And then with this grease again by the column chromatography purification, with methylene chloride (60/40) eluting, obtain 4-(4-bromo indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (256mg, 44%). 1H NMR spectrum: (CDCl 3) 1.47 (m, 2H), 1.60 (m, 4H), 2.14 (m, 2H), 2.44 (m, 4H), 2.54 (t, 2H), 4.08 (s, 3H), 4.27 (t, 2H), 6.67 (m, 1H), 7.15 (d, 1H), 7.32 (t, 1H), 7.36 (s, 1H), 7.42 (d, 1H), 7.69 (s, 1H) 8.55 (brs, 1H) and 8.62 (s, 1H) MS (ESI): 511,513 (MH) +Elementary analysis measured value C 58.2 H 5.3 N 10.8C 25H 27BrN 4O 30.25H 2O, value of calculation C 58.2 H 5.4 N 10.9%
Initial substance is prepared as follows:
(1.49g, 5mmol) (Jnl.Org.Chem.1984,49,4761) are dissolved in ethanol (10ml) and the water (3.5ml) with 4-bromo-5-oxyindole-2-carboxylic acid, ethyl ester.Add potassium hydroxide (840mg), and with mixture under blanket of nitrogen 50 ℃ stirred 1 hour, be cooled to room temperature then.Evaporating solvent and with residue water-soluble (25ml).Add the 2M aqueous hydrochloric acid solution to the pH of reactant mixture be 4, leach formed precipitate thereafter, washing and vacuum drying obtain 4-bromo-5-methoxyl group indole-2-carboxylic acid (1.30,96%). 1H NMR spectrum: (DMSO-d 6) 3.83 (and s, 3H), 6.90 (d, 1H), 7.16 (d, 1H), 7.40 (d, 1H) .11.88 (brs, 1H) and 13.19 (brs, 1H) MS (ESI): 268,270 (M-H)
Together mix 4-bromo-5-methoxyl group indole-2-carboxylic acid (1.25g, 4.19mmol), quinoline (15ml) and Cupric chromate(III). (313mg).Slowly logical nitrogen is 5 minutes in mixture, then heating blends to 245 ℃ rapidly in nitrogen atmosphere.After 90 minutes, cooling mixture adds ethyl acetate (100ml) dilution to room temperature, and washs with 2M aqueous hydrochloric acid solution (60ml).Filter ethyl acetate layer, dry (magnesium sulfate) filtrate and evaporating solvent.Residue and then by silica gel chromatography, with dichloromethane/hexane (1/1) eluting, 4-bromo-5-methoxyl group indole (635mg, 60%). 1H NMR composes (CDCl 3) 3.94 (s, 3H), 6.55 (m, 1H), 6.93 (d, 1H), 7.27 (m, 2H) .8.18 (brs, 1H) MD (ESI): 224,226 (M-H) -
(540mg, dichloromethane 2.4mmol) (12ml) solution is to-40 ℃ for cooling 4-bromo-5-methoxyl group indole in nitrogen atmosphere.(4.8ml 1M dichloromethane solution, 4.8mmol), warm then mixture stirred 1 hour to room temperature dropwise to add Boron tribromide.(5ml) diluted mixture that adds methylene chloride thing, and washed with 2M aqueous hydrochloric acid solution (3ml).Tell organic layer, dry (magnesium sulfate), evaporation obtains a dark grease.And then,, get 4-bromo-5-oxyindole (295mg, 55%) with dichloromethane/ethyl acetate (8/2) eluting by silica gel chromatography. 1H NMR spectrum: (CDCl 3) 6.46 (m, 1H), 7.92 (d, 1H), 7.22 (m, 2H), 8.80 (brs, 1H) MS (ESI): 210,212 (M-H) -Embodiment 291
To 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (335mg, 0.68mmol) (as preparation as described in the starting material among the embodiment 67), potassium carbonate (281.5mg, 2.04mmol), 5-hydroxyl-1-methylindole (100mg, 0.68mmol) with the mixture of DMA (4.0ml) in logical nitrogen 5 minutes.Then in nitrogen atmosphere 90 ℃ stirred the mixture 4 hours, be cooled to room temperature.Filter reaction mixture, and vacuum evaporation filtrate.Residue and then successively develop purification with methanol, water, 6-methoxyl group-4-(1-methylindole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (148mg, 49%). 1H NMR spectrum: (DMSO-d 6) 1.38 (m, 2H), 1.51 (m, 4H), 1.93 (m, 2H), 2.35 (m, 4H), 2.41 (t, 2H), 3.83 (s, 3H), 3.97 (s, 3H), 4.24 (t, 2H), 6.42 (d, 1H), 7.06 (dd, 1H), 7.33 (s, 1H), 7.42 (m, 2H), 7.50 (d, 1H), 7.59 (s, 1H) and 8.47 (s, 1H) MS (ESI): 447 (MH) +Elementary analysis measured value C 69.5 H 6.8 N 12.5C 26H 30N 4O 3Value of calculation C 69.9 H 6.8 N 12.6%
Initial substance is prepared as follows:
Use 10% palladium-carbon (0.5g) as catalyst, room temperature hydrogenation 5-benzyloxy-1-methylindole under 1 atmospheric pressure hydrogen atmospheric pressure (3.5g, ethanol 15.7mmol) (100ml) solution 4 hours.Filtration catalizer, and vacuum evaporation filtrate.Residue and then by silica gel chromatography, with ethyl acetate/dichloromethane (10/90) eluting, 5-hydroxyl-1-methylindole (2.1g, 97%).MS (ESI): 146 (M-H) - 1H NMR spectrum: (CDCl 3) 3.74 (s, 3H), 4.50 (S, 1H), 6.33 (d, 1H), 6.79 (dd, 1H), 7.00 (m, 2H), 7.17 (d, 1H) embodiment 292
Under the blanket of nitrogen, 75 ℃ of stirring (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.83mmol) and pyrrolidine (176mg, 2.48mmol) mixture in DMF (5ml) is 3 hours, is cooled to room temperature thereafter.Solvent removed in vacuo, residue is passed through silica gel purification, close (98/2-90/10) gradient elution of ammonia (7M) with dichloromethane, methylene chloride (95/5), methylene chloride, get (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (326mg, 87%). 1H NMR spectrum: (CDCl 3) 1.80 (m, 4H), 2.56 (m, 3H), 2.71 (m, 2H), 2.87 (m, 1H), 4.04 (s, 3H), 4.23 (m, 3H), 6.59 (m, 1H), 7.07 (dd, 1H), 7.25 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.50 (d, 1H), 7.61 (s, 1H), 8.30 (brs, 1H) and 8.60 (s, 1H) MS (ESI): 435 (MH) +Elementary analysis measured value C 63.4 H 5.9 N 12.3C 24H 26N 4O 4.1H 2O value of calculation C 63.7 H 6.2 N 12.4%
Initial substance is prepared as follows:
To 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (3.07g, 10mmol) (as preparation as described in the starting material among the embodiment 107), potassium carbonate (4.14g, 30mmol) and (2R)-(-)-(+)-2,3-Epoxy-1-propanol tosylate (4.57g, 20mmol) logical nitrogen 5 minutes in the mixture in DMA (35ml).Then in nitrogen atmosphere 60 ℃ stirred the mixture 2 hours, then be cooled to room temperature.Filter reaction mixture, and vacuum evaporation filtrate.Residue and then by silica gel chromatography, with methylene chloride (100/0-95/5) gradient elution, yellow solid (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (1.92g, 53%). 1H NMR spectrum: (DMSOd 6) 2.75 (m, 1H), 2.89 (m, 1H), 3.44 (m, 1H), 3.97 (s, 3H), 4.06 (m, 1H), 4.58 (dd, 1H), 6.44 (m, 1H), 6.95 (dd, 1H), 7.40 (m, 4H) 7.62 (s, 1H), 8.47 (s, 1H), 11.19 (brs 1H) MS (ESI): 364 (MH) +Embodiment 293
Adopt the similar approach of describing among the embodiment 292, make (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.83mmol) (as preparation as described in the initial substance among the embodiment 292) and morpholine (211mg, 2.49mmol) reaction, generate (2R)-7-(2-hydroxyl-3-morpholino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (338mg, 85%). 1H NMR spectrum: (CDCl 3) 2.48 (m, 2H), 2.624 (m, 2H), 2.68 (m, 2H), 3.78 (m, 4H), 4.04 (s, 3H), 4.24 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.29 (m, 1H), 7.34 (s, 1H), 7.46 (d, 1H), 7.50 (d, 1H), 7.62 (s, 1H), 8.31 (brs, 1H) and 8.62 (s, 1H) MS (ESI): 451 (MH) +Elementary analysis measured value C 60.3 H 5.9 N 12.3C 24H 26N 4O 5.1.5H 2O value of calculation C 60.4 H 6.1 N 11.7% embodiment 294
Adopt the similar approach of describing among the embodiment 292, make (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.83mmol) (as preparation as described in the initial substance among the embodiment 292) and piperidines (211mg, 2.49mmol) reaction, generate (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (325mg, 86%). 1H NMR spectrum: (CDCl 3) 1.47 (m, 2H), 1.61 (m, 4H), 2.39 (m, 2H), 2.54 (d, 2H), 2.64 (m, 2H), 4.04 (s, 3H), 4.24 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.29 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.48 (d, 1H), 7.62 (s, 1H), 8.28 (brs, 1H) and 8.60 (s, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 65.9 H 6.3 N 12.3C 25H 28N 4O 4.0.5H 2O value of calculation C 65.6 H 6.4 N 12.3% embodiment 295
Under the blanket of nitrogen, 75 ℃ of stirring (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.83mmol) (as preparation as described in embodiment 292 starting materials) and dimethylamine (1.24ml, 2M THF solution, 2.48mmol) mixture in DMF (5ml) 3 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, residue are got (2R)-7-(2-hydroxyl-3-dimethylamino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (265mg, 63%) by purifying with the methanol development. 1H NMR spectrum: (DMSOd 6) 2.21 (s, 6H), 2.38 m, 2H), 3.97 (s, 3H), 4.073 (m, 2H), 4.21 (m, 1H), 4.96 (d, 1H), 6.43 (m, 1H), 6.97 (dd, 1H), 7.37 (s, 1H), 7.43 (m, 3H), 7.62 (s, 1H), 8.48 (s, 1H) and 11.20 (brs, 1H) MS (ESI): 409 (MH) +Elementary analysis measured value C 62.8 H 5.8 N 13.2C 22H 24N 4O 4.0.7H 2O value of calculation C 62.8 H 6.1 N 13.3% embodiment 296
Under the blanket of nitrogen, 70 ℃ of stirring (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (300mg, 0.83mmol) (as preparation as described in embodiment 292 starting materials) and diisopropylamine (1.35ml, 9.7mmol) mixture in DMF (5ml) 19 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, residue and then pass through silica gel purification, use dichloromethane, methylene chloride (95/5), methylene chloride to close (98/2-90/10) gradient elution of ammonia (7M), get (2R)-7-(2-hydroxyl-3-((N, the N-diisopropyl) propoxyl group amino))-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (343mg, 86%). 1H NMR spectrum: (CDCl 3) 1.08 (m, 12H), 1.57 (m, 1H), 1.75 (m, 1H), 3.10 (m, 2H), 4.04 (s, 3H), 4.16 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.26 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.50 (d, 1H), 7.61 (s, 1H), 8.32 (brs, 1H) and 8.61 (s, 1H) MS (ESI): 465 (MH) +Elementary analysis measured value C 64.8 H 6.8 N 11.9C 26H 32N 4O 4.1.0H 2O value of calculation C 64.6 H 7.0 N 11.6% embodiment 297
Under the blanket of nitrogen, 75 ℃ of stirring (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) and pyrrolidine (60mg, 0.84mmol) mixture in DMF (5ml) is 3 hours, is cooled to room temperature thereafter.Solvent removed in vacuo, residue and then pass through silica gel purification, use dichloromethane, methylene chloride (95/5), methylene chloride to close (98/2-90/10) gradient elution of ammonia (7M), get (2S)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (114mg, 92%). 1H NMR spectrum: (CDCl 3) 1.80 (m, 4H), 2.56 (m, 3 H), 2.71 (m, 2H), 2.86 (m, 1H), 4.04 (s, 3H), 4.23 (m, 3H), 6.59 (m, 1H), 7.07 (dd, 1H), 7.25 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.50 (d, 1H), 7.61 (s, 1H), 8.30 (brs, 1H) and 8.60 (s, 1H) MS (ESI): 435 (MH) +Elementary analysis measured value C 64.7 H 6.0 N 12.6C 24H 26N 4O.0.5H 2O value of calculation C 64.9 H 6.1 N 12.7%
Initial substance is prepared as follows:
To 7-hydroxyl-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (3.07g, 10mmol) (as preparation as described in the starting material among the embodiment 107), potassium carbonate (4.14g, 30mmol) and (2S)-(+)-(+)-2,3-Epoxy-1-propanol tosylate (4.57g, 20mmol) logical nitrogen 5 minutes in the mixture in DMA (35ml).Then in nitrogen atmosphere 60 ℃ stirred the mixture 2 hours, then be cooled to room temperature.Filter reaction mixture, and vacuum evaporation filtrate.Residue and then by silica gel chromatography, with methylene chloride (100/0-95/5) gradient elution.Solvent removed in vacuo, and residue developed with ether, yellow solid (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (1.88g, 52%). 1H NMR spectrum: (DMSOd 6) 2.75 (m, 1H), 2.89 (m, 1H), 3.44 (m, 1H), 3.97 (s, 3H), 4.06 (m, 1H), 4.58 (dd, 1H), 6.44 (m, 1H), 6.95 (dd, 1H), 7.46 (m, 4H) 7.62 (s, 1H), 8.47 (s, 1H) and 11.19 (brs 1H) MS (ESI): 364 (MH) +Embodiment 298
Adopt embodiment 297 described similar approach, make (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 297 starting materials) and morpholine (73.2mg, 0.84mmol) reaction, generate (2S)-7-(2-hydroxyl-3-morpholino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (82mg, 63%). 1H NMR spectrum: (CDCl 3) 2.48 (m, 2H), 2.62 (m, 2H), 2.68 (m, 2H), 3.78 (m, 4H), 4.04 (s, 3H), 4.29 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.29 (m, and 1H) 7.34 (s, 1H), 7.46 (d, 1H), 7.50 (d, 1H), 7.62 (s, 1H), 8.31 (brs, 1H) and 8.62 (s, 1H) MS (ESI): 451 (MH) +Elementary analysis measured value C 61.7 H 5.7 N 11.8C 24H 26N 4O 5.1.0H 2O value of calculation C 61.5 H 6.0 N 12.0% embodiment 299
Adopt embodiment 297 described similar approach, make (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 297 starting materials) and piperidines (70mg, 0.83mmol) reaction, generate (2S)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (93mg, 73%). 1H NMR spectrum: (CDCl 3) 1.47 (m, 2H), 1.61 (m, 4H), 2.39 (m, 2H), 2.54 (d, 2H), 2.64 (m, 2H), 4.04 (s, 3H), 4.29 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.29 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.48 (d, 1H), 7.62 (s, 1H), 8.28 (brs, 1H) and 8.60 (s, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 65.8 H 6.2 N 12.2C 25H 28N 4O 4.0.5H 2O value of calculation C 65.6 H 6.4 N 12.3% embodiment 300
Under the blanket of nitrogen, 75 ℃ of stirring (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 297 starting materials) and dimethylamine (0.42ml, 2M THF solution, 0.84 mmol) mixture in DMF (5ml) is 3 hours, is cooled to room temperature thereafter.Solvent removed in vacuo, residue and then by developing in addition purification with methanol, (2S)-7-(2-hydroxyl-3-dimethylamino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (100mg, 85%). 1H NMR spectrum: (DMSOd 6) 2.21 (s, 6H), 2.38 (m, 2H), 3.97 (s, 3H), 4.083 (m, 2H), 4.21 (m, 1H), 4.96 (d, 1H), 6.43 (m, 1H), 6.97 (dd, 1H), 7.37 (s, 1H), 7.43 (m, 3H), 7.62 (s, 1H), 8.48 (s, 1H) and 11.20 (brs, 1H) MS (ESI): 409 (MH) +Elementary analysis measured value C 63.6 H 6.0 N 13.3C 22H 24N 4O 4.0.5H 20 value of calculation C, 63.3 H, 6.0 N, 13.4% embodiment 301
Under the blanket of nitrogen, 70 ℃ of stirring (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 297 starting materials) and diisopropylamine (0.45ml, 3.2mmol) mixture in DMF (5ml) 19 hours, be cooled to room temperature thereafter.Solvent removed in vacuo, residue and then pass through silica gel purification, use methylene chloride (100/0-95/5), methylene chloride to close (98/2-90/10) gradient elution of ammonia (7M), get (2S)-7-(2-hydroxyl-3-((N, the N-diisopropyl) propoxyl group amino))-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (43mg, 33%). 1H NMR spectrum: (CDCl 3) 1.08 (m, 12H), 1.57 (m, 1H), 1.759 (m, 1H), 3.10 (m, 2H), 4.04 (s, 3H), 4.16 (m, 3H), 6.58 (m, 1H), 7.08 (dd, 1H), 7.26 (m, 1H), 7.32 (s, 1H), 7.45 (d, 1H), 7.50 (d, 1H), 7.61 (s, 1H), 8.32 (brs, 1H) and 8.61 (s, 1H) MS (ESI): 465 (MH) +Elementary analysis measured value C 67.2 H 7.0 N 11.9C 26H 32N 4O 4. value of calculation C 67.2 H 6.9 N 12.1% embodiment 302
Under the blanket of nitrogen, 75 ℃ of stirring (2R)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 292 starting materials) and the mixture of 2-aminopropane. (1.0ml) in THF (10ml) 18 hours, be cooled to room temperature thereafter.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2R)-7-(2-hydroxyl-8-(isopropyl amino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (82mg, 68%). 1H NMR spectrum: (DMSOd 6) 0.98 (m, 6H), 2.68 (m, 3H), 3.96 (m, 4H), 4.13 (m, 2H), 5.06 (brs, 1H), 6.44 (s, 1H), 6.98 (dd, 1H), 7.439 (r, 4H), 7.60 (s, 1H), 8.46 (s, 1H) and 11.22 (s, 1H) MS (ESI): 423 (MH) +Elementary analysis measured value C 63.6 H 6.4 N 12.9C 23H 26N 4O 4.0.6H 2O value of calculation C 63.8 H 6.3 N 12.9% embodiment 303
Under the blanket of nitrogen, 75 ℃ of stirring (2S)-4-(indole-5-base oxygen base)-6-methoxyl group-7-(oxirane-2-ylmethoxy) quinazoline (100mg, 0.28mmol) (as preparation as described in embodiment 297 starting materials) and the mixture of 2-aminopropane. (1.0ml) in THF (10ml) 18 hours, be cooled to room temperature thereafter.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2S)-7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline (66mg, 56%). 1H NMR spectrum: (DMSOd 6) 0.985 (m, 6H), 2.68 (m, 3H), 3.96 (m, 4H), 4.13 (m, 2H), 5.06 (brs, 1H), 6.44 (s, 1H), 6.98 (dd, 1H), 7.43 (m, 4H), 7.60 (s, 1H), 8.46 (s, 1H) and 11.22 (s, 1H) MS (ESI): 423 (MH) +Elementary analysis measured value C 63.1 H 6.3 N 12.7C 23H 26N 4O 4.0.9H 2O value of calculation C 63.0 H 6.4 N 12.8% embodiment 304
Under the blanket of nitrogen, 75 ℃ of stirring (2S)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (250mg, 0.66mmol) and the mixture of pyrrolidine (1.5ml) in THF (10ml) 3 hours, be cooled to room temperature thereafter.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2S)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (106mg, 36%). 1H NMR spectrum: (DMSOd 6) 1.60 (s, 4H), 2.38 (s, 3H); 2.57 (m, 6H), 4.11 (m, 6H), 4.95 (d, 1H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.29 (m, 2H), 7.37 (s, 1H), 7.59 (s, 1H), 8.48 (s, 1H) and 11.00 (s, 1H) MS (ESI): 450 (MH) +Elementary analysis measured value C 67.0 H 6.5 N 12.0C 25H 28N 4O 4.0.1H 2O value of calculation C 66.7 H 6.3 N 12.4%
Initial substance is prepared as follows:
60 ℃ are stirred 7-hydroxyl-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (300mg, 0.93mmol) (as preparation as described in the embodiment 49), potassium carbonate (385mg, 2.79mmol) and (2S)-(-)-(+)-2,3-Epoxy-1-propanol tosylate (426mg, 2.79mmol) mixture in DMF (15ml) 2 hours, be cooled to room temperature thereafter.Filter reaction mixture and vacuum evaporation filtrate.Residue is dissolved in dichloromethane, washs with saturated solution of sodium bicarbonate.Dry then (magnesium sulfate) organic layer filters and solvent removed in vacuo, obtains a yellow solid.And then with the ether development, filter and drying, get (2S)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline yellow solid (277mg, 78%). 1H NMR spectrum: (DMSO) 2.40 (s, 3H), 2.75 (m, 1H), 2.90 (m, 1H), 3.40 (m, 1H), 3.98 (s, 3H), 4.05 (m, 1H), 4.60 (m, 1H), 6.15 (s, 1H), 6.85 (dd, 1H), 7.30 (m, and 2H) 7.40 (s, 1H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.98 (s, 1H) MS (ESI): 378 (MH) +Embodiment 305
Under the blanket of nitrogen, 75 ℃ of stirring (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (250mg, 0.66mmol) (as preparation as described in embodiment 269 starting materials) and the mixture of pyrrolidine (1.5ml) in THF (10ml) 3 hours, be cooled to room temperature thereafter.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (165mg, 55%). 1H NMR spectrum: (DMSOd 6) 1.60 (s, 4H), 2.38 (s, 3H), 2.57 (m, 6H), 4.11 (m, 6H), 4.95 (d, 1H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.29 (m, 2H), 7.37 (s, 1H), 7.59 (s, 1H), 8.48 (s, 1H) and 11.00 (s, 1H) MS (ESI): 450 (MH) +Elementary analysis measured value C 66.8 H 6.3 N 12.4C 25H 28N 4O 4.0.1H 2O value of calculation C 66.7 H 6.3 N 12.4% embodiment 306
Under the blanket of nitrogen, 75 ℃ of stirring (2S)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (250mg, 0.66mmol) (as preparation as described in embodiment 304 starting materials) and the mixture of 2-aminopropane. (1.5ml) in THF (10ml) 18 hours, be cooled to room temperature then.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2S)-7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (210mg, 73%). 1H NMR spectrum: (DMSOd 6) 0.99 (d, 6H), 2.39 (s, 3H), 2.66 (m, 3H), 4.07 (m, 6H), 5.08 (d, 1H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.29 (m, 2H), 7.37 (s, 1H), 7.58 (s, 1H), 8.49 (s, 1H) and 11.03 (s, 1H) MS (ESI): 437 (MH) +Elementary analysis measured value C 64.3 H 6.4 N 12.3C 24H 28N 4O 4.0.5H 2O value of calculation C 64.7 H 6.6 N 12.6% embodiment 307
Under the blanket of nitrogen, 75 ℃ of stirring (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (250mg, 0.66mmol) (as preparation as described in embodiment 269 starting materials) and the mixture of 2-aminopropane. (1.5ml) in THF (10ml) 18 hours, be cooled to room temperature then.Filtering mixt and vacuum evaporation filtrate.Residue and then by the silica gel chromatography purification, close (100/0-90/10) gradient elution of ammonia (7M) with methylene chloride, get (2R)-7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline (243mg, 84%). 1H NMR spectrum: (DMSOd 6): 0.99 (d, 6H), 2.39 (s, 3H), 2.66 (m, 3H), 4.07 (m, 6H), 5.08 (d, 1H), 6.14 (s, 1H), 6.88 (dd, 1H), 7.29 (m, 2H), 7.37 (s, 1H), 7.58 (s, 1H), 8.49 (s, 1H) and 11.03 (s, 1H) MS (ESI): 437 (MH) +Elementary analysis measured value C 64.3 H 6.5 N 12.3C 24H 28N 4O 4.0.5H 2O value of calculation C 64.7 H 6.6 N 12.6% embodiment 308
To 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (400mg, 1.19mmol) (as preparation as described in embodiment 1 starting material), potassium carbonate (476mg, 3.45mmol0,5-hydroxyl-1-methylindole (220mg, 1.5mmol) logical nitrogen 5 minutes in the mixture of (as preparation as described in embodiment 291 starting materials) and DMA (5.0ml).Then under blanket of nitrogen 90 ℃ stirred the mixture 3 hours, be cooled to room temperature.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by developing purification with methanol, 6-methoxyl group-4-(1-methylindole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline (312mg, 59%). 1H NMR spectrum: (CDCl 3) 2.13 (m, 2H), 1.48 (t, 4H), 1.57 (t, 2H), 3.72 (t, 4H), 3.84 (s, 3H), 4.05 (s, 3H), 4.3 (t, 2H), 6.50 (d, 1H), and 7.08-7.13 (m, 2H), 7.32 (s, 1H), 7.37 (s, 1H), 7.47 (d, 1H), 7.62 (s, 1H) 8.59 (s, 1H) MS (ESI): 449 (MH) +Elementary analysis measured value C 66.5 H 6.4 N 12.3C 25H 28N 4O 4.0.1H 2O value of calculation C 66.7 H 6.3 N 12.4% embodiment 309
To 4-chloro-6-methoxyl group-7-(3-piperidino ethyoxyl) quinazoline (400mg, 1.24mmol) (as preparation as described in embodiment 180 starting materials), potassium carbonate (500mg, 3.62mmol), 5-hydroxyl-1-methylindole (231mg, 1.57mmol) logical nitrogen 5 minutes in the mixture of (as preparation as described in embodiment 291 starting materials) and DMA (5.0ml).Then under blanket of nitrogen 90 ℃ stirred the mixture 3 hours, be cooled to room temperature.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by developing in addition purification with methanol, thus 6-methoxyl group-4-(1-methylindole-5-base oxygen base)-7-(2-piperidino ethyoxyl) quinazoline (447mg, 83%) obtained. 1H NMR spectrum: (CDCl 3) 1.47 (m, 2H), 1.64 (m, 4H), 2.57 (t, 4H) 2.94 (t, 2H), 3.83 (s, 3H), 4.05 (s, 3H), 4.34 (t, 2H), 6.49 (d, 1H), 7.10 (m, 2H), 7.32 (s, 1H), 738 (d, 1H), 7.45 (d, 1H), 7.62 (s, 1H) 8.60 (s, 1H) MS (ESI): 433 (MH) +Elementary analysis measured value C 69.2 H 6.7 N 12.7C 25H 28N 4O 3Value of calculation C 69.4 H 6.5 N 13.0% embodiment 310
To 4-chloro-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (400mg, 1.24mmol) (as preparation as described in embodiment 9 starting materials), potassium carbonate (500mg, 3.62mmol), 5-hydroxyl-1-methylindole (231mg, 1.57mmol) logical nitrogen 5 minutes in the mixture of (as preparation as described in embodiment 291 starting materials) and DMA (5.0ml).Then under blanket of nitrogen 90 ℃ stirred the mixture 3 hours, be cooled to room temperature.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by the column chromatography purification uses methylene chloride to close (100/0-90/10) gradient elution of ammonia (7M), 6-methoxyl group-4-(1-methylindole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline (247mg, 44%). 1H NMR spectrum: (CDCl 3) 1.81 (m, 4H), 2.18 (m, 2H), 2.56 (m, 4H), 2.69 (t, 2H), 3.82 (s, 3H), 4.05 (s, 3H), 4.30 (t, 2H), 6.45 (d, 1H), 7.09 (dd, 2H), 7.31 (s, 1H), 7.38 (d, 1H), 7.47 (d, 1H), 7.62 (s, 1H) and 8.59 (s, 1H) MS (ESI): 433 (MH) +Elementary analysis measured value C 66.5 H 6.3 N 12.4C 25H 28N 4O 30.1 dichloromethane+0.7H 2O value of calculation C 66.7 H 6.6 N 12.4% embodiment 311
Under the room temperature, to 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (114mg, 0.34mmol) (as preparation as described in embodiment 67 starting materials), potassium carbonate (141mg, 1.02mmol), (60.5mg, logical nitrogen is 5 minutes 0.34mmol) and in the mixture of DMA (8.5ml) for 5-hydroxyl-4-nitroindoline.Then under blanket of nitrogen 90 ℃ stirred this mixture 4 hours, after this be cooled to room temperature.Filter reaction mixture and vacuum evaporation filtrate.Residue and then by silica gel chromatography uses methylene chloride (100/0-95/5) gradient elution, then the reuse methylene chloride is closed ammonia (7M) (95/5) eluting, obtains the refining grease of part.This grease further by silica gel chromatography, is closed ammonia gradient elution (95/5-80/20) with ethyl acetate/methanol, get 6-methoxyl group-(4-nitroindoline-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (63mg, 39%). 1H NMR spectrum: (CDCl 3) 1.46 (m, 2H), 1.60 (m, 4H), 2.16 (m, 2H), 2.43 (m, 4H), 2.54 (t, 2H), 3.85 (s, 3H), 4.33 (t, 2H), 7.04 (d, 1H), 7.10 (s, 1H), 7.47 (s, 1H), 7.57 (d, 1H), 7.83 (d, 1H), 7.95 (d, 1H) and 9.09 (s, 1H) MS (ESI): 478 (MH) +Elementary analysis measured value C 62.5 H 5.8 N 14.7C 25H 27N 5O 5Value of calculation C 62.9 H 5.7 N 14.7%
Initial substance is prepared as follows:
Stirring at room 5-methoxyl group indole-2-carboxylic ethyl ester (8.15g, 37.2mmol) (as heterocyclic Vol.43, No.2, p.263-266 described in preparation), be adsorbed on the mixture 18 hours of nitric acid (24g) on the silica gel and dichloromethane (150ml).Vacuum is removed dichloromethane, and product is with acetone eluting on silica gel.Vacuum evaporation acetone.Residue uses above-mentioned nitric acid/silica gel (1g) to handle once more, and repeats above-mentioned post-processing step, thereby obtains 5-hydroxyl-4-nitroindoline-2-carboxylic acid, ethyl ester (5.8g, 59%). 1H NMR spectrum: (DMSOd 6) 1.33 (and t, 3H), 3.95 (s, 3H), 4.35 (q, 2H), 7.19 (d, 1H), 7.35 (d, 1H), 7.75 (d, 1H) and 12.45 (brs, 1H)
(1.0g 3.8mmol) is suspended in ethanol (20ml) and water (5ml) mixed liquor with 5-hydroxyl-4-nitroindoline-2-carboxylic acid, ethyl ester.Add potassium hydroxide (840mg), 50 ℃ stirred the mixture 1 hour under blanket of nitrogen, were cooled to room temperature then.Vacuum evaporating solvent, and with residue water-soluble again (25ml).Regulate pH to 2 with hydrochloric acid (2M).Leach the precipitate that is produced, washing and vacuum drying get 5-methoxyl group-4-nitroindoline-2-carboxylic acid (790mg).This product need not to be further purified and directly uses.
Together stir above-mentioned 5-methoxyl group-4-nitroindoline-2-crude carboxylic acid (720mg, 3.05mmol), quinoline (9ml) and Cupric chromate(III). (180mg).Slowly logical nitrogen is 5 minutes in mixture, heating blends to 225 ℃ rapidly then, and under this temperature, in blanket of nitrogen, stirred 40 minutes.Cooling mixture adds ethyl acetate (80ml) dilution, thereafter the elimination insoluble matter to room temperature.Filtrate is extracted twice successively with hydrochloric acid (2M) and saturated aqueous solution of sodium bicarbonate.Dry (magnesium sulfate) ethyl acetate layer, evaporation and with residue by silica gel chromatography, use the dichloromethane eluting, thereby obtain 5-methoxyl group-4-nitroindoline (129mg, 22%). 1H NMR spectrum: (CDCl 3) 3.99 (and s, 3H), 6.88 (t, 1H), 6.97 (d, 1H), 7.37 (t, 1H) .7.55 (d, 1H) and 8.38 (brs, 1H) MS (ESI): 193 (MH) +
(110mg, dichloromethane 0.57mmol) (12ml) solution is cooled to-30 ℃ with 5-methoxyl group-4-nitroindoline in nitrogen atmosphere.(0.74ml 1M dichloromethane solution, 0.74mmol), warm mixture stirred 1 hour to room temperature dropwise to add Boron tribromide.Cooling mixture to 5 ℃ dilutes with dichloromethane (5ml) and water (10ml) then.Stir after 5 minutes, the elimination insoluble matter, and tell dichloromethane layer, and dry (magnesium sulfate), evaporation obtains a dark grease, and then again by silica gel chromatography, with the dichloromethane eluting, thereby obtains 5-hydroxyl-4-nitroindoline (68mg, 67%). 1H NMR spectrum: (CDCl 3) 6.95 (d, 1H), 7.29 (m, 1H), 7.43 (t, 1H), 7.63 (d, 1H) and 11.60 (brs, 1H) MS (ESI): 177 (M-H) -Embodiment 312
With 6-methoxyl group-(4-nitroindoline-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (45mg, 0.094mmol) (as preparation as described in the embodiment 311), ethanol (20ml) and 10% palladium-carbon hydrogenation 3.5 hours under 45 ℃ and 1 atmospheric pressure hydrogen air pressure.Cooling mixture is to room temperature, filtration catalizer and vacuum evaporation filtrate.Residue and then silica gel chromatography use methylene chloride to close (100/0-95/5) gradient elution of ammonia (7M), get 4-(4-amino indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (39mg, 87%). 1H NMR spectrum: (CDCl 3) 1.39 (m, 2H), 1.50 (m, 4H), 1.96 (m, 2H), 2.35 (m, 4H), 2.43 (t, 2H), 3.80 (s, 3H), 4.28 (t, 2H), 4.84 (brs, 2H), 6.68 (d, 1H), 6.78 (d, 1H), 6.94 (s, 1H), 7.28 (s, 1H), 7.45 (s, 1H), 7.69 (s, 1H), 8.45 (brs, 1H) and 8.98 (s, 1H) MS (ESI): 448 (MH) +Elementary analysis measured value C 64.0 H 6.4 N 14.4C 25H 29N 5O 3.0.3H 2O+0.4 dichloromethane value of calculation C 63.6 H 6.3 N 14.4% embodiment 313
95 ℃ are stirred 4-chloro-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline (227mg, 0.68mmol) (as preparation as described in embodiment 67 starting materials), 5-hydroxyl-1H-pyrrolo-[2,3-b] pyridine (100mg, 0.75mmol) (as preparation as described in embodiment 182 starting materials) and potassium carbonate (350mg, 2.5mmol) mixture in DMF (4ml) 6 hours, be cooled to room temperature thereafter.Reactant mixture is handled with the 1.0N sodium hydrate aqueous solution, and stirred for several minute at room temperature.Leach the precipitate that is produced, washing, the air-dry crude product that obtains.And then with this crude product by the column chromatography purification, earlier with methylene chloride (85/15) eluting, separate obtaining low polar impurity, and then with methylene chloride/0.88 ammonia (100/8/1) eluting, separate targets chemical compound.Merge relevant fraction, vacuum evaporation obtains a white solid, and then with the acetone development, filters and drying, thereby obtains 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(1H-pyrrolidine [2,3-b] pyridine-5-base oxygen base) quinazoline (58mg, 20%). 1H NMR spectrum: (DMSO-d 6) 1.38 (m, 2H), 1.50 (m, 4H), 1.95 (m, 2H), 2.15 (m, 4H), 2.42 (t, 2H), 3.99 (s, 3H), 4.22 (t, 2H), 6.47 (m, 1H), 7.36 (s, 1H), 7.55 (m, 1H), 7.60 (s, 1H), 7.90 (d, 1H), 8.18 (d, 1H), 8.49 (s, 1H) and 11.76 (brs, 1H) MS (ESI): 434 (MH) +Elementary analysis measured value C 63.9 H 6.4 N 15.4C 24H 27N 5O 31.0H 2O value of calculation C 63.8 H 6.5 N 15.5% embodiment 314
To 7-(3-bromine propoxyl group)-4-(1H-indole-5-base oxygen base)-6-methoxyl group quinazoline (200mg, add in dichloromethane solution 0.47mmol) 4-piperidino piperidines (237mg, 1.41mmol), 40 ℃ of reacting by heating 1 hour.(100mg, 0.59mmol), further reacting by heating is 2 hours to add another part 4-piperidino piperidines again.Then reactant is passed through purification by flash chromatography, with dichloromethane-15% ethanol/methylene (+1% ammonium hydroxide) eluting.Evaporate with the ether development, filters and obtains yellow solid 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-piperidino) piperidino propoxyl group) quinazoline (200mg, 83%). 1H NMR spectrum: (CDCl 3) 1.48-2.18 (m, 19H), 2.58 (t, 2H), 3.06 (d, 2H), 4.05 (s, 3H), 4.26 (t, 2H), 6.59 (s, HH), 7.08 (dd, 1H), 7.28 (d, 1H), 7.36 (s, 1H), 7.50 (d, 1H), 7.63 (s, 1H), 8.30 (s, 1H), 8.59 (s, 1H) MS:516[MH]+
Initial substance is prepared as follows:
To 7-hydroxyl-4-(1H-indole-5-base oxygen base)-6-methoxyl group quinazoline (1g, 3.2mmol) add potassium carbonate powder (1.32g in DMF (50ml) solution of (as preparation as described in embodiment 107 starting materials), 9.6mmol) and 1, the 3-dibromopropane (6.43g, 32mmol).50 ℃ of reacting by heating 2 hours.The filtering inorganic matter is removed DMF then.Residue is assigned in dichloromethane/water.Tell Organic substance, dried over mgso, filtration, vacuum evaporation are also passed through purification by flash chromatography, with dichloromethane-5% methanol/95% dichloromethane eluting.The vacuum concentration product with the ether development, filters the solids that is produced, and obtains white solid 7-(3-bromine propoxyl group)-4-(1H-indole-5-base oxygen base)-6-methoxyl group quinazoline (900mg, 66%). 1H NMR spectrum: (CDCl 3) 2.46-2.57 (m, 2H), 3.68 (t, 2H), 4.08 (s, 3H), 4.38 (t, 2H), 6.58 (s, 1H), 7.09 (d, 1H), 7.27 (s, 1H), 7.35 (s, 1H), 7.46 (d, 1H), 7.50 (s, 1H), 7.63 (s, 1H), 8.30 (s, 1H) .8.62 (s, 1H) MS:428[MH]+embodiment 315
To 7-hydroxyl-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base) quinazoline (225mg; 0.7mmol) add potassium carbonate powder (290mg in the DMF solution of (as preparation as described in the embodiment 49); 2.1mmol) and (5S)-5-(ptoluene-sulfonyl methyl)-1-methyl-2-pyrrolidine (340mg, 1.2mmol).95 ℃ of reacting by heating things are 5 hours then.The filtering inorganic matter, and remove DMF by evaporation.Residue is then by chromatography purification, with dichloromethane-12% methanol/88% dichloromethane (+1% ammonium hydroxide) eluting.Evaporate obtains white solid (5S)-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base)-7-(1-methyl-2-oxo-pyrrolidine-5-ylmethoxy) quinazoline (100mg, 33%) with ether development after-filtration. 1H NMR spectrum: (DMSO-d 6) 1.84-1.96 (m, 1H), 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.43-2.53 (m, 1H), 2.80 (s, 3H), 3.98 (s, 4H), 4.22 (dd, 1H), 4.40 (dd, 1H), 6.10 (s, 1H), 6.84 (dd, 1H), 7.23 (d, 1H), 7.30 (d, 1H), 7.40 (s, 1H), 7.59 (s, 1H), 8.49 (s, 1H), 10.98 (brs, 1H) M S:429[MH]+elementary analysis: measured value C 64.4 H 5.4 N 12.6C 24H 24N 4O 40.8H 2O value of calculation C 64.5 H 5.8 N 12.5%
Initial substance is prepared as follows:
(0.8g 3mmol) is dissolved in anhydrous THF, is cooled to-70 ℃ with (5S)-5-(ptoluene-sulfonyl methyl)-2-Pyrrolidone.Slowly add the diisopropyl lithamide, stirring reaction adds methyl iodide (2ml, excessive) after 20 minutes.Warm reactant to room temperature kept 2 hours.Then reactant distribution is arrived within ethyl acetate and the water, tell organic layer, dried over mgso is filtered and vacuum evaporation.Residue and then by purification by flash chromatography, with dichloromethane-5% methanol/95% dichloromethane eluting, evaporate obtains brown oily (5S)-5-(ptoluene-sulfonyl-methyl)-1-Methyl-2-Pyrrolidone (340mg, 40%). 1H NMR spectrum: (CDCl 3) 2.10-2.44 (m, 4H), 2.48 (s, 3H), 2.76 (s, 3H), 3.30-3.54 (m, 1H), 4.04 (dd, 1H), 4.15 (dd, 1H), 7.38 (d, 2H), 7.78 (d, 2H) MS:284[MH]+embodiment 316
To 7-hydroxyl-4-(1H-indole-5-base oxygen base)-6-methoxyl group quinazoline (600mg; 1.95mmol) add potassium carbonate powder (540mg in DMF (20ml) solution of (as preparation as described in embodiment 107 starting materials); 3.9mmol) and (5S)-5-(ptoluene-sulfonyl methyl)-2-pyrrolidine (580mg, 2.16mmol).100 ℃ of reacting by heating things are 4 hours then.The filtering inorganic matter, and remove DMF by evaporation.Residue is then by chromatography purification, with dichloromethane-12% methanol/88% dichloromethane (+1% ammonium hydroxide) eluting.Evaporate obtains white solid (5S)-4-(1H-indole-5-base oxygen base)-6-methoxyl group-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline (240mg, 31%) with ether development after-filtration. 1H NMR spectrum: (DMSO-d 6) 1.87-2.48 (m, 4H), 3.97 (s, 3H), 4.17 (m, 2H), 6.45 (s, 1H), 6.96 (dd, 1H), 7.38-7.49 (m, 4H), 7.60 (s, 1H), 7.81 (s, 1H), 8.50 (s, 1H) MS:405[MH]+embodiment 317
To 7-hydroxyl-4-(1H-indole-5-base oxygen base)-6-methoxyl group quinazoline (800mg; 2.6mmol) add potassium carbonate powder (1.08g in DMF (20ml) solution of (as preparation as described in embodiment 107 starting materials); 7.8mmol) and (5R)-5-(ptoluene-sulfonyl methyl)-2-Pyrrolidone (1.13g, 4.2mmol).90 ℃ of reacting by heating are 4 hours then.The filtering inorganic matter is also removed DMF by evaporation.Residue is then by chromatography purification, with dichloromethane-12% methanol/88% dichloromethane (+1% ammonium hydroxide) eluting.Get fraction and refill post, use identical gradient elution agent eluting.Evaporate with the ether development, filters and obtains white solid (5R)-4-(1H-indole-5-base oxygen base)-6-methoxyl group-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline (70mg, 6.5%). 1H NMR spectrum: (DMSO-d 6) 1.64-2.45 (m, 4H), 3.78 (m, 1H), 3.99 (s, 3H), 4.18 (t, 2H), 6.42 (s, 1H), 6.97 (dd, 1H), 7.38-7.48 (m, 3H), 7.60 (s, 1H), 7.73 (s, 2H), 8.48 (s, 1H), 11.18 (brs, 1H) MS:405[MH]+
Initial substance is prepared as follows:
To (5R)-5-methylol-2-Pyrrolidone (5.0g, add in dichloromethane 43mmol) (100ml) solution 4-dimethylamino naphthyridine (15.7g, 129mmol) and p-toluenesulfonyl chloride (9.0g, 47mmol).Stirring at room reaction 16 hours.Reactant is used 1M salt acid elution then, and isolates organic layer.Use the dried over mgso organic layer then, filtration, evaporation obtain white solid (5R)-5-(ptoluene-sulfonyl methyl)-2-Pyrrolidone (10.3g, 89%). 1H NMR spectrum: (CDCl 3) 1.68-1.86 (m, 1H), 2.16-2.38 (m, 3H), 2.48 (s, 3H), 3.86-3.96 (m, 2H), 4.08 (dd, 1H), 6.20 (brs, 1H), 7.38 (d, 2H), 7.80 (d, 2H) MS:270[MH]+embodiment 318
To 7-hydroxyl-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base) quinazoline (1.36g; 4.24mmol) order adds potassium carbonate powder (2.34g in DMF (70ml) solution of (as preparation as described in the embodiment 49); 17.0mmol) and (5R)-5-(ptoluene-sulfonyl methyl)-2-Pyrrolidone (1.25g; 4.66mmol; 1.1eq.) (as preparation as described in embodiment 317 starting materials), and reflux gained yellow suspension.After 4 hours, still remain some initial substances, at this moment further add again (5R)-5-(ptoluene-sulfonyl methyl)-2-Pyrrolidone (0.57g, 2.12mmol, 0.5eq.).Further the heating reflux reaction thing is 2 hours, exhausts initial substance.The cooling reactant is to room temperature, filtering inorganic matter and vacuum evaporation filtrate, and remaining brown oil is down further passed through column chromatography purification (methylene chloride, (100/0-90/10)), obtains bright brown oil.With ether develop a thickness grease, and then chromatography with above-mentioned eluant eluting, obtains yellow oil.Ether is developed this grease and is obtained first pale solid (5R)-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline (5mg) (according to about 90% purity of nmr).Chromatography residue (with above-mentioned eluant eluting), then develop with ether, obtain another batch (5R)-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline, white solid 180mg wherein,＞95% purity (according to nmr), pale solid 800mg, about 95% purity (according to nmr). 1H NMR spectrum: (DMSOd 6) 1.8-2.2 (m, 5H), 2.4 (s, 3H), 4.0 (brs, 3H), 4.1-4.2 (m, 2H), 6.1 (brs, 1H), 6.9 (dd, 1H), 7.2 (d, 1H), 7.3 (d, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 7.8 (s, 1H), 8.5 (s, 1H), 11.0 (brs, 1H) MS:419[MH] +Elementary analysis: measured value C 60.8 H 5.3 N 12.1C 23H 22N 4O 42H 2O value of calculation C 60.8 H 5.7 N 12.3% embodiment 319
To 7-hydroxyl-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base) quinazoline (4.8g, 15.7mmol) add potassium carbonate (6.5g in DMF (100ml) solution of (as preparation as described in the embodiment 49), 47mmol) and 3-chloropropyl piperidines (3.3g, 20.4mmol).℃ reaction of reacting by heating thing to 100 is 4 hours then.DMF is removed in filtering inorganic matter and evaporation.Residue is then by chromatography purification, with dichloromethane-10% methanol/90% dichloromethane (+1% ammonium hydroxide) eluting.Concentrate relevant fraction, and then residue is dissolved in ethyl acetate again.Add hexane, leach precipitate subsequently.Evaporated filtrate, and then develop residue with ether, filter and obtain white solid 6-methoxyl group-4-(1-(3-piperidino propyl group)-1H-indole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline (170mg, 1.9%). 1H NMR spectrum: (DMSO-d 6) 1.38 (brs, 4H), 1.50 (brs, 8H), 1.92 (m, 4H), 2.14-2.48 (m, 12H), 3.98 (s, 3H), 4.24 (t, 4H), 6.43 (s, 1H), 7.02 (d, 1H), 7.38 (s, 1H), 7.42 (s, 2H), 7.53 (d, 1H), 7.58 (s, 1H), 8.44 (s, 1H) MS:558[MH]+embodiment 320
60 ℃ of stirring (2R)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (6.201g, 16.4mmol) (as preparation as described in embodiment 269 starting materials) and piperidines (4.8ml, 49.3mmol) mixture in DMF (100ml) 24 hours, be cooled to room temperature then.Solvent removed in vacuo, the residue silica gel purification is with dichloromethane, methylene chloride (95/5), last methylene chloride/0.880 ammonia (89: 10: 1) eluting.Product is used the acetonitrile recrystallization subsequently, gets pale solid (2R)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline (3.33g, 44%). 1H NMR spectrum: (DMSO 6) 1.35 (m, 2H), 1.51 (m, 4H), 2.30-2.40 (m, 9H), 3.98 (s, 3H), 4.08 (m, 2H), 4.21 (m, 1H), 4.86 (m, 1H), 6.10 (s, 1H), 6.87 (dd, 1H), 7.25 (d, 1H) 7.30 (d, 1H), 7.40 (s, 1H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.98 (brs, 1H) MS (ESI): 463 (MH) +Elementary analysis measured value C 66.5 H 6.6 N 12.0C 26H 30N 40 40.4H 20 value of calculation C, 66.5 H, 6.6 N 11.9%.Embodiment 321
60 ℃ of stirring (2S)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(oxirane-2-ylmethoxy) quinazoline (175mg, 0.46mmol) (as preparation as described in embodiment 304 starting materials) and piperidines (0.14ml, 1.39mmol) mixture in DMF (5ml) 24 hours, be cooled to room temperature then.Solvent removed in vacuo, the residue silica gel purification is with dichloromethane, methylene chloride (95/5), last methylene chloride/0.880 ammonia (89: 10: 1) gradient elution.Product is used the acetonitrile recrystallization thereafter, gets pale solid (2S)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline (88mg, 41%). 1H NMR spectrum: (DMSO 6) 1.35 (m, 2H), 1.51 (m, 4H), 2.30-2.40 (m, 9H), 3.98 (s, 3H), 4.08 (m, 2H), 4.21 (m, 1H), 4.86 (m, 1H), 6.10 (s, 1H), 6.87 (dd, 1H), 7.25 (d, 1H) 7.30 (d, 1H), 7.40 (s, 1H), 7.60 (s, 1H), 8.45 (s, 1H) and 10.98 (brs, 1H) MS (ESI): 463 (MH) +Elementary analysis measured value C 66.2 H 6.8 N 11.9C 26H 30N 4O 40.5H 2O value of calculation C 66.2 H 6.6 N 11.9%.Embodiment 322
95 ℃ of stirrings contain potassium carbonate (756mg, 5.48mmol) 4-chloro-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline (1.22g, 3.65mmol) (723mg, 4.38mmol) (as preparation as described in embodiment 237 starting materials) solution in DMF (20ml) is 3 hours for (as preparation as described in embodiment 241 starting materials), 4-fluoro-5-hydroxy-2-methyl indole.After the cooling, filtering mixt, and evaporated filtrate.Residue and then by the column chromatography purification is used methylene chloride (9/1), the saturated methanol solution of methylene chloride/ammonia (90/5/5) eluting successively.Merge to contain and expect and the fraction of product evaporate then.Residue and then with ether development filters ether washing and vacuum drying.The surplus solid of institute is dissolved in dichloromethane/ethyl acetate and the minimum methanol, and filtration and vacuum are removed volatile matter.Solids is developed with ether, filters, and ether washing back gets 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline (1.06g, 62%) in 60 ℃ of vacuum dryings.MS-ESI:465[MH]+ 1H NMR spectrum: (DMSOd 6) 1.1-1.3 (m, 2H); 1.35-1.5 (m, 1H); 1.6-1.9 (m, 6H); 2.12 (s, 3H); 2.4 (s, 3H); 2.75 (d, 2H); 3.95 (s, 3H); 4.22 (t, 2H); 6.2 (s, 1H); 6.95 (dd, 1H); 7.15 (d, 1H); 7.4 (s, 1H); 7.6 (s, 1H); 8.5 (s, 1H) embodiment 323
Under the argon atmospher, to 5-hydroxy-2-methyl benzimidazole (204mg, 0.89mmol)/add in the dry DMF (2.5ml) sodium hydride (71mg, 1.8mmol).Stirring at room mixture 10 minutes.Add 4-chloro-6, and the 7-dimethoxyquinazoline (200mg, 0.89mmol), 95 ℃ of stirred reaction mixtures 2 hours.After being cooled to room temperature, mixture is poured in the water, used ethyl acetate extraction.Organic facies salt water washing, dry (magnesium sulfate) adds silica gel evaporating solvent thereafter.The gained powder is added to easy processing silicagel column (ISOLUTE) top, product ethanol/methylene (3/97,5/95,8/92) gradient elution.Evaporating solvent gets 6,7-dimethoxy-4 '-(2-methyl isophthalic acid H-benzimidazole-6-base oxygen base) quinazoline (145mg, 48%). 1H NMR spectrum: (DMSOd 6) 2.50 (s, 3H); 3.95 (s, 3H); 4.0 (s, 3H); 7.05 (d, 1H); 7.38 (s, 1H); 7.39 (d, 1H); 7.51 (d, 1H); 7.60 (s, 1H); 8.50 (s, 1H) MS (ESI): 337[MH] +Embodiment 324
Figure A0080608503481
Under the nitrogen atmosphere, to 4-chloro-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline (180mg, 0.53mmol) add in DMF (3ml) suspension of (as preparation as described in embodiment 1 starting material) 7-hydroxyl quinazoline (87mg, 0.6mmol) and potassium carbonate (110mg, 0.8mmol).Reacting by heating mixture to 100 ℃ reaction 90 minutes.After being cooled to room temperature, add ethyl acetate and saturated ammonium chloride solution diluting reaction thing.Then water is extracted with ethyl acetate again, merge organic facies, dry (magnesium sulfate) and evaporating solvent.Residue and then by purification by flash chromatography uses ethanol/methylene (3/97,4/96,5/95) gradient elution.After developing with ether, evaporating solvent, residual solids thing obtain 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinazoline-7-base oxygen base) quinazoline (197mg, 83%). 1H NMR composes (DMSOd 6) 2.01 (t, 2H); 2.47 (m, 4H); 2.49 (m, 2H); 3.60 (m, and 4H) 4.01 (s, 3H); 4.29 (t, 2H); 7.45 (s, 1H); 7.65 (s, 1H); 7.80 (d, 1H); 8.01 (d, 1H); 8.32 (d, 1H); 8.60 (s, 1H); 9.34 (s, 1H); 9.69 (s, 1H) MS (ESI): 448[MH] +Elementary analysis measured value C 63.4 H 5.7 N 15.6C 24H 25N 5O 40.4H 2O value of calculation C 63.4 H 5.7 N 15.4%.
Initial substance is prepared as follows:
(400mg 2.08mmol) adds Ruan Shi nickel (about 200mg) (with ethanol pre-wash several) in the solution of (Tet.Lett.1999,40,3881), and this solution 1 hour of refluxing to 7-2-hydroxy-4-methylthio quinazoline.Add Ruan Shi nickel (100mg) again, mixture 1 hour further refluxes.Filtering mixt is with washing with alcohol and removing volatiles under vacuum.Residue and then by the column chromatography purification, with methylene chloride (97/3, then 96/4) eluting, 7-hydroxyl quinazoline (62mg, 20%).Embodiment 325
Adopt embodiment 201 described similar approach, make 7-hydroxyl-4-(indole-6-base is amino)-6-methoxyl group quinazoline (98mg, 0.32mmol) (as preparation as described in embodiment 217 starting materials) and 5-(2-hydroxyethyl)-4-methylthiazol (69mg, 0.48mmol) reaction, obtain 6-methoxyl group-4-(indole-6-base is amino)-7-(2-(4-methylthiazol-5-yl) ethyoxyl) quinazoline (47mg, 34%).MS-ESI:432[MH] + 1H NMR spectrum: (DMSOd 6) 2.4 (s, 3H); 3.3 (t, 2H); 4.0 (s, 3H); 4.35 (t, 2H); 6.45 (s, 1H); 7.2 (s, 1H); 7.25-7.4 (m, 2H); 7.55 (d, 1H); 7.9 (s, 1H); 8.05 (s, 1H); 8.45 (s, 1H); 8.87 (s, 1H); 9.45 (s, 1H) embodiment 326
Illustrate the representative drugs dosage form that is used for human treatment or preventive use below, wherein comprise formula I compound or pharmaceutically acceptable salt thereof (i.e. compounds X hereinafter).(a) tablet I mg/ sheet
Compounds X---------------------------100
Lactose (European Pharmacopoeia)--------------------182.75
Cross-linking sodium carboxymethyl cellulose----------------12.0
Corn starch paste (5%w/v paste)--------------2.25
Magnesium stearate--------------------------3.0 (b) tablet II mg/ sheet
Compounds X---------------------------50
Lactose (European Pharmacopoeia)--------------------223.75
Cross-linking sodium carboxymethyl cellulose----------------6.0
Corn starch--------------------------15.0
Polyvinylpyrrolidone (5%w/v paste)----------2.25
Magnesium stearate--------------------------3.0 (c) tablet III mg/ sheet
Compounds X---------------------------1.0
Lactose (European Pharmacopoeia)--------------------93.25
Cross-linking sodium carboxymethyl cellulose----------------4.0
Corn starch paste (5%w/v paste)--------------0.75
Magnesium stearate--------------------------1.0 (d) capsule mg/ capsule
Compounds X-------------------------10
Lactose (European Pharmacopoeia)---------------------488.5
Magnesium stearate---------------------------1.5 (e) injection I (50mg/ml)
Compounds X----------------------------5.0%w/v
1N sodium hydroxide solution---------------------15.0%v/v
0.1N hydrochloric acid (being adjusted to pH7.6)
PEG400------------------------4.5%w/v
Injection water-----------------------------add to 100% (f) injection II (10mg/ml)
Compounds X----------------------------1.0%w/v
Sodium phosphate BP---------------------------3.6%w/v
0.1N sodium hydroxide solution-------------------15.0%v/v
Water for injection---------------------------add to 100% (g) injection III (1mg/ml is buffered to pH6)
Compounds X----------------------------0.1%w/v
Sodium phosphate BP---------------------------2.26%w/v
Citric acid-----------------------------0.38%w/v
PEG400------------------------3.5%w/v
Water for injection---------------------------add to 100% note
Above-mentioned preparation can adopt that known conventional method makes in the pharmaceutical field.Tablet (a)-(c) can adopt the conventional method coating, for example forms the Cellacefate coating.

Claims (22)

1. formula I compound or its salt is used for producing application in the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect at homoiothermic animal such as human body in production: Wherein:
Ring C is 8,9,10,12 or 13 yuan of bicyclo-or three loop sections, and this part can be saturated or undersaturated, fragrance or nonaromatic, and can choose wantonly and comprise 1-3 hetero atom that independently is selected from O, N and S;
Z is-O--NH-,-S-,-CH 2-or direct key;
N is integer 0-5;
M is 0-3;
R 2Represent hydrogen, hydroxyl, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3R 4(R wherein 3And R 4Can be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5X 1-(X wherein 1Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2-,-NR 6C (O)-,-C (O) NR 7-,-SO 2NR 8-,-NR 9SO 2-or-NR 10-(R wherein 6, R 7, R 8, R 9And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 5Be selected from one of following 22 groups of groups:
1) hydrogen, Oxyranyle C 1-4Alkyl or C 1-5Alkyl, this C 1-5Alkyl can be unsubstituted or can be replaced by one or more hydroxyl, fluorine, chlorine, bromine and amino groups of being selected from;
2) C 1-5Alkyl X 2COR 11(X wherein 2Representative-O-or-NR 12-(R wherein 12Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, represent hydrogen separately, C 1-5Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-5Alkyl X 3R 16(X wherein 3Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 17C (O)-,-C (O) NR 18-,-SO 2NR 19-,-NR 20SO 2-or-NR 21-(R wherein 17, R 18, R 19, R 20And R 21The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 16Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, described cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
4) C 1-5Alkyl X 4C 1-5Alkyl X 5R 22(X wherein 4And X 5Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 23C (O)-,-C (O) NR 24-,-SO 2NR 25-,-NR 26SO 2-or-NR 27-(R wherein 23, R 24, R 25, R 26And R 27The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 22Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
5) R 28(R wherein 28For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this heterocyclic radical can have one or more C of being selected from 1-4The substituent group of alkyl));
6) C 1-5Alkyl R 28(R wherein 28As above definition);
7) C 2-5Alkenyl R 28(R wherein 28As above definition);
8) C 2-5Alkynyl R 28(R wherein 28As above definition);
9) R 29(R wherein 29Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 30R 31,-NR 32C (O) R 33(R wherein 30, R 31, R 32And R 33Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl) and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
10) C 1-5Alkyl R 20(R wherein 29As above definition);
11) C 2-5Alkenyl R 29(R wherein 29As above definition);
12) C 2-5Alkynyl R 29(R wherein 29As above definition);
13) C 1-5Alkyl X 6R 29(X wherein 6Representative-O-,-S-,-SO-,-SO 2,-NR 34C (O)-,-C (O) NR 35,-SO 2NR 36-,-NR 37SO 2-or-NR 38(R wherein 34, R 35, R 36, R 37And R 38The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
14) C 2-5Alkenyl X 7R 29(X wherein 7Representative-O-,-S-,-SO-,-SO 2,-NR 39C (O)-,-C (O) NR 40-,-SO 2NR 41-,-NR 42SO 2-or-NR 43-(R wherein 39, R 40, R 41, R 42And R 43The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
15) C 2-5Alkynyl X 8R 29(X wherein 8Representative-O-,-S-,-SO-,-SO 2,-NR 44C (O)-,-C (O) NR 45-,-SO 2NR 46-,-NR 47SO 2-or-NR 48-(R wherein 44, R 45, R 46, R 47And R 48The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
16) C 1-4Alkyl X 9C 1-4Alkyl R 29(X wherein 9Representative-O-,-S-,-SO-,-SO 2,-NR 49C (O)-,-C (O) NR 50-,-SO 2NR 51-,-NR 52SO 2-or-NR 53-(R wherein 49, R 50, R 51, R 52And R 53The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As above definition);
17) C 1-4Alkyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, chloro sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition);
21) C 2-5Alkynyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As above definition); With
22) C 1-4Alkyl R 54(C 1-4Alkyl) q(X 9) rR 55(X wherein 9As above definition, q is 0 or 1, r is O or 1, and R 54And R 55Be selected from hydrogen independently of one another, C 1-3Alkyl, cyclopenta, cyclohexyl and contain 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and cyclic group wherein can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl), condition is R 54Can not be hydrogen);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from).
R 1Represent hydrogen, oxo, halogen, hydroxyl, C 1-4Alkoxyl, C 1-4Alkyl, C 1-4Alkoxy methyl, C 1-4Alkanoyl, C 1-4Haloalkyl, cyano group, amino, C 2-5Alkenyl, C 2-5Alkynyl, C 1-3Alkanoyloxy, nitro, C 1-4Alkanoylamino, C 1-4Alkoxy carbonyl, C 1-4Alkylthio group, C 1-4Alkyl sulphinyl, C 1-4Alkyl sulphonyl, carbamoyl, N-C 1-4Alkyl-carbamoyl, N, N-two (C 1-4Alkyl) carbamoyl, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl, N, N-two (C 1-4Alkyl) amino-sulfonyl, N-(C 1-4Alkyl sulphonyl) amino, N-(C 1-4Alkyl sulphonyl)-N-(C 1-4Alkyl) amino, N, N-two (C 1-4Alkyl sulphonyl) amino, the C that is connected with two ring carbon atoms 3-C 7Alkylidene chain, C 1-4Alkanoylamino C 1-4Alkyl, carboxyl or radicals R 56X 10(X wherein 10Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2,-NR 57C (O)-,-C (O) NR 58-,-SO 2NR 59-,-NR 60SO 2-or-NR 61-(R wherein 57, R 58, R 59, R 60And R 61The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 58Be selected from following 22 groups of groups it-:
1) hydrogen, Oxyranyle C 1-4Alkyl or C 1-5Alkyl, this C 1-5Alkyl can be unsubstituted or can by-individual or a plurality ofly be selected from hydroxyl, fluorine, chlorine, bromine and amino groups replace;
2) C 1-5Alkyl X 11COR 62(X wherein 11Representative-O-or-NR 63-(R wherein 63Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 62Represent C 1-3Alkyl ,-NR 64R 65Or-OR 66(R wherein 64, R 65And R 66Can be identical or different, represent hydrogen separately, C 1-5Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-5Alkyl X 12R 67(X wherein 12Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 68C (O)-,-C (O) NR 69-,-SO 2NR 70-,-NR 71SO 2-or-NR 72-(R wherein 68, R 69, R 70, R 71And R 72The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 67Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, described cyclic group can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Fluorine-based alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
4) C 1-5Alkyl X 13C 1-5Alkyl X 14R 73(X wherein 13And X 14Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 74C (O)-,-C (O) NR 75-,-SO 2NR 76-,-NR 77SO 2-or-NR 78-(R wherein 74, R 75, R 76, R 77And R 78The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 73Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
5) R 79(R wherein 79For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
6) C 1-5Alkyl R 79(R wherein 79As above definition);
7) C 2-5Alkenyl R 79(R wherein 79As above definition);
8) C 2-5Alkynyl R 79(R wherein 79As above definition);
9) R 80(R wherein 80Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 81R 82,-NR 83C (O) R 84(R wherein 81, R 82, R 83And R 84Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl) and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl));
10) C 1-5Alkyl R 80(R wherein 80As above definition);
11) C 2-5Alkenyl R 80(R wherein 80As above definition);
12) C 2-5Alkynyl R 80(R wherein 80As above definition);
13) C 1-5Alkyl X 15R 80(X wherein 15Representative-O-,-S-,-SO-,-SO 2,-NR 85C (O)-,-C (O) NR 86,-SO 2NR 87-,-NR 88SO 2-or-NR 89-(R wherein 85, R 86, R 87, R 88And R 89The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
14) C 2-5Alkenyl X 16R 80(X wherein 16Representative-O-,-S-,-SO-,-SO 2,-NR 90C (O)-,-C (O) NR 91-,-SO 2NR 92-,-NR 93SO 2-or-NR 94-(R wherein 90, R 91, R 92, R 93And R 94The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
15) C 2-5Alkynyl X 17R 80(X wherein 17Representative-O-,-S-,-SO-,-SO 2,-NR 95C (O)-,-C (O) NR 96-,-SO 2NR 97-,-NR 98SO 2-or-NR 99-(R wherein 95, R 96, R 97, R 98And R 99The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
16) C 1-4Alkyl X 18C 1-4Alkyl R 80(X wherein 18Representative-O-,-S-,-SO-,-SO 2,-NR 100C (O)-,-C (O) NR 101-,-SO 2NR 102,-NR 103SO 2-or-NR 104-(R wherein 100, R 101, R 102, R 103And R 104The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 80As above definition);
17) C 1-4Alkyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition);
21) C 2-5Alkynyl X 18C 1-4Alkyl R 79(X wherein 18And R 79As above definition); With
22) C 1-4Alkyl R 105(C 1-4Alkyl) x(X 18) yR 106(X wherein 18As above definition, x is 0 or 1, y is 0 or 1, and R 105And R 106Be selected from hydrogen independently of one another, C 1-3Alkyl, cyclopenta, cyclohexyl and contain 1-2 the first saturated heterocyclyl of heteroatomic 5-6-that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and cyclic group wherein can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl), condition is R 105Can not be hydrogen);
In addition, R wherein 56X 10-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from).
According to the formula I chemical compound of claim 1 and salt thereof and its prodrug for example ester, amide and thioether be used for producing application aspect the medicine of angiogenesis inhibitor and/or vascular permeability reduction effect in preparation at homoiothermic animal such as human body: Wherein:
Ring C is 9-10 unit two loop sections, and it can be saturated or undersaturated, fragrance or nonaromatic, and can choose wantonly and comprise 1-3 hetero atom that independently is selected from O, N and S;
Z is-O--NH-,-S-,-CH 2-or direct key;
R 1Represent hydrogen, oxo, halogen, hydroxyl, C 1-4Alkoxyl, C 1-4Alkyl, C 1-4Alkoxy methyl, C 1-4Alkanoyl, C 1-4Haloalkyl, cyano group, amino, C 2-5Alkenyl, C 2-5Alkynyl, C 1-3Alkanoyloxy, nitro, C 1-4Alkanoylamino, C 1-4Alkoxy carbonyl, C 1-4Alkylthio group, C 1-4Alkyl sulphinyl, C 1-4Alkyl sulphonyl, carbamoyl, N-C 1-4Alkyl-carbamoyl, N, N-two (C 1-4Alkyl) carbamoyl, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl, N, N-two (C 1-4Alkyl) amino-sulfonyl, N-(C 1-4Alkyl sulphonyl) amino, N-(C 1-4Alkyl sulphonyl)-N-(C 1-4Alkyl) amino, N, N-two (C 1-4Alkyl sulphonyl) the amino or C that is connected with two ring carbon atoms 3-C 7Alkylidene chain;
N is integer 0-5;
M is integer 0-3;
R 2Represent hydrogen, hydroxyl, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3R 4(R wherein 3And R 4Can be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5X 1-(X wherein 1Represent direct key ,-O-,-CH 2-,-OC (O)-,-C (O)-,-S-,-SO-,-SO 2-,-NR 6C (O)-,-C (O) NR 7-,-SO 2NR 8-,-NR 9SO 2-or-NR 10-(R wherein 6, R 7, R 8, R 9And R 10Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 5Be selected from one of following 21 groups of groups:
1) hydrogen or C 1-5Alkyl, this group can be unsubstituted or can be replaced by one or more hydroxyl, fluorine and amino groups of being selected from;
2) C 1-5Alkyl X 2COR 11(X wherein 2Representative-O-or-NR 12-(R wherein 12Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 11Represent C 1-3Alkyl ,-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, represent hydrogen separately, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl));
3) C 1-5Alkyl X 3R 15(X wherein 3Representative-O-,-S-,-SO-,-SO 2,-OC (O)-,-NR 17C (O)-,-C (O) NR 18-,-SO 2NR 19-,-NR 20SO 2-or-NR 21-(R wherein 17, R 18, R 19, R 20And R 21The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 18Represent hydrogen, C 1-3Alkyl, cyclopenta, cyclohexyl or contain 1-2 heteroatomic 5-6-unit saturated heterocyclyl that independently is selected from O, S and N, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-4The substituent group of alkoxyl, and described cyclic group can have 1 or 2 and is selected from oxo, hydroxyl, halogen, C 1-4Alkyl, C 1-4Hydroxy alkyl and C 1-4The substituent group of alkoxyl);
4) C 1-5Alkyl X 4C 1-5Alkyl X 5R 22(X wherein 4And X 5Can be identical or different, and respectively do for oneself-O--S-,-SO-,-SO 2,-NR 23C (O)-,-C (O) NR 24-,-SO 2NR 25-,-NR 26SO 2-or-NR 27-(R wherein 23, R 24, R 25, R 26And R 27The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28For containing 1-2 the first saturated heterocyclyl (being connected through carbon or nitrogen) of heteroatomic 5-6-that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Fluorine-based alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl and C 1-4Alkyl sulphonyl C 1-4Alkyl);
6) C 1-5Alkyl R 28(R wherein 28As above definition);
7) C 2-5Alkenyl R 28(R wherein 28As above definition);
8) C 2-5Alkynyl R 28(R wherein 28As above definition);
9) R 29(R wherein 29Represent pyriconyl, phenyl or contain the heteroatomic 5-6-unit aromatic heterocyclic radical (being connected) that 1-3 is selected from O, N and S through carbon or nitrogen, and described pyriconyl, phenyl or aromatic heterocyclic radical can have 5 of as many as and be selected from following substituent group on carbon atom: hydroxyl, halogen, amino, C 1-4Alkyl, C 1-4Alkoxyl, C 1-4Hydroxy alkyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, C 1-4Hydroxy alkoxy base, carboxyl, trifluoromethyl, cyano group ,-C (O) NR 30R 31With-NR 32C (O) R 33(R wherein 30, R 31, R 32And R 33Can be identical or different, represent hydrogen separately, C 1-4Alkyl or C 1-3Alkoxy C 2-3Alkyl));
10) C 1-5Alkyl R 29(R wherein 29As the definition of this claim);
11) C 2-5Alkenyl R 29(R wherein 29As the definition of this claim);
12) C 2-5Alkynyl R 29(R wherein 29As the definition of this claim);
13) C 1-5Alkyl X 6R 29(X wherein 6Representative-O-,-S-,-SO-,-SO 2,-NR 34C (O)-,-C (O) NR 35-,-SO 2NR 36-,-NR 37SO 2-or-NR 38-(R wherein 34, R 35, R 36, R 37And R 38The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As the definition of this claim);
14) C 2-5Alkenyl X 7R 29(X wherein 7Representative-O-,-S-,-SO-,-SO 2,-NR 39C (O)-,-C (O) NR 40-,-SO 2NR 41-,-NR 42SO 2-or-NR 43-(R wherein 39, R 40, R 41, R 42And R 43The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As the definition of this claim);
15) C 2-5Alkynyl X 8R 29(X wherein 8Representative-O-,-S-,-SO-,-SO 2,-NR 44C (O)-,-C (O) NR 45-,-SO 2NR 46-,-NR 47SO 2-or-NR 48-(R wherein 44, R 45, R 46, R 47And R 48The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As the definition of this claim);
16) C 1-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9Representative-O-,-S-,-SO-,-SO 2,-NR 49C (O)-,-C (O) NR 50-,-SO 2NR 51-,-NR 52SO 2-or-NR 53-(R wherein 49, R 50, R 51, R 52And R 53The independent separately hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As the definition of this claim);
17) C 1-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As the definition of this claim);
18) C 2-5Alkenyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be by one or more hydroxyl, fluorine, amino, C of being selected from 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-5Alkenyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As the definition of this claim); With
21) C 2-5Alkynyl X 9C 1-4Alkyl R 28(X wherein 9And R 28As the definition of this claim).
3. according to the purposes of the formula I chemical compound of claim 1, R wherein 2Representation hydroxy, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, amino or R 5X 1-[X wherein 1As claim 1 definition, and R 5Be selected from one of following 22 groups of groups:
1) C unsubstituted or that replaced by one or more groups that are selected from fluorine, chlorine and bromine 1-4Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino groups replace by one or more 2-5Alkyl
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As claim 1 definition, and R 11Representative-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, C respectively does for oneself 1-4Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As claim 1 definition, R 16For being selected from C 1-3The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl and THP trtrahydropyranyl, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-2The substituent group of alkoxyl, and described cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl or THP trtrahydropyranyl can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl));
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As claim 1 definition, and R 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28As claim 1 definition);
6) C 1-4Alkyl R 110(R wherein 110For being selected from following carbon atom and the C of passing through 1-4The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, imidazolidine-1-base, azelidinyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, and described group can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3Or C the substituent group of alkyl)) 2-4Alkyl R 111(R wherein 111For being selected from morpholino, thiomorpholine generation, azetidin-1-base, pyrrolidine-1-base, the group of piperazine-1-base and piperidino, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Fluorine-based alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl));
7) C 3-4Alkenyl R 112(R wherein 112Representative is as the R of this claim definition 110Or R 111);
8) C 3-4Alkynyl R 112(R wherein 112Representative is as the R of this claim definition 110Or R 111);
9) R 29(R wherein 29As claim 1 definition);
10) C 1-4Alkyl R 29(R wherein 29As claim 1 definition);
11) 1-R 29Third-1-alkene-3-base or 1-R 29But-2-ene-4-base (R wherein 29As claim 1 definition, condition is to work as R 5Be 1-R 29When third-1-alkene-3-is basic, R 29Be connected with alkenyl through carbon atom);
12) 1-R 29Third-1-alkynes-3-base or 1-R 29Fourth-2-alkynes-4-base (R wherein 29As claim 1 definition, condition is to work as R 5Be 1-R 29When third-1-alkynes-3-is basic, R 29Be connected with alkynyl through carbon atom);
13) C 1-5Alkyl X 6R 29(X wherein 6And R 29As claim 1 definition);
14) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As claim 1 definition);
15) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As claim 1 definition);
16) C 2-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9And R 29As claim 1 definition);
17) C 2-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As claim 1 definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two-(C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-4Alkenyl X 9C 1-3Alkyl R 28(X wherein 8And R 28As claim 1 definition);
21) C 2-4Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As claim 1 definition); With
22) C 1-3Alkyl R 54(C 1-3Alkyl) q(X 9) rR 55(X wherein 9, q, r, R 54And R 55As claim 1 definition);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from].
4. according to the purposes of each formula I chemical compound in the aforementioned claim, wherein Z is-O-,-NH-or-S-.
5. according to the purposes of each formula I chemical compound in the aforementioned claim, its medium ring C contains 1-3 first aromatics two cyclic groups of heteroatomic 9-10-that independently are selected from O, N and S.
6. according to the purposes of each formula I chemical compound in the aforementioned claim, R wherein 1Represent oxo, halogen, hydroxyl, C 1-2Alkoxyl, C 1-2Alkyl, C 1-2Alkoxy methyl, C 5-2Alkanoyl, C 1-2Haloalkyl, cyano group, amino, C 3-4Alkenyl, C 2-4Alkynyl, C 2-3Alkanoyloxy, nitro, C 2-3Alkanoylamino, C 1-2Alkoxy carbonyl, C 1-2Alkylthio group, C 1-2Alkyl sulphinyl, C 1-2Alkyl sulphonyl, carbamoyl, N-C 1-2Alkyl-carbamoyl, N, N-two (C 1-2Alkyl) carbamoyl, amino-sulfonyl, N-C 1-2Alkyl amino sulfonyl, N, N-two (C 1-2Alkyl) amino-sulfonyl, N-(C 1-2Alkyl sulphonyl) amino, N-(C 1-2Alkyl sulphonyl)-N-(C 1-2Alkyl) the amino or C that is connected with two ring carbon atoms 3-C 7Alkylidene chain.
7. according to the purposes of each formula I chemical compound in the aforementioned claim, wherein n is 0,1 or 2.
8. according to the purposes of each formula I chemical compound in the aforementioned claim, wherein m is 1 or 2.
9. formula II compound or its salt:
Figure A0080608500151
[wherein:
Ring C, R 1, R 2With definition in n such as the claim 1, Zb is-O-or-S-, and R 2aRepresent hydrogen, halogen, C 1-3Alkyl, trifluoromethyl, C 1-3Alkoxyl, C 1-3Alkylthio group ,-NR 3aR 4a(R wherein 3aAnd R 4aCan be identical or different, represent hydrogen or C separately 1-3Or R alkyl), 5a(CH 2) Z3X 1a-(R wherein 5aFor containing 1-2 heteroatomic 5-or 6-unit saturated heterocyclyl that independently is selected from O, S and N, this heterocyclic radical can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-4Cyano group alkyl, C 1-4Alkyl, C 1-4Hydroxy alkyl, C 1-4Alkoxyl, C 1-4Alkoxy C 1-4Alkyl, C 1-4Alkyl sulphonyl C 1-4Alkyl, C 1-4Alkoxy carbonyl, C 1-4Aminoalkyl, C 1-4Alkyl amino, two (C 1-4Alkyl) amino, C 1-4Alkyl amino C 1-4Alkyl, two (C 1-4Alkyl) amino C 1-4Alkyl, C 1-4Alkyl amino C 1-4Alkoxyl, two (C 1-4Alkyl) amino C 1-4Alkoxyl and group-(O-) f(C 1-4Alkyl) f(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D contains 1-2 the first saturated heterocyclyl of heteroatomic 5-6 that independently is selected from O, S and N, and this cyclic group can have one or more and be selected from C 1-4The substituent group of alkyl), za is integer 0-4, and X 1aRepresent direct key ,-O-,-CH 2-,-S-,-SO-,-SO 2-,-NR 6aC (O)-,-C (O) NR 7a-,-SO 2NR 8a-,-NR 9aSO 2-or-NR 10a-(R wherein 6a, R 7a, R 8a, R 9aAnd R 10aRepresent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl));
Condition is R 2Can not be hydrogen, and not comprise following compounds: 6,7-dimethoxy-4 '-(1-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(2-naphthalene sulfenyl) quinazoline, 6,7-dimethoxy-4 '-(1-naphthoxy) quinazoline and 6,7-dimethoxy-4 '-(2-naphthoxy) quinazoline.
10. according to the formula II chemical compound of claim 9, R wherein 2Representation hydroxy, halogen, cyano group, nitro, trifluoromethyl, C 1-3Alkyl, amino or R 5X 1-[X wherein 1In 1, define, and R 5Be selected from one of following 22 groups of groups:
1) C unsubstituted or that replaced by one or more groups that are selected from fluorine, chlorine and bromine 1-4Alkyl, or unsubstituted or be selected from the C that hydroxyl and amino groups replace by one or more 2-5Alkyl
2) C 2-3Alkyl X 2C (O) R 11(X wherein 2As 1 definition in the claim, and R 11Representative-NR 13R 14Or-OR 15(R wherein 13, R 14And R 15Can be identical or different, C respectively does for oneself 1-4Alkyl or C 1-2Alkoxyethyl));
3) C 2-4Alkyl X 3R 16(X wherein 3As claim 1 definition, R 16For being selected from C 1-3The group of alkyl, cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl and THP trtrahydropyranyl, wherein said C 1-3Alkyl can have 1 or 2 and be selected from oxo, hydroxyl, halogen and C 1-2The substituent group of alkoxyl, and described cyclopenta, cyclohexyl, pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl or THP trtrahydropyranyl can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and these heterocyclic radicals can have one or more and be selected from C 1-3The substituent group of alkyl));
4) C 2-3Alkyl X 4C 2-3Alkyl X 5R 22(X wherein 4And X 5As definition in the claim 1, and R 22Represent hydrogen or C 1-3Alkyl);
5) R 28(R wherein 28As claim 1 definition);
6) C 1-4Alkyl R 110(R wherein 110For being selected from following carbon atom and the C of passing through 1-4The group that alkyl connects: pyrrolidinyl, piperazinyl, piperidyl, imidazolidine-1-base, azelidinyl, 1,3-dioxolanes-2-base, 1,3-diox-2-base, 1,3-dithiolane-2-base and 1,3-dithiane-2-base, and described group can have 1 or 2 and is selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3Or C the substituent group of alkyl)) 2-4Alkyl R 111(R wherein 111For being selected from morpholino, thiomorpholine generation, azetidin-1-base, pyrrolidine-1-base, the group of piperazine-1-base and piperidino, these groups can have 1 or 2 and be selected from following substituent group: oxo, hydroxyl, halogen, cyano group, C 1-3Cyano group alkyl, C 1-3Alkyl, C 1-3Hydroxy alkyl, C 1-3Alkoxyl, C 1-2Alkoxy C 1-3Alkyl, C 1-2Alkyl sulphonyl C 1-3Alkyl, C 1-3Alkoxy carbonyl, C 1-3Alkyl amino, two (C 1-3Alkyl) amino, C 1-3Alkyl amino C 1-3Alkyl, two (C 1-3Alkyl) amino C 1-3Alkyl, C 1-3Alkyl amino C 1-3Alkoxyl, two (C 1-3Alkyl) amino C 1-3Alkoxyl and group-(O-) f(C 1-3Alkyl) g(wherein f is 0 or 1 to ring D, and g is 0 or 1, and ring D is the heterocyclic radical that is selected from pyrrolidinyl, piperazinyl, piperidyl, imidazolidinyl, azelidinyl, morpholino and thiomorpholine generation, and this cyclic group can have one or more and be selected from C 1-3The substituent group of alkyl));
7) C 3-4Alkenyl R 112(R wherein 112Representative is as the R of this claim definition 110Or R 111);
8) C 3-4Alkynyl R 112(R wherein 112Representative is as the R of this claim definition 110Or R 111);
9) R 29(R wherein 29As claim 1 definition);
10) C 1-4Alkyl R 29(R wherein 29As claim 1 definition);
11) 1-R 29Third-1-alkene-3-base or 1-R 29But-2-ene-4-base (R wherein 29As claim 1 definition, condition is to work as R 5Be 1-R 29When third-1-alkene-3-is basic, R 29Be connected with alkenyl through carbon atom);
12) 1-R 29Third-1-alkynes-3-base or 1-R 29Fourth-2-alkynes-4-base (R wherein 29As claim 1 definition, condition is to work as R 5Be 1-R 29When third-1-alkynes-3-is basic, R 29Be connected with alkynyl through carbon atom);
13) C 1-5Alkyl X 6R 29(X wherein 6And R 29As claim 1 definition);
14) 1-(R 29X 7) but-2-ene-4-base (X wherein 7And R 29As claim 1 definition);
15) 1-(R 29X 8) fourth-2-alkynes-4-base (X wherein 8And R 29As claim 1 definition);
16) C 2-3Alkyl X 9C 1-3Alkyl R 29(X wherein 9And R 29As claim 1 definition);
17) C 2-3Alkyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As claim 1 definition);
18) C 2-5Alkenyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
19) C 2-5Alkynyl, it can be unsubstituted or can be replaced by one or more fluorine atoms or be selected from hydroxyl, fluorine, amino, C by one or two 1-4Alkyl amino, N, N-two (C 1-4Alkyl) amino, amino-sulfonyl, N-C 1-4Alkyl amino sulfonyl and N, N-two (C 1-4Alkyl) group of amino-sulfonyl replaces;
20) C 2-4Alkenyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As claim 1 definition);
21) C 2-4Alkynyl X 9C 1-3Alkyl R 28(X wherein 9And R 28As claim 1 definition); With
22) C 1-3Alkyl R 54(C 1-3Alkyl) q(X 9) rR 55(X wherein 9, q, r, R 54And R 55As claim 1 definition);
In addition, R wherein 5X 1-in any C 1-5Alkyl, C 2-5Alkenyl or C 2-5Alkynyl all can have one or more hydroxyl, halogen and amino substituent groups of being selected from].
11. according to each chemical compound in claim 9 and 10, wherein Zb is-O-.
12. according to each chemical compound in the claim 9,10 and 11, its medium ring C contains 1-3 heteroatomic 9-10-unit aromatics two cyclic groups that independently are selected from O, N and S.
13. according to each chemical compound in the claim 9,10,11 and 12, wherein R 1Represent oxo, halogen, hydroxyl, C 1-2Alkoxyl, C 1-2Alkyl, C 1-2Alkoxy methyl, C 2-3Alkanoyl, C 1-2Haloalkyl, cyano group, amino, C 2-4Alkenyl, C 2-4Alkynyl, C 2-3Alkanoyloxy, nitro, C 2-3Alkanoylamino, C 1-2Alkoxy carbonyl, C 1-2Alkylthio group, C 1-2Alkyl sulphinyl, C 1-2Alkyl sulphonyl, carbamoyl, N-C 1-2Alkyl-carbamoyl, N, N-two (C 1-2Alkyl) carbamoyl, amino-sulfonyl, N-C 1-2Alkyl amino sulfonyl, N, N-two (C 1-2Alkyl) amino-sulfonyl, N-(C 1-2Alkyl sulphonyl) amino, N-(C 1-2Alkyl sulphonyl)-N-(C 1-2Alkyl) the amino or C that is connected with two ring carbon atoms 3-C 7Alkylidene chain.
14. according in the claim 9,10,11,12 and 13-chemical compound, wherein n is 0,1 or 2.
15. formula IIb compound or its salt:
Figure A0080608500191
[wherein:
Ring C, R 1, R 2With definition in n such as the claim 1, Zb is-O-and R 2aAs definition in the claim 9, condition is R 2Can not have any following implication: hydrogen replaces or unsubstituted C 1-5Alkyl, halogen, C 1-5Alkoxyl, C 2-5Alkenyl, phenoxy group or phenyl C 1-5Alkoxyl].
16. compound or its salt according to claim 9; it is selected from: 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(2-naphthoxy) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(4-chloroquinoline-7-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group)-4-(4-methylquinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(4-methylquinoline-7-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-7-((1-(2-mesyl ethyl) piperidin-4-yl) methoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group)-4-(2-trifluoro methyl indole-5-base oxygen base) quinazoline; (R; S)-4-(3-fluorine quinoline-7-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-3-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-mesyl propoxyl group) quinazoline; 7-(3-N; the N-dimethylamino propoxy)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-morpholino ethyoxyl) ethyoxyl) quinazoline; 7-(2-(N; the N-diethylamino) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidines-1-yl) ethyoxyl) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1; 2; the 4-triazol-1-yl) quinazoline ethyoxyl); 6-methoxyl group-7-(3-piperidino propoxyl group)-4-(6-trifluoro methyl indole-5-base oxygen base) quinazoline; 7-(3-(mesyl) propoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(3-(N; the N-dimethylamino) propoxyl group)-4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(2; 3-dimethyl indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-3-ylmethoxy) quinazoline; 7-(2-(N; the N-diethylamino) ethyoxyl)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-2-yl) ethyoxyl)-quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(piperidines-1-yl) ethyoxyl)-quinazoline; 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; 7-(3-(ethylsulfonyl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(3-methylindole-5-base oxygen base)-7-(3-piperidino propoxyl group)-quinazoline; 7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methylamino) ethyoxyl) quinazoline, and 7-(2-hydroxyl-3-(isopropyl amino) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline.
17. compound or its salt according to claim 9; it is selected from: 6-methoxyl group-7-(3-morpholino propoxyl group)-4-(quinoline-7-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-pyrrolidine-1-base propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-mesyl propoxyl group) quinazoline; 7-((1-cyano methyl) piperidin-4-yl methoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-morpholino ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-pyrrolidine-1-base oxethyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-methyl piperidine-3-ylmethoxy) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-piperidino ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-(4-pyridine radicals) amino) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-morpholino propoxyl group) quinazoline; 6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl)-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(1H-1; 2; the 4-triazol-1-yl) quinazoline ethyoxyl); 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(2-(4-methyl piperazine-1-yl) ethyoxyl) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-piperidino propoxyl group) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline; 6-methoxyl group-7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-((2-(2-pyrrolidine-1-base ethyl) carbamoyl) vinyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(piperidin-4-yl oxygen base) ethyoxyl) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(N-methyl-N-mesyl amino) ethyoxyl) quinazoline; 7-(2-(1-(2-cyano ethyl) piperidin-4-yl oxygen base) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline; (2 methyl indole-5-base oxygen base)-(3-(1 for 7-for 4-; 1-dioxo thiomorpholine generation) quinazoline propoxyl group); 4-(2 methyl indole-5-base oxygen base)-7-(piperidin-4-yl methoxyl group) quinazoline, 4-(indole-5-base oxygen base)-6-methoxyl group-7-(2-(2-methoxy ethoxy) ethyoxyl) quinazoline, 7-(3-(N; the N-dimethylamino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 7-(3-(N, N-diethylamino) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (3-(1 for 7-; 1-dioxo thiomorpholine generation) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; 4-(indole-5-base oxygen base)-6-methoxy-7-(2-(4-pyridine radicals oxygen base) ethyoxyl) quinazoline, 4-(indole-6-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 7-(1-(2-methoxy ethyl) piperidin-4-yl methoxyl group)-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-hydroxyl-3-morpholino propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(2-(1-(2-methoxy ethyl) piperidin-4-yl) ethyoxyl)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 7-(2-hydroxyl-3-pyrrolidine-1-base propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 7-(3-(N; the N-diethylamino)-2-hydroxyl propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline; 7-(3-(1,1-dioxo thiomorpholine generation) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(2-(4-pyridine radicals oxygen base) ethyoxyl) quinazoline; 4-(indole-5-base oxygen base)-6-methoxyl group-7-(3-morpholino propoxyl group) quinazoline; (2R)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline, (5R)-6-methoxyl group-4-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-oxo-pyrrolidine-5-ylmethoxy) quinazoline, 4-(4-bromo indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline; 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-(pyrrolidine-1-yl) ethyl)-piperidin-4-yl methoxyl group) quinazoline; (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2R)-7-(2-hydroxyl-3-morpholino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline; (2S)-7-(2-hydroxyl-3-((N; the N-diisopropyl) propoxyl group amino))-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2S)-7-(2-hydroxyl-3-piperidino propoxyl group)-4-(indole-5-base oxygen base)-6-methoxyl group quinazoline, (2R)-7-(2-hydroxyl-3-piperidino propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline; (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(3-methylindole-5-base oxygen base) quinazoline; (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, (2R)-7-(2-hydroxyl-3-(4-methyl piperazine-1-yl) propoxyl group)-6-methoxyl group-4-(2 methyl indole-5-base oxygen base) quinazoline, 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(1-(2-morpholino ethyl) piperidin-4-yl methoxyl group) quinazoline; 4-(3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline; 4-(3-fluoro-quinoline-7-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group)-4-(1H-pyrrolo-[2,3-b] pyridine-5-base oxygen base) quinazoline; (2S)-6-methoxyl group-(2-Methyl-1H-indole-5-base oxygen base)-7-(2-hydroxyl-3-piperidino propoxyl group) quinazoline, and 4-(6-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline.
18. compound or its salt according to claim 9, it is selected from: 6-methoxyl group-4-(2 methyl indole-5-base oxygen base)-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(1-methyl piperidine-4-ylmethoxy) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline, 4-(6-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(pyrrolidine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-piperidino propoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-((1-methyl piperidine-4-yl) methoxyl group) quinazoline, 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(3-(4-methyl piperazine-1-yl) propoxyl group) quinazoline, 4-(4-fluoro indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline, (2R)-7-(2-hydroxyl-3-(pyrrolidine-1-yl) propoxyl group)-4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group quinazoline, and 4-(4-fluoro-2 methyl indole-5-base oxygen base)-6-methoxyl group-7-(2-(1-methyl piperidine-4-yl) ethyoxyl) quinazoline.
19. the chemical compound of the claim 9 of pharmaceutical acceptable salt.
20. the method for preparation I compound or its salt, this method comprises:
(a) make the formula III chemical compound:
Figure A0080608500261
(R wherein 2With definition in m such as the claim 1, L 1Be displaceable group), react with formula IV chemical compound:
Figure A0080608500262
(its medium ring C, R 1, definition in Z and n such as the claim 1);
(b) at least one R wherein 2Be R 5X 1, and R wherein 5As definition in the claim 1, X 1For-O-,-S-,-OC (O)-or-NR 10-(R wherein 10The independent hydrogen, C represented 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) but formula I compound or its salt through type V chemical compound:
Figure A0080608500263
(its medium ring C, Z, R 1, R 2With definition in n such as the claim 1, X 1Then such as this section definition, and s is integer 0-2) with formula VI chemical compound prepared in reaction:
R 5-L 1(VI) (R wherein 5As definition in the claim 1, L 1Definition then with this claim);
(c) at least one R wherein 2Be R 5X 1, and R wherein 5As definition in the claim 1, X 1For-O-,-S-,-OC (O)-or-NR 10-(R wherein 10Represent hydrogen, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl) but formula I compound or its salt through type VII chemical compound:
Figure A0080608500271
With formula VIII chemical compound prepared in reaction:
R 5-X 1-H (VIII) (R wherein 1, R 2, R 5, ring C, definition in Z and n such as the claim 1, L 1, s and X 1Definition with this claim);
(d) at least one R wherein 2Be R 5X 1, and X wherein 1As definition in the claim 1, R 5Be C 1-5Alkyl R 113, R wherein 113Be selected from one of following nine groups of groups:
1) X 19C 1-3Alkyl (X wherein 19Representative-O-,-S-,-SO 2-,-NR 114C (O)-or-NR 115SO 2-(R wherein 114And R 115Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl));
2) NR 116R 117(R wherein 116And R 117Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3Alkyl);
3) X 20C 1-5Alkyl X 5R 22(X wherein 20Representative-O-,-S-,-SO 2-,-NR 118C (O)-,-NR 119SO 2-or-NR 120-(R wherein 118, R 119And R 120Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3And X alkyl), 5And R 22As definition in the claim 1);
4) R 28(R wherein 28As definition in the claim 1);
5) X 21R 29(X wherein 21Representative-O-,-S-,-SO 2-,-NR 121C (O)-,-NR 122SO 2-or-NR 123-(R wherein 121, R 122And R 123Can be identical or different, the hydrogen of respectively doing for oneself, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As definition in the claim 1); With
6) X 22C 1-3Alkyl R 29(X wherein 22Representative-O-,-S-,-SO 2-,-NR 124C (O)-,-NR 125SO 2-or-NR 126-(R wherein 124, R 125And R 126Represent hydrogen independently of one another, C 1-3Alkyl or C 1-3Alkoxy C 2-3And R alkyl), 29As definition in the claim 1);
7) R 29(R wherein 29As definition in the claim 1);
8) X 22C 1-4Alkyl R 28(X wherein 22And R 28As definition in the claim 1); With
9) R 54(C 1-4Alkyl) q(X 9) rR 55(q wherein, r, X 9, R 54And R 55In 1, define); But formula I compound or its salt through type IX chemical compound:
Figure A0080608500281
(X wherein 1, R 1, R 2, ring C, definition in Z and n such as the claim 1, and L 1With the definition of s with this claim) with formula X chemical compound prepared in reaction:
R 113-H (X) (R wherein 113Definition with this claim);
(e) by making wherein substituent group (R 2) mBe the formula I chemical compound and the alkylation reactions of amino, can make this formula I compound or its salt, wherein substituent group (R 2) mIn one or more representative-NR 127R 128, R wherein 127And R 128One of (and another is a hydrogen) or the two be C 1-3Alkyl or
(f) X wherein 1For-SO-or-SO 2-formula I compound or its salt can be by oxidation X wherein 1For-S-or-the respective compound preparation of SO-; And when needing the salt of formula I chemical compound, make gained chemical compound and acid or alkali reaction, thereby obtain required salt.
21. a pharmaceutical composition, it comprises as the formula I compound or pharmaceutically acceptable salt thereof of the claim 9 of active component and pharmaceutically acceptable excipient or carrier.
22. produce the method for angiogenesis inhibitor and/or vascular permeability reduction effect in the homoiothermic animal body of needs treatments, this method comprises 1 the formula I compound or pharmaceutically acceptable salt thereof of described animal being used effective dose.
CNB008060851A 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors Expired - Lifetime CN1167422C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99400305 1999-02-10
EP99400305.1 1999-02-10
PCT/GB2000/000373 WO2000047212A1 (en) 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100589826A Division CN100360505C (en) 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
CN1346271A true CN1346271A (en) 2002-04-24
CN1167422C CN1167422C (en) 2004-09-22

Family

ID=8241873

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2004100589826A Expired - Lifetime CN100360505C (en) 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors
CNB008060851A Expired - Lifetime CN1167422C (en) 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB2004100589826A Expired - Lifetime CN100360505C (en) 1999-02-10 2000-02-08 Quinazoline derivatives as angiogenesis inhibitors

Country Status (32)

Country Link
US (3) US7074800B1 (en)
EP (3) EP1154774B1 (en)
JP (3) JP3893026B2 (en)
KR (2) KR100838617B1 (en)
CN (2) CN100360505C (en)
AT (2) ATE298237T1 (en)
AU (1) AU763618B2 (en)
BR (2) BRPI0008128B8 (en)
CA (2) CA2674803C (en)
CY (1) CY1110979T1 (en)
CZ (3) CZ305827B6 (en)
DE (2) DE60020941T2 (en)
DK (2) DK1553097T3 (en)
EE (3) EE200900039A (en)
ES (2) ES2242596T3 (en)
HK (2) HK1041212B (en)
HU (2) HU230000B1 (en)
ID (1) ID30552A (en)
IL (4) IL144745A0 (en)
IS (2) IS2512B (en)
MX (1) MXPA01008182A (en)
NO (3) NO321604B1 (en)
NZ (2) NZ513204A (en)
PL (2) PL199802B1 (en)
PT (2) PT1553097E (en)
RU (1) RU2262935C2 (en)
SI (2) SI1154774T1 (en)
SK (3) SK288378B6 (en)
TR (2) TR200102314T2 (en)
UA (1) UA73932C2 (en)
WO (1) WO2000047212A1 (en)
ZA (1) ZA200106340B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898232B (en) * 2003-12-24 2011-08-17 阿斯利康(瑞典)有限公司 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
CN102356063A (en) * 2009-03-16 2012-02-15 Eos伦理肿瘤学公司（简称“Eos公司”） A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof
CN1863794B (en) * 2003-08-06 2012-04-25 阿斯利康(瑞典)有限公司 Quinazoline derivatives as angiogenesis inhibitors
CN102584798A (en) * 2006-11-02 2012-07-18 阿斯利康(瑞典)有限公司 Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates
CN103509005A (en) * 2013-09-26 2014-01-15 苏州海特比奥生物技术有限公司 Quinazoline compound as well as preparation method and application thereof
WO2014166386A1 (en) * 2013-04-09 2014-10-16 广州康睿生物医药科技有限公司 Anti-angiogenesis compound, intermediate and use thereof
CN105461698A (en) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 Cediranib salt and crystal form thereof, and preparation methods and pharmaceutical composition of cediranib salt and crystal form thereof
CN106061261A (en) * 2013-11-01 2016-10-26 卡拉制药公司 Crystalline forms of therapeutic compounds and uses thereof
CN106831729A (en) * 2016-12-19 2017-06-13 浙江工业大学 A kind of purification process of AZD2171
CN107915751A (en) * 2013-02-20 2018-04-17 卡拉制药公司 Therapeutic compound and its purposes

Families Citing this family (313)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360505C (en) * 1999-02-10 2008-01-09 阿斯特拉曾尼卡有限公司 Quinazoline derivatives as angiogenesis inhibitors
ATE398120T1 (en) 1999-11-05 2008-07-15 Astrazeneca Ab NEW QUINAZOLINE DERIVATIVES
AU2001235804A1 (en) * 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
SK2142003A3 (en) * 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
AU2001292138A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
JP2004511480A (en) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ Quinazoline derivatives
DE60137273D1 (en) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Process for the preparation of 4-phenoxyquinoline derivatives
ATE502928T1 (en) 2000-11-01 2011-04-15 Millennium Pharm Inc NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
NZ526542A (en) 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
ATE353889T1 (en) * 2001-03-23 2007-03-15 Bayer Pharmaceuticals Corp RHO KINASE INHIBITORS
DE60211317T2 (en) * 2001-03-23 2007-04-12 Bayer Corp. RHO-KINASE INHIBITORS
EP1381599B1 (en) 2001-04-19 2008-09-24 Astrazeneca AB Quinazoline derivatives
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
ATE341545T1 (en) * 2001-07-16 2006-10-15 Astrazeneca Ab QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
GB0128109D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
HUP0402588A3 (en) 2002-02-01 2009-09-28 Astrazeneca Ab Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
JP4389205B2 (en) 2002-02-06 2009-12-24 宇部興産株式会社 Preparation of 4-aminoquinazoline compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP2005536486A (en) * 2002-07-09 2005-12-02 アストラゼネカ アクチボラグ Quinazoline derivatives for use in the treatment of cancer
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
CN1688549A (en) * 2002-08-23 2005-10-26 麒麟麦酒株式会社 Compound having TGF-beta inhibitory activity and medicinal composition containing the same
KR101089462B1 (en) * 2002-11-04 2011-12-07 아스트라제네카 아베 Quinazoline derivatives as src tyrosine kinase inhibitors
ATE508747T1 (en) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-KIT KINASE INHIBITORS
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318423D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
WO2005016346A1 (en) * 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PT2213661E (en) 2003-09-26 2011-12-15 Exelixis Inc C-met modulators and methods of use
WO2005044788A1 (en) 2003-11-11 2005-05-19 Eisai Co., Ltd. Urea derivative and process for producing the same
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
US7435823B2 (en) * 2004-01-23 2008-10-14 Amgen Inc. Compounds and methods of use
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20060130764A (en) * 2004-03-23 2006-12-19 아스트라제네카 아베 Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (en) 2004-09-24 2006-12-06 Hoffmann La Roche DERIVATIVES OF FTALAZINONA; ITS OBTAINING AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
EP1802591B1 (en) 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
AU2005312048B2 (en) 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
PT1838733E (en) 2004-12-21 2011-12-13 Medimmune Ltd Antibodies directed to angiopoietin-2 and uses thereof
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
DE602006010243D1 (en) 2005-05-18 2009-12-17 Array Biopharma Inc 4- (phenylamino) -6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative disorders
JP2009500347A (en) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド Bisaryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
JP5066446B2 (en) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CN101277720A (en) * 2005-09-01 2008-10-01 卫材R&D管理有限公司 Method for preparation of pharmaceutical composition having improved disintegradability
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
EP1949902B1 (en) 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061130A1 (en) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
AU2006328201B2 (en) * 2005-12-22 2010-08-19 Astrazeneca Ab Combination of AZD2171 and pemetrexed
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
JP2009528365A (en) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド Cinnoline and quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (en) * 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20090209580A1 (en) * 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2662587C (en) 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
AU2012204077B2 (en) * 2006-11-02 2012-11-29 Astrazeneca Ab Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
AU2007338793B2 (en) 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
KR20090116782A (en) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
PE20081887A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Novel adenine compound
CN101678001A (en) * 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 Combination therapy comprising AZD2171 and AZD6244 or MEK-inhibitor II
PT2154967E (en) 2007-04-16 2014-06-05 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
WO2009030224A2 (en) * 2007-09-07 2009-03-12 Schebo Biotech Ag Novel quinazoline compounds and the use thereof for treating cancerous diseases
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
EP2190287B1 (en) 2007-09-10 2014-10-29 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
PL2201012T3 (en) 2007-10-11 2014-11-28 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PT2222675E (en) 2007-12-19 2013-11-13 Genentech Inc 5-anilinoimidazopyridines and methods of use
KR20100099185A (en) 2007-12-21 2010-09-10 제넨테크, 인크. Azaindolizines and methods of use
CN101215274B (en) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 Technique for preparing N-substituted morpholines organic compounds
ES2385118T3 (en) * 2008-01-17 2012-07-18 Bayer Pharma Aktiengesellschaft Sulfoximin-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicines
WO2009094211A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
DK2245026T3 (en) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Spirocyclic heterocycles, drug containing these compounds, their use and process for their preparation
CN102014912A (en) * 2008-02-21 2011-04-13 阿斯利康(瑞典)有限公司 Combination therapy 238
EP2276488A1 (en) * 2008-03-26 2011-01-26 Novartis AG 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
KR20110014192A (en) 2008-05-13 2011-02-10 아스트라제네카 아베 Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy)quinazoline
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2149565A1 (en) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfoximine substituted chinazoline derivatives as immune modulators for the treatment of inflammatory and allergic diseases
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
JP5778577B2 (en) 2008-09-19 2015-09-16 メディミューン，エルエルシー Antibodies against DLL4 and uses thereof
EP2532657B9 (en) * 2008-10-14 2017-04-19 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
NZ594594A (en) 2009-01-16 2013-11-29 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
ES2427917T3 (en) 2009-02-10 2013-11-04 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
US8785457B2 (en) 2009-03-13 2014-07-22 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
JP5583751B2 (en) * 2009-03-21 2014-09-03 クイ ニング Amino ester derivatives, salts thereof, and methods of use
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
EA022120B1 (en) 2009-10-20 2015-11-30 Целльзом Лимитид Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
KR20120113709A (en) 2009-11-18 2012-10-15 아스트라제네카 아베 Benzoimidazole compounds and uses thereof
NO2504364T3 (en) 2009-11-24 2018-01-06
JP2013512859A (en) 2009-12-03 2013-04-18 大日本住友製薬株式会社 Imidazoquinoline acting through a toll-like receptor (TLR)
WO2011090738A2 (en) * 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CA2786465C (en) 2010-01-15 2018-09-25 Suzhou Neupharma Co., Ltd. Bufalin derivatives for the treatment of cancer
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
MX2012012328A (en) 2010-04-30 2013-05-06 Cellzome Ltd Pyrazole compounds as jak inhibitors.
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
BR112012032462A2 (en) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd antitumor agent employing compounds which, in combination, have kinase inhibiting effect.
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
EP2640716A1 (en) 2010-11-19 2013-09-25 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2012128868A1 (en) 2011-02-15 2012-09-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP5937111B2 (en) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ FAK inhibitor
JP5937112B2 (en) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Selective FAK inhibitor
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2694511A1 (en) 2011-04-04 2014-02-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
UY34013A (en) 2011-04-13 2012-11-30 Astrazeneca Ab ? CHROMENONE COMPOUNDS WITH ANTI-TUMORAL ACTIVITY ?.
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
RU2580609C2 (en) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer therapeutic agent
ES2841809T3 (en) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarkers to predict and evaluate the degree of response of subjects with thyroid and kidney cancer to lenvatinib compounds
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
US20140179664A1 (en) 2011-07-28 2014-06-26 Cellzome Limited Heterocyclyl Pyrimidine Analogues As JAK Inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
EP2747767B8 (en) 2011-08-26 2019-07-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013033250A1 (en) 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20140323504A1 (en) 2011-09-20 2014-10-30 Cellzome Limited Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
EP2758379B1 (en) 2011-09-21 2016-10-19 Cellzome Limited Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
US20140235573A1 (en) 2011-09-29 2014-08-21 The University Of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR20140084130A (en) 2011-10-07 2014-07-04 셀좀 리미티드 Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2794598A1 (en) 2011-12-23 2014-10-29 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
EP3453713B1 (en) 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
DK2859017T3 (en) 2012-06-08 2019-05-13 Sutro Biopharma Inc ANTIBODIES INCLUDING PLACE-SPECIFIC NON-NATURAL AMINO ACID, PROCEDURE FOR MANUFACTURING ITS AND METHODS OF USE THEREOF
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
HRP20220455T1 (en) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104955459B (en) 2012-11-05 2019-02-01 南特知识产权控股有限责任公司 Substituted indoles -5- amphyl and its treatment use
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014117274A1 (en) 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and uses thereof
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
SI2970263T1 (en) 2013-03-13 2018-09-28 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
CN105142648A (en) 2013-03-15 2015-12-09 玛格塞蒂克斯公司 Magnesium compositions and uses thereof for cancers
BR112015022307A2 (en) 2013-03-15 2017-07-18 Nantbioscience Inc indol-5-ol substituted derivatives and their therapeutic applications
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP2806480B1 (en) * 2013-05-20 2017-08-09 Nintendo Co., Ltd. Battery accomodation structure and battery accomodation method
CN103275069B (en) * 2013-05-22 2015-03-11 苏州明锐医药科技有限公司 Preparation method of cediranib
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
EP3336103B1 (en) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2729381T3 (en) 2013-08-23 2019-11-04 Neupharma Inc Certain chemical entities, compositions and methods
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2868702A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Disperse dyes, their preparation and their use
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3062795A4 (en) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
SI3524595T1 (en) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
PT3263106T (en) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
KR20240064733A (en) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
MX2017015896A (en) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Anticancer agent.
CN108349964B (en) 2015-08-04 2021-06-01 常州千红生化制药股份有限公司 N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds
BR112018006873A2 (en) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York autophageal flow activators and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
MX2018009867A (en) 2016-02-15 2019-05-27 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib.
PL3442535T3 (en) 2016-04-15 2022-10-24 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
JP7101165B2 (en) 2016-08-15 2022-07-14 ニューファーマ， インコーポレイテッド Specific chemical entities, compositions, and methods
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) * 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017332839B2 (en) 2016-09-22 2021-11-11 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
JP6755775B2 (en) * 2016-11-04 2020-09-16 富士アミドケミカル株式会社 4-Fluoroisoquinoline manufacturing method
WO2018098361A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
CN110418789B (en) 2017-02-01 2022-03-25 常州千红生化制药股份有限公司 Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN108864079B (en) 2017-05-15 2021-04-09 深圳福沃药业有限公司 Triazine compound and pharmaceutically acceptable salt thereof
ES2975661T3 (en) 2017-05-26 2024-07-11 Cancer Research Tech Ltd BCL6 inhibitors derived from 2-quinolone
KR102628675B1 (en) 2017-05-26 2024-01-25 캔써 리서치 테크놀로지 리미티드 Inhibitor of BCL6 derived from benzimidazolone
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CA3070903A1 (en) 2017-08-18 2019-02-21 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
EP3684814A1 (en) 2017-09-18 2020-07-29 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
MX2020007183A (en) * 2017-10-20 2021-03-31 Kala Pharmaceuticals Inc Ret9 and vegfr2 inhibitors.
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
WO2019136514A1 (en) 2018-01-15 2019-07-18 University Of South Australia 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
EP3749310A4 (en) 2018-02-08 2021-08-18 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
WO2019197842A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
FR3080620B1 (en) 2018-04-27 2021-11-12 Univ Paris Sud COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
WO2019236496A1 (en) 2018-06-04 2019-12-12 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CN112996784B (en) * 2018-09-18 2023-05-30 北京越之康泰生物医药科技有限公司 Indole derivatives and their use in medicine
SG11202102981SA (en) 2018-09-25 2021-04-29 Black Diamond Therapeutics Inc Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
CN111747931A (en) 2019-03-29 2020-10-09 深圳福沃药业有限公司 Azaaromatic cyclic amide derivatives for the treatment of cancer
EP3946618A1 (en) 2019-04-05 2022-02-09 Storm Therapeutics Ltd Mettl3 inhibitory compounds
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
AU2020335054A1 (en) 2019-08-31 2022-03-24 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole derivative for FGFR inhibitor and preparation method therefor
MX2022003276A (en) 2019-09-20 2022-04-11 Ideaya Biosciences Inc 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors.
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
AU2022276958A1 (en) 2021-05-17 2023-12-07 Hk Inno.N Corporation Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023161881A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024059169A1 (en) * 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
WO2024094962A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
WO2024094963A1 (en) 2022-11-02 2024-05-10 Cancer Research Technology Limited 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
WO2024173453A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173524A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173530A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
US20240336628A1 (en) 2023-03-10 2024-10-10 Breakpoint Therapeutics Gmbh Novel compounds, compositions, and therapeutic uses thereof
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
US4460584A (en) 1981-03-13 1984-07-17 Imperial Chemical Industries Plc Nitrogen heterocycles
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
GB8819307D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Antiarrhythmic agents
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5736534A (en) 1994-02-23 1998-04-07 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
AU3619695A (en) 1994-10-07 1996-05-02 Zenyaku Kogyo Kabushiki Kaisha Thioquinolone derivative
DE4436509A1 (en) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituted spiroalkylamino and alkoxy heterocycles, processes for their preparation and their use as pesticides and fungicides
GB9505651D0 (en) * 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP4009681B2 (en) 1995-11-07 2007-11-21 キリンファーマ株式会社 Quinoline derivatives and quinazoline derivatives that inhibit platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing them
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (en) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituted pyridines / pyrimidines, processes for their preparation and their use as pesticides
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
ATE227283T1 (en) 1996-07-13 2002-11-15 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
CN1252054C (en) * 1996-09-25 2006-04-19 曾尼卡有限公司 Qinoline derivatives inhibiting effect of growth factors such as VEGF
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JP2002501532A (en) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド Novel angiogenesis inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ATE368665T1 (en) 1997-08-22 2007-08-15 Astrazeneca Ab OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999028159A1 (en) 1997-11-27 1999-06-10 Continental Teves Ag & Co. Ohg Method and device for supplying data to motor vehicles or for exchanging data
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN100360505C (en) * 1999-02-10 2008-01-09 阿斯特拉曾尼卡有限公司 Quinazoline derivatives as angiogenesis inhibitors
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP3822494B2 (en) 1999-10-19 2006-09-20 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
CN1245402C (en) 2000-08-09 2006-03-15 阿斯特拉曾尼卡有限公司 Chemical compounds
NZ523388A (en) 2000-08-09 2004-09-24 Astrazeneca Ab Cinnoline compounds
KR20030036686A (en) 2000-08-09 2003-05-09 아스트라제네카 아베 Quinoline derivatives having vegf inhibiting activity
HUP0402588A3 (en) * 2002-02-01 2009-09-28 Astrazeneca Ab Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CL2007003158A1 (en) 2006-11-02 2008-05-16 Astrazeneca Ab PROCEDURE FOR PREPARATION OF COMPOUNDS DERIVED FROM QUINAZOLINA OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; INTERMEDIARY COMPOUNDS; PREPARATION PROCEDURE

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863794B (en) * 2003-08-06 2012-04-25 阿斯利康(瑞典)有限公司 Quinazoline derivatives as angiogenesis inhibitors
CN1898232B (en) * 2003-12-24 2011-08-17 阿斯利康(瑞典)有限公司 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
CN102153543B (en) * 2003-12-24 2013-01-02 阿斯利康(瑞典)有限公司 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
CN102584798A (en) * 2006-11-02 2012-07-18 阿斯利康(瑞典)有限公司 Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates
CN101528688B (en) * 2006-11-02 2012-09-05 阿斯利康(瑞典)有限公司 Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates
CN102356063A (en) * 2009-03-16 2012-02-15 Eos伦理肿瘤学公司（简称“Eos公司”） A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof
CN107915751A (en) * 2013-02-20 2018-04-17 卡拉制药公司 Therapeutic compound and its purposes
CN104334543A (en) * 2013-04-09 2015-02-04 广州慧柏瑞生物医药科技有限公司 Anti-angiogenesis compound, intermediate and use thereof
WO2014166386A1 (en) * 2013-04-09 2014-10-16 广州康睿生物医药科技有限公司 Anti-angiogenesis compound, intermediate and use thereof
US9540381B2 (en) 2013-04-09 2017-01-10 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Anti-angiogenesis compound, intermediate and use thereof
CN104334543B (en) * 2013-04-09 2017-08-25 广州慧柏瑞生物医药科技有限公司 The compound of anti-new vessels, its intermediate and application thereof
US10064864B2 (en) 2013-04-09 2018-09-04 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Anti-angiogenesis compound, intermediate and use thereof
CN103509005A (en) * 2013-09-26 2014-01-15 苏州海特比奥生物技术有限公司 Quinazoline compound as well as preparation method and application thereof
CN106061261A (en) * 2013-11-01 2016-10-26 卡拉制药公司 Crystalline forms of therapeutic compounds and uses thereof
CN106061261B (en) * 2013-11-01 2018-04-24 卡拉制药公司 Crystal form of therapeutic compounds and application thereof
CN108530458A (en) * 2013-11-01 2018-09-14 卡拉制药公司 Crystal form of therapeutic compounds and application thereof
CN105461698A (en) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 Cediranib salt and crystal form thereof, and preparation methods and pharmaceutical composition of cediranib salt and crystal form thereof
CN106831729A (en) * 2016-12-19 2017-06-13 浙江工业大学 A kind of purification process of AZD2171

Also Published As

Publication number Publication date
SK288138B6 (en) 2013-11-04
CN1597667A (en) 2005-03-23
DK1553097T3 (en) 2010-12-13
HU228964B1 (en) 2013-07-29
ES2242596T3 (en) 2005-11-16
CN1167422C (en) 2004-09-22
US20120197027A1 (en) 2012-08-02
SK288365B6 (en) 2016-07-01
NO20013882L (en) 2001-10-09
NZ530832A (en) 2005-05-27
NO20052773L (en) 2001-10-09
HUP0104964A3 (en) 2003-02-28
BR0008128A (en) 2002-02-13
IS8708A (en) 2008-01-25
CA2362715A1 (en) 2000-08-17
CY1110979T1 (en) 2015-06-11
CZ303692B6 (en) 2013-03-13
NO321604B1 (en) 2006-06-12
HK1041212B (en) 2005-12-02
IL191581A0 (en) 2008-12-29
KR100838617B1 (en) 2008-06-16
BRPI0008128B8 (en) 2021-05-25
CA2674803C (en) 2012-10-09
CZ306810B6 (en) 2017-07-19
PL199802B1 (en) 2008-10-31
BRPI0017548B8 (en) 2023-05-02
IS6022A (en) 2001-07-24
CA2674803A1 (en) 2000-08-17
RU2262935C2 (en) 2005-10-27
CN100360505C (en) 2008-01-09
SK500022013A3 (en) 2002-01-07
IL144745A (en) 2008-11-03
PT1553097E (en) 2010-12-13
ATE298237T1 (en) 2005-07-15
DE60020941D1 (en) 2005-07-28
BRPI0017548A2 (en) 2010-07-27
JP2011037887A (en) 2011-02-24
HUP0104964A2 (en) 2002-04-29
KR20080015482A (en) 2008-02-19
EE201100025A (en) 2011-08-15
ATE482946T1 (en) 2010-10-15
SI1154774T1 (en) 2005-10-31
CA2362715C (en) 2010-10-19
EP1553097B1 (en) 2010-09-29
DE60020941T2 (en) 2006-05-11
IL191580A (en) 2011-08-31
NO332895B1 (en) 2013-01-28
NO20052773D0 (en) 2005-06-08
IL191580A0 (en) 2008-12-29
US8492560B2 (en) 2013-07-23
JP2002536414A (en) 2002-10-29
SI1553097T1 (en) 2010-12-31
NO331175B1 (en) 2011-10-24
WO2000047212A1 (en) 2000-08-17
BR0008128B1 (en) 2014-11-18
UA73932C2 (en) 2005-10-17
AU2447500A (en) 2000-08-29
US7074800B1 (en) 2006-07-11
JP4651576B2 (en) 2011-03-16
NZ513204A (en) 2004-04-30
ES2351699T3 (en) 2011-02-09
KR20010102044A (en) 2001-11-15
CZ305827B6 (en) 2016-03-30
CZ20012889A3 (en) 2001-11-14
IS2512B (en) 2009-05-15
EP1553097A1 (en) 2005-07-13
HK1076104A1 (en) 2006-01-06
TR200102314T2 (en) 2002-01-21
EE05345B1 (en) 2010-10-15
NO20111095L (en) 2001-10-09
PT1154774E (en) 2005-10-31
ID30552A (en) 2001-12-20
MXPA01008182A (en) 2003-08-20
NO20013882D0 (en) 2001-08-09
US20060004017A1 (en) 2006-01-05
EP1154774B1 (en) 2005-06-22
ZA200106340B (en) 2002-11-01
JP2006273860A (en) 2006-10-12
IL144745A0 (en) 2002-06-30
EE200900039A (en) 2011-02-15
JP5710931B2 (en) 2015-04-30
AU763618B2 (en) 2003-07-31
TR200500745T2 (en) 2005-05-23
HU230000B1 (en) 2015-04-28
DK1154774T3 (en) 2005-09-26
PL205557B1 (en) 2010-05-31
BRPI0017548B1 (en) 2015-06-09
EP2050744A1 (en) 2009-04-22
EE200100409A (en) 2002-12-16
PL350565A1 (en) 2002-12-16
HK1041212A1 (en) 2002-07-05
DE60045047D1 (en) 2010-11-11
IS2807B (en) 2012-09-15
SK11402001A3 (en) 2002-01-07
SK50292011A3 (en) 2002-01-07
EE05708B1 (en) 2014-04-15
JP3893026B2 (en) 2007-03-14
EP1154774A1 (en) 2001-11-21
SK288378B6 (en) 2016-07-01

Similar Documents

Publication Publication Date Title
CN1167422C (en) Quinazoline derivatives as angiogenesis inhibitors
CN1161352C (en) Quinazoline derivatives
CN1142920C (en) Quinazoline derivatives and pharmaceutical compositions containing them
CN1183114C (en) Quinoline derivatives and quinazoline derivatives
CN1252054C (en) Qinoline derivatives inhibiting effect of growth factors such as VEGF
CN1256326C (en) Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency
CN1625555A (en) Quinazoline compounds
CN100347169C (en) Quinazoline derivatives
CN1133625C (en) Quinazoline derivatives
CN1240688C (en) Quinazoline compounds
CN1277829C (en) Oxazolidinone derivatives with antibiotic activity
CN1252065C (en) Cinnoline compounds
CN1245402C (en) Chemical compounds
CN1993349A (en) Quinazoline derivatives as ERBB receptor tyrosine kinases
CN1446212A (en) Quinoline derivatives having VEGF inhibiting activity
CN1656081A (en) 4-anilino quinazoline derivatives as antiproliferative agents
CN1514828A (en) Pyrazole derivatives for treating HIV
CN1688549A (en) Compound having TGF-beta inhibitory activity and medicinal composition containing the same
CN1620296A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
CN1320118A (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
CN1856475A (en) Isoquinoline potassium channel inhibitors
CN1809557A (en) Compound
CN1914182A (en) Quinazoline derivatives
CN1753889A (en) Quinazoline compounds
CN1856477A (en) Isoquinoline potassium channel inhibitors

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040922

CX01 Expiry of patent term